

2022 Incentive Formulary:

This Incentive Formulary applies to members of an employer/retiree, union, or trust fund health plan

For Medicare Part D: 5 Tier Incentive Formulary

Please click here.

For Medicare Part D: Prior Authorization Criteria

Please click here.

For Medicare Part D: Step Therapy Criteria

Please click here.

For more recent information or other questions, please contact:

Freedom Blue PPO (DE) Customer Service at 1-844-576-1246
Freedom Blue PPO (PA) Customer Service at 1-800-550-8722
Freedom Blue PPO (WV) Customer Service at 1-888-459-4020
Security Blue HMO-POS Customer Service at 1-800-935-2583
Community Blue Medicare HMO Customer Service at 1-888-234-5397
Community Blue Medicare PPO Customer Service at 1-888-757-2946
Community Blue Medicare Plus PPO Customer Service at 1-888-757-2946
Blue Rx PDP Customer Service at 1-800-290-3914

For TTY users, *711 National Relay Service*, Monday through Sunday, 8 a.m. to 8 p.m.
Visit medicare.highmark.com.

Formulary ID: 22036 Version: 34

Updated: 12/2022

Note to existing members: This formulary has changed since last year. Please review this document to make sure that it still contains the drugs you take.

When this drug list (formulary) refers to “we,” “us,” or “our,” it means Highmark Senior Health Company, Highmark Choice Company, Highmark Senior Solutions Company, Highmark BCBSD Inc., or Highmark Health Insurance Company.

When it refers to “plan” or “our plan,” it means 2022 Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP.

This document includes a list of the drugs (formulary) for our plan which is current as of July 1, 2022. For an updated formulary, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You must generally use network pharmacies to use your prescription drug benefit. Benefits, formulary, pharmacy network, and/or copayments/coinsurance may change on January 1, 2022, and from time to time during the year.

What is the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?

A formulary is a list of covered drugs selected by our plans in consultation with a team of health care providers, which represents the prescription therapies believed to be a necessary part of a quality treatment program. Our plans will generally cover the drugs listed in our formulary as long as the drug is medically necessary, the prescription is filled at one of our plan’s network pharmacies, and other plan rules are followed. For more information on how to fill your prescriptions, please review your Evidence of Coverage.

Can the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary (drug list) change?

Most changes in drug coverage happen on January 1, but we may add or remove drugs on the Drug List during the year, move them to different cost-sharing tiers, or add new restrictions. We must follow Medicare rules in making these changes.

Changes that can affect you this year: In the below cases, you will be affected by coverage changes during the year:

- **New generic drugs.** We may immediately remove a brand name drug on our Drug List if we are replacing it with a new generic drug that will appear on the same or lower cost sharing tier and with the same or fewer restrictions. Also, when adding the new generic drug, we may decide to keep the brand name drug on our Drug List, but immediately move it to a different cost-sharing tier or add new restrictions. If you are currently taking that brand name drug, we may not tell you in advance before we make that change, but we will later provide you with information about the specific change(s) we have made.
 - If we make such a change, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO or Blue Rx PDP Formulary?”
- **Drugs removed from the market.** If the Food and Drug Administration deems a drug on our formulary to be unsafe or the drug’s manufacturer removes the drug from the market, we will immediately remove the drug from our formulary and provide notice to members who take the drug.
- **Other changes.** We may make other changes that affect members currently taking a drug. For instance, we may add a generic drug that is not new to market to replace a brand name drug currently on the formulary or add new restrictions to the brand name drug or move it to a different cost-sharing tier or both. Or we may make changes based on new clinical guidelines. If we remove drugs from our formulary, add prior authorization, quantity limits and/or step therapy restrictions on a drug, or move a drug to a higher cost-sharing tier, we must notify affected members of the change at least 30 days before the change becomes effective, or at the time the member requests a refill of the drug, at which time the member will receive a 31-day supply of the drug.
 - If we make these other changes, you or your prescriber can ask us to make an exception and continue to cover the brand name drug for you. The notice we provide you will also include information on how to request an exception, and you can also find information in the section below entitled “How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO or Blue Rx PDP Formulary?”

Changes that will not affect you if you are currently taking the drug. Generally, if you are taking a drug on our 2022 formulary that was covered at the beginning of the year, we will not discontinue or reduce coverage of the drug during the 2022 coverage year except as described above. This means these drugs will remain available at the same cost-sharing and with no new restrictions for those members taking them for the remainder of the coverage year.

You will not get direct notice this year about changes that do not affect you. However, on January 1 of the next year, such changes would affect you, and it is important to check the Drug List for the new benefit year for any changes to drugs.

The enclosed formulary is current as of July 1, 2022. To get updated information about the drugs covered by our plans, please contact us. Our contact information appears on the front and back cover pages. In the event of mid-year non-maintenance formulary changes, members will be notified by mail and prospective members will receive an update with this formulary. The most up-to-date formulary is available on our website, medicare.highmark.com

How do I use the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?

There are two ways to find your drug within the formulary:

Medical Condition

The formulary begins on page 9. The drugs in this formulary are grouped into categories depending on the type of medical conditions that they are used to treat. For example, drugs used to treat a heart condition are listed under the category, "Cardiovascular – Hypertension & Lipids." If you know what your drug is used for, look for the category name in the list that begins on page number 9. Then look under the category name for your drug.

Alphabetical Listing

If you are not sure what category to look under, you should look for your drug in the Index that begins at the end of this document. The Index provides an alphabetical list of all of the drugs included in this document. Both brand name drugs and generic drugs are listed in the Index. Look in the Index and find your drug. Next to your drug, you will see the page number where you can find coverage information. Turn to the page listed in the Index and find the name of your drug in the first column of the list.

What are generic drugs?

Our plans cover both brand name drugs and generic drugs. A generic drug is approved by the FDA as having the same active ingredient as the brand name drug. Generally, generic drugs cost less than brand name drugs.

Are there any restrictions on my coverage?

Some covered drugs may have additional requirements or limits on coverage. These requirements and limits may include:

- **Prior Authorization:** Our plans require you or your physician to get prior authorization for certain drugs. This means that you will need to get approval from our plans before you fill your prescriptions. If you don't get approval, our plans may not cover the drug.
- **Quantity Limits:** For certain drugs, our plans limit the amount of the drug that is covered. For example, our plans provide 8 tablets per prescription for 100mg Imitrex. This may be in addition to a standard one-month or three-month supply.
- **Step Therapy:** In some cases, our plans require to first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, our plans may not cover Drug B unless you try Drug A first. If Drug A does not work for you, our plans will then cover Drug B.

You can find out if your drug has any additional requirements or limits by looking in the formulary that begins on page 9. You can also get more information about the restrictions applied to specific covered drugs by visiting our website. We have posted online document(s) that explain(s) our prior authorization and step therapy restrictions. You may also ask us to send you a copy. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

You can ask our plans to make an exception to these restrictions or limits or for a list of other, similar drugs that may treat your health condition. See the section, "How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary?" on page 6 for information about how to request an exception.

What if my drug is not on the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, and Blue Rx PDP Formulary?

If your drug is not included in this formulary (list of covered drugs), you should first contact Customer Service and ask if your drug is covered.

If you learn that our plan does not cover your drug, you have two options:

- You can ask Customer Service for a list of similar drugs that are covered by our plan. When you receive the list, show it to your doctor and ask your doctor to prescribe a similar drug that is covered by our plan.
- You can ask our plan to make an exception and cover your drug. See below for information about how to request an exception.

How do I request an exception to the Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary?

You can ask our plan to make an exception to our coverage rules. There are several types of exceptions that you can ask us to make.

- You can ask us to cover a drug even if it is not on our formulary. If approved, this drug will be covered at a pre-determined cost-sharing level, and you would not be able to ask us to provide the drug at a lower cost-sharing level.
- You can ask us to cover a formulary drug at a lower cost-sharing level if this drug is not on the specialty tier. If approved, this would lower the amount you must pay for your drug.
- You can ask us to waive coverage restrictions or limits on your drug. For example, for certain drugs, our plan limits the amount of the drug that we will cover. If your drug has a quantity limit, you can ask us to waive the limit and cover a greater amount.

Generally, our plan will only approve your request for an exception if the alternative drugs included on the plan's formulary, the lower cost-sharing drug or additional utilization restrictions, would not be as effective in treating your condition and/or would cause you to have adverse medical effects.

You should contact us to ask us for an initial coverage decision for a formulary, or utilization restriction exception. **When you request a formulary or utilization restriction exception, you should submit a statement from your prescriber or physician supporting your request.** Generally, we must make our decision within 72 hours of getting your prescriber's supporting statement. You can request an expedited (fast) exception if you or your doctor believe that your health could be seriously harmed by waiting up to 72 hours for a decision. If your request to expedite is granted, we must give you a decision no later than 24 hours after we get a supporting statement from your doctor or other prescriber.

What do I do before I can talk to my doctor about changing my drugs or requesting an exception?

As a new or continuing member in our plan you may be taking drugs that are not on our formulary. Or you may be taking a drug that is on our formulary but your ability to get it is limited. For example, you may need a prior authorization from us before you can fill your prescription. You should talk to your doctor to decide if you should switch to an appropriate drug that we cover or request a formulary exception so that we will cover the drug you take. While you talk to your doctor to determine the right course of action for you, we may cover your drug in certain cases during the first 90 days you are a member of our plan.

For each of your drugs that is not on our formulary or if your ability to get your drugs is limited, we will cover a temporary 31-day supply. If your prescription is written for fewer days, we'll allow refills to provide up to a maximum 31-day supply of medication. After your first 31-day supply, we will not pay for these drugs, even if you have been a member of the plan less than 90 days.

If you are a resident of a long-term care facility and you need a drug that is not on our formulary or if your ability to get your drugs is limited, but you are past the first 90 days of membership in our plan, we will cover a 31-day emergency supply of that drug while you pursue a formulary exception.

The above transition process will be implemented to accommodate you if you have an immediate need for a non-formulary drug or a drug that requires prior authorization due to a change in your level of care while you are waiting for an exception request to be processed.

For more information

For more detailed information about your plan's prescription drug coverage, please review your Evidence of Coverage and other plan materials.

If you have questions about your plan, please contact us. Our contact information, along with the date we last updated the formulary, appears on the front and back cover pages.

If you have general questions about Medicare prescription drug coverage, please call Medicare at 1-800-MEDICARE (1-800-633-4227) 24 hours a day / 7 days a week. TTY users should call 1-877-486-2048. Or visit <http://www.medicare.gov>.

Freedom Blue PPO, Security Blue HMO-POS, Community Blue Medicare HMO, Community Blue Medicare PPO, Community Blue Medicare Plus PPO, or Blue Rx PDP Formulary

The formulary that begins on the next page provides coverage information about the drugs covered by your plan. If you have trouble finding your drug in the list, turn to the Index that begins at the end of this document.

The first column of the chart lists the drug name. Brand name drugs are capitalized (e.g., ABELCET) and generic drugs are listed in lowercase italics (e.g., *abacavir*).

The information in the Requirements/Limits column tells you if our plan has any special requirements for coverage of your drug.

The following is a Formulary Format Example Only:

| Drug Name | Incentive Drug Tier | Requirements/ Limits |
|-------------------|---------------------|----------------------|
| Anti - Infectives | | |
| XYZ DRUG | NF | QL- 28 |

Table of Contents

| | |
|---|-----|
| Anti - Infectives..... | 5 |
| Antineoplastic / Immunosuppressant Drugs..... | 17 |
| Autonomic / Cns Drugs, Neurology / Psych..... | 24 |
| Cardiovascular, Hypertension / Lipids..... | 53 |
| Dermatologicals/Topical Therapy..... | 64 |
| Diagnostics / Miscellaneous Agents..... | 73 |
| Ear, Nose / Throat Medications..... | 75 |
| Endocrine/Diabetes..... | 76 |
| Gastroenterology..... | 84 |
| Immunology, Vaccines / Biotechnology..... | 89 |
| Miscellaneous Supplies..... | 94 |
| Musculoskeletal / Rheumatology..... | 94 |
| Obstetrics / Gynecology..... | 96 |
| Ophthalmology..... | 102 |
| Respiratory And Allergy..... | 106 |
| Urologicals..... | 111 |
| Vitamins, Hematinics / Electrolytes..... | 112 |

List of Abbreviations

T1: Cost-Sharing Tier 1 includes preferred generic drugs. This is the lowest cost-sharing tier.

T2: Cost-Sharing Tier 2 includes generic drugs.

T3: Cost-Sharing Tier 3 includes preferred brand name drugs and may include some single-sourced drugs (those generic drugs made by a single manufacturer).

T4: Cost-Sharing Tier 4 includes non-preferred brand name drugs and may include some single-sourced generic drugs (those generic drugs made by a single manufacturer).

T5: Cost-Sharing Tier 5 includes specialty drugs. This is the highest cost-sharing tier.

LA: Limited access

PA: Prior authorization required

PA-BvD: This drug may be covered under Medicare part B or D depending on the circumstance. Information may need to be submitted describing the use and setting of the drug to make the determination.

PA-NS: Prior authorization required for new starts only

QL: Quantity limit applies. The quantity limit is noted for each drug. For example, if the quantity limit is QL (90 EA per 180 days), the quantity limit would be 90 units per 180-day supply.

QL: Quantity limit applies. The quantity limit is noted for each drug. For example, if the quantity limit is QL (90 EA per 180 days), the quantity limit would be 90 units per 180-day supply.

SI: Select Insulin Drug under the Part D Senior Savings Model. For complete coverage details on these preferred select insulins see Chapter 6 of your Evidence of Coverage.

ST: Step therapy applies

ST-NS: Step therapy applies to new starts only

Below is a list of drug name formatting patterns that may appear in the following pages.

List of Patterns

lowercase italics: Generic drugs

UPPERCASE BOLD: Brand name drugs

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| Anti - Infectives | | |
| <i>abacavir</i> | T3 | |
| <i>abacavir-lamivudine</i> | T4 | |
| ABELCET | T4 | PA-BvD |
| ACTICLATE | T4 | |
| <i>acyclovir oral capsule</i> | T2 | |
| <i>acyclovir oral suspension 200 mg/5 ml</i> | T2 | |
| <i>acyclovir oral tablet</i> | T2 | |
| <i>acyclovir sodium intravenous solution</i> | T2 | PA-BvD |
| <i>adefovir</i> | T4 | |
| AEMCOLO | T4 | QL (12 EA per 3 days) |
| <i>albendazole</i> | T4 | |
| <i>amantadine hcl oral capsule</i> | T2 | QL (124 EA per 31 days) |
| <i>amantadine hcl oral solution</i> | T2 | |
| <i>amantadine hcl oral tablet</i> | T2 | |
| AMBISOME | T5 | PA-BvD |
| <i>amikacin injection solution 500 mg/2 ml</i> | T2 | |
| <i>amoxicillin oral capsule</i> | T1 | |
| <i>amoxicillin oral suspension for reconstitution</i> | T1 | |
| <i>amoxicillin oral tablet</i> | T1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | T1 | |
| <i>amoxicillin-pot clavulanate</i> | T2 | |
| <i>amphotericin b</i> | T4 | PA-BvD |
| <i>ampicillin oral capsule 500 mg</i> | T2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | T2 | |
| <i>ampicillin-sulbactam injection</i> | T2 | |
| ANCOBON | T4 | |
| APTIVUS | T5 | |
| ARIKAYCE | T5 | PA |
| <i>atazanavir</i> | T4 | |
| <i>atovaquone</i> | T4 | |
| <i>atovaquone-proguanil</i> | T2 | |
| AVYCAZ | T5 | |
| AZACTAM | T4 | |
| <i>azithromycin</i> | T2 | |
| <i>aztreonam</i> | T2 | |
| BACTRIM | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| BACTRIM DS | T4 | |
| BARACLUDE ORAL SOLUTION | T3 | |
| BARACLUDE ORAL TABLET | T5 | |
| BAXDELA INTRAVENOUS | T4 | |
| BAXDELA ORAL | T5 | |
| <i>benznidazole</i> | T4 | PA |
| BETHKIS | T4 | PA |
| BICILLIN C-R | T3 | |
| BICILLIN L-A | T3 | |
| BIKTARVY | T5 | QL (31 EA per 31 days) |
| BILTRICIDE | T4 | |
| CANCIDAS INTRAVENOUS RECON SOLN 50 MG | T4 | |
| CANCIDAS INTRAVENOUS RECON SOLN 70 MG | T5 | |
| <i>casprofungin intravenous recon soln 50 mg</i> | T5 | |
| <i>casprofungin intravenous recon soln 70 mg</i> | T4 | |
| CAYSTON | T5 | |
| <i>cefaclor oral capsule</i> | T2 | |
| <i>cefaclor oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml, 375 mg/5 ml</i> | T2 | |
| <i>cefaclor oral tablet extended release 12 hr</i> | T2 | |
| <i>cefadroxil oral capsule</i> | T2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | T2 | |
| <i>cefadroxil oral tablet</i> | T2 | |
| <i>cefazolin injection recon soln 1 gram, 10 gram, 500 mg</i> | T2 | |
| <i>cefdinir</i> | T2 | |
| <i>cefepime injection</i> | T2 | |
| <i>cefixime</i> | T2 | |
| <i>cefotetan injection</i> | T2 | |
| <i>cefoxitin</i> | T2 | |
| <i>cefpodoxime</i> | T2 | |
| <i>cefprozil</i> | T2 | |
| <i>ceftazidime</i> | T2 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | T2 | |
| <i>cefuroxime axetil oral tablet</i> | T2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>cefuroxime sodium intravenous recon soln 1.5 gram</i> | T2 | |
| <i>cephalexin</i> | T2 | |
| <i>chloroquine phosphate oral tablet 250 mg</i> | T2 | PA; QL (50 EA per 30 days) |
| <i>chloroquine phosphate oral tablet 500 mg</i> | T2 | PA; QL (25 EA per 30 days) |
| CIMDUO | T5 | QL (31 EA per 31 days) |
| CIPRO ORAL SUSPENSION, MICROCAPSULE RECON | T3 | |
| CIPRO ORAL TABLET 250 MG, 500 MG | T4 | |
| <i>ciprofloxacin hcl oral</i> | T1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml</i> | T2 | |
| <i>clarithromycin</i> | T2 | |
| CLEOCIN HCL | T4 | |
| CLEOCIN PEDIATRIC | T4 | |
| <i>clindamycin hcl</i> | T2 | |
| <i>clindamycin in 5 % dextrose</i> | T2 | |
| CLINDAMYCIN PEDIATRIC | T2 | |
| <i>clindamycin phosphate injection</i> | T2 | |
| <i>clindamycin phosphate intravenous</i> | T2 | |
| <i>clotrimazole mucous membrane</i> | T2 | |
| COARTEM | T4 | |
| <i>colistin (colistimethate na)</i> | T4 | |
| COMBIVIR | T5 | |
| COMPLERA | T5 | |
| CRESEMBA ORAL | T5 | |
| CUBICIN RF | T5 | |
| DALVANCE | T5 | |
| <i>dapsone oral</i> | T3 | |
| <i>daptomycin</i> | T5 | |
| DARAPRIM | T5 | PA |
| DELSTRIGO | T5 | QL (31 EA per 31 days) |
| <i>demeclocycline</i> | T2 | |
| DESCOVY ORAL TABLET 200-25 MG | T5 | QL (31 EA per 31 days) |
| <i>dicloxacillin</i> | T2 | |
| DIFICID ORAL SUSPENSION FOR RECONSTITUTION | T5 | QL (136 ML per 12 days) |
| DIFICID ORAL TABLET | T5 | QL (20 EA per 10 days) |
| DIFLUCAN | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| DORYX MPC ORAL TABLET,DELAYED RELEASE (DR/EC) 120 MG | T4 | |
| DORYX ORAL TABLET,DELAYED RELEASE (DR/EC) 200 MG, 50 MG | T4 | |
| DOVATO | T5 | QL (31 EA per 31 days) |
| DOXY-100 | T2 | |
| <i>doxycycline hyclate oral capsule</i> | T2 | |
| <i>doxycycline hyclate oral tablet 100 mg</i> | T2 | |
| <i>doxycycline hyclate oral tablet 150 mg, 50 mg, 75 mg</i> | T4 | |
| <i>doxycycline hyclate oral tablet 20 mg</i> | T1 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 100 mg, 200 mg, 50 mg</i> | T2 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 150 mg, 75 mg</i> | T1 | |
| <i>doxycycline hyclate oral tablet, delayed release (dr/ec) 80 mg</i> | T4 | |
| <i>doxycycline monohydrate oral capsule 100 mg, 50 mg</i> | T2 | |
| <i>doxycycline monohydrate oral capsule 150 mg, 75 mg</i> | T4 | |
| <i>doxycycline monohydrate oral suspension for reconstitution</i> | T2 | |
| <i>doxycycline monohydrate oral tablet</i> | T2 | |
| E.E.S. 400 ORAL TABLET | T2 | |
| E.E.S. GRANULES | T4 | |
| EDURANT | T5 | |
| <i>efavirenz</i> | T3 | |
| <i>efavirenz-emtricitabin-tenofov</i> | T5 | |
| <i>efavirenz-lamivu-tenofov disop</i> | T5 | QL (31 EA per 31 days) |
| <i>emtricitabine</i> | T3 | |
| <i>emtricitabine-tenofov (tdf)</i> | T5 | |
| EMTRIVA ORAL CAPSULE | T4 | |
| EMTRIVA ORAL SOLUTION | T3 | |
| EMVERM | T5 | |
| <i>entecavir</i> | T4 | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | T5 | PA; QL (28 EA per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | T5 | PA; QL (56 EA per 28 days) |
| EPCLUSA ORAL TABLET | T5 | PA; QL (28 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| EPIVIR | T4 | |
| EPIVIR HBV ORAL SOLUTION | T3 | |
| EPIVIR HBV ORAL TABLET | T4 | |
| EPZICOM | T5 | |
| ERAXIS(WATER DILUENT) | T4 | |
| <i>ertapenem</i> | T4 | |
| ERYPED 200 | T4 | |
| ERYPED 400 | T4 | |
| ERY-TAB ORAL TABLET,DELAYED RELEASE (DR/EC) 250 MG, 333 MG | T2 | |
| ERY-TAB ORAL TABLET,DELAYED RELEASE (DR/EC) 500 MG | T3 | |
| ERYTHROCIN (AS STEARATE) ORAL TABLET 250 MG | T2 | |
| ERYTHROCIN INTRAVENOUS RECON SOLN 500 MG | T3 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> | T2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> | T5 | |
| <i>erythromycin ethylsuccinate oral tablet</i> | T2 | |
| <i>erythromycin oral</i> | T2 | |
| <i>ethambutol</i> | T2 | |
| <i>etravirine oral tablet 100 mg</i> | T4 | |
| <i>etravirine oral tablet 200 mg</i> | T5 | |
| EVOTAZ | T3 | |
| <i>famciclovir</i> | T2 | |
| FIRVANQ | T4 | |
| FLAGYL ORAL CAPSULE | T4 | |
| <i>fluconazole</i> | T2 | |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | T2 | |
| <i>flucytosine</i> | T4 | |
| <i>fosamprenavir</i> | T3 | |
| <i>fosfomycin tromethamine</i> | T4 | |
| FUZEON SUBCUTANEOUS RECON SOLN | T5 | |
| <i>gentamicin in nacl (iso-osm) intravenous piggyback 100 mg/100 ml, 60 mg/50 ml, 80 mg/100 ml, 80 mg/50 ml</i> | T2 | |
| <i>gentamicin injection solution 40 mg/ml</i> | T1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| GENVOYA | T5 | |
| <i>griseofulvin microsize</i> | T2 | |
| <i>griseofulvin ultramicrosize</i> | T2 | |
| HARVONI ORAL PELLETS IN PACKET | T5 | PA; QL (28 EA per 28 days) |
| HARVONI ORAL TABLET 90-400 MG | T5 | PA; QL (28 EA per 28 days) |
| HEPSERA | T5 | |
| HIPREX | T4 | |
| HUMATIN | T4 | |
| <i>hydroxychloroquine oral tablet 100 mg</i> | T4 | QL (93 EA per 31 days) |
| <i>hydroxychloroquine oral tablet 200 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>hydroxychloroquine oral tablet 300 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>hydroxychloroquine oral tablet 400 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>imipenem-cilastatin</i> | T2 | |
| IMPAVIDO | T5 | |
| INTELENCE ORAL TABLET 100 MG, 200 MG | T5 | |
| INTELENCE ORAL TABLET 25 MG | T4 | |
| INVANZ INJECTION | T4 | |
| ISENTRESS | T3 | |
| ISENTRESS HD | T5 | |
| <i>isoniazid oral solution</i> | T2 | |
| <i>isoniazid oral tablet</i> | T1 | |
| <i>itraconazole oral capsule</i> | T2 | PA |
| <i>itraconazole oral solution</i> | T4 | PA |
| <i>ivermectin oral</i> | T2 | |
| JULUCA | T5 | |
| KALETRA ORAL SOLUTION | T5 | |
| KALETRA ORAL TABLET 100-25 MG | T4 | |
| KALETRA ORAL TABLET 200-50 MG | T5 | |
| <i>ketoconazole oral</i> | T2 | |
| KRINTAFEL | T4 | |
| <i>lamivudine</i> | T2 | |
| <i>lamivudine-zidovudine</i> | T2 | |
| LAMPIT | T4 | PA |
| <i>ledipasvir-sofosbuvir</i> | T5 | PA; QL (28 EA per 28 days) |
| <i>levofloxacin in d5w intravenous piggyback 500 mg/100 ml, 750 mg/150 ml</i> | T2 | |
| <i>levofloxacin intravenous</i> | T2 | |
| <i>levofloxacin oral</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| LEXIVA ORAL SUSPENSION | T3 | |
| LEXIVA ORAL TABLET | T5 | |
| <i>linezolid</i> | T4 | |
| <i>linezolid in dextrose 5%</i> | T4 | |
| LIVTENCITY | T5 | PA; QL (124 EA per 31 days) |
| <i>lopinavir-ritonavir oral solution</i> | T4 | |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> | T3 | |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> | T5 | |
| MACROBID | T4 | QL (90 EA per 365 days) |
| MACRODANTIN ORAL CAPSULE 100 MG | T4 | QL (90 EA per 365 days) |
| MACRODANTIN ORAL CAPSULE 25 MG | T4 | QL (360 EA per 365 days) |
| MACRODANTIN ORAL CAPSULE 50 MG | T4 | QL (180 EA per 365 days) |
| MALARONE | T4 | |
| MALARONE PEDIATRIC | T4 | |
| <i>maraviroc</i> | T5 | |
| MAVYRET ORAL PELLETS IN PACKET | T5 | PA; QL (140 EA per 28 days) |
| MAVYRET ORAL TABLET | T5 | PA; QL (84 EA per 28 days) |
| <i>mefloquine</i> | T2 | |
| MEPRON | T5 | |
| <i>meropenem</i> | T2 | |
| <i>methenamine hippurate</i> | T2 | |
| <i>metronidazole in nacl (iso-os)</i> | T2 | |
| <i>metronidazole oral capsule</i> | T2 | |
| <i>metronidazole oral tablet</i> | T1 | |
| <i>micafungin</i> | T5 | |
| <i>minocycline oral capsule</i> | T2 | |
| <i>minocycline oral tablet</i> | T2 | |
| <i>minocycline oral tablet extended release 24 hr 105 mg, 115 mg, 135 mg, 45 mg, 65 mg, 80 mg, 90 mg</i> | T2 | |
| <i>minocycline oral tablet extended release 24 hr 55 mg</i> | T4 | |
| MINOLIRA ER | T4 | |
| MONUROL | T4 | |
| <i>moxifloxacin oral</i> | T3 | |
| <i>moxifloxacin-sod.chloride(iso)</i> | T4 | |
| MYAMBUTOL ORAL TABLET 400 MG | T4 | |
| MYCOBUTIN | T4 | |
| <i>nafcillin injection</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| NEBUPENT | T4 | PA-BvD |
| <i>neomycin</i> | T2 | |
| <i>nevirapine</i> | T2 | |
| <i>nitazoxanide</i> | T4 | |
| <i>nitrofurantoin</i> | T4 | QL (1800 ML per 365 days) |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg</i> | T2 | QL (90 EA per 365 days) |
| <i>nitrofurantoin macrocrystal oral capsule 25 mg</i> | T2 | QL (360 EA per 365 days) |
| <i>nitrofurantoin macrocrystal oral capsule 50 mg</i> | T2 | QL (180 EA per 365 days) |
| <i>nitrofurantoin monohyd/m-cryst</i> | T2 | QL (90 EA per 365 days) |
| NORVIR ORAL POWDER IN PACKET | T3 | |
| NORVIR ORAL SOLUTION | T3 | |
| NORVIR ORAL TABLET | T4 | |
| NOXAFIL ORAL SUSPENSION | T5 | |
| NOXAFIL ORAL TABLET,DELAYED RELEASE (DR/EC) | T5 | |
| NUZYRA | T5 | |
| <i>nystatin oral</i> | T2 | |
| ODEFSEY | T5 | QL (31 EA per 31 days) |
| <i>ofloxacin oral tablet 300 mg, 400 mg</i> | T2 | |
| ORACEA | T4 | |
| <i>oseltamivir oral capsule 30 mg</i> | T2 | QL (170 EA per 365 days) |
| <i>oseltamivir oral capsule 45 mg, 75 mg</i> | T2 | QL (90 EA per 365 days) |
| <i>oseltamivir oral suspension for reconstitution</i> | T3 | QL (1080 ML per 365 days) |
| <i>oxacillin in dextrose(iso-osm)</i> | T2 | |
| <i>oxacillin injection</i> | T2 | |
| <i>paromomycin</i> | T2 | |
| PASER | T4 | |
| <i>penicillin g pot in dextrose intravenous piggyback 2 million unit/50 ml, 3 million unit/50 ml</i> | T4 | |
| <i>penicillin g potassium injection recon soln 20 million unit</i> | T2 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml</i> | T2 | |
| <i>penicillin g sodium</i> | T4 | |
| <i>penicillin v potassium</i> | T1 | |
| PENTAM | T4 | |
| <i>pentamidine inhalation</i> | T4 | PA-BvD; QL (1 EA per 28 days) |
| <i>pentamidine injection</i> | T4 | |
| PIFELTRO | T5 | QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | T2 | |
| PLAQUENIL | T4 | QL (93 EA per 31 days) |
| <i>polymyxin b sulfate</i> | T2 | |
| <i>posaconazole</i> | T5 | |
| <i>praziquantel</i> | T4 | |
| <i>pretomanid</i> | T4 | PA; QL (31 EA per 31 days) |
| PREVYMIS ORAL TABLET 240 MG | T4 | |
| PREVYMIS ORAL TABLET 480 MG | T5 | |
| PREZCOBIX | T5 | |
| PREZISTA ORAL SUSPENSION | T5 | |
| PREZISTA ORAL TABLET 150 MG, 600 MG, 800 MG | T5 | |
| PREZISTA ORAL TABLET 75 MG | T3 | |
| PRIFTIN | T4 | |
| <i>primaquine</i> | T3 | |
| PRIMAXIN IV INTRAVENOUS RECON SOLN 500 MG | T4 | |
| <i>pyrazinamide</i> | T2 | |
| <i>pyrimethamine</i> | T5 | PA |
| QUALAQUIN | T4 | PA |
| <i>quinine sulfate</i> | T3 | PA; QL (42 EA per 28 days) |
| RELENZA DISKHALER | T3 | |
| RETROVIR ORAL CAPSULE | T4 | |
| RETROVIR ORAL SYRUP | T4 | |
| REYATAZ ORAL CAPSULE 200 MG | T5 | |
| REYATAZ ORAL CAPSULE 300 MG | T3 | |
| REYATAZ ORAL POWDER IN PACKET | T4 | |
| <i>ribavirin oral capsule</i> | T2 | |
| <i>ribavirin oral tablet 200 mg</i> | T2 | |
| <i>rifabutin</i> | T2 | |
| <i>rifampin</i> | T2 | |
| <i>rimantadine</i> | T2 | |
| <i>ritonavir</i> | T3 | |
| RUKOBIA | T5 | QL (62 EA per 31 days) |
| SELZENTRY ORAL SOLUTION | T5 | |
| SELZENTRY ORAL TABLET 150 MG, 300 MG, 75 MG | T5 | |
| SELZENTRY ORAL TABLET 25 MG | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| SEYSARA | T4 | |
| SIRTURO | T5 | |
| SITAVIG | T4 | |
| SIVEXTRO INTRAVENOUS | T5 | |
| SIVEXTRO ORAL | T5 | QL (6 EA per 31 days) |
| <i>sofosbuvir-velpatasvir</i> | T5 | PA; QL (28 EA per 28 days) |
| SOLODYN ORAL TABLET EXTENDED RELEASE 24 HR 105 MG, 115 MG, 55 MG, 65 MG, 80 MG | T4 | |
| SOLOSEC | T4 | |
| SOVALDI ORAL PELLETS IN PACKET | T5 | PA; QL (28 EA per 28 days) |
| SOVALDI ORAL TABLET 400 MG | T5 | PA; QL (28 EA per 28 days) |
| SPORANOX | T5 | PA |
| <i>streptomycin</i> | T3 | |
| STRIBILD | T5 | |
| STROMEKTOL | T4 | |
| <i>sulfadiazine</i> | T2 | |
| <i>sulfamethoxazole-trimethoprim oral</i> | T1 | |
| SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 200 MG/5 ML | T4 | |
| SUPRAX ORAL SUSPENSION FOR RECONSTITUTION 500 MG/5 ML | T3 | |
| SUPRAX ORAL TABLET,CHEWABLE | T3 | |
| SUSTIVA ORAL CAPSULE | T3 | |
| SUSTIVA ORAL TABLET | T5 | |
| SYMFI | T5 | QL (31 EA per 31 days) |
| SYMFI LO | T5 | QL (31 EA per 31 days) |
| SYMTUZA | T5 | QL (31 EA per 31 days) |
| TAMIFLU ORAL CAPSULE 30 MG | T3 | QL (170 EA per 365 days) |
| TAMIFLU ORAL CAPSULE 45 MG, 75 MG | T3 | QL (90 EA per 365 days) |
| TAMIFLU ORAL SUSPENSION FOR RECONSTITUTION | T3 | QL (1080 ML per 365 days) |
| TARGADOX | T4 | |
| TAZICEF INJECTION | T4 | |
| TEFLARO | T5 | |
| <i>tenofovir disoproxil fumarate</i> | T3 | |
| <i>terbinafine hcl oral</i> | T1 | QL (90 EA per 180 days) |
| <i>tetracycline</i> | T2 | |
| <i>tigecycline</i> | T5 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>tinidazole</i> | T2 | |
| TIVICAY ORAL TABLET 10 MG | T4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | T5 | |
| TIVICAY PD | T4 | |
| TOBI | T4 | PA |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE | T3 | PA; QL (224 EA per 56 days) |
| <i>tobramycin in 0.225 % nacl</i> | T5 | PA |
| <i>tobramycin inhalation</i> | T4 | PA |
| <i>tobramycin sulfate injection solution</i> | T1 | |
| TOLSURA | T5 | PA; QL (130 EA per 31 days) |
| TRECTOR | T4 | |
| <i>trimethoprim</i> | T2 | |
| TRIUMEQ | T5 | |
| TRIUMEQ PD | T5 | QL (186 EA per 31 days) |
| TRIZIVIR | T5 | |
| TRUVADA | T5 | |
| TYBOST | T3 | |
| TYGACIL | T5 | |
| UNASYN INJECTION RECON SOLN 15 GRAM, 3 GRAM | T4 | |
| VABOMERE | T4 | |
| <i>valacyclovir</i> | T2 | |
| VALCYTE ORAL RECON SOLN | T4 | |
| VALCYTE ORAL TABLET | T5 | |
| <i>valganciclovir oral recon soln</i> | T5 | |
| <i>valganciclovir oral tablet</i> | T3 | |
| VALTREX | T4 | |
| VANCOCIN ORAL CAPSULE 125 MG | T5 | QL (124 EA per 31 days) |
| VANCOCIN ORAL CAPSULE 250 MG | T5 | QL (248 EA per 31 days) |
| <i>vancomycin intravenous recon soln 1,000 mg, 10 gram, 500 mg, 750 mg</i> | T2 | |
| <i>vancomycin oral capsule 125 mg</i> | T4 | QL (124 EA per 31 days) |
| <i>vancomycin oral capsule 250 mg</i> | T4 | QL (248 EA per 31 days) |
| <i>vancomycin oral recon soln</i> | T4 | |
| VEMLIDY | T5 | QL (31 EA per 31 days) |
| VFEND IV | T4 | PA |
| VFEND ORAL SUSPENSION FOR RECONSTITUTION | T5 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| VFEND ORAL TABLET 200 MG | T4 | |
| VFEND ORAL TABLET 50 MG | T5 | |
| VIBRAMYCIN (CALCIUM) | T4 | |
| VIBRAMYCIN (MONO) | T4 | |
| VIBRAMYCIN ORAL CAPSULE 100 MG | T4 | |
| VIRACEPT ORAL TABLET | T5 | |
| VIREAD ORAL POWDER | T3 | |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | T3 | |
| VIREAD ORAL TABLET 300 MG | T5 | |
| VIVJOA | T4 | PA; QL (18 EA per 84 days) |
| <i>voriconazole intravenous</i> | T5 | PA |
| <i>voriconazole oral suspension for reconstitution</i> | T5 | |
| <i>voriconazole oral tablet</i> | T4 | |
| VOSEVI | T5 | PA; QL (28 EA per 28 days) |
| XENLETA ORAL | T5 | |
| XIFAXAN ORAL TABLET 200 MG | T4 | QL (9 EA per 3 days) |
| XIFAXAN ORAL TABLET 550 MG | T5 | PA; QL (62 EA per 31 days) |
| XIMINO | T4 | |
| XOFLUZA ORAL TABLET 40 MG, 80 MG | T3 | QL (9 EA per 365 days) |
| ZEMDRI | T5 | |
| ZEPATIER | T5 | PA; QL (28 EA per 28 days) |
| ZERBAXA | T5 | |
| ZIAGEN ORAL SOLUTION | T3 | |
| ZIAGEN ORAL TABLET | T4 | |
| <i>zidovudine</i> | T2 | |
| ZITHROMAX INTRAVENOUS | T4 | |
| ZITHROMAX ORAL PACKET | T4 | |
| ZITHROMAX ORAL SUSPENSION FOR RECONSTITUTION | T4 | |
| ZITHROMAX ORAL TABLET 250 MG, 500 MG | T4 | |
| ZITHROMAX TRI-PAK | T4 | |
| ZITHROMAX Z-PAK | T4 | |
| ZOSYN IN DEXTROSE (ISO-OSM) INTRAVENOUS PIGGYBACK 2.25 GRAM/50 ML, 3.375 GRAM/50 ML | T3 | |
| ZOVIRAX ORAL SUSPENSION | T4 | |
| ZYVOX INTRAVENOUS PIGGYBACK 600 MG/300 ML | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| ZYVOX ORAL | T5 | |
| Antineoplastic / Immunosuppressant Drugs | | |
| <i>abiraterone oral tablet 250 mg</i> | T5 | PA-NS; QL (124 EA per 31 days) |
| <i>abiraterone oral tablet 500 mg</i> | T5 | PA-NS; QL (62 EA per 31 days) |
| AFINITOR | T5 | PA-NS; QL (31 EA per 31 days) |
| AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 5 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 3 MG | T5 | PA-NS; QL (93 EA per 31 days) |
| ALECENSA | T5 | PA-NS; QL (248 EA per 31 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| ALUNBRIG ORAL TABLET 30 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK | T5 | PA-NS; QL (30 EA per 365 days) |
| <i>anastrozole</i> | T2 | |
| ARIMIDEX | T4 | |
| AROMASIN | T5 | |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG | T3 | PA-BvD |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG | T4 | PA-BvD |
| AYVAKIT | T5 | PA-NS; QL (31 EA per 31 days) |
| AZASAN | T4 | PA-BvD |
| <i>azathioprine oral tablet 100 mg, 75 mg</i> | T4 | PA-BvD |
| <i>azathioprine oral tablet 50 mg</i> | T2 | PA-BvD |
| BALVERSA | T5 | PA-NS |
| <i>bexarotene oral</i> | T5 | PA-NS |
| <i>bexarotene topical</i> | T5 | PA-NS; QL (60 GM per 28 days) |
| <i>bicalutamide</i> | T2 | |
| BOSULIF | T5 | PA-NS |
| BRAFTOVI ORAL CAPSULE 75 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| BRUKINSA | T5 | PA-NS; QL (124 EA per 31 days) |
| CABOMETYX | T5 | PA-NS; QL (31 EA per 31 days) |
| CALQUENCE | T5 | PA-NS; QL (62 EA per 31 days) |
| CALQUENCE (ACALABRUTINIB MAL) | T5 | PA-NS; QL (62 EA per 31 days) |
| CAPRELSA | T5 | PA-NS |
| CASODEX | T4 | |
| CELLCEPT ORAL CAPSULE | T4 | PA-BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| CELLCEPT ORAL SUSPENSION FOR RECONSTITUTION | T4 | PA-BvD |
| CELLCEPT ORAL TABLET | T5 | PA-BvD |
| COMETRIQ | T5 | PA-NS |
| COPIKTRA | T5 | PA-NS; QL (62 EA per 31 days) |
| COTELLIC | T5 | PA-NS; LA |
| <i>cyclophosphamide oral</i> | T3 | PA-BvD |
| <i>cyclosporine modified</i> | T2 | PA-BvD |
| <i>cyclosporine oral capsule</i> | T2 | PA-BvD |
| DAURISMO ORAL TABLET 100 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| DAURISMO ORAL TABLET 25 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| DROXIA | T4 | |
| ELIGARD | T4 | |
| ELIGARD (3 MONTH) | T4 | |
| ELIGARD (4 MONTH) | T4 | |
| ELIGARD (6 MONTH) | T4 | |
| EMCYT | T3 | |
| ENSPRYNG | T5 | PA; QL (1 ML per 28 days) |
| ENVARUSUS XR | T4 | PA-BvD |
| ERIVEDGE | T5 | PA-NS; QL (31 EA per 31 days) |
| ERLEADA | T5 | PA-NS; QL (124 EA per 31 days) |
| <i>erlotinib</i> | T5 | PA-NS; QL (31 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet 10 mg, 2.5 mg, 7.5 mg</i> | T5 | PA-NS; QL (31 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet 5 mg</i> | T5 | PA-NS; QL (62 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 5 mg</i> | T5 | PA-NS; QL (62 EA per 31 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 3 mg</i> | T5 | PA-NS; QL (93 EA per 31 days) |
| <i>everolimus (immunosuppressive)</i> | T5 | PA-BvD |
| <i>exemestane</i> | T2 | |
| EXKIVITY | T5 | PA-NS; QL (124 EA per 31 days) |
| FARESTON | T4 | |
| FEMARA | T4 | |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | T5 | |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | T4 | |
| FOTIVDA | T5 | PA-NS; QL (21 EA per 28 days) |
| GAVRETO | T5 | PA-NS; QL (124 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| GENGRAF | T2 | PA-BvD |
| GILOTRIF | T5 | PA-NS; QL (31 EA per 31 days) |
| GLEEVEC ORAL TABLET 100 MG | T4 | PA-NS; QL (93 EA per 31 days) |
| GLEEVEC ORAL TABLET 400 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| HYDREA | T4 | |
| <i>hydroxyurea</i> | T2 | |
| IBRANCE | T5 | PA-NS; QL (21 EA per 28 days) |
| ICLUSIG | T5 | PA-NS; QL (31 EA per 31 days) |
| IDHIFA ORAL TABLET 100 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| IDHIFA ORAL TABLET 50 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| <i>imatinib oral tablet 100 mg</i> | T5 | PA-NS; QL (93 EA per 31 days) |
| <i>imatinib oral tablet 400 mg</i> | T5 | PA-NS; QL (62 EA per 31 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| IMBRUVICA ORAL SUSPENSION | T5 | PA-NS; QL (216 ML per 25 days) |
| IMBRUVICA ORAL TABLET | T5 | PA-NS; QL (31 EA per 31 days) |
| IMURAN | T4 | PA-BvD |
| INLYTA | T5 | PA-NS; QL (124 EA per 31 days) |
| INQOVI | T5 | PA-NS; QL (5 EA per 28 days) |
| INREBIC | T5 | PA-NS; QL (124 EA per 31 days) |
| IRESSA | T5 | PA-NS |
| JAKAFI | T5 | PA-NS; QL (62 EA per 31 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | T5 | PA-NS; QL (49 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | T5 | PA-NS; QL (70 EA per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | T5 | PA-NS; QL (91 EA per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | T5 | PA-NS; QL (21 EA per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | T5 | PA-NS; QL (42 EA per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | T5 | PA-NS; QL (63 EA per 28 days) |
| KLISYRI | T4 | PA |
| KOSELUGO ORAL CAPSULE 10 MG | T5 | PA-NS; QL (279 EA per 31 days) |
| KOSELUGO ORAL CAPSULE 25 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| <i>lapatinib</i> | T5 | PA-NS |
| <i>lenalidomide</i> | T5 | PA-NS; QL (21 EA per 28 days) |
| LENVIMA | T5 | PA-NS |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>letrozole</i> | T2 | |
| <i>leucovorin calcium oral</i> | T2 | |
| LEUKERAN | T4 | |
| <i>leuprolide subcutaneous kit</i> | T2 | |
| LONSURF | T5 | PA-NS |
| LORBRENA ORAL TABLET 100 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| LORBRENA ORAL TABLET 25 MG | T5 | PA-NS; QL (93 EA per 31 days) |
| LUMAKRAS | T5 | PA-NS; QL (248 EA per 31 days) |
| LUPKYNIS | T5 | PA; QL (186 EA per 31 days) |
| LUPRON DEPOT | T5 | ST |
| LUPRON DEPOT (3 MONTH) | T5 | ST |
| LUPRON DEPOT (4 MONTH) | T5 | ST |
| LUPRON DEPOT (6 MONTH) | T5 | ST |
| LYNPARZA | T5 | PA-NS; QL (124 EA per 31 days) |
| LYSODREN | T3 | |
| MATULANE | T5 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | T2 | PA |
| <i>megestrol oral tablet</i> | T2 | PA-NS |
| MEKINIST | T5 | PA-NS |
| MEKTOVI | T5 | PA-NS; QL (186 EA per 31 days) |
| <i>mercaptopurine</i> | T2 | |
| MESNEX ORAL | T3 | |
| <i>methotrexate sodium (pf) injection solution</i> | T2 | PA-BvD |
| <i>methotrexate sodium injection</i> | T2 | PA-BvD |
| <i>methotrexate sodium oral</i> | T1 | PA-BvD |
| MYCAPSSA | T5 | PA; QL (124 EA per 31 days) |
| <i>mycophenolate mofetil</i> | T2 | PA-BvD |
| <i>mycophenolate sodium</i> | T2 | PA-BvD |
| MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 180 MG | T3 | PA-BvD |
| MYFORTIC ORAL TABLET,DELAYED RELEASE (DR/EC) 360 MG | T5 | PA-BvD |
| NEORAL | T3 | PA-BvD |
| NERLYNX | T5 | PA-NS; QL (186 EA per 31 days) |
| NEXAVAR | T5 | PA-NS; QL (124 EA per 31 days) |
| NILANDRON | T5 | |
| <i>nilutamide</i> | T5 | |
| NINLARO | T5 | PA-NS |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| NUBEQA | T5 | PA-NS; QL (124 EA per 31 days) |
| <i>octreotide acetate injection solution 1,000 mcg/ml, 200 mcg/ml</i> | T3 | PA |
| <i>octreotide acetate injection solution 100 mcg/ml, 50 mcg/ml</i> | T2 | PA |
| <i>octreotide acetate injection solution 500 mcg/ml</i> | T5 | PA |
| ODOMZO | T5 | PA-NS; LA |
| ONUREG | T5 | PA-NS; QL (14 EA per 28 days) |
| ORGOVYX | T5 | PA-NS; QL (31 EA per 31 days) |
| PEMAZYRE | T5 | PA-NS; QL (14 EA per 21 days) |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | T5 | PA-NS; QL (28 EA per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | T5 | PA-NS; QL (56 EA per 28 days) |
| POMALYST | T5 | PA-NS; QL (21 EA per 28 days) |
| PROGRAF ORAL | T4 | PA-BvD |
| PURIXAN | T4 | |
| QINLOCK | T5 | PA-NS; QL (93 EA per 31 days) |
| RAPAMUNE ORAL SOLUTION | T5 | PA-BvD |
| RAPAMUNE ORAL TABLET 0.5 MG | T4 | PA-BvD |
| RAPAMUNE ORAL TABLET 1 MG, 2 MG | T5 | PA-BvD |
| RETEVMO ORAL CAPSULE 40 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| RETEVMO ORAL CAPSULE 80 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| REVLIMID | T5 | PA-NS; QL (21 EA per 28 days) |
| REZUROCK | T5 | PA; QL (62 EA per 31 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | T5 | PA-NS; QL (155 EA per 31 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | T5 | PA-NS; QL (93 EA per 31 days) |
| RUBRACA | T5 | PA-NS; QL (124 EA per 31 days) |
| RYDAPT | T5 | PA-NS; QL (248 EA per 31 days) |
| SANDIMMUNE ORAL CAPSULE 100 MG | T5 | PA-BvD |
| SANDIMMUNE ORAL CAPSULE 25 MG | T3 | PA-BvD |
| SANDIMMUNE ORAL SOLUTION | T3 | PA-BvD |
| SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML | T4 | PA |
| SCEMBLIX ORAL TABLET 20 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| SCEMBLIX ORAL TABLET 40 MG | T5 | PA-NS; QL (310 EA per 31 days) |
| SIGNIFOR | T5 | PA |
| SIKLOS ORAL TABLET 1,000 MG | T5 | |
| SIKLOS ORAL TABLET 100 MG | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------------|
| <i>sirolimus</i> | T2 | PA-BvD |
| SOLTAMOX | T4 | |
| <i>sorafenib</i> | T5 | PA-NS; QL (124 EA per 31 days) |
| SPRYCEL | T5 | PA-NS; QL (31 EA per 31 days) |
| STIVARGA | T5 | PA-NS; QL (84 EA per 28 days) |
| <i>sunitinib</i> | T5 | PA-NS |
| SUTENT | T5 | PA-NS |
| SYNRIBO | T5 | |
| TABLOID | T3 | |
| TABRECTA | T5 | PA-NS; QL (124 EA per 31 days) |
| <i>tacrolimus oral</i> | T2 | PA-BvD |
| TAFINLAR | T5 | PA-NS |
| TAGRISSO | T5 | PA-NS; LA; QL (31 EA per 31 days) |
| TALZENNA ORAL CAPSULE 0.25 MG | T5 | PA-NS; QL (93 EA per 31 days) |
| TALZENNA ORAL CAPSULE 0.5 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| TALZENNA ORAL CAPSULE 0.75 MG, 1 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| <i>tamoxifen</i> | T1 | |
| TARCEVA | T5 | PA-NS; QL (31 EA per 31 days) |
| TARGRETIN ORAL | T5 | PA-NS |
| TARGRETIN TOPICAL | T5 | PA-NS; QL (60 GM per 28 days) |
| TASIGNA | T5 | PA-NS; QL (124 EA per 31 days) |
| TAZVERIK | T5 | PA-NS; QL (248 EA per 31 days) |
| TEPMETKO | T5 | PA-NS; QL (62 EA per 31 days) |
| THALOMID ORAL CAPSULE 100 MG, 150 MG, 50 MG | T5 | PA-NS; QL (28 EA per 28 days) |
| THALOMID ORAL CAPSULE 200 MG | T5 | PA-NS; QL (56 EA per 28 days) |
| TIBSOVO | T5 | PA-NS; QL (62 EA per 31 days) |
| <i>toremifene</i> | T3 | |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG | T3 | PA |
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 3.75 MG | T5 | PA |
| <i>tretinoin (antineoplastic)</i> | T5 | |
| TREXALL | T3 | PA-BvD |
| TRUSELTIQ ORAL CAPSULE 100 MG/DAY (100 MG X 1) | T5 | PA-NS; QL (21 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| TRUSELTIQ ORAL CAPSULE 125 MG/DAY(100 MG X1-25MG X1), 50 MG/DAY (25 MG X 2) | T5 | PA-NS; QL (42 EA per 28 days) |
| TRUSELTIQ ORAL CAPSULE 75 MG/DAY (25 MG X 3) | T5 | PA-NS; QL (63 EA per 28 days) |
| TUKYSA ORAL TABLET 150 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| TUKYSA ORAL TABLET 50 MG | T5 | PA-NS; QL (248 EA per 31 days) |
| TURALIO | T5 | PA-NS; QL (124 EA per 31 days) |
| TYKERB | T5 | PA-NS |
| VENCLEXTA ORAL TABLET 10 MG | T4 | PA-NS |
| VENCLEXTA ORAL TABLET 100 MG, 50 MG | T5 | PA-NS |
| VENCLEXTA STARTING PACK | T5 | PA-NS |
| VERZENIO | T5 | PA-NS; QL (62 EA per 31 days) |
| VIJOICE ORAL TABLET 125 MG, 50 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| VIJOICE ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1) | T5 | PA-NS; QL (56 EA per 28 days) |
| VITRAKVI ORAL CAPSULE 100 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| VITRAKVI ORAL CAPSULE 25 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| VITRAKVI ORAL SOLUTION | T5 | PA-NS; QL (310 ML per 31 days) |
| VIZIMPRO | T5 | PA-NS; QL (31 EA per 31 days) |
| VONJO | T5 | PA-NS; QL (124 EA per 31 days) |
| VOTRIENT | T5 | PA-NS; QL (124 EA per 31 days) |
| WELIREG | T5 | PA-NS; QL (93 EA per 31 days) |
| XALKORI | T5 | PA-NS; QL (62 EA per 31 days) |
| XATMEP | T4 | PA-BvD |
| XERMELO | T5 | PA; QL (93 EA per 31 days) |
| XGEVA | T5 | PA-NS |
| XOSPATA | T5 | PA-NS; QL (124 EA per 31 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2) | T5 | PA-NS; QL (8 EA per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | T5 | PA-NS; QL (4 EA per 28 days) |
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | T5 | PA-NS; QL (24 EA per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | T5 | PA-NS; QL (32 EA per 28 days) |
| XTANDI ORAL CAPSULE | T5 | PA-NS; QL (124 EA per 31 days) |
| XTANDI ORAL TABLET 40 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| XTANDI ORAL TABLET 80 MG | T5 | PA-NS; QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| YONSA | T5 | PA-NS; QL (124 EA per 31 days) |
| ZEJULA | T5 | PA-NS; QL (93 EA per 31 days) |
| ZELBORAF | T5 | PA-NS |
| ZOLINZA | T5 | PA-NS |
| ZORTRESS | T5 | PA-BvD |
| ZYDELIG | T5 | PA-NS; QL (62 EA per 31 days) |
| ZYKADIA | T5 | PA-NS; QL (93 EA per 31 days) |
| ZYTIGA ORAL TABLET 250 MG | T5 | PA-NS; QL (124 EA per 31 days) |
| ZYTIGA ORAL TABLET 500 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| Autonomic / Cns Drugs, Neurology / Psych | | |
| ABILIFY MAINTENA | T5 | QL (1 EA per 28 days) |
| ABILIFY MYCITE ORAL TABLET WITH SENSOR AND PATCH 10 MG, 15 MG, 2 MG, 20 MG, 5 MG | T5 | PA-NS |
| ABILIFY ORAL TABLET | T5 | PA-NS |
| <i>acetaminophen-caff-dihydrocod oral capsule</i> | T4 | PA; QL (372 EA per 31 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | T1 | PA; QL (5167 ML per 31 days) |
| <i>acetaminophen-codeine oral tablet</i> | T2 | PA; QL (403 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 1,200 MCG | T5 | PA; QL (40 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 1,600 MCG | T5 | PA; QL (30 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 200 MCG | T5 | PA; QL (124 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 400 MCG | T5 | PA; QL (119 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 600 MCG | T5 | PA; QL (79 EA per 31 days) |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 800 MCG | T5 | PA; QL (59 EA per 31 days) |
| ADDERALL ORAL TABLET 20 MG | T4 | ST; QL (93 EA per 31 days) |
| ADDERALL ORAL TABLET 5 MG, 7.5 MG | T4 | ST; QL (62 EA per 31 days) |
| ADDERALL XR | T4 | ST; QL (31 EA per 31 days) |
| ADLARITY | T4 | PA; QL (4 EA per 28 days) |
| ADZENYS XR-ODT | T4 | ST; QL (31 EA per 31 days) |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML | T3 | PA; QL (1 ML per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 70 MG/ML | T3 | PA; QL (2 ML per 28 days) |
| AJOVY AUTOINJECTOR | T3 | PA; QL (1.5 ML per 28 days) |
| AJOVY SYRINGE | T3 | PA; QL (1.5 ML per 28 days) |
| ALLZITAL | T4 | QL (372 EA per 31 days) |
| <i>almotriptan malate oral tablet 12.5 mg</i> | T2 | QL (8 EA per 28 days) |
| <i>almotriptan malate oral tablet 6.25 mg</i> | T2 | QL (16 EA per 28 days) |
| ALPRAZOLAM INTENSOL | T2 | PA |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>alprazolam oral tablet 1 mg, 2 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg</i> | T2 | PA; QL (31 EA per 31 days) |
| <i>alprazolam oral tablet extended release 24 hr 2 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| <i>alprazolam oral tablet extended release 24 hr 3 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>alprazolam oral tablet, disintegrating 1 mg, 2 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| AMBIEN | T4 | PA; QL (31 EA per 31 days) |
| AMBIEN CR | T4 | PA; QL (31 EA per 31 days) |
| <i>amitriptyline</i> | T2 | PA-NS |
| <i>amitriptyline-chlordiazepoxide</i> | T2 | PA-NS |
| <i>amoxapine</i> | T1 | |
| <i>amphetamine sulfate</i> | T4 | PA |
| AMPYRA | T5 | PA; QL (62 EA per 31 days) |
| AMRIX | T4 | PA; QL (31 EA per 31 days) |
| ANAFRANIL | T4 | PA-NS |
| ALENZIN ORAL TABLET EXTENDED RELEASE 24 HR 174 MG | T4 | |
| ALENZIN ORAL TABLET EXTENDED RELEASE 24 HR 348 MG, 522 MG | T5 | |
| APOKYN | T5 | PA; QL (60 ML per 30 days) |
| <i>apomorphine</i> | T5 | PA; QL (60 ML per 30 days) |
| APTENSIO XR | T4 | ST; QL (31 EA per 31 days) |
| APTIOM ORAL TABLET 200 MG, 800 MG | T4 | |
| APTIOM ORAL TABLET 400 MG, 600 MG | T5 | |
| ARICEPT | T4 | |
| <i>aripiprazole oral solution</i> | T3 | PA-NS |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 5 mg</i> | T3 | PA-NS |
| <i>aripiprazole oral tablet 20 mg, 30 mg</i> | T4 | PA-NS |
| <i>aripiprazole oral tablet, disintegrating</i> | T4 | PA-NS |
| ARISTADA INITIO | T5 | QL (4.8 ML per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 1,064 MG/3.9 ML | T5 | QL (3.9 ML per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 441 MG/1.6 ML | T5 | QL (1.6 ML per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 662 MG/2.4 ML | T5 | QL (2.4 ML per 28 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION, EXTENDED REL SYRING 882 MG/3.2 ML | T5 | QL (3.2 ML per 28 days) |
| <i>armodafinil</i> | T4 | PA; QL (31 EA per 31 days) |
| ARTHROTEC 50 | T4 | |
| ARTHROTEC 75 | T4 | |
| ASCOMP WITH CODEINE | T2 | PA; QL (372 EA per 31 days) |
| <i>asenapine maleate</i> | T4 | QL (62 EA per 31 days) |
| ATIVAN ORAL TABLET 0.5 MG | T4 | QL (124 EA per 31 days) |
| ATIVAN ORAL TABLET 1 MG | T5 | QL (186 EA per 31 days) |
| ATIVAN ORAL TABLET 2 MG | T5 | QL (155 EA per 31 days) |
| <i>atomoxetine oral capsule 10 mg, 25 mg, 40 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>atomoxetine oral capsule 18 mg</i> | T4 | QL (124 EA per 31 days) |
| AUBAGIO | T5 | PA; QL (31 EA per 31 days) |
| AUSTEDO ORAL TABLET 12 MG, 6 MG | T5 | PA; QL (124 EA per 31 days) |
| AUSTEDO ORAL TABLET 9 MG | T5 | PA; QL (155 EA per 31 days) |
| AZILECT | T3 | |
| AZSTARYS | T4 | ST; QL (31 EA per 31 days) |
| <i>baclofen oral tablet 10 mg</i> | T1 | |
| <i>baclofen oral tablet 20 mg</i> | T2 | |
| <i>baclofen oral tablet 5 mg</i> | T4 | |
| BAFIERTAM | T5 | PA; QL (124 EA per 31 days) |
| BANZEL | T5 | PA-NS |
| BELBUCA | T4 | PA; QL (62 EA per 31 days) |
| BELSOMRA | T4 | |
| <i>benztropine oral</i> | T2 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| BRIVIACT ORAL | T5 | |
| <i>bromocriptine</i> | T2 | |
| BUPAP | T4 | QL (403 EA per 31 days) |
| <i>buprenorphine</i> | T4 | PA; QL (4 EA per 28 days) |
| <i>buprenorphine hcl sublingual tablet 2 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>buprenorphine hcl sublingual tablet 8 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 4-1 mg, 8-2 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual film 2-0.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>buprenorphine-naloxone sublingual tablet</i> | T4 | ST; QL (93 EA per 31 days) |
| <i>bupropion hcl oral tablet</i> | T2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>bupropion hcl oral tablet extended release 24 hr 300 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>bupropion hcl oral tablet extended release 24 hr 450 mg</i> | T4 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr</i> | T2 | QL (62 EA per 31 days) |
| <i>bupirone</i> | T2 | |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg</i> | T2 | PA; QL (403 EA per 31 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | T2 | PA; QL (372 EA per 31 days) |
| <i>butalbital-acetaminophen oral capsule</i> | T2 | QL (403 EA per 31 days) |
| <i>butalbital-acetaminophen oral tablet 50-300 mg</i> | T2 | QL (403 EA per 31 days) |
| <i>butalbital-acetaminophen oral tablet 50-325 mg</i> | T2 | QL (372 EA per 31 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg</i> | T2 | QL (403 EA per 31 days) |
| <i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i> | T2 | QL (372 EA per 31 days) |
| <i>butalbital-acetaminophen-caff oral tablet</i> | T2 | QL (372 EA per 31 days) |
| <i>butalbital-aspirin-caffeine oral capsule</i> | T2 | |
| <i>butorphanol nasal</i> | T2 | QL (5 ML per 28 days) |
| BUTRANS | T4 | PA; QL (4 EA per 28 days) |
| CAMBIA | T4 | |
| CAPLYTA | T5 | PA-NS; QL (31 EA per 31 days) |
| <i>carbamazepine oral capsule, er multiphase 12 hr</i> | T2 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> | T1 | |
| <i>carbamazepine oral tablet</i> | T1 | |
| <i>carbamazepine oral tablet extended release 12 hr</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>carbamazepine oral tablet,chewable</i> | T1 | |
| CARBATROL | T4 | |
| <i>carbidopa</i> | T4 | |
| <i>carbidopa-levodopa</i> | T2 | |
| <i>carbidopa-levodopa-entacapone</i> | T2 | |
| <i>carisoprodol</i> | T2 | PA |
| CELEBREX | T4 | ST; QL (62 EA per 31 days) |
| <i>celecoxib</i> | T2 | ST; QL (62 EA per 31 days) |
| CELEXA ORAL TABLET | T4 | |
| CELONTIN ORAL CAPSULE 300 MG | T4 | |
| <i>chlordiazepoxide hcl</i> | T2 | |
| <i>chlorpromazine oral</i> | T2 | |
| <i>chlorzoxazone oral tablet 250 mg</i> | T5 | PA |
| <i>chlorzoxazone oral tablet 375 mg, 500 mg, 750 mg</i> | T2 | PA |
| <i>citalopram oral capsule</i> | T4 | PA-NS; QL (31 EA per 31 days) |
| <i>citalopram oral solution</i> | T1 | |
| <i>citalopram oral tablet</i> | T1 | |
| <i>clobazam oral suspension</i> | T4 | PA-NS; QL (496 ML per 31 days) |
| <i>clobazam oral tablet</i> | T4 | PA-NS; QL (62 EA per 31 days) |
| <i>clomipramine</i> | T2 | PA-NS |
| <i>clonazepam oral tablet 0.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clonazepam oral tablet 1 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>clonazepam oral tablet 2 mg</i> | T2 | QL (310 EA per 31 days) |
| <i>clonazepam oral tablet,disintegrating 0.125 mg, 0.25 mg, 0.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clonazepam oral tablet,disintegrating 1 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>clonazepam oral tablet,disintegrating 2 mg</i> | T2 | QL (310 EA per 31 days) |
| <i>clonidine hcl oral tablet extended release 12 hr</i> | T2 | PA |
| <i>clorazepate dipotassium oral tablet 15 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>clorazepate dipotassium oral tablet 3.75 mg, 7.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clozapine oral tablet 100 mg, 25 mg</i> | T2 | QL (279 EA per 31 days) |
| <i>clozapine oral tablet 200 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>clozapine oral tablet 50 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clozapine oral tablet,disintegrating 100 mg, 25 mg</i> | T2 | QL (279 EA per 31 days) |
| <i>clozapine oral tablet,disintegrating 12.5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | T4 | QL (186 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>clozapine oral tablet, disintegrating 200 mg</i> | T4 | QL (124 EA per 31 days) |
| CLOZARIL ORAL TABLET 100 MG, 25 MG | T4 | QL (279 EA per 31 days) |
| CLOZARIL ORAL TABLET 200 MG | T4 | QL (124 EA per 31 days) |
| CLOZARIL ORAL TABLET 50 MG | T4 | QL (93 EA per 31 days) |
| <i>codeine sulfate</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>codeine-butalbital-asa-caff</i> | T2 | PA; QL (372 EA per 31 days) |
| COMTAN | T5 | |
| CONCERTA | T4 | ST; QL (31 EA per 31 days) |
| CONZIP | T4 | PA; QL (30 EA per 30 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 20 MG/ML | T5 | ST; QL (31 ML per 31 days) |
| COPAXONE SUBCUTANEOUS SYRINGE 40 MG/ML | T5 | ST; QL (12 ML per 28 days) |
| COTEMPLA XR-ODT | T4 | ST; QL (62 EA per 31 days) |
| <i>cyclobenzaprine oral capsule, extended release 24hr</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>cyclobenzaprine oral tablet 10 mg, 7.5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>cyclobenzaprine oral tablet 5 mg</i> | T2 | PA; QL (155 EA per 31 days) |
| CYMBALTA ORAL CAPSULE, DELAYED RELEASE(DR/EC) 20 MG, 60 MG | T4 | QL (62 EA per 31 days) |
| CYMBALTA ORAL CAPSULE, DELAYED RELEASE(DR/EC) 30 MG | T4 | QL (31 EA per 31 days) |
| <i>dalfampridine</i> | T5 | PA; QL (62 EA per 31 days) |
| DANTRIUM ORAL CAPSULE 25 MG | T4 | |
| <i>dantrolene oral</i> | T2 | |
| DAYPRO | T4 | |
| DAYTRANA | T4 | PA; QL (30 EA per 30 days) |
| DAYVIGO | T4 | QL (31 EA per 31 days) |
| DEMEROL (PF) INJECTION SYRINGE 25 MG/ML | T4 | PA; QL (824 ML per 31 days) |
| DEMEROL INJECTION SOLUTION 50 MG/ML | T4 | PA; QL (412 ML per 31 days) |
| DEPAKOTE | T4 | |
| DEPAKOTE ER | T4 | |
| DEPAKOTE SPRINKLES | T4 | |
| <i>desipramine</i> | T2 | |
| DESOXYN | T4 | PA |
| <i>desvenlafaxine</i> | T4 | |
| <i>desvenlafaxine succinate</i> | T4 | QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 10 MG | T4 | ST; QL (155 EA per 31 days) |
| DEXEDRINE SPANSULE ORAL CAPSULE, EXTENDED RELEASE 15 MG | T4 | ST; QL (124 EA per 31 days) |
| <i>dexmethylphenidate oral capsule, er biphasic 50-50</i> | T2 | QL (31 EA per 31 days) |
| <i>dexmethylphenidate oral tablet 10 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>dexmethylphenidate oral tablet 2.5 mg, 5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 10 mg</i> | T2 | QL (155 EA per 31 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 15 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>dextroamphetamine sulfate oral capsule, extended release 5 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>dextroamphetamine sulfate oral solution</i> | T3 | |
| <i>dextroamphetamine sulfate oral tablet 10 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>dextroamphetamine sulfate oral tablet 15 mg, 20 mg, 30 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>dextroamphetamine sulfate oral tablet 5 mg</i> | T2 | QL (341 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr</i> | T2 | QL (31 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 30 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral tablet 12.5 mg, 15 mg, 5 mg, 7.5 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>dextroamphetamine-amphetamine oral tablet 20 mg</i> | T2 | QL (93 EA per 31 days) |
| DHIVY | T4 | ST |
| DIACOMIT ORAL CAPSULE 250 MG | T5 | PA-NS; QL (341 EA per 31 days) |
| DIACOMIT ORAL CAPSULE 500 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | T5 | PA-NS; QL (341 EA per 31 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | T5 | PA-NS; QL (186 EA per 31 days) |
| DIASTAT | T4 | |
| DIASTAT ACUDIAL | T4 | |
| DIAZEPAM INTENSOL | T2 | QL (248 ML per 31 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | T2 | QL (1500 ML per 31 days) |
| <i>diazepam oral tablet</i> | T2 | QL (124 EA per 31 days) |
| <i>diazepam rectal</i> | T4 | |
| <i>diclofenac epolamine</i> | T4 | PA; QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>diclofenac potassium oral capsule</i> | T5 | |
| <i>diclofenac potassium oral tablet 25 mg</i> | T4 | |
| <i>diclofenac potassium oral tablet 50 mg</i> | T1 | |
| <i>diclofenac sodium oral</i> | T1 | |
| <i>diclofenac sodium topical drops</i> | T2 | QL (450 ML per 28 days) |
| <i>diclofenac sodium topical gel 1 %</i> | T3 | QL (900 GM per 28 days) |
| <i>diclofenac sodium topical solution in metered-dose pump</i> | T5 | QL (224 GM per 28 days) |
| <i>diclofenac-misoprostol</i> | T2 | |
| <i>diflunisal</i> | T2 | |
| <i>dihydroergotamine nasal</i> | T4 | PA; QL (8 ML per 31 days) |
| DILANTIN | T4 | |
| DILANTIN EXTENDED | T4 | |
| DILANTIN INFATABS | T4 | |
| DILANTIN-125 | T4 | |
| DILAUDID ORAL LIQUID | T4 | PA; QL (1550 ML per 31 days) |
| DILAUDID ORAL TABLET 2 MG | T4 | PA; QL (186 EA per 31 days) |
| DILAUDID ORAL TABLET 4 MG, 8 MG | T5 | PA; QL (186 EA per 31 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> | T5 | PA; QL (120 EA per 365 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 240 mg</i> | T5 | PA; QL (62 EA per 31 days) |
| <i>divalproex oral capsule, delayed rel sprinkle</i> | T2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg</i> | T2 | |
| <i>divalproex oral tablet extended release 24 hr 500 mg</i> | T3 | |
| <i>divalproex oral tablet, delayed release (dr/ec)</i> | T2 | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> | T2 | |
| <i>donepezil oral tablet 23 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>donepezil oral tablet, disintegrating</i> | T2 | |
| <i>doxepin oral capsule</i> | T2 | PA-NS |
| <i>doxepin oral concentrate</i> | T2 | PA-NS |
| <i>doxepin oral tablet</i> | T2 | PA |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG | T4 | PA-NS; QL (93 EA per 31 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 30 MG, 60 MG | T4 | PA-NS; QL (62 EA per 31 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | T4 | PA-NS; QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| DUEXIS | T5 | PA; QL (93 EA per 31 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 60 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 30 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 40 mg</i> | T3 | QL (31 EA per 31 days) |
| DUOPA | T5 | PA-BvD |
| DYANAVEL XR ORAL SUSPEN, IR - ER, BIPHASIC 24HR | T4 | ST; QL (248 ML per 31 days) |
| DYANAVEL XR ORAL TABLET, IR - ER, BIPHASIC 24HR | T4 | ST; QL (31 EA per 31 days) |
| EDLUAR | T4 | PA; QL (31 EA per 31 days) |
| EFFEXOR XR ORAL CAPSULE, EXTENDED RELEASE 24HR 150 MG, 37.5 MG | T4 | QL (31 EA per 31 days) |
| EFFEXOR XR ORAL CAPSULE, EXTENDED RELEASE 24HR 75 MG | T4 | QL (93 EA per 31 days) |
| <i>eletriptan oral tablet 20 mg</i> | T4 | QL (12 EA per 28 days) |
| <i>eletriptan oral tablet 40 mg</i> | T4 | QL (6 EA per 28 days) |
| ELYXYB | T4 | PA |
| EMGALITY PEN | T3 | PA; QL (1 ML per 28 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | T3 | PA; QL (1 ML per 28 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | T3 | PA; QL (3 ML per 28 days) |
| EMSAM | T5 | QL (30 EA per 30 days) |
| ENDOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG | T2 | PA; QL (372 EA per 31 days) |
| <i>entacapone</i> | T2 | |
| EPIDIOLEX | T5 | PA-NS |
| EPITOL | T1 | |
| EPRONTIA | T4 | PA-NS; QL (496 ML per 31 days) |
| EQUETRO | T4 | |
| <i>ergoloid</i> | T2 | PA |
| <i>ergotamine-caffeine</i> | T2 | PA |
| <i>escitalopram oxalate oral solution</i> | T4 | QL (620 ML per 31 days) |
| <i>escitalopram oxalate oral tablet 10 mg</i> | T2 | QL (45 EA per 30 days) |
| <i>escitalopram oxalate oral tablet 20 mg, 5 mg</i> | T2 | QL (30 EA per 30 days) |
| ESGIC ORAL TABLET | T5 | QL (372 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>estazolam</i> | T2 | |
| <i>eszopiclone</i> | T2 | PA; QL (31 EA per 31 days) |
| <i>ethosuximide oral capsule</i> | T3 | |
| <i>ethosuximide oral solution</i> | T2 | |
| <i>etodolac</i> | T2 | |
| EVEKEO | T4 | PA |
| EVRYSDI | T5 | PA; QL (240 ML per 31 days) |
| EXELON PATCH | T4 | QL (30 EA per 30 days) |
| FANAPT ORAL TABLET | T4 | QL (62 EA per 31 days) |
| FANAPT ORAL TABLETS,DOSE PACK | T4 | QL (16 EA per 365 days) |
| <i>felbamate</i> | T2 | |
| FELBATOL | T4 | |
| FELDENE | T4 | |
| <i>fenopropfen oral capsule 400 mg</i> | T4 | |
| <i>fenopropfen oral tablet</i> | T2 | |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg</i> | T5 | PA; QL (40 EA per 31 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,600 mcg</i> | T5 | PA; QL (30 EA per 31 days) |
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | T4 | PA; QL (124 EA per 31 days) |
| <i>fentanyl citrate buccal lozenge on a handle 400 mcg</i> | T5 | PA; QL (119 EA per 31 days) |
| <i>fentanyl citrate buccal lozenge on a handle 600 mcg</i> | T5 | PA; QL (79 EA per 31 days) |
| <i>fentanyl citrate buccal lozenge on a handle 800 mcg</i> | T5 | PA; QL (59 EA per 31 days) |
| <i>fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg</i> | T5 | PA; QL (124 EA per 31 days) |
| <i>fentanyl citrate buccal tablet, effervescent 400 mcg</i> | T5 | PA; QL (119 EA per 31 days) |
| <i>fentanyl citrate buccal tablet, effervescent 600 mcg</i> | T5 | PA; QL (79 EA per 31 days) |
| <i>fentanyl citrate buccal tablet, effervescent 800 mcg</i> | T5 | PA; QL (59 EA per 31 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr</i> | T3 | PA; QL (10 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 12 mcg/hr</i> | T3 | PA; QL (20 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 25 mcg/hr</i> | T2 | PA; QL (20 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 37.5 mcg/hour</i> | T4 | PA; QL (20 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 50 mcg/hr</i> | T2 | PA; QL (17 EA per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| <i>fentanyl transdermal patch 72 hour 62.5 mcg/hour</i> | T4 | PA; QL (15 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 75 mcg/hr</i> | T3 | PA; QL (12 EA per 30 days) |
| <i>fentanyl transdermal patch 72 hour 87.5 mcg/hour</i> | T4 | PA; QL (11 EA per 30 days) |
| FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG | T5 | PA; QL (124 EA per 31 days) |
| FENTORA BUCCAL TABLET, EFFERVESCENT 400 MCG | T5 | PA; QL (119 EA per 31 days) |
| FENTORA BUCCAL TABLET, EFFERVESCENT 600 MCG | T5 | PA; QL (79 EA per 31 days) |
| FENTORA BUCCAL TABLET, EFFERVESCENT 800 MCG | T5 | PA; QL (59 EA per 31 days) |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK | T4 | PA-NS; QL (56 EA per 365 days) |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 40 MG, 80 MG | T4 | PA-NS; QL (31 EA per 31 days) |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 20 MG | T4 | PA-NS; QL (93 EA per 31 days) |
| FEXMID | T4 | PA; QL (124 EA per 31 days) |
| <i>fingolimod</i> | T5 | PA; QL (31 EA per 31 days) |
| FINTEPLA | T5 | PA-NS; QL (360 ML per 30 days) |
| FIORICET | T4 | QL (403 EA per 31 days) |
| FIORICET WITH CODEINE | T4 | PA; QL (403 EA per 31 days) |
| FIRDAPSE | T5 | PA; QL (248 EA per 31 days) |
| FLECTOR | T4 | PA; QL (62 EA per 31 days) |
| FLEQSUVY | T4 | PA; QL (496 ML per 31 days) |
| <i>fluoxetine (pmd)</i> | T1 | |
| <i>fluoxetine oral capsule</i> | T1 | |
| <i>fluoxetine oral capsule,delayed release(dr/ec)</i> | T2 | |
| <i>fluoxetine oral solution</i> | T1 | |
| <i>fluoxetine oral tablet 10 mg, 20 mg</i> | T1 | |
| <i>fluoxetine oral tablet 60 mg</i> | T4 | |
| <i>fluphenazine decanoate</i> | T2 | |
| <i>fluphenazine hcl injection</i> | T2 | |
| <i>fluphenazine hcl oral concentrate</i> | T2 | |
| <i>fluphenazine hcl oral elixir</i> | T1 | |
| <i>fluphenazine hcl oral tablet</i> | T1 | |
| <i>flurazepam</i> | T2 | |
| <i>flurbiprofen oral tablet 100 mg</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| <i>fluvoxamine</i> | T2 | |
| FOCALIN ORAL TABLET 10 MG | T4 | ST; QL (62 EA per 31 days) |
| FOCALIN ORAL TABLET 2.5 MG, 5 MG | T4 | ST; QL (93 EA per 31 days) |
| FOCALIN XR | T4 | ST; QL (31 EA per 31 days) |
| FORFIVO XL | T4 | |
| FROVA | T4 | QL (12 EA per 28 days) |
| <i>frovatriptan</i> | T3 | QL (12 EA per 28 days) |
| FYCOMPA ORAL SUSPENSION | T5 | |
| FYCOMPA ORAL TABLET 10 MG, 12 MG, 4 MG, 6 MG, 8 MG | T5 | |
| FYCOMPA ORAL TABLET 2 MG | T4 | |
| <i>gabapentin oral capsule 100 mg, 400 mg</i> | T2 | PA-NS; QL (270 EA per 30 days) |
| <i>gabapentin oral capsule 300 mg</i> | T2 | PA-NS; QL (360 EA per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> | T2 | PA-NS; QL (2160 ML per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> | T2 | PA-NS; QL (180 EA per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> | T2 | PA-NS; QL (120 EA per 30 days) |
| GABITRIL ORAL TABLET 12 MG, 16 MG, 2 MG | T4 | |
| GABITRIL ORAL TABLET 4 MG | T5 | |
| <i>galantamine</i> | T2 | |
| GEODON INTRAMUSCULAR | T4 | |
| GEODON ORAL | T4 | QL (62 EA per 31 days) |
| GILENYA ORAL CAPSULE 0.5 MG | T5 | PA; QL (31 EA per 31 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> | T5 | QL (31 ML per 31 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> | T5 | QL (12 ML per 28 days) |
| GLATOPA SUBCUTANEOUS SYRINGE 20 MG/ML | T5 | QL (31 ML per 31 days) |
| GLATOPA SUBCUTANEOUS SYRINGE 40 MG/ML | T5 | QL (12 ML per 28 days) |
| GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG | T5 | PA; QL (62 EA per 31 days) |
| GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 68.5 MG | T5 | PA; QL (124 EA per 31 days) |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG | T4 | PA; QL (155 EA per 31 days) |
| GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 600 MG | T4 | PA; QL (93 EA per 31 days) |
| <i>guanfacine oral tablet extended release 24 hr</i> | T2 | PA |
| HALCION ORAL TABLET 0.25 MG | T4 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| HALDOL DECANOATE | T4 | |
| <i>haloperidol</i> | T1 | |
| <i>haloperidol decanoate</i> | T2 | |
| <i>haloperidol lactate injection</i> | T1 | |
| <i>haloperidol lactate oral</i> | T2 | |
| HETLIOZ | T5 | PA; QL (31 EA per 31 days) |
| HETLIOZ LQ | T5 | PA; QL (158 ML per 31 days) |
| HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG | T4 | PA; QL (90 EA per 30 days) |
| HORIZANT ORAL TABLET EXTENDED RELEASE 600 MG | T4 | PA; QL (60 EA per 30 days) |
| <i>hydrocodone bitartrate oral capsule, oral only, er 12hr</i> | T4 | PA; QL (100 EA per 31 days) |
| <i>hydrocodone bitartrate oral tablet,oral only,ext.rel.24 hr</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml</i> | T2 | PA; QL (5723 ML per 31 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg</i> | T2 | PA; QL (403 EA per 31 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | PA; QL (372 EA per 31 days) |
| <i>hydrocodone-ibuprofen</i> | T2 | PA; QL (155 EA per 31 days) |
| <i>hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml</i> | T2 | PA; QL (124 ML per 31 days) |
| <i>hydromorphone oral liquid</i> | T2 | PA; QL (1550 ML per 31 days) |
| <i>hydromorphone oral tablet</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 8 mg</i> | T2 | PA; QL (62 EA per 31 days) |
| <i>hydromorphone oral tablet extended release 24 hr 32 mg</i> | T2 | PA; QL (48 EA per 31 days) |
| HYSINGLA ER | T4 | PA; QL (31 EA per 31 days) |
| IBU ORAL TABLET 600 MG, 800 MG | T1 | |
| <i>ibuprofen oral suspension</i> | T1 | |
| <i>ibuprofen oral tablet 400 mg, 600 mg, 800 mg</i> | T1 | |
| <i>ibuprofen-famotidine</i> | T4 | PA; QL (93 EA per 31 days) |
| <i>imipramine hcl</i> | T2 | PA-NS |
| <i>imipramine pamoate</i> | T2 | PA-NS |
| IMITREX NASAL SPRAY,NON-AEROSOL 20 MG/ACTUATION | T4 | QL (8 EA per 28 days) |
| IMITREX NASAL SPRAY,NON-AEROSOL 5 MG/ACTUATION | T4 | QL (32 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| IMITREX ORAL TABLET 100 MG | T4 | QL (9 EA per 28 days) |
| IMITREX ORAL TABLET 25 MG | T4 | QL (36 EA per 28 days) |
| IMITREX ORAL TABLET 50 MG | T4 | QL (18 EA per 28 days) |
| IMITREX STATDOSE PEN SUBCUTANEOUS PEN INJECTOR 4 MG/0.5 ML | T4 | QL (6 ML per 28 days) |
| IMITREX STATDOSE REFILL SUBCUTANEOUS CARTRIDGE 6 MG/0.5 ML | T4 | QL (4 ML per 28 days) |
| INBRIJA INHALATION CAPSULE, W/INHALATION DEVICE | T5 | PA; QL (300 EA per 30 days) |
| INDOCIN | T4 | |
| <i>indomethacin oral</i> | T1 | |
| INGREZZA INITIATION PACK | T5 | PA; QL (56 EA per 365 days) |
| INGREZZA ORAL CAPSULE 40 MG | T5 | PA; QL (62 EA per 31 days) |
| INGREZZA ORAL CAPSULE 60 MG, 80 MG | T5 | PA; QL (31 EA per 31 days) |
| INTUNIV ER | T4 | PA |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | T4 | QL (3.5 ML per 180 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | T4 | QL (5 ML per 180 days) |
| INVEGA ORAL TABLET EXTENDED RELEASE 24HR 3 MG | T4 | QL (31 EA per 31 days) |
| INVEGA ORAL TABLET EXTENDED RELEASE 24HR 6 MG | T4 | QL (62 EA per 31 days) |
| INVEGA ORAL TABLET EXTENDED RELEASE 24HR 9 MG | T5 | QL (31 EA per 31 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | T5 | QL (0.75 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | T5 | QL (1 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | T5 | QL (1.5 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | T4 | QL (0.25 ML per 28 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | T5 | QL (0.5 ML per 28 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | T5 | QL (0.875 ML per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | T5 | QL (1.315 ML per 84 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | T5 | QL (1.75 ML per 84 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | T5 | QL (2.625 ML per 84 days) |
| JORNAY PM | T4 | ST; QL (31 EA per 31 days) |
| KAPVAY | T4 | PA |
| KEPPRA ORAL SOLUTION | T5 | |
| KEPPRA ORAL TABLET 1,000 MG | T5 | |
| KEPPRA ORAL TABLET 250 MG, 500 MG, 750 MG | T4 | |
| KEPPRA XR | T4 | |
| KESIMPTA PEN | T5 | PA; QL (0.4 ML per 28 days) |
| <i>ketoprofen oral capsule 25 mg</i> | T2 | |
| <i>ketoprofen oral capsule, ext rel. pellets 24 hr 200 mg</i> | T2 | |
| <i>ketorolac nasal</i> | T4 | QL (5 EA per 31 days) |
| <i>ketorolac oral</i> | T2 | |
| KEVEYIS | T5 | PA; QL (124 EA per 31 days) |
| KLONOPIN ORAL TABLET 0.5 MG | T4 | QL (93 EA per 31 days) |
| KLONOPIN ORAL TABLET 1 MG | T4 | QL (124 EA per 31 days) |
| KLONOPIN ORAL TABLET 2 MG | T4 | QL (310 EA per 31 days) |
| KLOXXADO | T3 | |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | T5 | PA; QL (155 EA per 31 days) |
| <i>lacosamide oral</i> | T4 | |
| LAMICTAL ODT | T4 | |
| LAMICTAL ORAL TABLET 100 MG, 150 MG | T5 | |
| LAMICTAL ORAL TABLET 200 MG, 25 MG | T4 | |
| LAMICTAL ORAL TABLET, CHEWABLE DISPERSIBLE 25 MG, 5 MG | T4 | |
| LAMICTAL STARTER (BLUE) KIT | T4 | |
| LAMICTAL STARTER (GREEN) KIT | T4 | |
| LAMICTAL STARTER (ORANGE) KIT | T4 | |
| LAMICTAL XR | T4 | |
| LAMICTAL XR STARTER (BLUE) | T4 | |
| LAMICTAL XR STARTER (GREEN) | T4 | |
| LAMICTAL XR STARTER (ORANGE) | T4 | |
| <i>lamotrigine oral tablet</i> | T2 | |
| <i>lamotrigine oral tablet disintegrating, dose pk 25 mg(14)-50 mg (14)-100 mg (7)</i> | T2 | |
| <i>lamotrigine oral tablet extended release 24hr</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>lamotrigine oral tablet, chewable dispersible</i> | T2 | |
| <i>lamotrigine oral tablet, disintegrating</i> | T2 | |
| <i>lamotrigine oral tablets, dose pack 25 mg (35), 25 mg (42) - 100 mg (7)</i> | T2 | |
| <i>lamotrigine oral tablets, dose pack 25 mg (84) - 100 mg (14)</i> | T4 | |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG | T5 | PA-NS; QL (31 EA per 31 days) |
| LATUDA ORAL TABLET 80 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| <i>levetiracetam oral solution 100 mg/ml</i> | T2 | |
| <i>levetiracetam oral tablet</i> | T2 | |
| <i>levetiracetam oral tablet extended release 24 hr</i> | T2 | |
| <i>levorphanol tartrate</i> | T5 | PA; QL (186 EA per 31 days) |
| LEXAPRO ORAL TABLET 10 MG | T4 | QL (45 EA per 30 days) |
| LEXAPRO ORAL TABLET 20 MG, 5 MG | T4 | QL (30 EA per 30 days) |
| LICART | T4 | PA; QL (31 EA per 31 days) |
| <i>lithium carbonate</i> | T1 | |
| LITHOBID | T4 | |
| LODINE ORAL TABLET | T4 | |
| LODOSYN | T4 | |
| LOFENA | T4 | |
| LORAZEPAM INTENSOL | T2 | QL (155 ML per 31 days) |
| <i>lorazepam oral tablet 0.5 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>lorazepam oral tablet 1 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>lorazepam oral tablet 2 mg</i> | T2 | QL (155 EA per 31 days) |
| LOREEV XR ORAL CAPSULE, EXTENDED RELEASE 24HR 1 MG, 3 MG | T4 | QL (93 EA per 31 days) |
| LOREEV XR ORAL CAPSULE, EXTENDED RELEASE 24HR 1.5 MG, 2 MG | T4 | QL (155 EA per 31 days) |
| LORZONE | T4 | PA |
| <i>loxapine succinate</i> | T2 | |
| LUCEMYRA | T5 | |
| LUNESTA ORAL TABLET 1 MG, 3 MG | T4 | PA; QL (31 EA per 31 days) |
| LUNESTA ORAL TABLET 2 MG | T5 | PA; QL (31 EA per 31 days) |
| LYBALVI | T5 | PA-NS; QL (31 EA per 31 days) |
| LYRICA CR | T4 | PA; QL (31 EA per 31 days) |
| LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 25 MG, 50 MG, 75 MG | T4 | PA-NS; QL (93 EA per 31 days) |
| LYRICA ORAL CAPSULE 225 MG, 300 MG | T4 | PA-NS; QL (62 EA per 31 days) |
| LYRICA ORAL SOLUTION | T4 | PA-NS; QL (930 ML per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| LYVISPAH | T4 | PA; QL (124 EA per 31 days) |
| MARPLAN | T3 | |
| MAVENCLAD (10 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (4 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (5 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (6 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (7 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (8 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAVENCLAD (9 TABLET PACK) | T5 | PA; QL (40 EA per 365 days) |
| MAXALT ORAL TABLET 10 MG | T4 | QL (12 EA per 28 days) |
| MAXALT-MLT ORAL TABLET,DISINTEGRATING 10 MG | T4 | QL (12 EA per 28 days) |
| MAYZENT ORAL TABLET 0.25 MG | T5 | PA; QL (155 EA per 31 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | T5 | PA; QL (31 EA per 31 days) |
| MAYZENT STARTER(FOR 1MG MAINT) | T4 | PA; QL (14 EA per 365 days) |
| MAYZENT STARTER(FOR 2MG MAINT) | T5 | PA; QL (24 EA per 365 days) |
| <i>meclofenamate</i> | T2 | |
| <i>mefenamic acid</i> | T4 | |
| <i>meloxicam oral tablet</i> | T1 | |
| <i>meloxicam submicronized</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>memantine oral capsule,sprinkle,er 24hr</i> | T3 | |
| <i>memantine oral solution</i> | T3 | |
| <i>memantine oral tablet</i> | T2 | |
| <i>memantine oral tablets,dose pack</i> | T4 | |
| <i>meperidine (pf) injection solution 100 mg/ml</i> | T2 | PA; QL (200 ML per 31 days) |
| <i>meperidine (pf) injection solution 25 mg/ml</i> | T2 | PA; QL (800 ML per 31 days) |
| <i>meperidine (pf) injection solution 50 mg/ml</i> | T2 | PA; QL (400 ML per 31 days) |
| <i>meperidine oral solution</i> | T2 | PA; QL (6200 ML per 31 days) |
| <i>meperidine oral tablet 50 mg</i> | T2 | PA; QL (1240 EA per 31 days) |
| <i>meprobamate oral tablet 200 mg</i> | T2 | QL (341 EA per 31 days) |
| <i>meprobamate oral tablet 400 mg</i> | T2 | QL (186 EA per 31 days) |
| MESTINON ORAL SYRUP | T4 | |
| MESTINON ORAL TABLET | T5 | |
| MESTINON TIMESPAN | T5 | |
| <i>metaxalone</i> | T2 | PA |
| <i>methadone oral solution 10 mg/5 ml</i> | T2 | PA; QL (1033 ML per 31 days) |
| <i>methadone oral solution 5 mg/5 ml</i> | T2 | PA; QL (2066 ML per 31 days) |
| <i>methadone oral tablet 10 mg</i> | T2 | PA; QL (206 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>methadone oral tablet 5 mg</i> | T2 | PA; QL (248 EA per 31 days) |
| <i>methamphetamine</i> | T4 | PA |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | T2 | |
| METHYLIN ORAL SOLUTION | T4 | ST |
| <i>methylphenidate hcl oral cap,er sprinkle,biphasic 40-60</i> | T4 | QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral capsule, er biphasic 30-70</i> | T2 | QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 10 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 20 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 30 mg, 40 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>methylphenidate hcl oral capsule,er biphasic 50-50 60 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral solution</i> | T2 | |
| <i>methylphenidate hcl oral tablet</i> | T2 | QL (93 EA per 31 days) |
| <i>methylphenidate hcl oral tablet extended release 10 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral tablet extended release 20 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 18 mg, 18 mg (bx rating), 27 mg, 27 mg (bx rating), 36 mg, 36 mg (bx rating), 54 mg, 54 mg (bx rating)</i> | T2 | QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral tablet extended release 24hr 72 mg</i> | T4 | ST; QL (31 EA per 31 days) |
| <i>methylphenidate hcl oral tablet,chewable 10 mg</i> | T2 | QL (186 EA per 31 days) |
| <i>methylphenidate hcl oral tablet,chewable 2.5 mg, 5 mg</i> | T2 | QL (93 EA per 31 days) |
| MIGERGOT | T5 | |
| MIGRANAL | T4 | PA; QL (8 ML per 31 days) |
| MIRAPEX ER | T4 | |
| <i>mirtazapine</i> | T2 | |
| <i>modafinil</i> | T2 | PA; QL (31 EA per 31 days) |
| <i>molindone</i> | T4 | |
| <i>morphine concentrate oral solution</i> | T2 | PA; QL (310 ML per 31 days) |
| <i>morphine oral capsule, er multiphase 24 hr 120 mg</i> | T2 | PA; QL (51 EA per 31 days) |
| <i>morphine oral capsule, er multiphase 24 hr 30 mg, 45 mg, 60 mg, 75 mg, 90 mg</i> | T2 | PA; QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>morphine oral capsule, extend. release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg</i> | T2 | PA; QL (62 EA per 31 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | T2 | PA; QL (2800 ML per 31 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | T2 | PA; QL (1400 ML per 31 days) |
| <i>morphine oral tablet</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>morphine oral tablet extended release 100 mg</i> | T2 | PA; QL (62 EA per 31 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg, 60 mg</i> | T2 | PA; QL (100 EA per 31 days) |
| <i>morphine oral tablet extended release 200 mg</i> | T2 | PA; QL (31 EA per 31 days) |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG | T4 | PA; QL (62 EA per 31 days) |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 15 MG, 30 MG, 60 MG | T4 | PA; QL (100 EA per 31 days) |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 200 MG | T4 | PA; QL (31 EA per 31 days) |
| MYDAYIS | T4 | ST; QL (31 EA per 31 days) |
| MYSOLINE | T5 | |
| <i>nabumetone</i> | T1 | |
| NALFON ORAL CAPSULE 400 MG | T4 | |
| NALFON ORAL TABLET | T4 | |
| <i>naloxone injection solution</i> | T2 | |
| <i>naloxone injection syringe</i> | T2 | |
| <i>naloxone nasal</i> | T3 | |
| <i>naltrexone</i> | T2 | |
| NAMENDA ORAL TABLET | T4 | PA |
| NAMENDA TITRATION PAK | T4 | PA |
| NAMENDA XR ORAL CAPSULE, SPRINKLE, ER 24HR | T4 | PA |
| NAMZARIC | T4 | PA |
| NAPRELAN CR | T4 | |
| <i>naproxen oral suspension</i> | T1 | |
| <i>naproxen oral tablet</i> | T1 | |
| <i>naproxen oral tablet, delayed release (dr/ec)</i> | T2 | |
| <i>naproxen sodium oral tablet 275 mg, 550 mg</i> | T1 | |
| <i>naproxen sodium oral tablet, er multiphase 24 hr 375 mg, 500 mg</i> | T4 | |
| <i>naproxen-esomeprazole</i> | T5 | PA; QL (62 EA per 31 days) |
| <i>naratriptan oral tablet 1 mg</i> | T2 | QL (20 EA per 28 days) |
| <i>naratriptan oral tablet 2.5 mg</i> | T2 | QL (9 EA per 28 days) |
| NARCAN | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| NARDIL | T4 | |
| NAYZILAM | T4 | PA-NS; QL (10 EA per 30 days) |
| <i>nefazodone</i> | T2 | |
| NEUPRO | T4 | |
| NEURONTIN ORAL CAPSULE 100 MG, 400 MG | T4 | PA-NS; QL (270 EA per 30 days) |
| NEURONTIN ORAL CAPSULE 300 MG | T4 | PA-NS; QL (360 EA per 30 days) |
| NEURONTIN ORAL SOLUTION | T4 | PA-NS; QL (2160 ML per 30 days) |
| NEURONTIN ORAL TABLET 600 MG | T4 | PA-NS; QL (180 EA per 30 days) |
| NEURONTIN ORAL TABLET 800 MG | T4 | PA-NS; QL (120 EA per 30 days) |
| NORGESIC | T4 | PA |
| NORGESIC FORTE | T4 | PA |
| NORPRAMIN ORAL TABLET 10 MG, 25 MG | T4 | |
| <i>nortriptyline</i> | T2 | |
| NOURIANZ | T5 | PA; QL (31 EA per 31 days) |
| NUCYNTA | T4 | PA; QL (186 EA per 31 days) |
| NUCYNTA ER | T4 | PA; QL (62 EA per 31 days) |
| NUEDEXTA | T3 | PA; QL (62 EA per 31 days) |
| NUPLAZID | T5 | PA-NS; QL (31 EA per 31 days) |
| NURTEC ODT | T5 | QL (18 EA per 28 days) |
| NUVIGIL | T4 | PA; QL (31 EA per 31 days) |
| <i>olanzapine intramuscular</i> | T2 | |
| <i>olanzapine oral</i> | T2 | QL (31 EA per 31 days) |
| <i>olanzapine-fluoxetine</i> | T2 | |
| ONFI ORAL SUSPENSION | T4 | PA-NS; QL (496 ML per 31 days) |
| ONFI ORAL TABLET | T5 | PA-NS; QL (62 EA per 31 days) |
| ONGENTYS | T4 | PA; QL (31 EA per 31 days) |
| ONZETRA XSAIL | T5 | QL (16 EA per 28 days) |
| <i>orphenadrine citrate oral</i> | T2 | PA |
| <i>orphenadrine-asa-caffeine oral tablet 25-385-30 mg</i> | T2 | PA |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG | T4 | PA; QL (31 EA per 31 days) |
| OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 322 MG/DAY(129 MG X1-193MG X1) | T4 | PA; QL (60 EA per 30 days) |
| <i>oxaprozin</i> | T2 | |
| <i>oxazepam</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| <i>oxcarbazepine</i> | T2 | |
| OXTELLAR XR | T4 | |
| <i>oxycodone oral capsule</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>oxycodone oral concentrate</i> | T2 | PA; QL (180 ML per 31 days) |
| <i>oxycodone oral solution</i> | T2 | PA; QL (4133 ML per 31 days) |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20 mg, 5 mg</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>oxycodone oral tablet 30 mg</i> | T3 | PA; QL (138 EA per 31 days) |
| <i>oxycodone oral tablet,oral only,ext.rel.12 hr 10 mg, 20 mg, 40 mg</i> | T4 | PA; QL (100 EA per 31 days) |
| <i>oxycodone oral tablet,oral only,ext.rel.12 hr 80 mg</i> | T4 | PA; QL (62 EA per 31 days) |
| <i>oxycodone-acetaminophen oral solution 5-325 mg/5 ml</i> | T4 | PA; QL (1908 ML per 31 days) |
| <i>oxycodone-acetaminophen oral tablet 10-300 mg, 5-300 mg, 7.5-300 mg</i> | T4 | PA; QL (403 EA per 31 days) |
| <i>oxycodone-acetaminophen oral tablet 10-325 mg</i> | T3 | PA; QL (372 EA per 31 days) |
| <i>oxycodone-acetaminophen oral tablet 2.5-325 mg, 5-325 mg, 7.5-325 mg</i> | T2 | PA; QL (372 EA per 31 days) |
| OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG | T4 | PA; QL (100 EA per 31 days) |
| OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 60 MG | T5 | PA; QL (69 EA per 31 days) |
| OXYCONTIN ORAL TABLET,ORAL ONLY,EXT.REL.12 HR 80 MG | T5 | PA; QL (62 EA per 31 days) |
| <i>oxymorphone oral tablet</i> | T2 | PA; QL (186 EA per 31 days) |
| <i>oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 5 mg, 7.5 mg</i> | T2 | PA; QL (100 EA per 31 days) |
| <i>oxymorphone oral tablet extended release 12 hr 30 mg</i> | T2 | PA; QL (69 EA per 31 days) |
| <i>oxymorphone oral tablet extended release 12 hr 40 mg</i> | T2 | PA; QL (51 EA per 31 days) |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg, 3 mg, 9 mg</i> | T4 | QL (31 EA per 31 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> | T4 | QL (62 EA per 31 days) |
| PAMELOR | T4 | |
| PARLODEL | T4 | |
| PARNATE | T4 | |
| <i>paroxetine hcl oral suspension</i> | T4 | |
| <i>paroxetine hcl oral tablet</i> | T1 | |
| <i>paroxetine hcl oral tablet extended release 24 hr</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|--------------------------------|
| <i>paroxetine mesylate(menop.sym)</i> | T4 | |
| PAXIL | T4 | |
| PAXIL CR | T4 | |
| PENNSAID TOPICAL SOLUTION IN METERED-DOSE PUMP | T5 | QL (224 GM per 28 days) |
| <i>pentazocine-naloxone</i> | T2 | QL (335 EA per 31 days) |
| PERCOCET | T4 | PA; QL (372 EA per 31 days) |
| <i>perphenazine</i> | T2 | |
| <i>perphenazine-amitriptyline</i> | T2 | PA-NS |
| PERSERIS | T5 | QL (1 EA per 28 days) |
| PEXEVA ORAL TABLET 10 MG, 20 MG, 30 MG | T4 | |
| <i>phenelzine</i> | T2 | |
| <i>phenobarbital</i> | T2 | PA-NS |
| PHENYTEK | T4 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> | T2 | |
| <i>phenytoin oral tablet,chewable</i> | T2 | |
| <i>phenytoin sodium extended</i> | T2 | |
| <i>pimozide</i> | T2 | |
| <i>piroxicam</i> | T2 | |
| PONVORY | T5 | PA; QL (31 EA per 31 days) |
| PONVORY 14-DAY STARTER PACK | T5 | PA; QL (28 EA per 365 days) |
| <i>pramipexole</i> | T2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> | T2 | PA-NS; QL (93 EA per 31 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> | T2 | PA-NS; QL (62 EA per 31 days) |
| <i>pregabalin oral solution</i> | T2 | PA-NS; QL (930 ML per 31 days) |
| <i>pregabalin oral tablet extended release 24 hr</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>primidone</i> | T2 | |
| PRISTIQ | T4 | QL (31 EA per 31 days) |
| PROCENTRA | T3 | |
| PROLATE ORAL TABLET | T4 | PA; QL (403 EA per 31 days) |
| <i>protriptyline</i> | T2 | |
| PROVIGIL ORAL TABLET 100 MG | T4 | PA; QL (31 EA per 31 days) |
| PROVIGIL ORAL TABLET 200 MG | T5 | PA; QL (31 EA per 31 days) |
| PROZAC ORAL CAPSULE | T4 | |
| <i>pyridostigmine bromide oral syrup</i> | T2 | |
| <i>pyridostigmine bromide oral tablet 30 mg</i> | T3 | |
| <i>pyridostigmine bromide oral tablet 60 mg</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| <i>pyridostigmine bromide oral tablet extended release</i> | T2 | |
| QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 100 MG, 200 MG | T4 | PA; QL (93 EA per 31 days) |
| QELBREE ORAL CAPSULE,EXTENDED RELEASE 24HR 150 MG | T4 | PA; QL (62 EA per 31 days) |
| QUDEXY XR | T4 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> | T2 | QL (62 EA per 31 days) |
| <i>quetiapine oral tablet 25 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>quetiapine oral tablet extended release 24 hr</i> | T3 | QL (62 EA per 31 days) |
| QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 20 MG, 40 MG | T4 | ST; QL (31 EA per 31 days) |
| QUILLICHEW ER ORAL TABLET,CHEW,IR-ER.BIPHASIC24HR 30 MG | T4 | ST; QL (62 EA per 31 days) |
| QUILLIVANT XR | T4 | ST; QL (360 ML per 30 days) |
| QULIPTA | T5 | PA; QL (31 EA per 31 days) |
| QUVIVIQ | T4 | QL (31 EA per 31 days) |
| RADICAVA ORS STARTER KIT SUSP | T5 | PA; QL (70 ML per 28 days) |
| <i>ramelteon</i> | T4 | QL (31 EA per 31 days) |
| <i>rasagiline</i> | T3 | |
| RAZADYNE ER | T4 | |
| RELAFEN DS | T5 | |
| RELEXXII ORAL TABLET EXTENDED RELEASE 24HR 72 MG | T4 | ST; QL (31 EA per 31 days) |
| RELPAK ORAL TABLET 20 MG | T4 | QL (12 EA per 28 days) |
| RELPAK ORAL TABLET 40 MG | T4 | QL (6 EA per 28 days) |
| REMERON ORAL TABLET 15 MG, 30 MG | T4 | |
| REMERON SOLTAB | T4 | |
| RESTORIL ORAL CAPSULE 15 MG, 22.5 MG, 7.5 MG | T4 | QL (31 EA per 31 days) |
| RESTORIL ORAL CAPSULE 30 MG | T5 | QL (31 EA per 31 days) |
| REXULTI | T5 | PA-NS; QL (31 EA per 31 days) |
| REYVOW ORAL TABLET 100 MG | T4 | QL (8 EA per 28 days) |
| REYVOW ORAL TABLET 50 MG | T4 | QL (4 EA per 28 days) |
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 12.5 MG/2 ML, 25 MG/2 ML, 37.5 MG/2 ML | T4 | QL (2 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| RISPERDAL CONSTA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 50 MG/2 ML | T5 | QL (2 EA per 28 days) |
| RISPERDAL ORAL SOLUTION | T4 | QL (496 ML per 31 days) |
| RISPERDAL ORAL TABLET 0.5 MG, 1 MG, 2 MG | T4 | QL (31 EA per 31 days) |
| RISPERDAL ORAL TABLET 3 MG | T4 | QL (93 EA per 31 days) |
| RISPERDAL ORAL TABLET 4 MG | T4 | QL (124 EA per 31 days) |
| <i>risperidone oral solution</i> | T1 | QL (496 ML per 31 days) |
| <i>risperidone oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>risperidone oral tablet 3 mg</i> | T1 | QL (93 EA per 31 days) |
| <i>risperidone oral tablet 4 mg</i> | T1 | QL (124 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 0.25 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 0.5 mg, 1 mg, 2 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 3 mg</i> | T1 | QL (93 EA per 31 days) |
| <i>risperidone oral tablet,disintegrating 4 mg</i> | T1 | QL (124 EA per 31 days) |
| RITALIN | T4 | ST; QL (93 EA per 31 days) |
| RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 10 MG | T4 | ST; QL (186 EA per 31 days) |
| RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 20 MG, 40 MG | T4 | ST; QL (31 EA per 31 days) |
| RITALIN LA ORAL CAPSULE,ER BIPHASIC 50-50 30 MG | T4 | ST; QL (62 EA per 31 days) |
| <i>rivastigmine</i> | T2 | QL (30 EA per 30 days) |
| <i>rivastigmine tartrate</i> | T2 | |
| <i>rizatriptan oral tablet 10 mg</i> | T2 | QL (12 EA per 28 days) |
| <i>rizatriptan oral tablet 5 mg</i> | T2 | QL (24 EA per 28 days) |
| <i>rizatriptan oral tablet,disintegrating 10 mg</i> | T2 | QL (12 EA per 28 days) |
| <i>rizatriptan oral tablet,disintegrating 5 mg</i> | T2 | QL (24 EA per 28 days) |
| <i>ropinirole</i> | T2 | |
| ROWEEPRA ORAL TABLET 500 MG | T2 | |
| ROXICODONE ORAL TABLET 15 MG | T4 | PA; QL (186 EA per 31 days) |
| ROXICODONE ORAL TABLET 30 MG | T4 | PA; QL (138 EA per 31 days) |
| ROZEREM | T4 | QL (31 EA per 31 days) |
| <i>rufinamide</i> | T5 | PA-NS |
| RYTARY | T3 | ST |
| SABRIL | T5 | PA-NS |
| SAPHRIS | T4 | QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| SECUADO | T5 | QL (31 EA per 31 days) |
| SEGLENTIS | T4 | PA; QL (124 EA per 31 days) |
| <i>selegiline hcl</i> | T2 | |
| SEROQUEL | T4 | QL (62 EA per 31 days) |
| SEROQUEL XR ORAL TABLET EXTENDED RELEASE 24 HR | T4 | QL (62 EA per 31 days) |
| <i>sertraline oral capsule</i> | T4 | PA-NS; QL (31 EA per 31 days) |
| <i>sertraline oral concentrate</i> | T1 | |
| <i>sertraline oral tablet</i> | T1 | |
| SILENOR | T4 | PA |
| SINEMET ORAL TABLET 10-100 MG, 25-100 MG | T4 | |
| SOMA ORAL TABLET 250 MG | T4 | PA |
| SOMA ORAL TABLET 350 MG | T5 | PA |
| SPRITAM | T4 | |
| SPRIX | T5 | QL (5 EA per 31 days) |
| STALEVO 100 | T4 | |
| STALEVO 125 | T4 | |
| STALEVO 150 | T4 | |
| STALEVO 200 | T4 | |
| STALEVO 75 | T4 | |
| STRATTERA ORAL CAPSULE 10 MG, 25 MG, 40 MG | T4 | ST; QL (62 EA per 31 days) |
| STRATTERA ORAL CAPSULE 100 MG, 60 MG, 80 MG | T4 | ST; QL (31 EA per 31 days) |
| STRATTERA ORAL CAPSULE 18 MG | T4 | ST; QL (124 EA per 31 days) |
| SUBOXONE SUBLINGUAL FILM 12-3 MG, 4-1 MG, 8-2 MG | T4 | ST; QL (62 EA per 31 days) |
| SUBOXONE SUBLINGUAL FILM 2-0.5 MG | T4 | ST; QL (93 EA per 31 days) |
| <i>sulindac</i> | T2 | |
| <i>sumatriptan nasal spray,non-aerosol 20 mg/actuation</i> | T2 | QL (8 EA per 28 days) |
| <i>sumatriptan nasal spray,non-aerosol 5 mg/actuation</i> | T2 | QL (32 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> | T2 | QL (9 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 25 mg</i> | T2 | QL (36 EA per 28 days) |
| <i>sumatriptan succinate oral tablet 50 mg</i> | T2 | QL (18 EA per 28 days) |
| <i>sumatriptan succinate subcutaneous cartridge 4 mg/0.5 ml</i> | T2 | QL (6 ML per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>sumatriptan succinate subcutaneous cartridge 6 mg/0.5 ml</i> | T2 | QL (4 ML per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> | T2 | QL (6 ML per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> | T2 | QL (4 ML per 28 days) |
| <i>sumatriptan succinate subcutaneous solution</i> | T2 | QL (4 ML per 28 days) |
| <i>sumatriptan-naproxen</i> | T4 | QL (9 EA per 28 days) |
| SUNOSI | T4 | PA; QL (31 EA per 31 days) |
| SYMBYAX ORAL CAPSULE 3-25 MG, 6-25 MG | T4 | |
| SYMPAZAN ORAL FILM 10 MG, 20 MG | T5 | PA-NS; QL (62 EA per 31 days) |
| SYMPAZAN ORAL FILM 5 MG | T4 | PA-NS; QL (62 EA per 31 days) |
| TASMAR ORAL TABLET 100 MG | T5 | |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG (14)- 240 MG (46) | T5 | PA; QL (120 EA per 365 days) |
| TECFIDERA ORAL CAPSULE,DELAYED RELEASE(DR/EC) 120 MG, 240 MG | T5 | PA; QL (62 EA per 31 days) |
| TEGRETOL ORAL SUSPENSION | T4 | |
| TEGRETOL ORAL TABLET | T4 | |
| TEGRETOL XR | T4 | |
| TEGSEDI | T5 | PA; QL (6 ML per 28 days) |
| <i>temazepam</i> | T2 | QL (31 EA per 31 days) |
| TENCON | T2 | QL (372 EA per 31 days) |
| <i>tetrabenazine oral tablet 12.5 mg</i> | T5 | PA; QL (93 EA per 31 days) |
| <i>tetrabenazine oral tablet 25 mg</i> | T5 | PA; QL (124 EA per 31 days) |
| <i>thioridazine</i> | T2 | |
| <i>thiothixene</i> | T1 | |
| <i>tiagabine</i> | T2 | |
| <i>tizanidine</i> | T2 | |
| <i>tolcapone</i> | T5 | |
| TOPAMAX | T4 | |
| <i>topiramate oral capsule, sprinkle</i> | T2 | |
| <i>topiramate oral capsule,sprinkle,er 24hr</i> | T4 | |
| <i>topiramate oral tablet</i> | T2 | |
| TOSYMRA | T4 | QL (12 EA per 28 days) |
| <i>tramadol oral capsule,er biphasic 24 hr 17-83</i> | T4 | PA; QL (30 EA per 30 days) |
| <i>tramadol oral capsule,er biphasic 24 hr 25-75 100 mg, 200 mg</i> | T4 | PA; QL (30 EA per 30 days) |
| <i>tramadol oral tablet 100 mg</i> | T4 | PA; QL (124 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-------------------------------|
| <i>tramadol oral tablet 50 mg</i> | T1 | PA; QL (240 EA per 30 days) |
| <i>tramadol oral tablet extended release 24 hr</i> | T2 | PA; QL (30 EA per 30 days) |
| <i>tramadol oral tablet, er multiphase 24 hr</i> | T2 | PA; QL (30 EA per 30 days) |
| <i>tramadol-acetaminophen</i> | T2 | PA; QL (372 EA per 31 days) |
| TRANXENE T-TAB | T4 | QL (372 EA per 31 days) |
| <i>tranylcypromine</i> | T2 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 50 mg</i> | T1 | |
| <i>trazodone oral tablet 300 mg</i> | T2 | |
| TREXIMET | T5 | QL (9 EA per 28 days) |
| TREZIX | T4 | PA; QL (372 EA per 31 days) |
| <i>triazolam</i> | T2 | PA |
| <i>trifluoperazine</i> | T2 | |
| <i>trihexyphenidyl</i> | T2 | |
| TRILEPTAL | T4 | |
| <i>trimipramine</i> | T3 | PA-NS |
| TRINTELLIX | T3 | PA-NS |
| TROKENDI XR | T4 | |
| TRUDHESA | T4 | PA; QL (12 ML per 28 days) |
| UBRELVY ORAL TABLET 100 MG | T5 | QL (17 EA per 28 days) |
| UBRELVY ORAL TABLET 50 MG | T5 | QL (34 EA per 28 days) |
| VALIUM | T4 | QL (124 EA per 31 days) |
| <i>valproic acid</i> | T2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | T2 | |
| VALTOCO | T4 | PA-NS; QL (10 EA per 30 days) |
| <i>venlafaxine besylate</i> | T4 | PA-NS; QL (62 EA per 31 days) |
| <i>venlafaxine oral capsule,extended release 24hr 150 mg, 37.5 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>venlafaxine oral capsule,extended release 24hr 75 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>venlafaxine oral tablet</i> | T2 | |
| <i>venlafaxine oral tablet extended release 24hr 150 mg, 37.5 mg, 75 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>venlafaxine oral tablet extended release 24hr 225 mg</i> | T4 | QL (31 EA per 31 days) |
| VERSACLOZ | T4 | QL (558 ML per 31 days) |
| <i>vigabatrin</i> | T5 | PA-NS |
| VIGADRONE | T5 | PA-NS |
| VIIBRYD ORAL TABLET | T4 | PA-NS; QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|--------------------------------|
| VIIBRYD ORAL TABLETS,DOSE PACK 10 MG (7)- 20 MG (23) | T3 | PA-NS; QL (60 EA per 365 days) |
| <i>vilazodone</i> | T3 | PA-NS; QL (31 EA per 31 days) |
| VIMOVO | T5 | PA; QL (62 EA per 31 days) |
| VIMPAT ORAL SOLUTION | T4 | |
| VIMPAT ORAL TABLET 100 MG, 150 MG, 200 MG | T5 | |
| VIMPAT ORAL TABLET 50 MG | T4 | |
| VIVITROL | T5 | |
| VRAYLAR ORAL CAPSULE | T5 | PA-NS; QL (31 EA per 31 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK | T4 | PA-NS; QL (14 EA per 365 days) |
| VTOL LQ | T2 | QL (5723 ML per 31 days) |
| VUMERITY | T5 | PA; QL (124 EA per 31 days) |
| VYVANSE | T4 | ST; QL (31 EA per 31 days) |
| WAKIX | T5 | PA; QL (62 EA per 31 days) |
| WELLBUTRIN SR | T4 | QL (62 EA per 31 days) |
| WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 150 MG | T4 | QL (93 EA per 31 days) |
| WELLBUTRIN XL ORAL TABLET EXTENDED RELEASE 24 HR 300 MG | T4 | QL (31 EA per 31 days) |
| XANAX ORAL TABLET 0.25 MG, 0.5 MG | T4 | PA; QL (93 EA per 31 days) |
| XANAX ORAL TABLET 1 MG, 2 MG | T4 | PA; QL (155 EA per 31 days) |
| XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG | T4 | PA; QL (31 EA per 31 days) |
| XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 2 MG | T4 | PA; QL (155 EA per 31 days) |
| XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 3 MG | T4 | PA; QL (93 EA per 31 days) |
| XCOPRI | T5 | PA-NS |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | T5 | PA-NS |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14) | T4 | PA-NS |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | T5 | PA-NS |
| XENAZINE ORAL TABLET 12.5 MG | T5 | PA; QL (93 EA per 31 days) |
| XENAZINE ORAL TABLET 25 MG | T5 | PA; QL (124 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 13.5 MG, 18 MG, 27 MG, 9 MG | T4 | PA; QL (62 EA per 31 days) |
| XTAMPZA ER ORAL CAP,SPRINKL,ER12HR(DONT CRUSH) 36 MG | T5 | PA; QL (62 EA per 31 days) |
| XYREM | T5 | PA; QL (540 ML per 30 days) |
| XYWAV | T5 | PA; QL (540 ML per 30 days) |
| <i>zaleplon oral capsule 10 mg</i> | T2 | PA; QL (62 EA per 31 days) |
| <i>zaleplon oral capsule 5 mg</i> | T2 | PA; QL (93 EA per 31 days) |
| ZANAFLEX | T4 | |
| ZARONTIN | T4 | |
| ZEBUTAL | T2 | QL (372 EA per 31 days) |
| ZELAPAR | T5 | |
| ZEMBRACE SYMTOUCH | T5 | QL (8 ML per 28 days) |
| ZENZEDI ORAL TABLET 10 MG, 5 MG | T2 | QL (62 EA per 31 days) |
| ZENZEDI ORAL TABLET 15 MG, 2.5 MG, 20 MG, 30 MG, 7.5 MG | T4 | QL (62 EA per 31 days) |
| ZEPOSIA | T5 | PA; QL (31 EA per 31 days) |
| ZEPOSIA STARTER KIT | T5 | PA; QL (74 EA per 365 days) |
| ZEPOSIA STARTER PACK | T5 | PA; QL (14 EA per 365 days) |
| ZIMHI | T4 | |
| <i>ziprasidone hcl</i> | T2 | QL (62 EA per 31 days) |
| <i>ziprasidone mesylate</i> | T2 | |
| ZIPSOR | T5 | |
| <i>zolmitriptan nasal spray,non-aerosol 5 mg</i> | T4 | QL (8 EA per 28 days) |
| <i>zolmitriptan oral tablet 2.5 mg</i> | T2 | QL (16 EA per 28 days) |
| <i>zolmitriptan oral tablet 5 mg</i> | T2 | QL (8 EA per 28 days) |
| <i>zolmitriptan oral tablet,disintegrating 2.5 mg</i> | T2 | QL (16 EA per 28 days) |
| <i>zolmitriptan oral tablet,disintegrating 5 mg</i> | T2 | QL (8 EA per 28 days) |
| ZOLOFT | T4 | |
| <i>zolpidem oral</i> | T2 | PA; QL (31 EA per 31 days) |
| <i>zolpidem sublingual</i> | T3 | PA; QL (31 EA per 31 days) |
| ZOMIG NASAL SPRAY,NON-AEROSOL 2.5 MG | T4 | QL (16 EA per 28 days) |
| ZOMIG NASAL SPRAY,NON-AEROSOL 5 MG | T4 | QL (8 EA per 28 days) |
| ZOMIG ORAL TABLET 2.5 MG | T4 | QL (16 EA per 28 days) |
| ZOMIG ORAL TABLET 5 MG | T4 | QL (8 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ZONEGRAN ORAL CAPSULE 100 MG, 25 MG | T5 | |
| <i>zonisamide</i> | T2 | |
| ZUBSOLV SUBLINGUAL TABLET 0.7-0.18 MG, 2.9-0.71 MG, 8.6-2.1 MG | T3 | QL (62 EA per 31 days) |
| ZUBSOLV SUBLINGUAL TABLET 1.4-0.36 MG | T3 | QL (93 EA per 31 days) |
| ZUBSOLV SUBLINGUAL TABLET 11.4-2.9 MG, 5.7-1.4 MG | T3 | QL (31 EA per 31 days) |
| ZYPREXA INTRAMUSCULAR | T4 | |
| ZYPREXA ORAL | T4 | QL (31 EA per 31 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | T4 | QL (2 EA per 28 days) |
| ZYPREXA ZYDIS | T4 | QL (31 EA per 31 days) |
| Cardiovascular, Hypertension / Lipids | | |
| ACCUPRIL | T4 | |
| ACCURETIC | T4 | |
| <i>acebutolol</i> | T1 | |
| ALDACTAZIDE | T4 | |
| ALDACTONE | T4 | |
| <i>aliskiren</i> | T4 | |
| ALTACE ORAL CAPSULE 1.25 MG | T4 | QL (62 EA per 31 days) |
| ALTACE ORAL CAPSULE 10 MG | T4 | QL (93 EA per 31 days) |
| ALTACE ORAL CAPSULE 2.5 MG, 5 MG | T4 | |
| ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HR 20 MG, 60 MG | T4 | |
| ALTOPREV ORAL TABLET EXTENDED RELEASE 24 HR 40 MG | T5 | |
| <i>amiloride</i> | T1 | |
| <i>amiloride-hydrochlorothiazide</i> | T1 | |
| <i>amiodarone oral</i> | T2 | |
| <i>amlodipine</i> | T1 | |
| <i>amlodipine-atorvastatin</i> | T2 | |
| <i>amlodipine-benazepril</i> | T1 | |
| <i>amlodipine-olmesartan</i> | T3 | QL (31 EA per 31 days) |
| <i>amlodipine-valsartan</i> | T2 | |
| ANTARA ORAL CAPSULE 30 MG, 90 MG | T4 | |
| ARIXTRA SUBCUTANEOUS SYRINGE 10 MG/0.8 ML, 5 MG/0.4 ML, 7.5 MG/0.6 ML | T5 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| ARIXTRA SUBCUTANEOUS SYRINGE 2.5 MG/0.5 ML | T4 | |
| <i>aspirin-dipyridamole</i> | T2 | |
| ASPRUZYO SPRINKLE | T4 | PA; QL (60 EA per 30 days) |
| ATACAND | T4 | |
| ATACAND HCT | T4 | |
| <i>atenolol</i> | T1 | |
| <i>atenolol-chlorthalidone</i> | T1 | |
| <i>atorvastatin</i> | T1 | |
| AVALIDE | T4 | QL (31 EA per 31 days) |
| AVAPRO | T4 | QL (31 EA per 31 days) |
| AZOR | T4 | QL (31 EA per 31 days) |
| <i>benazepril</i> | T1 | |
| <i>benazepril-hydrochlorothiazide</i> | T1 | |
| BENICAR HCT | T4 | QL (31 EA per 31 days) |
| BENICAR ORAL TABLET 20 MG, 40 MG | T4 | QL (31 EA per 31 days) |
| BENICAR ORAL TABLET 5 MG | T4 | QL (93 EA per 31 days) |
| BETAPACE AF | T4 | |
| <i>betaxolol oral</i> | T1 | |
| BIDIL | T4 | |
| <i>bisoprolol fumarate</i> | T1 | |
| <i>bisoprolol-hydrochlorothiazide</i> | T1 | |
| BRILINTA | T3 | |
| <i>bumetanide</i> | T1 | |
| BYSTOLIC ORAL TABLET 10 MG, 2.5 MG | T4 | QL (93 EA per 31 days) |
| BYSTOLIC ORAL TABLET 20 MG | T4 | QL (62 EA per 31 days) |
| BYSTOLIC ORAL TABLET 5 MG | T4 | QL (217 EA per 31 days) |
| CABLIVI INJECTION KIT | T5 | PA; QL (31 EA per 31 days) |
| CADUET | T4 | |
| CALAN SR | T4 | |
| CAMZYOS | T5 | PA; QL (31 EA per 31 days) |
| <i>candesartan</i> | T1 | |
| <i>candesartan-hydrochlorothiazid</i> | T1 | |
| <i>captopril</i> | T1 | |
| CARDIZEM CD | T4 | |
| CARDIZEM LA | T4 | |
| CARDIZEM ORAL TABLET 120 MG, 30 MG, 60 MG | T4 | |
| CARDURA | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| CARDURA XL | T4 | |
| CAROSPIR | T4 | |
| CARTIA XT | T1 | |
| <i>carvedilol</i> | T1 | |
| <i>carvedilol phosphate</i> | T4 | |
| CATAPRES-TTS-1 | T4 | |
| CATAPRES-TTS-2 | T4 | |
| CATAPRES-TTS-3 | T4 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | T1 | |
| <i>cholestyramine (with sugar) oral powder in packet</i> | T2 | |
| CHOLESTYRAMINE LIGHT ORAL POWDER IN PACKET | T2 | |
| <i>cilostazol</i> | T2 | |
| <i>clonidine</i> | T2 | |
| <i>clonidine hcl oral tablet</i> | T1 | |
| <i>clopidogrel oral tablet 75 mg</i> | T1 | |
| <i>colesevelam</i> | T3 | |
| COLESTID ORAL PACKET | T4 | |
| COLESTID ORAL TABLET | T4 | |
| <i>colestipol oral packet</i> | T2 | |
| <i>colestipol oral tablet</i> | T2 | |
| CONJUPRI | T4 | ST; QL (31 EA per 31 days) |
| COREG | T4 | |
| COREG CR | T4 | |
| CORGARD | T4 | |
| CORLANOR ORAL SOLUTION | T4 | PA; QL (420 ML per 28 days) |
| CORLANOR ORAL TABLET 5 MG | T4 | PA; QL (93 EA per 31 days) |
| CORLANOR ORAL TABLET 7.5 MG | T4 | PA; QL (62 EA per 31 days) |
| COZAAR ORAL TABLET 100 MG | T4 | QL (31 EA per 31 days) |
| COZAAR ORAL TABLET 25 MG | T4 | QL (93 EA per 31 days) |
| COZAAR ORAL TABLET 50 MG | T4 | QL (62 EA per 31 days) |
| CRESTOR | T4 | |
| <i>dabigatran etexilate</i> | T4 | QL (62 EA per 31 days) |
| DEMSER | T4 | |
| DIBENZYLINE | T5 | PA |
| DIGITEK ORAL TABLET 125 MCG (0.125 MG) | T1 | QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| DIGITEK ORAL TABLET 250 MCG (0.25 MG) | T2 | QL (31 EA per 31 days) |
| <i>digoxin oral solution</i> | T2 | QL (155 ML per 31 days) |
| <i>digoxin oral tablet 125 mcg (0.125 mg)</i> | T1 | QL (62 EA per 31 days) |
| <i>digoxin oral tablet 250 mcg (0.25 mg)</i> | T2 | QL (31 EA per 31 days) |
| <i>digoxin oral tablet 62.5 mcg (0.0625 mg)</i> | T4 | QL (124 EA per 31 days) |
| <i>diltiazem hcl oral capsule,extended release 12 hr</i> | T1 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 360 mg, 420 mg</i> | T1 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> | T1 | |
| <i>diltiazem hcl oral tablet</i> | T1 | |
| <i>diltiazem hcl oral tablet extended release 24 hr 180 mg, 240 mg, 300 mg, 360 mg</i> | T1 | |
| DILT-XR | T1 | |
| DIOVAN HCT | T4 | QL (31 EA per 31 days) |
| DIOVAN ORAL TABLET 160 MG, 40 MG, 80 MG | T4 | QL (62 EA per 31 days) |
| DIOVAN ORAL TABLET 320 MG | T4 | QL (31 EA per 31 days) |
| <i>dipyridamole oral</i> | T2 | |
| <i>disopyramide phosphate oral capsule</i> | T2 | |
| DIURIL | T4 | |
| <i>dofetilide</i> | T3 | |
| DOPTELET (10 TAB PACK) | T5 | PA |
| DOPTELET (15 TAB PACK) | T5 | PA |
| DOPTELET (30 TAB PACK) | T5 | PA |
| <i>doxazosin</i> | T1 | |
| DYRENIUM | T4 | |
| EDARBI | T4 | |
| EDARBYCLOR | T4 | |
| EDECIN | T3 | |
| EFFIENT | T4 | |
| ELIQUIS DVT-PE TREAT 30D START | T3 | QL (74 EA per 30 days) |
| ELIQUIS ORAL TABLET 2.5 MG | T3 | QL (60 EA per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | T3 | QL (74 EA per 30 days) |
| <i>enalapril maleate oral solution</i> | T4 | |
| <i>enalapril maleate oral tablet</i> | T1 | |
| <i>enalapril-hydrochlorothiazide</i> | T1 | |
| <i>enoxaparin subcutaneous syringe 100 mg/ml, 120 mg/0.8 ml, 150 mg/ml</i> | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml, 40 mg/0.4 ml, 60 mg/0.6 ml, 80 mg/0.8 ml</i> | T2 | |
| ENTRESTO ORAL TABLET 24-26 MG | T3 | QL (186 EA per 31 days) |
| ENTRESTO ORAL TABLET 49-51 MG | T3 | QL (93 EA per 31 days) |
| ENTRESTO ORAL TABLET 97-103 MG | T3 | QL (62 EA per 31 days) |
| <i>eplerenone</i> | T2 | |
| <i>ethacrynic acid</i> | T2 | |
| EXFORGE | T4 | |
| EXFORGE HCT | T4 | |
| EZALLOR SPRINKLE | T4 | |
| <i>ezetimibe</i> | T2 | |
| <i>ezetimibe-rosuvastatin</i> | T4 | ST; QL (31 EA per 31 days) |
| <i>ezetimibe-simvastatin</i> | T3 | |
| <i>felodipine</i> | T2 | |
| <i>fenofibrate micronized oral capsule 130 mg, 134 mg, 200 mg, 43 mg, 67 mg</i> | T2 | |
| <i>fenofibrate micronized oral capsule 30 mg, 90 mg</i> | T4 | |
| <i>fenofibrate nanocrystallized</i> | T2 | |
| <i>fenofibrate oral capsule</i> | T4 | |
| <i>fenofibrate oral tablet 120 mg, 40 mg</i> | T4 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | T2 | |
| <i>fenofibric acid (choline)</i> | T3 | |
| FENOGLIDE | T4 | |
| <i>flecainide</i> | T2 | |
| FLOLIPID | T4 | |
| <i>fluvastatin oral capsule</i> | T1 | |
| <i>fluvastatin oral tablet extended release 24 hr</i> | T3 | |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml, 5 mg/0.4 ml, 7.5 mg/0.6 ml</i> | T5 | |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> | T2 | |
| <i>fosinopril</i> | T1 | |
| <i>fosinopril-hydrochlorothiazide</i> | T1 | |
| FRAGMIN SUBCUTANEOUS SOLUTION 25,000 ANTI-XA UNIT/ML | T5 | |
| FRAGMIN SUBCUTANEOUS SYRINGE 10,000 ANTI-XA UNIT/ML, 12,500 ANTI-XA UNIT/0.5 ML, 18,000 ANTI-XA UNIT/0.72 ML, 7,500 ANTI-XA UNIT/0.3 ML | T5 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| FRAGMIN SUBCUTANEOUS SYRINGE 15,000 ANTI-XA UNIT/0.6 ML, 2,500 ANTI- XA UNIT/0.2 ML, 5,000 ANTI-XA UNIT/0.2 ML | T3 | |
| <i>furosemide injection</i> | T2 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | T2 | |
| <i>furosemide oral tablet</i> | T1 | |
| <i>gemfibrozil</i> | T1 | |
| <i>guanfacine oral tablet</i> | T2 | |
| <i>heparin (porcine) injection solution</i> | T2 | |
| <i>hydralazine oral</i> | T1 | |
| <i>hydrochlorothiazide</i> | T1 | |
| HYZAAR | T4 | |
| <i>icosapent ethyl oral capsule 0.5 gram</i> | T4 | QL (248 EA per 31 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> | T4 | QL (124 EA per 31 days) |
| <i>indapamide</i> | T1 | |
| INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 60 MG, 80 MG | T4 | |
| INDERAL LA ORAL CAPSULE,EXTENDED RELEASE 24 HR 160 MG | T5 | |
| INNOPRAN XL | T4 | |
| INSPRA | T4 | |
| <i>irbesartan</i> | T1 | QL (31 EA per 31 days) |
| <i>irbesartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| ISORDIL | T4 | |
| ISORDIL TITRADOSE ORAL TABLET 5 MG | T4 | |
| <i>isosorbide dinitrate oral tablet</i> | T2 | |
| <i>isosorbide mononitrate</i> | T1 | |
| <i>isosorbide-hydralazine</i> | T4 | |
| <i>isradipine</i> | T2 | |
| JANTOVEN | T1 | |
| JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG | T5 | PA |
| KATERZIA | T4 | |
| KERENDIA | T4 | PA; QL (31 EA per 31 days) |
| <i>labetalol oral</i> | T1 | |
| LANOXIN ORAL TABLET 125 MCG (0.125 MG) | T4 | QL (62 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| LANOXIN ORAL TABLET 250 MCG (0.25 MG) | T4 | QL (31 EA per 31 days) |
| LANOXIN ORAL TABLET 62.5 MCG (0.0625 MG) | T4 | QL (124 EA per 31 days) |
| LASIX | T4 | |
| LESCOL XL | T4 | |
| <i>levamlodipine</i> | T4 | ST; QL (31 EA per 31 days) |
| LIPITOR | T4 | |
| LIPOFEN | T4 | |
| <i>lisinopril</i> | T1 | |
| <i>lisinopril-hydrochlorothiazide</i> | T1 | |
| LIVALO | T4 | |
| LOPID | T4 | |
| LOPRESSOR ORAL | T4 | |
| <i>losartan oral tablet 100 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>losartan oral tablet 25 mg</i> | T1 | QL (93 EA per 31 days) |
| <i>losartan oral tablet 50 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>losartan-hydrochlorothiazide</i> | T1 | |
| LOTENSIN ORAL TABLET 10 MG, 20 MG, 40 MG | T4 | |
| LOTREL ORAL CAPSULE 10-20 MG, 10-40 MG, 5-10 MG, 5-20 MG | T4 | |
| <i>lovastatin</i> | T1 | |
| LOVAZA | T3 | PA; QL (124 EA per 31 days) |
| LOVENOX SUBCUTANEOUS SYRINGE 100 MG/ML | T5 | |
| LOVENOX SUBCUTANEOUS SYRINGE 120 MG/0.8 ML, 150 MG/ML, 30 MG/0.3 ML, 40 MG/0.4 ML, 60 MG/0.6 ML, 80 MG/0.8 ML | T4 | |
| MATZIM LA | T1 | |
| MAXZIDE | T4 | |
| MAXZIDE-25MG | T4 | |
| <i>metolazone</i> | T2 | |
| <i>metoprolol succinate</i> | T1 | |
| <i>metoprolol ta-hydrochlorothiaz</i> | T1 | |
| <i>metoprolol tartrate oral</i> | T1 | |
| <i>metyrosine</i> | T3 | |
| <i>mexiletine</i> | T2 | |
| MICARDIS | T4 | |
| MICARDIS HCT | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| MINIPRESS | T4 | |
| <i>minoxidil oral</i> | T2 | |
| <i>moexipril</i> | T1 | |
| MULPLETA | T5 | PA |
| MULTAQ | T4 | |
| <i>nadolol</i> | T1 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg</i> | T4 | QL (93 EA per 31 days) |
| <i>nebivolol oral tablet 20 mg</i> | T4 | QL (62 EA per 31 days) |
| <i>nebivolol oral tablet 5 mg</i> | T4 | QL (217 EA per 31 days) |
| NEXLETOL | T4 | PA; QL (31 EA per 31 days) |
| NEXLIZET | T4 | PA; QL (31 EA per 31 days) |
| <i>niacin oral tablet 500 mg</i> | T5 | |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 750 mg</i> | T3 | |
| <i>niacin oral tablet extended release 24 hr 500 mg</i> | T3 | QL (31 EA per 31 days) |
| NIACOR | T4 | |
| <i>nicardipine oral</i> | T2 | |
| <i>nifedipine</i> | T2 | |
| <i>nimodipine</i> | T2 | |
| <i>nisoldipine</i> | T2 | |
| NITRO-BID | T2 | |
| NITRO-DUR | T3 | |
| <i>nitroglycerin sublingual</i> | T2 | |
| <i>nitroglycerin transdermal patch 24 hour</i> | T2 | |
| <i>nitroglycerin translingual</i> | T2 | |
| NITROLINGUAL | T4 | |
| NITROSTAT | T4 | |
| NORLIQVA | T4 | PA; QL (496 ML per 31 days) |
| NORPACE | T4 | |
| NORPACE CR | T4 | |
| NORVASC | T4 | |
| NYMALIZE ORAL SYRINGE 60 MG/10 ML | T4 | |
| <i>olmesartan oral tablet 20 mg, 40 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>olmesartan oral tablet 5 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>olmesartan-amlodipin-hcthiazyd</i> | T3 | |
| <i>olmesartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| <i>omega-3 acid ethyl esters</i> | T3 | QL (124 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG | T4 | PA; QL (93 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| ORENITRAM ORAL TABLET EXTENDED RELEASE 0.25 MG | T4 | PA; QL (186 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 1 MG | T5 | PA; QL (186 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 2.5 MG | T5 | PA; QL (521 EA per 31 days) |
| ORENITRAM ORAL TABLET EXTENDED RELEASE 5 MG | T5 | PA; QL (261 EA per 31 days) |
| PACERONE ORAL TABLET 100 MG, 200 MG, 400 MG | T2 | |
| <i>pentoxifylline</i> | T2 | |
| <i>perindopril erbumine</i> | T1 | |
| <i>phenoxybenzamine</i> | T5 | PA |
| <i>pindolol</i> | T1 | |
| PLAVIX ORAL TABLET 75 MG | T4 | |
| PRADAXA ORAL CAPSULE 110 MG | T4 | QL (124 EA per 31 days) |
| PRADAXA ORAL CAPSULE 150 MG, 75 MG | T4 | QL (62 EA per 31 days) |
| PRALUENT PEN | T4 | PA; QL (2 ML per 28 days) |
| <i>prasugrel</i> | T3 | |
| <i>pravastatin</i> | T1 | |
| <i>prazosin</i> | T1 | |
| PREVALITE ORAL POWDER IN PACKET | T2 | |
| PROCARDIA XL | T4 | |
| PROMACTA ORAL POWDER IN PACKET 12.5 MG | T5 | PA; QL (372 EA per 31 days) |
| PROMACTA ORAL POWDER IN PACKET 25 MG | T5 | PA; QL (31 EA per 31 days) |
| PROMACTA ORAL TABLET 12.5 MG, 25 MG | T5 | PA; QL (31 EA per 31 days) |
| PROMACTA ORAL TABLET 50 MG, 75 MG | T5 | PA; QL (62 EA per 31 days) |
| <i>propafenone</i> | T2 | |
| <i>propranolol oral capsule, extended release 24 hr</i> | T2 | |
| <i>propranolol oral solution</i> | T1 | |
| <i>propranolol oral tablet</i> | T1 | |
| QBRELIS | T4 | |
| QUESTRAN LIGHT | T4 | |
| QUESTRAN ORAL POWDER | T4 | |
| <i>quinapril</i> | T1 | |
| <i>quinapril-hydrochlorothiazide</i> | T1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>quinidine gluconate oral</i> | T2 | |
| <i>quinidine sulfate oral tablet</i> | T2 | |
| <i>ramipril</i> | T1 | |
| RANEXA | T4 | QL (62 EA per 31 days) |
| <i>ranolazine</i> | T3 | QL (62 EA per 31 days) |
| REPATHA PUSHTRONEX | T3 | PA; QL (7 ML per 28 days) |
| REPATHA SURECLICK | T3 | PA; QL (3 ML per 28 days) |
| REPATHA SYRINGE | T3 | PA; QL (3 ML per 28 days) |
| <i>rosuvastatin</i> | T1 | |
| ROSZET | T4 | ST; QL (31 EA per 31 days) |
| RYTHMOL SR | T4 | |
| SAVAYSA | T4 | QL (31 EA per 31 days) |
| <i>simvastatin oral tablet</i> | T1 | |
| SOAANZ | T4 | ST |
| SORINE | T1 | |
| SOTALOL AF | T1 | |
| <i>sotalol oral</i> | T1 | |
| SOTYLIZE | T4 | |
| <i>spironolactone</i> | T1 | |
| <i>spironolacton-hydrochlorothiaz</i> | T1 | |
| SULAR ORAL TABLET EXTENDED RELEASE 24 HR 17 MG, 34 MG, 8.5 MG | T4 | |
| TAVALISSE | T5 | PA; QL (62 EA per 31 days) |
| TAZTIA XT | T1 | |
| TEKTRUNA | T4 | |
| <i>telmisartan</i> | T1 | |
| <i>telmisartan-amlodipine</i> | T1 | |
| <i>telmisartan-hydrochlorothiazid</i> | T1 | |
| TENORETIC 100 | T4 | |
| TENORETIC 50 | T4 | |
| TENORMIN | T4 | |
| <i>terazosin</i> | T1 | |
| THALITONE | T4 | |
| TIADYLT ER | T1 | |
| TIAZAC | T4 | |
| TIKOSYN | T3 | |
| <i>timolol maleate oral</i> | T1 | |
| TOPROL XL | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>torseamide oral</i> | T1 | |
| <i>trandolapril</i> | T1 | |
| <i>trandolapril-verapamil</i> | T2 | |
| <i>triamterene</i> | T4 | |
| <i>triamterene-hydrochlorothiazid</i> | T1 | |
| TRIBENZOR | T4 | |
| TRICOR | T4 | |
| TRILIPIX | T4 | |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | T5 | PA; QL (62 EA per 31 days) |
| UPTRAVI ORAL TABLET 200 MCG | T5 | PA; QL (224 EA per 28 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK | T5 | PA; QL (400 EA per 365 days) |
| <i>valsartan oral solution</i> | T5 | QL (2480 ML per 31 days) |
| <i>valsartan oral tablet 160 mg, 40 mg, 80 mg</i> | T1 | QL (62 EA per 31 days) |
| <i>valsartan oral tablet 320 mg</i> | T1 | QL (31 EA per 31 days) |
| <i>valsartan-hydrochlorothiazide</i> | T2 | QL (31 EA per 31 days) |
| VASCEPA ORAL CAPSULE 0.5 GRAM | T4 | QL (248 EA per 31 days) |
| VASCEPA ORAL CAPSULE 1 GRAM | T4 | QL (124 EA per 31 days) |
| VASERETIC | T4 | |
| VASOTEC | T4 | |
| VECAMYL | T4 | |
| <i>verapamil oral</i> | T2 | |
| VERELAN | T4 | |
| VERELAN PM | T4 | |
| VERQUVO | T4 | PA; QL (31 EA per 31 days) |
| VYNDAMAX | T5 | PA; QL (31 EA per 31 days) |
| VYNDAQEL | T5 | PA; QL (124 EA per 31 days) |
| VYTORIN 10-10 | T4 | |
| VYTORIN 10-20 | T4 | |
| VYTORIN 10-40 | T4 | |
| VYTORIN 10-80 | T4 | |
| <i>warfarin</i> | T1 | |
| WELCHOL | T4 | |
| XARELTO DVT-PE TREAT 30D START | T3 | QL (51 EA per 30 days) |
| XARELTO ORAL SUSPENSION FOR RECONSTITUTION | T3 | PA; QL (930 ML per 31 days) |
| XARELTO ORAL TABLET 10 MG, 20 MG | T3 | QL (31 EA per 31 days) |
| XARELTO ORAL TABLET 15 MG | T3 | QL (52 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| XARELTO ORAL TABLET 2.5 MG | T3 | QL (62 EA per 31 days) |
| ZESTORETIC | T4 | |
| ZESTRIL | T4 | |
| ZETIA | T4 | |
| ZIAC | T4 | |
| ZOCOR ORAL TABLET 10 MG, 20 MG, 40 MG | T4 | |
| ZONTIVITY | T4 | |
| ZYPITAMAG | T4 | |
| Dermatologicals/Topical Therapy | | |
| ABSORICA | T4 | |
| ABSORICA LD | T4 | |
| ACANYA TOPICAL GEL WITH PUMP | T4 | |
| ACUTANE | T2 | |
| <i>acitretin</i> | T4 | PA |
| <i>acyclovir topical cream</i> | T3 | |
| <i>acyclovir topical ointment</i> | T1 | QL (30 GM per 30 days) |
| ACZONE | T4 | QL (90 GM per 28 days) |
| <i>adapalene topical cream</i> | T2 | PA |
| <i>adapalene topical gel 0.3 %</i> | T2 | PA |
| <i>adapalene topical swab</i> | T2 | PA |
| <i>adapalene-benzoyl peroxide</i> | T4 | |
| ADBRY | T5 | PA; QL (4 ML per 28 days) |
| AKLIEF | T4 | PA |
| ALA-CORT TOPICAL CREAM 1 % | T1 | |
| ALA-CORT TOPICAL CREAM 2.5 % | T1 | QL (30 GM per 28 days) |
| ALA-SCALP | T4 | |
| <i>alclometasone</i> | T1 | |
| ALTABAX | T4 | |
| ALTRENO | T4 | PA; QL (45 GM per 28 days) |
| <i>amcinonide</i> | T2 | |
| <i>ammonium lactate</i> | T2 | |
| AMNESTEEM | T2 | |
| AMZEEQ | T4 | |
| APEXICON E | T4 | QL (60 GM per 28 days) |
| ARAZLO | T4 | QL (45 GM per 28 days) |
| ATRALIN | T4 | PA; QL (45 GM per 28 days) |
| AVITA | T4 | PA; QL (45 GM per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>azelaic acid</i> | T4 | QL (50 GM per 28 days) |
| AZELEX | T4 | QL (50 GM per 28 days) |
| BENZAMYCIN | T4 | |
| <i>betamethasone dipropionate</i> | T1 | |
| <i>betamethasone valerate topical cream</i> | T1 | |
| <i>betamethasone valerate topical foam</i> | T4 | |
| <i>betamethasone valerate topical lotion</i> | T1 | |
| <i>betamethasone valerate topical ointment</i> | T1 | |
| <i>betamethasone, augmented</i> | T2 | |
| BRYHALI | T4 | QL (100 GM per 28 days) |
| <i>calcipotriene scalp</i> | T2 | QL (60 ML per 28 days) |
| <i>calcipotriene topical cream</i> | T2 | QL (60 GM per 28 days) |
| <i>calcipotriene topical foam</i> | T4 | ST |
| <i>calcipotriene topical ointment</i> | T2 | QL (60 GM per 28 days) |
| <i>calcipotriene-betamethasone topical ointment</i> | T4 | ST; QL (400 GM per 28 days) |
| <i>calcipotriene-betamethasone topical suspension</i> | T5 | ST; QL (400 GM per 28 days) |
| <i>calcitriol topical</i> | T3 | ST |
| CAPEX | T4 | QL (840 ML per 28 days) |
| CARAC | T5 | PA |
| CENTANY | T4 | ST |
| CIBINQO | T5 | PA; QL (31 EA per 31 days) |
| <i>ciclopirox topical cream</i> | T2 | QL (90 GM per 28 days) |
| <i>ciclopirox topical gel</i> | T2 | QL (45 GM per 28 days) |
| <i>ciclopirox topical shampoo</i> | T2 | QL (120 ML per 28 days) |
| <i>ciclopirox topical solution</i> | T2 | |
| <i>ciclopirox topical suspension</i> | T2 | QL (60 ML per 28 days) |
| CLARAVIS | T2 | |
| CLEOCIN T TOPICAL LOTION | T4 | QL (60 ML per 28 days) |
| CLINDACIN P | T4 | |
| CLINDAGEL | T5 | |
| <i>clindamycin phosphate topical foam</i> | T2 | QL (100 GM per 28 days) |
| <i>clindamycin phosphate topical gel</i> | T2 | QL (75 GM per 28 days) |
| <i>clindamycin phosphate topical lotion</i> | T2 | QL (60 ML per 28 days) |
| <i>clindamycin phosphate topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>clindamycin phosphate topical swab</i> | T2 | |
| <i>clindamycin-benzoyl peroxide topical gel</i> | T2 | |
| <i>clindamycin-benzoyl peroxide topical gel with pump 1.2-2.5 %</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>clindamycin-tretinoin</i> | T2 | PA; QL (60 GM per 28 days) |
| <i>clobetasol scalp</i> | T2 | QL (50 ML per 28 days) |
| <i>clobetasol topical cream</i> | T3 | QL (60 GM per 28 days) |
| <i>clobetasol topical foam</i> | T2 | QL (100 GM per 28 days) |
| <i>clobetasol topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>clobetasol topical lotion</i> | T2 | QL (118 ML per 28 days) |
| <i>clobetasol topical ointment</i> | T3 | QL (60 GM per 28 days) |
| <i>clobetasol topical shampoo</i> | T2 | QL (118 ML per 28 days) |
| <i>clobetasol topical spray,non-aerosol</i> | T2 | QL (125 ML per 28 days) |
| <i>clobetasol-emollient topical cream</i> | T3 | QL (60 GM per 28 days) |
| <i>clobetasol-emollient topical foam</i> | T3 | QL (100 GM per 28 days) |
| CLOBEX TOPICAL LOTION | T4 | QL (118 ML per 28 days) |
| CLOBEX TOPICAL SHAMPOO | T4 | QL (118 ML per 28 days) |
| CLOBEX TOPICAL SPRAY,NON-AEROSOL | T4 | QL (125 ML per 28 days) |
| <i>clocortolone pivalate</i> | T4 | |
| CLODAN | T2 | QL (118 ML per 28 days) |
| CLODERM | T4 | |
| <i>clotrimazole topical cream</i> | T2 | QL (45 GM per 28 days) |
| <i>clotrimazole topical solution</i> | T2 | QL (30 ML per 28 days) |
| <i>clotrimazole-betamethasone topical cream</i> | T2 | QL (45 GM per 28 days) |
| <i>clotrimazole-betamethasone topical lotion</i> | T2 | QL (60 ML per 28 days) |
| CONDYLOX TOPICAL GEL | T3 | |
| CORDRAN TAPE LARGE ROLL | T3 | |
| CORDRAN TOPICAL CREAM | T3 | QL (120 GM per 28 days) |
| CORDRAN TOPICAL LOTION | T3 | QL (120 ML per 28 days) |
| CORDRAN TOPICAL OINTMENT | T3 | QL (60 GM per 28 days) |
| COSENTYX (2 SYRINGES) | T5 | PA; QL (2 ML per 28 days) |
| COSENTYX PEN (2 PENS) | T5 | PA; QL (2 ML per 28 days) |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| CROTAN | T4 | |
| <i>dapsone topical</i> | T4 | QL (90 GM per 28 days) |
| DENAVIR | T3 | |
| DERMA-SMOOTH/FS SCALP OIL | T4 | QL (118.28 ML per 28 days) |
| <i>desonide topical cream</i> | T3 | QL (60 GM per 28 days) |
| <i>desonide topical gel</i> | T3 | QL (60 GM per 28 days) |
| <i>desonide topical lotion</i> | T3 | QL (118 ML per 28 days) |
| <i>desonide topical ointment</i> | T3 | QL (60 GM per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| DESOWEN TOPICAL CREAM | T4 | QL (60 GM per 28 days) |
| <i>desoximetasone topical cream</i> | T2 | QL (100 GM per 28 days) |
| <i>desoximetasone topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>desoximetasone topical ointment 0.05 %</i> | T4 | QL (100 GM per 28 days) |
| <i>desoximetasone topical ointment 0.25 %</i> | T2 | QL (100 GM per 28 days) |
| <i>desoximetasone topical spray,non-aerosol</i> | T2 | QL (100 ML per 28 days) |
| DESRX | T3 | QL (60 GM per 28 days) |
| <i>diclofenac sodium topical gel 3 %</i> | T4 | PA; QL (100 GM per 28 days) |
| DIFFERIN TOPICAL CREAM | T4 | PA |
| DIFFERIN TOPICAL GEL WITH PUMP | T4 | PA |
| DIFFERIN TOPICAL LOTION | T4 | PA |
| <i>diflorasone</i> | T4 | QL (60 GM per 28 days) |
| DIPROLENE (AUGMENTED) TOPICAL OINTMENT | T4 | |
| DOVONEX TOPICAL | T4 | ST; QL (60 GM per 28 days) |
| <i>doxepin topical</i> | T4 | PA; QL (45 GM per 28 days) |
| DUOBRII | T4 | PA; QL (200 GM per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML | T5 | PA; QL (2.28 ML per 28 days) |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | T5 | PA; QL (4 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | T5 | PA; QL (1.34 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 200 MG/1.14 ML | T5 | PA; QL (2.28 ML per 28 days) |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 300 MG/2 ML | T5 | PA; QL (8 ML per 28 days) |
| <i>econazole</i> | T2 | QL (85 GM per 28 days) |
| EFUDEX TOPICAL CREAM | T4 | |
| ELIDEL | T4 | QL (100 GM per 28 days) |
| ENSTILAR | T5 | ST; QL (60 GM per 28 days) |
| EPIDUO FORTE | T4 | |
| EPIDUO TOPICAL GEL WITH PUMP | T4 | |
| EPSOLAY | T4 | QL (30 GM per 28 days) |
| ERTACZO | T4 | ST; QL (60 GM per 28 days) |
| ERY PADS | T2 | |
| ERYGEL | T3 | QL (60 GM per 28 days) |
| <i>erythromycin with ethanol topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>erythromycin with ethanol topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>erythromycin-benzoyl peroxide</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| EUCRISA | T4 | PA; QL (60 GM per 30 days) |
| EVOCLIN | T4 | QL (100 GM per 28 days) |
| EXELDERM | T4 | ST |
| EXTINA | T4 | ST; QL (100 GM per 28 days) |
| FABIOR | T4 | PA; QL (100 GM per 28 days) |
| FINACEA | T4 | QL (50 GM per 28 days) |
| <i>fluocinolone and shower cap</i> | T2 | QL (118.28 ML per 28 days) |
| <i>fluocinolone topical cream 0.01 %</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinolone topical cream 0.025 %</i> | T2 | QL (120 GM per 28 days) |
| <i>fluocinolone topical ointment</i> | T2 | QL (120 GM per 28 days) |
| <i>fluocinolone topical solution</i> | T2 | QL (90 ML per 28 days) |
| <i>fluocinonide topical cream 0.05 %</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinonide topical cream 0.1 %</i> | T4 | QL (120 GM per 28 days) |
| <i>fluocinonide topical gel</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinonide topical ointment</i> | T2 | QL (60 GM per 28 days) |
| <i>fluocinonide topical solution</i> | T2 | QL (60 ML per 28 days) |
| FLUOCINONIDE-E | T2 | QL (60 GM per 28 days) |
| <i>fluorouracil topical cream 0.5 %</i> | T5 | |
| <i>fluorouracil topical cream 5 %</i> | T2 | |
| <i>fluorouracil topical solution</i> | T2 | |
| <i>flurandrenolide topical cream</i> | T3 | QL (120 GM per 28 days) |
| <i>flurandrenolide topical lotion</i> | T3 | QL (120 ML per 28 days) |
| <i>fluticasone propionate topical cream</i> | T2 | |
| <i>fluticasone propionate topical lotion</i> | T4 | QL (120 ML per 28 days) |
| <i>fluticasone propionate topical ointment</i> | T2 | |
| <i>gentamicin topical</i> | T2 | QL (60 GM per 28 days) |
| <i>halcinonide</i> | T4 | |
| <i>halobetasol propionate topical cream</i> | T2 | QL (50 GM per 28 days) |
| <i>halobetasol propionate topical ointment</i> | T2 | QL (50 GM per 28 days) |
| HALOG | T4 | |
| <i>hydrocortisone butyrate topical cream</i> | T2 | QL (45 GM per 28 days) |
| <i>hydrocortisone butyrate topical lotion</i> | T4 | QL (118 ML per 28 days) |
| <i>hydrocortisone butyrate topical ointment</i> | T2 | QL (45 GM per 28 days) |
| <i>hydrocortisone butyrate topical solution</i> | T2 | QL (60 ML per 28 days) |
| <i>hydrocortisone topical cream 1 %</i> | T1 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | T1 | QL (118 ML per 28 days) |
| <i>hydrocortisone topical ointment 1 %, 2.5 %</i> | T1 | |
| <i>hydrocortisone valerate</i> | T2 | QL (60 GM per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| HYFTOR | T5 | PA; QL (30 GM per 30 days) |
| ILUMYA | T5 | PA; QL (1 ML per 84 days) |
| <i>imiquimod topical cream in packet 3.75 %</i> | T5 | |
| <i>imiquimod topical cream in packet 5 %</i> | T2 | |
| IMPEKLO | T4 | QL (136 GM per 28 days) |
| <i>isotretinoin</i> | T2 | |
| <i>ivermectin topical cream</i> | T4 | |
| JUBLIA | T5 | |
| KENALOG TOPICAL | T3 | |
| KERYDIN | T5 | |
| <i>ketoconazole topical cream</i> | T2 | QL (60 GM per 28 days) |
| <i>ketoconazole topical foam</i> | T4 | QL (100 GM per 28 days) |
| <i>ketoconazole topical shampoo</i> | T2 | |
| KETODAN | T2 | ST; QL (100 GM per 28 days) |
| KLARON | T4 | |
| LEXETTE | T4 | QL (200 GM per 28 days) |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | T2 | PA; QL (50 ML per 28 days) |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | T2 | PA; QL (93 EA per 31 days) |
| <i>lidocaine topical ointment</i> | T2 | PA; QL (50 GM per 28 days) |
| LIDOCAINE VISCOUS | T2 | |
| <i>lidocaine-prilocaine topical cream</i> | T2 | PA; QL (30 GM per 28 days) |
| LIDODERM | T4 | PA; QL (93 EA per 31 days) |
| LOCOID LIPOCREAM | T4 | QL (60 GM per 28 days) |
| LOCOID TOPICAL LOTION | T4 | QL (118 ML per 28 days) |
| LOPROX (AS OLAMINE) TOPICAL CREAM | T4 | QL (90 GM per 28 days) |
| LOPROX TOPICAL SHAMPOO | T4 | QL (120 ML per 28 days) |
| <i>luliconazole</i> | T4 | |
| LUXIQ | T4 | |
| LUZU | T4 | |
| <i>mafenide acetate</i> | T4 | |
| <i>malathion</i> | T2 | |
| MENTAX | T4 | |
| <i>methoxsalen</i> | T2 | |
| METROCREAM | T4 | |
| METROGEL TOPICAL GEL 1 % | T4 | |
| METROLOTION | T4 | |
| <i>metronidazole topical cream</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>metronidazole topical gel 0.75 %</i> | T2 | |
| <i>metronidazole topical gel 1 %</i> | T1 | |
| <i>metronidazole topical lotion</i> | T2 | |
| MIRVASO TOPICAL GEL WITH PUMP | T4 | |
| <i>mometasone topical</i> | T2 | |
| <i>mupirocin</i> | T2 | |
| <i>mupirocin calcium</i> | T4 | ST |
| MYORISAN | T2 | |
| <i>naftifine topical cream 1 %</i> | T4 | ST; QL (90 GM per 28 days) |
| <i>naftifine topical cream 2 %</i> | T4 | ST; QL (60 GM per 28 days) |
| NAFTIN TOPICAL GEL 1 % | T4 | ST; QL (90 GM per 28 days) |
| NAFTIN TOPICAL GEL 2 % | T4 | ST; QL (60 GM per 28 days) |
| NATROBA | T4 | |
| NEO-SYNALAR | T4 | |
| NEUAC | T2 | |
| NORITATE | T5 | |
| NYAMYC | T2 | QL (60 GM per 28 days) |
| <i>nystatin topical cream</i> | T2 | QL (30 GM per 28 days) |
| <i>nystatin topical ointment</i> | T2 | QL (30 GM per 28 days) |
| <i>nystatin topical powder</i> | T2 | QL (60 GM per 28 days) |
| <i>nystatin-triamcinolone</i> | T3 | |
| NYSTOP | T2 | QL (60 GM per 28 days) |
| OLUX | T4 | QL (100 GM per 28 days) |
| OLUX-E | T4 | QL (100 GM per 28 days) |
| ONEXTON TOPICAL GEL WITH PUMP | T4 | |
| OPZELURA | T5 | PA; QL (60 GM per 7 days) |
| OVIDE | T4 | |
| <i>oxiconazole</i> | T4 | ST; QL (90 GM per 28 days) |
| OXISTAT TOPICAL CREAM | T4 | ST; QL (90 GM per 28 days) |
| OXISTAT TOPICAL LOTION | T4 | ST; QL (60 ML per 28 days) |
| PANDEL | T4 | |
| PANRETIN | T5 | PA-NS |
| <i>permethrin</i> | T2 | |
| <i>pimecrolimus</i> | T3 | QL (100 GM per 28 days) |
| PLIAGLIS | T4 | |
| <i>podofilox</i> | T2 | |
| <i>prednicarbate topical ointment</i> | T2 | QL (60 GM per 28 days) |
| PROTOPIC | T4 | QL (100 GM per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| PRUDOXIN | T4 | PA; QL (45 GM per 28 days) |
| PSORCON | T4 | QL (60 GM per 28 days) |
| QBREXZA | T4 | |
| REGRANEX | T5 | PA |
| RETIN-A | T4 | PA; QL (45 GM per 28 days) |
| RETIN-A MICRO | T4 | PA; QL (45 GM per 28 days) |
| RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 % | T5 | PA; QL (50 GM per 28 days) |
| RHOFADE | T4 | |
| SANTYL | T3 | QL (180 GM per 30 days) |
| <i>selenium sulfide topical lotion</i> | T1 | |
| SILIQ | T5 | PA; QL (6 ML per 28 days) |
| SILVADENE | T4 | |
| <i>silver sulfadiazine</i> | T1 | |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR | T5 | PA; QL (1 ML per 84 days) |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | T5 | PA; QL (1 ML per 84 days) |
| SKYRIZI SUBCUTANEOUS SYRINGE KIT | T5 | PA; QL (1 EA per 84 days) |
| SOOLANTRA | T4 | |
| SORILUX | T4 | ST |
| <i>spinosad</i> | T4 | |
| SSD | T4 | |
| STELARA SUBCUTANEOUS SOLUTION | T5 | PA; QL (0.5 ML per 84 days) |
| STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | T5 | PA; QL (0.5 ML per 84 days) |
| STELARA SUBCUTANEOUS SYRINGE 90 MG/ML | T5 | PA; QL (1 ML per 56 days) |
| <i>sulfacetamide sodium (acne)</i> | T1 | |
| SULFAMYLON TOPICAL CREAM | T3 | |
| SYNALAR TOPICAL CREAM | T4 | QL (120 GM per 28 days) |
| SYNALAR TOPICAL SOLUTION | T4 | QL (90 ML per 28 days) |
| TACLONEX | T5 | ST; QL (400 GM per 28 days) |
| <i>tacrolimus topical</i> | T2 | QL (100 GM per 28 days) |
| TALTZ AUTOINJECTOR | T5 | PA; QL (1 ML per 28 days) |
| TALTZ SYRINGE | T5 | PA; QL (1 ML per 28 days) |
| <i>tavaborole</i> | T4 | |
| <i>tazarotene topical cream</i> | T4 | PA; QL (60 GM per 28 days) |
| <i>tazarotene topical foam</i> | T4 | PA; QL (100 GM per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| <i>tazarotene topical gel</i> | T4 | PA; QL (100 GM per 28 days) |
| TAZORAC TOPICAL CREAM | T4 | PA; QL (60 GM per 28 days) |
| TAZORAC TOPICAL GEL | T4 | PA; QL (100 GM per 28 days) |
| TEXACORT | T4 | |
| TOPICORT TOPICAL CREAM | T4 | QL (100 GM per 28 days) |
| TOPICORT TOPICAL GEL | T4 | QL (60 GM per 28 days) |
| TOPICORT TOPICAL OINTMENT 0.05 % | T4 | QL (100 GM per 28 days) |
| TOPICORT TOPICAL SPRAY, NON-AEROSOL | T4 | QL (100 ML per 28 days) |
| TOVET EMOLLIENT | T3 | QL (100 GM per 28 days) |
| TREMFYA | T5 | PA; QL (1 ML per 56 days) |
| <i>tretinoin</i> | T2 | PA; QL (45 GM per 28 days) |
| <i>tretinoin microspheres topical gel</i> | T2 | PA; QL (50 GM per 28 days) |
| <i>triamcinolone acetonide topical aerosol</i> | T4 | |
| <i>triamcinolone acetonide topical cream</i> | T1 | |
| <i>triamcinolone acetonide topical lotion</i> | T1 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | T1 | |
| <i>triamcinolone acetonide topical ointment 0.05 %</i> | T4 | |
| TRIANEX | T4 | |
| TRIDERM TOPICAL CREAM | T1 | |
| TRITOCIN | T4 | |
| TWYNEO | T4 | PA; QL (30 GM per 28 days) |
| ULTRAVATE TOPICAL LOTION | T5 | QL (120 ML per 28 days) |
| VALCHLOR | T5 | PA-NS |
| VANOS | T4 | QL (120 GM per 28 days) |
| VECTICAL | T4 | ST |
| VELTIN | T4 | PA; QL (60 GM per 28 days) |
| VERDESO | T4 | QL (100 GM per 28 days) |
| VEREGEN | T4 | |
| VTAMA | T5 | PA; QL (60 GM per 28 days) |
| WINLEVI | T4 | PA; QL (60 GM per 28 days) |
| XERESE | T5 | |
| XOLEGEL | T4 | ST; QL (45 GM per 28 days) |
| ZENATANE | T2 | |
| ZIANA | T4 | PA; QL (60 GM per 28 days) |
| ZILXI | T4 | |
| ZONALON | T4 | PA; QL (30 GM per 28 days) |
| ZOVIRAX TOPICAL CREAM | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| ZOVIRAX TOPICAL OINTMENT | T4 | QL (30 GM per 30 days) |
| ZTLIDO | T4 | PA; QL (93 EA per 31 days) |
| ZYCLARA TOPICAL CREAM IN METERED-DOSE PUMP 2.5 % | T5 | |
| ZYCLARA TOPICAL CREAM IN PACKET | T5 | |
| Diagnostics / Miscellaneous Agents | | |
| <i>acamprosate</i> | T2 | |
| AGRYLIN | T4 | |
| <i>anagrelide</i> | T2 | |
| ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG | T5 | PA |
| AURYXIA | T5 | PA; QL (372 EA per 31 days) |
| BUPHENYL | T5 | PA |
| <i>bupropion hcl (smoking deter)</i> | T2 | QL (62 EA per 31 days) |
| CARBAGLU | T5 | PA |
| <i>carglumic acid</i> | T5 | PA |
| CARNITOR ORAL | T4 | PA-BvD |
| <i>cevimeline</i> | T2 | |
| CHEMET | T3 | |
| CLINIMIX 4.25%/D5W SULFIT FREE | T4 | PA-BvD |
| CLINIMIX E 2.75%/D5W SULF FREE | T4 | PA-BvD |
| <i>d10 %-0.45 % sodium chloride</i> | T2 | |
| <i>d2.5 %-0.45 % sodium chloride</i> | T2 | |
| <i>d5 % and 0.9 % sodium chloride</i> | T2 | |
| <i>d5 %-0.45 % sodium chloride</i> | T2 | |
| <i>deferasirox oral granules in packet</i> | T4 | PA |
| <i>deferasirox oral tablet 180 mg, 90 mg</i> | T4 | PA |
| <i>deferasirox oral tablet 360 mg</i> | T5 | PA |
| <i>deferasirox oral tablet, dispersible 125 mg</i> | T4 | PA |
| <i>deferasirox oral tablet, dispersible 250 mg, 500 mg</i> | T5 | PA |
| <i>deferiprone</i> | T5 | PA |
| <i>dextrose 10 % and 0.2 % nacl</i> | T2 | |
| <i>dextrose 10 % in water (d10w)</i> | T2 | |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | T2 | |
| <i>dextrose 5%-0.2 % sod chloride</i> | T2 | |
| <i>disulfiram</i> | T2 | |
| <i>droxidopa</i> | T5 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| ENDARI | T4 | PA; QL (180 EA per 30 days) |
| EVOXAC | T4 | |
| EXJADE | T5 | PA |
| EXSERVAN | T5 | PA; QL (62 EA per 31 days) |
| FERRIPROX | T5 | PA |
| FOSRENOL ORAL POWDER IN PACKET | T5 | |
| FOSRENOL ORAL TABLET,CHEWABLE 1,000 MG, 750 MG | T5 | |
| FOSRENOL ORAL TABLET,CHEWABLE 500 MG | T4 | |
| GLASSIA | T5 | PA |
| INCRELEX | T5 | PA |
| JADENU ORAL TABLET 180 MG, 90 MG | T4 | PA |
| JADENU ORAL TABLET 360 MG | T5 | PA |
| JADENU SPRINKLE | T4 | PA |
| <i>lanthanum oral tablet,chewable 1,000 mg, 750 mg</i> | T4 | |
| <i>lanthanum oral tablet,chewable 500 mg</i> | T5 | |
| <i>levocarnitine (with sugar)</i> | T2 | PA-BvD |
| <i>levocarnitine oral tablet</i> | T2 | PA-BvD |
| LITHOSTAT | T4 | |
| LOKELMA | T3 | PA; QL (93 EA per 31 days) |
| <i>midodrine</i> | T2 | |
| NICOTROL | T3 | |
| NICOTROL NS | T4 | |
| <i>nitisinone</i> | T5 | |
| NITYR | T5 | |
| NORTHERA | T5 | PA |
| ORFADIN | T5 | |
| OXBRYTA ORAL TABLET | T5 | PA; QL (155 EA per 31 days) |
| OXBRYTA ORAL TABLET FOR SUSPENSION | T5 | PA; QL (248 EA per 31 days) |
| PHEBURANE | T5 | PA; QL (620 GM per 31 days) |
| <i>pilocarpine hcl oral</i> | T2 | |
| PROLASTIN-C INTRAVENOUS RECON SOLN | T5 | PA |
| PYRUKYND ORAL TABLET 20 MG, 50 MG | T5 | PA; QL (62 EA per 31 days) |
| PYRUKYND ORAL TABLET 5 MG, 5 MG (4-WEEK PACK) | T5 | PA |
| PYRUKYND ORAL TABLETS,DOSE PACK | T5 | PA; QL (2 EA per 365 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| RAVICTI | T5 | PA |
| RENAGEL ORAL TABLET 800 MG | T5 | |
| REVELA | T4 | |
| REVCOVI | T5 | |
| RILUTEK | T5 | |
| <i>riluzole</i> | T4 | |
| <i>risedronate oral tablet 30 mg</i> | T2 | |
| SALAGEN (PILOCARPINE) | T4 | |
| <i>sevelamer carbonate</i> | T3 | |
| <i>sevelamer hcl</i> | T3 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | T2 | |
| <i>sodium chloride irrigation</i> | T2 | |
| <i>sodium phenylbutyrate</i> | T5 | |
| <i>sodium polystyrene sulfonate oral powder</i> | T2 | |
| SPS (WITH SORBITOL) ORAL | T2 | |
| SYPRINE | T3 | QL (248 EA per 31 days) |
| TAVNEOS | T5 | PA; QL (186 EA per 31 days) |
| THIOLA | T5 | PA |
| THIOLA EC | T5 | PA |
| TIGLUTIK | T5 | PA |
| <i>tiopronin</i> | T5 | PA |
| <i>trientine</i> | T3 | QL (248 EA per 31 days) |
| <i>varenicline oral tablet</i> | T4 | QL (60 EA per 30 days) |
| <i>varenicline oral tablets,dose pack</i> | T4 | QL (106 EA per 365 days) |
| VELPHORO | T5 | |
| VELTASSA | T3 | PA; QL (30 EA per 30 days) |
| XURIDEN | T5 | PA; QL (124 EA per 31 days) |
| ZEMAIRA | T5 | PA |
| Ear, Nose / Throat Medications | | |
| <i>acetic acid otic (ear)</i> | T2 | |
| <i>azelastine nasal</i> | T2 | QL (30 ML per 25 days) |
| CETRAXAL | T4 | |
| <i>chlorhexidine gluconate mucous membrane</i> | T1 | |
| CIPRO HC | T4 | |
| CIPRODEX | T3 | |
| <i>ciprofloxacin hcl otic (ear)</i> | T1 | |
| <i>ciprofloxacin-dexamethasone</i> | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>ciprofloxacin-fluocinolone</i> | T4 | |
| DERMOTIC OIL | T4 | |
| FLAC OTIC OIL | T2 | |
| <i>fluocinolone acetonide oil</i> | T2 | |
| <i>hydrocortisone-acetic acid</i> | T2 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | T1 | QL (30 ML per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | T1 | QL (15 ML per 28 days) |
| <i>neomycin-polymyxin-hc otic (ear)</i> | T2 | |
| <i>ofloxacin otic (ear)</i> | T2 | |
| <i>olopatadine nasal</i> | T2 | QL (30.5 GM per 30 days) |
| OTOVEL | T4 | |
| PATANASE | T4 | QL (30.5 GM per 30 days) |
| PERIOGARD | T1 | |
| <i>triamcinolone acetonide dental</i> | T2 | |
| Endocrine/Diabetes | | |
| <i>acarbose</i> | T1 | QL (93 EA per 31 days) |
| ACTHAR | T5 | PA |
| ACTOPLUS MET ORAL TABLET 15-850 MG | T4 | QL (93 EA per 31 days) |
| ACTOS | T4 | QL (31 EA per 31 days) |
| ADLYXIN | T4 | QL (6 ML per 28 days) |
| ADMELOG SOLOSTAR U-100 INSULIN | T4 | |
| ADMELOG U-100 INSULIN LISPRO | T4 | |
| AFREZZA | T4 | |
| ALCOHOL PADS | T2 | |
| ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 0.5 MG | T4 | PA |
| ALKINDI SPRINKLE ORAL CAPSULE, SPRINKLE 1 MG, 2 MG, 5 MG | T5 | PA |
| <i>alogliptin</i> | T4 | ST; QL (31 EA per 31 days) |
| <i>alogliptin-metformin</i> | T4 | ST; QL (62 EA per 31 days) |
| <i>alogliptin-pioglitazone oral tablet 12.5-30 mg, 12.5-45 mg, 25-15 mg, 25-30 mg, 25-45 mg</i> | T4 | ST; QL (31 EA per 31 days) |
| AMARYL | T4 | |
| ANDRODERM | T3 | PA |
| ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP | T3 | PA |
| APIDRA SOLOSTAR U-100 INSULIN | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|---------------------------------|
| APIDRA U-100 INSULIN | T4 | |
| AVEED | T4 | PA |
| BAQSIMI | T3 | |
| BASAGLAR KWIKPEN U-100 INSULIN | T4 | |
| BYDUREON BCISE | T4 | ST; QL (3.4 ML per 28 days) |
| BYETTA SUBCUTANEOUS PEN INJECTOR 10 MCG/DOSE(250 MCG/ML) 2.4 ML | T4 | ST; QL (2.4 ML per 30 days) |
| BYETTA SUBCUTANEOUS PEN INJECTOR 5 MCG/DOSE (250 MCG/ML) 1.2 ML | T4 | ST; QL (1.2 ML per 30 days) |
| <i>cabergoline</i> | T2 | |
| <i>calcitonin (salmon) nasal</i> | T2 | PA-BvD |
| <i>calcitriol oral capsule</i> | T2 | PA-BvD |
| <i>calcitriol oral solution</i> | T3 | PA-BvD |
| CERDELGA | T5 | PA; QL (62 EA per 31 days) |
| <i>cinacalcet oral tablet 30 mg</i> | T3 | PA-BvD; QL (62 EA per 31 days) |
| <i>cinacalcet oral tablet 60 mg</i> | T5 | PA-BvD; QL (62 EA per 31 days) |
| <i>cinacalcet oral tablet 90 mg</i> | T5 | PA-BvD; QL (124 EA per 31 days) |
| CORTEF | T4 | |
| CORTROPHIN GEL | T5 | PA |
| CYCLOSET | T4 | |
| CYTOMEL | T4 | |
| <i>danazol</i> | T2 | |
| DDAVP ORAL | T4 | |
| DEPO-TESTOSTERONE | T4 | PA |
| <i>desmopressin nasal spray with pump</i> | T4 | |
| <i>desmopressin oral</i> | T2 | |
| DEXABLISS | T2 | |
| <i>dexamethasone oral elixir</i> | T1 | |
| <i>dexamethasone oral tablet</i> | T1 | |
| <i>dexamethasone oral tablets,dose pack</i> | T2 | |
| <i>diazoxide</i> | T3 | |
| <i>doxercalciferol oral capsule 0.5 mcg, 2.5 mcg</i> | T2 | PA-BvD |
| <i>doxercalciferol oral capsule 1 mcg</i> | T4 | PA-BvD |
| DUETACT | T4 | QL (31 EA per 31 days) |
| EMFLAZA | T5 | PA |
| EUTHYROX | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| FARXIGA | T4 | ST; QL (31 EA per 31 days) |
| FIASP FLEXTOUCH U-100 INSULIN | T3 | |
| FIASP PENFILL U-100 INSULIN | T3 | |
| FIASP U-100 INSULIN | T3 | |
| <i>fludrocortisone</i> | T2 | |
| FORTESTA | T4 | PA |
| GALAFOLD | T5 | PA; QL (14 EA per 28 days) |
| <i>glimepiride</i> | T1 | |
| <i>glipizide</i> | T1 | |
| <i>glipizide-metformin</i> | T1 | |
| GLUCAGEN HYPOKIT | T3 | |
| GLUCAGON EMERGENCY KIT (HUMAN) | T3 | |
| GLUCOTROL XL | T4 | |
| GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 1,000 MG | T4 | ST; QL (62 EA per 31 days) |
| GLUMETZA ORAL TABLET,ER GAST.RETENTION 24 HR 500 MG | T4 | ST; QL (31 EA per 31 days) |
| <i>glyburide</i> | T2 | |
| <i>glyburide micronized</i> | T2 | |
| <i>glyburide-metformin</i> | T2 | |
| GLYNASE | T4 | |
| GLYXAMBI | T3 | QL (31 EA per 31 days) |
| GVOKE | T3 | |
| GVOKE HYPOPEN 2-PACK | T3 | |
| GVOKE PFS 1-PACK SYRINGE | T3 | |
| HEMADY | T4 | PA-NS |
| HUMALOG JUNIOR KWIKPEN U-100 | T3 | |
| HUMALOG KWIKPEN INSULIN | T3 | |
| HUMALOG MIX 50-50 INSULN U-100 | T3 | |
| HUMALOG MIX 50-50 KWIKPEN | T3 | |
| HUMALOG MIX 75-25 KWIKPEN | T3 | |
| HUMALOG MIX 75-25(U-100)INSULN | T3 | |
| HUMALOG U-100 INSULIN | T3 | |
| HUMULIN 70/30 U-100 INSULIN | T3 | |
| HUMULIN 70/30 U-100 KWIKPEN | T3 | |
| HUMULIN N NPH INSULIN KWIKPEN | T3 | |
| HUMULIN N NPH U-100 INSULIN | T3 | |
| HUMULIN R REGULAR U-100 INSULN | T3 | |
| HUMULIN R U-500 (CONC) INSULIN | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| HUMULIN R U-500 (CONC) KWIKPEN | T3 | |
| <i>hydrocortisone oral</i> | T1 | |
| <i>insulin asp prt-insulin aspart</i> | T3 | |
| <i>insulin aspart u-100</i> | T3 | |
| <i>insulin degludec</i> | T4 | |
| <i>insulin glargine</i> | T4 | |
| <i>insulin lispro</i> | T3 | |
| <i>insulin lispro protamin-lispro</i> | T3 | |
| INVOKAMET | T3 | QL (62 EA per 31 days) |
| INVOKAMET XR | T3 | QL (62 EA per 31 days) |
| INVOKANA ORAL TABLET 100 MG | T3 | QL (62 EA per 31 days) |
| INVOKANA ORAL TABLET 300 MG | T3 | QL (31 EA per 31 days) |
| ISTURISA | T5 | PA |
| JANUMET | T3 | QL (62 EA per 31 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG, 50-500 MG | T3 | QL (31 EA per 31 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG | T3 | QL (62 EA per 31 days) |
| JANUVIA ORAL TABLET 100 MG, 50 MG | T3 | QL (31 EA per 31 days) |
| JANUVIA ORAL TABLET 25 MG | T3 | QL (93 EA per 31 days) |
| JARDIANCE ORAL TABLET 10 MG | T3 | QL (62 EA per 31 days) |
| JARDIANCE ORAL TABLET 25 MG | T3 | QL (31 EA per 31 days) |
| JATENZO ORAL CAPSULE 158 MG | T4 | PA; QL (155 EA per 31 days) |
| JATENZO ORAL CAPSULE 198 MG | T4 | PA; QL (124 EA per 31 days) |
| JATENZO ORAL CAPSULE 237 MG | T4 | PA; QL (62 EA per 31 days) |
| JAVYGTOR ORAL POWDER IN PACKET 100 MG | T5 | PA |
| JENTADUETO | T3 | QL (62 EA per 31 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | T3 | QL (62 EA per 31 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | T3 | QL (31 EA per 31 days) |
| JYNARQUE ORAL TABLET | T5 | PA; QL (112 EA per 28 days) |
| JYNARQUE ORAL TABLETS, SEQUENTIAL | T5 | PA; QL (56 EA per 28 days) |
| KAZANO | T4 | ST; QL (62 EA per 31 days) |
| KOMBIGLYZE XR | T4 | ST |
| KORLYM | T5 | PA; QL (124 EA per 31 days) |
| KUVAN | T5 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| LANTUS SOLOSTAR U-100 INSULIN | T3 | |
| LANTUS U-100 INSULIN | T3 | |
| LEVEMIR FLEXTOUCH U-100 INSULIN | T3 | |
| LEVEMIR U-100 INSULIN | T3 | |
| LEVO-T | T4 | |
| <i>levothyroxine oral capsule</i> | T4 | |
| <i>levothyroxine oral tablet</i> | T1 | |
| LEVOXYL ORAL TABLET 100 MCG, 112 MCG, 125 MCG, 137 MCG, 150 MCG, 175 MCG, 200 MCG, 25 MCG, 50 MCG, 75 MCG, 88 MCG | T3 | |
| <i>liothyronine oral</i> | T2 | |
| LYUMJEV KWIKPEN U-100 INSULIN | T4 | |
| LYUMJEV KWIKPEN U-200 INSULIN | T4 | |
| LYUMJEV U-100 INSULIN | T4 | |
| MEDROL (PAK) | T4 | |
| MEDROL ORAL TABLET 16 MG, 2 MG, 4 MG, 8 MG | T4 | |
| <i>metformin oral solution</i> | T4 | ST; QL (791 ML per 31 days) |
| <i>metformin oral tablet 1,000 mg, 500 mg, 850 mg</i> | T1 | |
| <i>metformin oral tablet 625 mg</i> | T4 | QL (124 EA per 31 days) |
| <i>metformin oral tablet extended release 24 hr</i> | T1 | |
| <i>metformin oral tablet extended release 24hr 1,000 mg</i> | T4 | ST; QL (62 EA per 31 days) |
| <i>metformin oral tablet extended release 24hr 500 mg</i> | T4 | ST; QL (31 EA per 31 days) |
| <i>metformin oral tablet,er gast.retention 24 hr 1,000 mg</i> | T4 | ST; QL (62 EA per 31 days) |
| <i>metformin oral tablet,er gast.retention 24 hr 500 mg</i> | T4 | ST; QL (31 EA per 31 days) |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | T2 | |
| METHITEST | T5 | PA |
| <i>methylprednisolone</i> | T2 | |
| <i>methyltestosterone oral capsule</i> | T5 | PA |
| <i>miglitol</i> | T2 | |
| <i>miglustat</i> | T5 | PA; QL (93 EA per 31 days) |
| MILLIPRED ORAL TABLET | T2 | |
| MOUNJARO | T3 | QL (2 ML per 28 days) |
| MYALEPT | T5 | PA |
| <i>nateglinide</i> | T1 | QL (93 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| NATESTO | T4 | PA |
| NATPARA | T5 | PA; QL (31 EA per 31 days) |
| NESINA | T4 | ST; QL (31 EA per 31 days) |
| NOCDURNA (MEN) | T4 | QL (31 EA per 31 days) |
| NOCDURNA (WOMEN) | T4 | QL (31 EA per 31 days) |
| NOVOLIN 70/30 U-100 INSULIN | T3 | |
| NOVOLIN 70-30 FLEXPEN U-100 | T3 | |
| NOVOLIN N FLEXPEN | T3 | |
| NOVOLIN N NPH U-100 INSULIN | T3 | |
| NOVOLIN R FLEXPEN | T3 | |
| NOVOLIN R REGULAR U-100 INSULN | T3 | |
| NOVOLOG FLEXPEN U-100 INSULIN | T3 | |
| NOVOLOG MIX 70-30 U-100 INSULN | T3 | |
| NOVOLOG MIX 70-30FLEXPEN U-100 | T3 | |
| NOVOLOG PENFILL U-100 INSULIN | T3 | |
| NOVOLOG U-100 INSULIN ASPART | T3 | |
| ONGLYZA | T4 | ST; QL (31 EA per 31 days) |
| ORAPRED ODT | T4 | |
| ORILISSA ORAL TABLET 150 MG | T5 | PA; QL (31 EA per 31 days) |
| ORILISSA ORAL TABLET 200 MG | T5 | PA; QL (62 EA per 31 days) |
| OSENI | T4 | ST; QL (31 EA per 31 days) |
| <i>oxandrolone oral tablet 10 mg</i> | T4 | PA |
| <i>oxandrolone oral tablet 2.5 mg</i> | T2 | PA |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | T3 | QL (3 ML per 28 days) |
| PALYNZIQ | T5 | PA |
| <i>paricalcitol oral</i> | T2 | PA-BvD |
| <i>pioglitazone</i> | T1 | QL (31 EA per 31 days) |
| <i>pioglitazone-glimepiride</i> | T1 | QL (31 EA per 31 days) |
| <i>pioglitazone-metformin</i> | T1 | QL (93 EA per 31 days) |
| <i>prednisolone oral solution</i> | T2 | |
| <i>prednisolone sodium phosphate oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml), 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | T2 | |
| <i>prednisolone sodium phosphate oral tablet, disintegrating</i> | T2 | |
| PREDNISONE INTENSOL | T4 | |
| <i>prednisone oral solution</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|---------------------------------|
| <i>prednisone oral tablet</i> | T1 | |
| <i>prednisone oral tablets,dose pack</i> | T2 | |
| PROGLYCEM | T4 | |
| <i>propylthiouracil</i> | T2 | |
| QTERN | T4 | ST; QL (31 EA per 31 days) |
| RAYALDEE | T5 | QL (62 EA per 31 days) |
| RAYOS ORAL TABLET,DELAYED RELEASE (DR/EC) 1 MG | T4 | |
| RAYOS ORAL TABLET,DELAYED RELEASE (DR/EC) 2 MG, 5 MG | T5 | |
| RECORLEV | T5 | PA; QL (248 EA per 31 days) |
| <i>repaglinide oral tablet 0.5 mg</i> | T1 | QL (124 EA per 31 days) |
| <i>repaglinide oral tablet 1 mg</i> | T2 | QL (124 EA per 31 days) |
| <i>repaglinide oral tablet 2 mg</i> | T2 | QL (248 EA per 31 days) |
| RIOMET | T4 | ST; QL (791 ML per 31 days) |
| ROCALTROL | T4 | PA-BvD |
| RYBELSUS | T3 | QL (31 EA per 31 days) |
| SAMSCA | T5 | PA |
| <i>sapropterin</i> | T5 | PA |
| SEGLUROMET | T4 | ST; QL (62 EA per 31 days) |
| SENSIPAR ORAL TABLET 30 MG | T4 | PA-BvD; QL (62 EA per 31 days) |
| SENSIPAR ORAL TABLET 60 MG | T5 | PA-BvD; QL (62 EA per 31 days) |
| SENSIPAR ORAL TABLET 90 MG | T5 | PA-BvD; QL (124 EA per 31 days) |
| SOLQUA 100/33 | T3 | QL (18 ML per 30 days) |
| SOMAVERT | T5 | PA |
| STEGLATRO | T4 | ST; QL (31 EA per 31 days) |
| STEGLUJAN | T4 | ST; QL (31 EA per 31 days) |
| SYMLINPEN 120 | T3 | QL (10.8 ML per 28 days) |
| SYMLINPEN 60 | T3 | QL (6 ML per 28 days) |
| SYNAREL | T5 | |
| SYNJARDY | T3 | QL (62 EA per 31 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 12.5-1,000 MG, 5-1,000 MG | T3 | QL (62 EA per 31 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 25-1,000 MG | T3 | QL (31 EA per 31 days) |
| SYNTHROID | T3 | |
| TAPERDEX | T4 | |
| TARPEYO | T5 | PA; QL (124 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| TESTIM | T4 | PA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> | T2 | PA |
| <i>testosterone enanthate</i> | T2 | PA |
| <i>testosterone transdermal gel in metered-dose pump 10 mg/0.5 gram /actuation, 12.5 mg/ 1.25 gram (1 %)</i> | T4 | PA |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> | T3 | PA |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram), 1 % (50 mg/5 gram)</i> | T4 | PA |
| <i>testosterone transdermal gel in packet 1.62 % (20.25 mg/1.25 gram), 1.62 % (40.5 mg/2.5 gram)</i> | T3 | PA |
| <i>testosterone transdermal solution in metered pump w/app</i> | T4 | PA |
| THYQUIDITY | T4 | |
| TIROSINT | T4 | |
| TIROSINT-SOL | T4 | |
| TLANDO | T4 | PA; QL (124 EA per 31 days) |
| <i>tolvaptan</i> | T5 | PA |
| TOUJEO MAX U-300 SOLOSTAR | T3 | |
| TOUJEO SOLOSTAR U-300 INSULIN | T3 | |
| TRADJENTA | T3 | QL (31 EA per 31 days) |
| TRESIBA FLEXTOUCH U-100 | T3 | |
| TRESIBA FLEXTOUCH U-200 | T3 | |
| TRESIBA U-100 INSULIN | T3 | |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | T3 | QL (31 EA per 31 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | T3 | QL (62 EA per 31 days) |
| TRULICITY | T3 | QL (2 ML per 28 days) |
| UNITHROID | T3 | |
| VICTOZA 3-PAK | T3 | QL (9 ML per 30 days) |
| VOGELXO TRANSDERMAL GEL | T4 | PA |
| VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP | T4 | PA |
| VOXZOGO | T5 | PA; QL (31 EA per 31 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 10-500 MG, 5-500 MG | T4 | ST; QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-1,000 MG | T4 | ST; QL (62 EA per 31 days) |
| XULTOPHY 100/3.6 | T3 | |
| XYOSTED | T4 | PA |
| ZAVESCA | T5 | PA; QL (93 EA per 31 days) |
| ZEGALOGUE AUTOINJECTOR | T3 | |
| ZEGALOGUE SYRINGE | T3 | |
| ZEMPLAR ORAL CAPSULE 1 MCG, 2 MCG | T4 | PA-BvD |
| Gastroenterology | | |
| ACIPHEX | T4 | QL (62 EA per 31 days) |
| <i>alosetron oral tablet 0.5 mg</i> | T5 | PA; QL (93 EA per 31 days) |
| <i>alosetron oral tablet 1 mg</i> | T5 | PA; QL (62 EA per 31 days) |
| AMITIZA | T4 | QL (62 EA per 31 days) |
| <i>amoxicil-clarithromy-lansopraz</i> | T2 | |
| ANTIVERT ORAL TABLET 50 MG | T4 | |
| ANTIVERT ORAL TABLET,CHEWABLE | T4 | |
| ANUSOL-HC TOPICAL | T4 | |
| ANZEMET ORAL TABLET 50 MG | T4 | PA-BvD |
| <i>aprepitant</i> | T4 | PA-BvD |
| APRISO | T4 | |
| AZULFIDINE | T4 | |
| AZULFIDINE EN-TABS | T4 | |
| <i>balsalazide</i> | T2 | |
| <i>betaine</i> | T3 | |
| BONJESTA | T4 | PA; QL (62 EA per 31 days) |
| <i>budesonide oral capsule,delayed,extend.release</i> | T4 | |
| <i>budesonide oral tablet,delayed and ext.release</i> | T5 | |
| BYLVAY ORAL CAPSULE 1,200 MCG | T5 | PA; QL (155 EA per 31 days) |
| BYLVAY ORAL CAPSULE 400 MCG | T5 | PA; QL (465 EA per 31 days) |
| BYLVAY ORAL PELLETT 200 MCG | T5 | PA; QL (930 EA per 31 days) |
| CANASA | T5 | |
| CARAFATE ORAL SUSPENSION | T3 | |
| CARAFATE ORAL TABLET | T4 | |
| CHENODAL | T5 | PA |
| <i>chlordiazepoxide-clidinium</i> | T2 | |
| CHOLBAM | T5 | PA |
| <i>cimetidine</i> | T2 | |
| <i>cimetidine hcl oral</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| CIMZIA | T5 | PA; QL (2 EA per 28 days) |
| CIMZIA POWDER FOR RECONST | T5 | PA; QL (2 EA per 28 days) |
| CLENPIQ | T4 | |
| COLAZAL | T4 | |
| COMPRO | T2 | |
| CONSTULOSE | T2 | |
| CREON | T3 | |
| <i>cromolyn oral</i> | T4 | |
| CUVPOSA | T4 | |
| CYSTADANE | T3 | |
| CYTOTEC | T4 | |
| DARTISLA | T4 | PA; QL (124 EA per 31 days) |
| DELZICOL | T4 | |
| DEXILANT | T4 | QL (31 EA per 31 days) |
| <i>dexlansoprazole</i> | T4 | QL (31 EA per 31 days) |
| DICLEGIS | T4 | PA; QL (124 EA per 31 days) |
| <i>dicyclomine oral capsule</i> | T2 | |
| <i>dicyclomine oral solution</i> | T2 | |
| <i>dicyclomine oral tablet</i> | T2 | |
| DIPENTUM | T5 | |
| <i>diphenoxylate-atropine oral liquid</i> | T3 | |
| <i>diphenoxylate-atropine oral tablet</i> | T2 | |
| <i>doxylamine-pyridoxine (vit b6)</i> | T4 | PA; QL (124 EA per 31 days) |
| <i>dronabinol oral capsule 10 mg</i> | T4 | PA-BvD |
| <i>dronabinol oral capsule 2.5 mg, 5 mg</i> | T2 | PA-BvD |
| EMEND ORAL CAPSULE 80 MG | T4 | PA-BvD |
| EMEND ORAL CAPSULE,DOSE PACK | T4 | PA-BvD |
| EMEND ORAL SUSPENSION FOR RECONSTITUTION | T4 | PA-BvD |
| ENULOSE | T2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec)</i> | T2 | QL (31 EA per 31 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet</i> | T2 | |
| <i>famotidine oral suspension</i> | T1 | |
| <i>famotidine oral tablet 20 mg, 40 mg</i> | T1 | |
| GASTROCROM | T4 | |
| GATTEX 30-VIAL | T5 | PA |
| GAVILYTE-C | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| GAVILYTE-G | T2 | |
| GENERLAC | T2 | |
| GIMOTI | T4 | PA; QL (9.8 ML per 28 days) |
| GLYCATE | T4 | PA |
| <i>glycopyrrolate oral solution</i> | T4 | |
| <i>glycopyrrolate oral tablet 1 mg, 2 mg</i> | T2 | |
| <i>glycopyrrolate oral tablet 1.5 mg</i> | T4 | PA |
| GOLYTELY | T4 | |
| <i>granisetron hcl oral</i> | T2 | PA-BvD |
| HELIDAC | T4 | |
| <i>hydrocortisone rectal</i> | T3 | |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> | T1 | |
| <i>hydrocortisone-pramoxine rectal cream 1-1 %</i> | T4 | |
| IBSRELA | T5 | PA; QL (62 EA per 31 days) |
| KRISTALOSE | T4 | ST |
| <i>lactulose oral packet</i> | T4 | ST |
| <i>lactulose oral solution 10 gram/15 ml</i> | T1 | |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> | T3 | QL (31 EA per 31 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> | T3 | QL (62 EA per 31 days) |
| <i>lansoprazole oral tablet, disintegrat, delay rel 15 mg</i> | T3 | QL (31 EA per 31 days) |
| <i>lansoprazole oral tablet, disintegrat, delay rel 30 mg</i> | T3 | QL (62 EA per 31 days) |
| LIALDA | T4 | |
| LIBRAX (WITH CLIDINIUM) | T5 | |
| LINZESS | T3 | QL (31 EA per 31 days) |
| LIVMARLI | T5 | PA; QL (93 ML per 31 days) |
| LOMOTIL | T4 | |
| <i>loperamide oral capsule</i> | T2 | |
| LOTRONEX ORAL TABLET 0.5 MG | T5 | PA; QL (93 EA per 31 days) |
| LOTRONEX ORAL TABLET 1 MG | T5 | PA; QL (62 EA per 31 days) |
| <i>lubiprostone</i> | T3 | QL (62 EA per 31 days) |
| MARINOL | T4 | PA-BvD |
| <i>meclizine oral tablet 12.5 mg, 25 mg</i> | T2 | |
| <i>mesalamine oral capsule (with del rel tablets)</i> | T3 | |
| <i>mesalamine oral capsule, extended release</i> | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>mesalamine oral capsule,extended release 24hr</i> | T4 | |
| <i>mesalamine oral tablet,delayed release (dr/ec) 1.2 gram</i> | T3 | |
| <i>mesalamine oral tablet,delayed release (dr/ec) 800 mg</i> | T4 | |
| <i>mesalamine rectal enema</i> | T2 | |
| <i>mesalamine rectal suppository</i> | T4 | |
| <i>methscopolamine</i> | T2 | |
| <i>metoclopramide hcl oral solution</i> | T2 | |
| <i>metoclopramide hcl oral tablet</i> | T2 | |
| <i>metoclopramide hcl oral tablet,disintegrating 5 mg</i> | T2 | |
| <i>misoprostol</i> | T2 | |
| MOTEGRITY | T4 | PA; QL (31 EA per 31 days) |
| MOVANTI | T3 | QL (31 EA per 31 days) |
| MOVIPREP | T4 | |
| MYTESI | T5 | QL (62 EA per 31 days) |
| NEXIUM | T4 | QL (31 EA per 31 days) |
| NEXIUM PACKET | T3 | |
| <i>nizatidine oral capsule</i> | T2 | |
| OICALIVA | T5 | PA; QL (31 EA per 31 days) |
| <i>omeprazole oral capsule,delayed release(dr/ec)</i> | T1 | |
| <i>omeprazole-sodium bicarbonate oral capsule</i> | T2 | |
| <i>omeprazole-sodium bicarbonate oral packet 20- 1,680 mg</i> | T4 | |
| <i>omeprazole-sodium bicarbonate oral packet 40- 1,680 mg</i> | T5 | |
| <i>ondansetron</i> | T2 | PA-BvD |
| <i>ondansetron hcl oral solution</i> | T2 | PA-BvD |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | T2 | PA-BvD |
| ORTIKOS | T4 | |
| OSMOPREP | T4 | |
| PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,500-35,500- 61,500 UNIT, 2,600-8,800- 15,200 UNIT, 4,200-14,200- 24,600 UNIT | T4 | |
| PANCREAZE ORAL CAPSULE,DELAYED RELEASE(DR/EC) 16,800-56,800- 98,400 UNIT, 21,000-54,700- 83,900 UNIT, 37,000- 97,300- 149,900 UNIT | T5 | |
| <i>pantoprazole oral granules dr for susp in packet</i> | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| <i>pantoprazole oral tablet, delayed release (dr/ec)</i> | T1 | |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> | T2 | |
| <i>peg3350-sod sul-nacl-kcl-asb-c</i> | T4 | |
| <i>peg-electrolyte soln</i> | T2 | |
| PENTASA | T3 | |
| PEPCID ORAL TABLET | T4 | |
| PERTZYE | T4 | |
| PLENVU | T4 | |
| PREVACID ORAL CAPSULE, DELAYED RELEASE (DR/EC) 30 MG | T4 | QL (62 EA per 31 days) |
| PREVACID SOLUTAB ORAL TABLET, DISINTEGRAT, DELAY REL 15 MG | T4 | QL (31 EA per 31 days) |
| PREVACID SOLUTAB ORAL TABLET, DISINTEGRAT, DELAY REL 30 MG | T4 | QL (62 EA per 31 days) |
| PRILOSEC ORAL SUSP, DELAYED RELEASE FOR RECON | T4 | |
| <i>prochlorperazine</i> | T2 | |
| <i>prochlorperazine maleate</i> | T2 | |
| PROCTO-MED HC | T2 | |
| PROCTO-PAK | T2 | |
| PROCTOSOL HC TOPICAL | T2 | |
| PROCTOZONE-HC | T2 | |
| PROTONIX ORAL | T4 | |
| PYLERA | T5 | |
| <i>rabeprazole oral tablet, delayed release (dr/ec)</i> | T2 | QL (62 EA per 31 days) |
| RECTIV | T4 | |
| REGLAN ORAL | T4 | |
| RELISTOR ORAL | T5 | PA; QL (93 EA per 31 days) |
| RELISTOR SUBCUTANEOUS SOLUTION | T4 | PA; QL (18.6 ML per 31 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML | T5 | PA; QL (18.6 ML per 31 days) |
| RELISTOR SUBCUTANEOUS SYRINGE 8 MG/0.4 ML | T5 | PA; QL (12.4 ML per 31 days) |
| RELTONE | T4 | |
| ROBINUL FORTE | T4 | |
| ROBINUL ORAL | T4 | |
| ROWASA RECTAL ENEMA KIT | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| SANCUSO | T4 | |
| <i>scopolamine base</i> | T3 | QL (10 EA per 30 days) |
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR | T5 | PA; QL (2.4 ML per 56 days) |
| <i>sodium,potassium,mag sulfates</i> | T4 | |
| SUCRAID | T5 | |
| <i>sucralfate</i> | T2 | |
| <i>sulfasalazine</i> | T2 | |
| SUPREP BOWEL PREP KIT | T3 | |
| SUTAB | T4 | |
| SYMPROIC | T4 | PA; QL (31 EA per 31 days) |
| SYNDROS | T5 | PA |
| TALICIA | T4 | |
| TRANSDERM-SCOP | T3 | QL (10 EA per 30 days) |
| <i>trimethobenzamide oral</i> | T2 | PA |
| TRULANCE | T4 | QL (31 EA per 31 days) |
| UCERIS | T4 | |
| URSO 250 | T4 | |
| URSO FORTE | T4 | |
| <i>ursodiol oral capsule 200 mg, 400 mg</i> | T4 | |
| <i>ursodiol oral capsule 300 mg</i> | T3 | |
| <i>ursodiol oral tablet</i> | T3 | |
| VARUBI | T4 | PA-BvD |
| VIBERZI | T5 | PA; QL (62 EA per 31 days) |
| VIOKACE | T4 | |
| ZEGERID | T4 | |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 10,000-32,000 -42,000 UNIT, 15,000-47,000 -63,000 UNIT, 20,000-63,000- 84,000 UNIT, 3,000-10,000 -14,000-UNIT, 5,000-17,000- 24,000 UNIT | T3 | |
| ZENPEP ORAL CAPSULE,DELAYED RELEASE(DR/EC) 25,000-79,000- 105,000 UNIT, 40,000-126,000- 168,000 UNIT | T5 | |
| Immunology, Vaccines / Biotechnology | | |
| ACTHIB (PF) | T3 | |
| ACTIMMUNE | T5 | PA |
| ADACEL(TDAP ADOLESN/ADULT)(PF) | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| ARANESP (IN POLYSORBATE) INJECTION SOLUTION 100 MCG/ML, 25 MCG/ML, 40 MCG/ML | T4 | PA-BvD |
| ARANESP (IN POLYSORBATE) INJECTION SOLUTION 200 MCG/ML, 60 MCG/ML | T5 | PA-BvD |
| ARANESP (IN POLYSORBATE) INJECTION SYRINGE 10 MCG/0.4 ML, 100 MCG/0.5 ML, 25 MCG/0.42 ML, 40 MCG/0.4 ML, 60 MCG/0.3 ML | T4 | PA-BvD |
| ARANESP (IN POLYSORBATE) INJECTION SYRINGE 150 MCG/0.3 ML, 200 MCG/0.4 ML, 300 MCG/0.6 ML, 500 MCG/ML | T5 | PA-BvD |
| ARCALYST | T5 | PA |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT | T5 | QL (4 EA per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT | T5 | QL (4 EA per 28 days) |
| <i>bcg vaccine, live (pf)</i> | T4 | |
| BESREMI | T5 | PA-NS; QL (2 ML per 28 days) |
| BETASERON SUBCUTANEOUS KIT | T5 | QL (14 EA per 28 days) |
| BEXSERO | T3 | |
| BIVIGAM | T5 | PA |
| BOOSTRIX TDAP | T3 | |
| DAPTACEL (DTAP PEDIATRIC) (PF) | T3 | |
| EGRIFTA SV | T5 | PA |
| ENGERIX-B (PF) | T3 | PA-BvD |
| ENGERIX-B PEDIATRIC (PF) | T3 | PA-BvD |
| EPOGEN INJECTION SOLUTION 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | T4 | PA-BvD |
| EXTAVIA SUBCUTANEOUS KIT | T5 | QL (15 EA per 30 days) |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 % | T5 | PA |
| FULPHILA | T5 | |
| GAMMAGARD LIQUID | T5 | PA |
| GAMMAGARD S-D (IGA < 1 MCG/ML) | T5 | PA |
| GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %) | T4 | PA |
| GAMMAPLEX | T5 | PA |
| GAMMAPLEX (WITH SORBITOL) | T5 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | T3 | PA |
| GARDASIL 9 (PF) | T3 | |
| GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.2 MG/0.25 ML | T4 | PA |
| GENOTROPIN MINIQUICK SUBCUTANEOUS SYRINGE 0.4 MG/0.25 ML, 0.6 MG/0.25 ML, 0.8 MG/0.25 ML, 1 MG/0.25 ML, 1.2 MG/0.25 ML, 1.4 MG/0.25 ML, 1.6 MG/0.25 ML, 1.8 MG/0.25 ML, 2 MG/0.25 ML | T5 | PA |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE 12 MG/ML (36 UNIT/ML) | T5 | PA |
| GENOTROPIN SUBCUTANEOUS CARTRIDGE 5 MG/ML (15 UNIT/ML) | T4 | PA |
| GRANIX | T5 | |
| GRASTEK | T4 | PA |
| HAVRIX (PF) | T3 | |
| HIBERIX (PF) | T3 | |
| HUMATROPE INJECTION CARTRIDGE 12 MG (36 UNIT), 24 MG (72 UNIT) | T5 | PA |
| HUMATROPE INJECTION CARTRIDGE 6 MG (18 UNIT) | T4 | PA |
| IMOVAX RABIES VACCINE (PF) | T3 | PA-BvD |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE | T3 | |
| INTRON A INJECTION RECON SOLN 10 MILLION UNIT (1 ML) | T3 | PA-NS |
| INTRON A INJECTION RECON SOLN 50 MILLION UNIT (1 ML) | T5 | PA-NS |
| IPOL | T3 | |
| IXIARO (PF) | T3 | |
| KINRIX (PF) INTRAMUSCULAR SYRINGE | T3 | |
| LEUKINE INJECTION RECON SOLN | T5 | PA |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION | T3 | |
| MENQUADFI (PF) | T4 | |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT | T3 | |
| M-M-R II (PF) | T3 | |
| NEULASTA | T5 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| NEUPOGEN INJECTION SOLUTION 300 MCG/ML | T4 | |
| NEUPOGEN INJECTION SOLUTION 480 MCG/1.6 ML | T5 | |
| NEUPOGEN INJECTION SYRINGE | T5 | |
| NIVESTYM | T5 | |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML) | T5 | PA |
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 5 MG/1.5 ML (3.3 MG/ML) | T4 | PA |
| NUTROPIN AQ NUSPIN | T5 | PA |
| NYVEPRIA | T5 | |
| OCTAGAM | T5 | PA |
| ODACTRA | T4 | PA |
| OMNITROPE SUBCUTANEOUS CARTRIDGE 10 MG/1.5 ML (6.7 MG/ML) | T5 | PA |
| OMNITROPE SUBCUTANEOUS CARTRIDGE 5 MG/1.5 ML (3.3 MG/ML) | T4 | PA |
| OMNITROPE SUBCUTANEOUS RECON SOLN | T5 | PA |
| ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY | T4 | PA |
| PANZYGA | T5 | PA |
| PEDIARIX (PF) | T3 | PA-BvD |
| PEDVAX HIB (PF) | T3 | |
| PEGASYS | T5 | PA |
| PENTACEL (PF) | T3 | |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | T5 | QL (1 ML per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | T5 | QL (1 ML per 28 days) |
| PREHEVBRIO (PF) | T3 | PA-BvD |
| PRIORIX (PF) | T3 | |
| PRIVIGEN | T5 | PA |
| PROCRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | T3 | PA-BvD |
| PROCRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML | T5 | PA-BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| PROQUAD (PF) | T3 | |
| QUADRACEL (PF) | T3 | |
| RABAVERT (PF) | T3 | PA-BvD |
| REBIF (WITH ALBUMIN) | T5 | QL (6 ML per 28 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 22 MCG/0.5 ML, 44 MCG/0.5 ML | T5 | QL (6 ML per 28 days) |
| REBIF REBIDOSE SUBCUTANEOUS PEN INJECTOR 8.8MCG/0.2ML-22 MCG/0.5ML (6) | T5 | QL (4.2 ML per 365 days) |
| REBIF TITRATION PACK | T5 | QL (8.4 ML per 365 days) |
| RECOMBIVAX HB (PF) | T3 | PA-BvD |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 3,000 UNIT/ML, 4,000 UNIT/ML | T3 | PA-BvD |
| RETACRIT INJECTION SOLUTION 20,000 UNIT/ML, 40,000 UNIT/ML | T5 | PA-BvD |
| ROTARIX | T3 | |
| ROTATEQ VACCINE | T3 | |
| SAIZEN | T5 | PA |
| SAIZEN SAIZENPREP | T5 | PA |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | T5 | PA |
| SHINGRIX (PF) | T3 | QL (2 EA per 999 days) |
| SKYTROFA | T5 | PA |
| TDVAX | T3 | |
| TENIVAC (PF) | T3 | |
| <i>tetanus, diphtheria tox ped(pf)</i> | T4 | |
| TICOVAC | T3 | |
| TRUMENBA | T3 | |
| TWINRIX (PF) | T3 | |
| TYPHIM VI | T3 | |
| UDENYCA | T5 | |
| VAQTA (PF) | T3 | |
| VARIVAX (PF) | T3 | |
| YF-VAX (PF) | T3 | |
| ZARXIO | T5 | |
| ZIEXTENZO | T5 | |
| ZOMACTON | T4 | PA |
| ZORBTIVE | T5 | PA |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|------------------------------|
| Miscellaneous Supplies | | |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | T4 | |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " | T2 | |
| <i>insulin syringe-needle u-100 syringe 0.3 ml 29 gauge, 1 ml 29 gauge x 1/2", 1/2 ml 28 gauge</i> | T3 | |
| <i>pen needle, diabetic needle 29 gauge x 1/2"</i> | T4 | |
| Musculoskeletal / Rheumatology | | |
| ACTEMRA ACTPEN | T5 | PA; QL (3.6 ML per 28 days) |
| ACTEMRA SUBCUTANEOUS | T5 | PA; QL (3.6 ML per 28 days) |
| ACTONEL ORAL TABLET 150 MG, 35 MG | T4 | |
| <i>alendronate oral solution</i> | T1 | |
| <i>alendronate oral tablet 10 mg, 35 mg, 70 mg</i> | T1 | |
| <i>allopurinol oral tablet 100 mg, 300 mg</i> | T1 | |
| ARAVA | T5 | |
| AELVIA | T4 | |
| BENLYSTA SUBCUTANEOUS | T5 | PA; QL (4 ML per 28 days) |
| BINOSTO | T4 | |
| <i>colchicine</i> | T4 | QL (62 EA per 31 days) |
| COLCRYS | T4 | QL (124 EA per 31 days) |
| CUPRIMINE | T5 | |
| DEPEN TITRATABS | T5 | |
| ENBREL MINI | T5 | PA; QL (7.84 ML per 28 days) |
| ENBREL SUBCUTANEOUS SOLUTION | T5 | PA; QL (4 ML per 28 days) |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5) | T5 | PA; QL (4 ML per 28 days) |
| ENBREL SUBCUTANEOUS SYRINGE 50 MG/ML (1 ML) | T5 | PA; QL (7.84 ML per 28 days) |
| ENBREL SURECLICK | T5 | PA; QL (7.84 ML per 28 days) |
| EVENITY SUBCUTANEOUS SYRINGE 210MG/2.34ML (105MG/1.17MLX2) | T5 | PA; QL (2.34 ML per 28 days) |
| EVISTA | T3 | |
| <i>febuxostat</i> | T4 | PA |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) | T5 | PA; QL (2.4 ML per 28 days) |
| FOSAMAX ORAL TABLET 70 MG | T4 | |
| FOSAMAX PLUS D | T4 | |
| HUMIRA PEN | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA PEN CROHNS-UC-HS START | T5 | PA; QL (6 EA per 28 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-------------------------------|
| HUMIRA PEN PSOR-UVEITS-ADOL HS | T5 | PA; QL (4 EA per 28 days) |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML | T5 | PA; QL (3 EA per 28 days) |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML-40 MG/0.4 ML | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) PEN | T5 | PA; QL (2 EA per 28 days) |
| HUMIRA(CF) PEN CROHNS-UC-HS | T5 | PA; QL (3 EA per 28 days) |
| HUMIRA(CF) PEN PEDIATRIC UC | T5 | PA; QL (4 EA per 28 days) |
| HUMIRA(CF) PEN PSOR-UV-ADOL HS | T5 | PA; QL (3 EA per 28 days) |
| <i>ibandronate oral</i> | T2 | |
| KEVZARA | T5 | PA; QL (2.28 ML per 28 days) |
| KINERET | T5 | PA; QL (18.76 ML per 28 days) |
| <i>leflunomide</i> | T2 | |
| MITIGARE | T3 | QL (62 EA per 31 days) |
| OLUMIANT ORAL TABLET 1 MG, 2 MG | T5 | PA; QL (31 EA per 31 days) |
| ORENCIA CLICKJECT | T5 | PA; QL (4 ML per 28 days) |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML | T5 | PA; QL (4 ML per 28 days) |
| ORENCIA SUBCUTANEOUS SYRINGE 50 MG/0.4 ML | T5 | PA; QL (1.6 ML per 28 days) |
| ORENCIA SUBCUTANEOUS SYRINGE 87.5 MG/0.7 ML | T5 | PA; QL (2.8 ML per 28 days) |
| OTEZLA | T5 | PA; QL (62 EA per 31 days) |
| OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47) | T5 | PA; QL (55 EA per 28 days) |
| OTREXUP (PF) | T4 | PA |
| <i>penicillamine</i> | T5 | |
| <i>probenecid</i> | T2 | |
| <i>probenecid-colchicine</i> | T2 | |
| PROLIA | T4 | PA; QL (1 ML per 180 days) |
| <i>raloxifene</i> | T3 | |
| RASUVO (PF) | T4 | PA |
| REDITREX (PF) | T4 | PA |
| RIDAURA | T3 | |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG | T5 | PA; QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 45 MG | T5 | PA; QL (112 EA per 365 days) |
| <i>risedronate oral tablet 150 mg, 35 mg, 35 mg (12 pack), 35 mg (4 pack), 5 mg</i> | T2 | |
| <i>risedronate oral tablet, delayed release (dr/ec)</i> | T2 | |
| SAVELLA | T4 | PA |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| SIMPONI SUBCUTANEOUS PEN INJECTOR 50 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML | T5 | PA; QL (1 ML per 28 days) |
| SIMPONI SUBCUTANEOUS SYRINGE 50 MG/0.5 ML | T5 | PA; QL (0.5 ML per 28 days) |
| <i>teriparatide</i> | T5 | PA; QL (2.48 ML per 28 days) |
| TYMLOS | T5 | PA; QL (1.56 ML per 30 days) |
| ULORIC | T4 | PA |
| XELJANZ ORAL SOLUTION | T5 | PA; QL (310 ML per 31 days) |
| XELJANZ ORAL TABLET | T5 | PA; QL (62 EA per 31 days) |
| XELJANZ XR | T5 | PA; QL (31 EA per 31 days) |
| ZYLOPRIM | T4 | |
| Obstetrics / Gynecology | | |
| ACTIVELLA ORAL TABLET 1-0.5 MG | T4 | |
| ALTAVERA (28) | T2 | |
| ALYACEN 1/35 (28) | T2 | |
| AMABELZ | T2 | |
| AMETHIA | T2 | |
| ANGELIQ | T4 | |
| ANNOVERA | T4 | |
| APRI | T2 | |
| ARANELLE (28) | T2 | |
| ASHLYNA | T2 | |
| AUBRA EQ | T2 | |
| AVIANE | T2 | |
| AYGESTIN | T4 | |
| BALCOLTRA | T4 | |
| BALZIVA (28) | T2 | |
| BEYAZ | T4 | |
| BIJUVA | T4 | |
| BLISOVI 24 FE | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| BLISOVI FE 1.5/30 (28) | T2 | |
| BRIELLYN | T2 | |
| CAMILA | T2 | |
| CAMRESE LO | T2 | |
| CLEOCIN VAGINAL | T4 | |
| CLIMARA | T4 | |
| CLIMARA PRO | T4 | |
| <i>clindamycin phosphate vaginal</i> | T2 | |
| CLINDESSE | T4 | |
| COMBIPATCH | T4 | |
| CRINONE | T4 | PA |
| CRYSELLE (28) | T2 | |
| CYRED EQ | T2 | |
| DEBLITANE | T2 | |
| DELESTROGEN | T4 | |
| DEPO-ESTRADIOL | T4 | |
| DEPO-PROVERA INTRAMUSCULAR SUSPENSION 150 MG/ML | T4 | |
| DEPO-SUBQ PROVERA 104 | T4 | |
| <i>desog-e.estradiol/e.estradiol</i> | T2 | |
| <i>desogestrel-ethinyl estradiol</i> | T2 | |
| DIVIGEL TRANSDERMAL GEL IN PACKET 0.5 MG/0.5 GRAM (0.1 %) | T4 | |
| DOLISHALE | T2 | |
| DOTTI | T2 | |
| <i>drospirenone-e.estradiol-lm.fa oral tablet 3-0.02- 0.451 mg (24) (4)</i> | T2 | |
| <i>drospirenone-ethinyl estradiol</i> | T2 | |
| DUAVEE | T4 | |
| ELESTRIN | T4 | |
| ELURYNG | T3 | |
| EMOQUETTE | T2 | |
| ENPRESSE | T2 | |
| ENSKYCE | T2 | |
| ERRIN | T2 | |
| ESTARYLLA | T2 | |
| ESTRACE | T4 | |
| <i>estradiol oral</i> | T1 | |
| <i>estradiol transdermal patch semiweekly</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>estradiol transdermal patch weekly</i> | T2 | |
| <i>estradiol vaginal</i> | T4 | |
| <i>estradiol valerate intramuscular oil 20 mg/ml, 40 mg/ml</i> | T2 | |
| <i>estradiol-norethindrone acet</i> | T2 | |
| ESTRING | T4 | |
| ESTROGEL | T4 | |
| <i>ethynodiol diac-eth estradiol</i> | T2 | |
| <i>etonogestrel-ethinyl estradiol</i> | T3 | |
| EVAMIST | T4 | |
| FALMINA (28) | T2 | |
| FEMRING | T4 | |
| FEMYNOR | T2 | |
| FINZALA | T2 | |
| FYAVOLV | T2 | |
| GEMMILY | T4 | |
| GENERESS FE | T4 | |
| GYNAZOLE-1 | T3 | |
| HAILEY 24 FE | T2 | |
| ICLEVIA | T2 | |
| IMVEXXY MAINTENANCE PACK | T4 | |
| IMVEXXY STARTER PACK | T4 | |
| INCASSIA | T2 | |
| INTRAROSA | T4 | PA; QL (28 EA per 28 days) |
| INTROVALE | T2 | |
| ISIBLOOM | T2 | |
| JASMIEL (28) | T2 | |
| JINTELI | T2 | |
| JULEBER | T2 | |
| JUNEL 1.5/30 (21) | T2 | |
| JUNEL 1/20 (21) | T2 | |
| JUNEL FE 1.5/30 (28) | T2 | |
| JUNEL FE 1/20 (28) | T2 | |
| JUNEL FE 24 | T2 | |
| KAITLIB FE | T2 | |
| KARIVA (28) | T2 | |
| KELNOR 1/35 (28) | T2 | |
| KELNOR 1-50 (28) | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| KURVELO (28) | T2 | |
| <i>l norgest/e.estradiol-e.estrad</i> | T2 | |
| LARIN 1.5/30 (21) | T2 | |
| LARIN 1/20 (21) | T2 | |
| LARIN FE 1.5/30 (28) | T2 | |
| LARIN FE 1/20 (28) | T2 | |
| LAYOLIS FE | T4 | |
| LEENA 28 | T2 | |
| LESSINA | T2 | |
| LEVONEST (28) | T2 | |
| <i>levonorgestrel-ethinyl estrad</i> | T2 | |
| <i>levonorg-eth estrad triphasic</i> | T2 | |
| LEVORA-28 | T2 | |
| LO LOESTRIN FE | T4 | |
| LOESTRIN 1.5/30 (21) | T4 | |
| LOESTRIN 1/20 (21) | T4 | |
| LOESTRIN FE 1.5/30 (28-DAY) | T4 | |
| LOESTRIN FE 1/20 (28-DAY) | T4 | |
| LORYNA (28) | T2 | |
| LOSEASONIQUE | T4 | |
| LOW-OGESTREL (28) | T2 | |
| LUTERA (28) | T2 | |
| LYLEQ | T2 | |
| LYLLANA | T2 | |
| LYSTEDA | T4 | |
| LYZA | T2 | |
| MARLISSA (28) | T2 | |
| <i>medroxyprogesterone</i> | T2 | |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG | T4 | |
| MENOSTAR | T4 | |
| MERZEE | T4 | |
| <i>metronidazole vaginal</i> | T2 | |
| MICONAZOLE-3 VAGINAL SUPPOSITORY | T2 | |
| MICROGESTIN 1.5/30 (21) | T2 | |
| MICROGESTIN 1/20 (21) | T2 | |
| MICROGESTIN 24 FE | T4 | |
| MICROGESTIN FE 1.5/30 (28) | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| MICROGESTIN FE 1/20 (28) | T2 | |
| MILI | T2 | |
| MIMVEY | T2 | |
| MINASTRIN 24 FE | T4 | |
| MINIVELLE | T4 | |
| MYFEMBREE | T5 | PA; QL (31 EA per 31 days) |
| NATAZIA | T4 | |
| NECON 0.5/35 (28) | T2 | |
| NEXTSTELLIS | T4 | |
| NIKKI (28) | T2 | |
| NORA-BE | T2 | |
| <i>noreth-ethinyl estradiol-iron</i> | T2 | |
| <i>norethindrone (contraceptive)</i> | T2 | |
| <i>norethindrone acetate</i> | T2 | |
| <i>norethindrone ac-eth estradiol oral tablet 0.5-2.5 mg-mcg, 1-20 mg-mcg, 1-5 mg-mcg</i> | T2 | |
| <i>norethindrone-e.estradiol-iron oral capsule</i> | T4 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1 mg-20 mcg (21)/75 mg (7), 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | T2 | |
| <i>norethindrone-e.estradiol-iron oral tablet, chewable</i> | T2 | |
| <i>norgestimate-ethinyl estradiol</i> | T2 | |
| NORTREL 0.5/35 (28) | T2 | |
| NORTREL 1/35 (21) | T2 | |
| NORTREL 1/35 (28) | T2 | |
| NORTREL 7/7/7 (28) | T2 | |
| NUVARING | T4 | |
| NYLIA 1/35 (28) | T2 | |
| NYLIA 7/7/7 (28) | T2 | |
| NYMYO | T2 | |
| OCELLA | T2 | |
| ORIAHNN | T5 | PA; QL (56 EA per 28 days) |
| OSPHENA | T4 | PA; QL (31 EA per 31 days) |
| PHEXXI | T4 | |
| PIMTREA (28) | T2 | |
| PIRMELLA ORAL TABLET 1-35 MG-MCG | T2 | |
| PORTIA 28 | T2 | |
| PREFEST | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---------------------------------------|------------------|----------------------------|
| PREMARIN ORAL | T4 | |
| PREMARIN VAGINAL | T3 | |
| PREMPHASE | T4 | |
| PREMPRO | T4 | |
| <i>progesterone micronized</i> | T2 | |
| PROMETRIUM | T4 | |
| PROVERA | T4 | |
| QUARTETTE | T4 | |
| RECLIPSEN (28) | T2 | |
| RIVELSA | T4 | |
| SAFYRAL | T4 | |
| SEASONIQUE | T4 | |
| SETLAKIN | T2 | |
| SHAROBEL | T2 | |
| SLYND | T4 | |
| SPRINTEC (28) | T2 | |
| SRONYX | T2 | |
| SYEDA | T2 | |
| TARINA 24 FE | T2 | |
| TARINA FE 1-20 EQ (28) | T2 | |
| TAYSOFY | T4 | |
| <i>terconazole</i> | T2 | |
| TILIA FE | T2 | |
| <i>tranexamic acid oral</i> | T2 | |
| TRI-ESTARYLLA | T2 | |
| TRI-LEGEST FE | T2 | |
| TRI-LO-ESTARYLLA | T2 | |
| TRI-LO-SPRINTEC | T2 | |
| TRI-MILI | T2 | |
| TRI-NYMYO | T2 | |
| TRI-SPRINTEC (28) | T2 | |
| TRIVORA (28) | T2 | |
| TRI-VYLIBRA | T2 | |
| TRI-VYLIBRA LO | T2 | |
| TYDEMY | T2 | |
| VAGIFEM | T4 | |
| VANDAZOLE | T3 | |
| VELIVET TRIPHASIC REGIMEN (28) | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| VESTURA (28) | T2 | |
| VIENVA | T2 | |
| VIVELLE-DOT | T4 | |
| VYFEMLA (28) | T2 | |
| VYLIBRA | T2 | |
| WYMZYA FE | T2 | |
| XULANE | T2 | |
| YASMIN (28) | T4 | |
| YAZ (28) | T4 | |
| YUVAFEM | T4 | |
| ZAFEMY | T2 | |
| ZOVIA 1-35 (28) | T2 | |
| Ophthalmology | | |
| <i>acetazolamide</i> | T2 | |
| ACULAR | T4 | |
| ACULAR LS | T4 | |
| ACUVAIL (PF) | T4 | |
| ALOCRIAL | T4 | |
| ALOMIDE | T3 | |
| ALPHAGAN P | T3 | |
| ALREX | T4 | |
| <i>apraclonidine</i> | T2 | |
| <i>atropine ophthalmic (eye) drops</i> | T2 | |
| AZASITE | T4 | |
| <i>azelastine ophthalmic (eye)</i> | T2 | |
| AZOPT | T4 | |
| <i>bacitracin ophthalmic (eye)</i> | T2 | |
| <i>bacitracin-polymyxin b</i> | T2 | |
| <i>bepotastine besilate</i> | T4 | |
| BEPREVE | T4 | |
| BESIVANCE | T4 | |
| <i>betaxolol ophthalmic (eye)</i> | T2 | |
| BETIMOL | T4 | |
| BETOPTIC S | T4 | |
| <i>bimatoprost ophthalmic (eye)</i> | T2 | |
| BLEPHAMIDE S.O.P. | T3 | |
| <i>brimonidine</i> | T2 | |
| <i>brimonidine-timolol</i> | T3 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| <i>brinzolamide</i> | T4 | |
| <i>bromfenac</i> | T2 | |
| BROMSITE | T4 | |
| <i>carteolol</i> | T2 | |
| CEQUA | T4 | ST; QL (60 EA per 30 days) |
| CILOXAN OPHTHALMIC (EYE) OINTMENT | T3 | |
| <i>ciprofloxacin hcl ophthalmic (eye)</i> | T1 | |
| COMBIGAN | T3 | |
| COSOPT | T4 | |
| COSOPT (PF) | T4 | |
| <i>cromolyn ophthalmic (eye)</i> | T2 | |
| <i>cyclosporine ophthalmic (eye)</i> | T3 | QL (60 EA per 30 days) |
| CYSTADROPS | T5 | PA; QL (20 ML per 28 days) |
| CYSTARAN | T5 | PA; QL (60 ML per 28 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye)</i> | T2 | |
| <i>diclofenac sodium ophthalmic (eye)</i> | T1 | |
| <i>difluprednate</i> | T3 | |
| <i>dorzolamide</i> | T2 | |
| <i>dorzolamide-timolol</i> | T2 | |
| <i>dorzolamide-timolol (pf) ophthalmic (eye) dropperette</i> | T4 | |
| DUREZOL | T4 | |
| <i>epinastine</i> | T2 | |
| <i>erythromycin ophthalmic (eye)</i> | T2 | |
| EYSUVIS | T4 | QL (8.3 ML per 30 days) |
| FLAREX | T4 | |
| <i>fluorometholone</i> | T2 | |
| <i>flurbiprofen sodium</i> | T2 | |
| FML FORTE | T4 | |
| FML LIQUIFILM | T4 | |
| <i>gatifloxacin</i> | T3 | |
| GENTAK OPHTHALMIC (EYE) OINTMENT | T2 | |
| <i>gentamicin ophthalmic (eye) drops</i> | T1 | |
| ILEVRO | T3 | |
| INVELTYS | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| IOPIDINE OPHTHALMIC (EYE) DROPPERETTE | T3 | |
| ISOPTO CARPINE OPHTHALMIC (EYE) DROPS 1 % | T4 | |
| ISTALOL | T4 | |
| <i>ketorolac ophthalmic (eye)</i> | T2 | |
| LACRISERT | T3 | |
| <i>latanoprost</i> | T1 | |
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | T1 | |
| <i>levofloxacin ophthalmic (eye) drops 0.5 %</i> | T2 | |
| LOTEMAX | T4 | |
| LOTEMAX SM | T4 | |
| <i>loteprednol etabonate</i> | T4 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | T3 | QL (5 ML per 31 days) |
| MAXIDEX | T4 | |
| MAXITROL | T4 | |
| <i>methazolamide</i> | T2 | |
| <i>moxifloxacin ophthalmic (eye) drops</i> | T3 | |
| NATACYN | T3 | |
| <i>neomycin-bacitracin-poly-hc</i> | T2 | |
| <i>neomycin-bacitracin-polymyxin</i> | T2 | |
| <i>neomycin-polymyxin b-dexameth</i> | T2 | |
| <i>neomycin-polymyxin-gramicidin</i> | T2 | |
| <i>neomycin-polymyxin-hc ophthalmic (eye)</i> | T2 | |
| NEVANAC | T4 | |
| OCUFLOX | T4 | |
| <i>ofloxacin ophthalmic (eye)</i> | T2 | |
| <i>olopatadine ophthalmic (eye)</i> | T3 | |
| OXERVATE | T5 | PA; QL (112 ML per 56 days) |
| PHOSPHOLINE IODIDE | T5 | PA; QL (5 ML per 25 days) |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | T2 | |
| <i>polymyxin b sulf-trimethoprim</i> | T1 | |
| POLYTRIM | T4 | |
| PRED FORTE | T4 | |
| PRED MILD | T4 | |
| PRED-G S.O.P. | T4 | |
| <i>prednisolone acetate</i> | T1 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| <i>prednisolone sodium phosphate ophthalmic (eye)</i> | T2 | |
| PROLENSA | T4 | |
| RESTASIS | T3 | QL (60 EA per 30 days) |
| RESTASIS MULTIDOSE | T3 | QL (5.5 ML per 27 days) |
| RHOPRESSA | T4 | ST |
| ROCKLATAN | T4 | ST |
| SIMBRINZA | T4 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops</i> | T2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment</i> | T1 | |
| <i>sulfacetamide-prednisolone</i> | T2 | |
| <i>timolol maleate (pf)</i> | T4 | |
| <i>timolol maleate ophthalmic (eye) drops</i> | T1 | |
| <i>timolol maleate ophthalmic (eye) drops, once daily</i> | T2 | |
| <i>timolol maleate ophthalmic (eye) gel forming solution</i> | T2 | |
| TIMOPTIC OCUDOSE (PF) | T4 | |
| TIMOPTIC-XE | T4 | |
| TOBRADEX OPHTHALMIC (EYE) DROPS,SUSPENSION | T4 | |
| TOBRADEX OPHTHALMIC (EYE) OINTMENT | T3 | |
| <i>tobramycin ophthalmic (eye)</i> | T1 | |
| <i>tobramycin-dexamethasone</i> | T2 | |
| TOBREX OPHTHALMIC (EYE) OINTMENT | T3 | |
| TRAVATAN Z | T4 | |
| <i>travoprost</i> | T3 | |
| <i>trifluridine</i> | T2 | |
| TYRVAYA | T4 | ST; QL (8.4 ML per 30 days) |
| VERKAZIA | T5 | PA; QL (120 EA per 30 days) |
| VIGAMOX | T4 | |
| VUITY | T4 | PA; QL (2.5 ML per 25 days) |
| VYZULTA | T4 | ST; QL (5 ML per 31 days) |
| XALATAN | T4 | |
| XELPROS | T4 | |
| XIIDRA | T3 | QL (60 EA per 30 days) |
| ZERVIAE | T4 | |
| ZIOPTAN (PF) | T4 | |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| ZIRGAN | T4 | ST |
| ZYLET | T4 | |
| ZYMAXID | T3 | |
| Respiratory And Allergy | | |
| ACCOLATE ORAL TABLET 10 MG | T4 | QL (93 EA per 31 days) |
| ACCOLATE ORAL TABLET 20 MG | T4 | QL (62 EA per 31 days) |
| <i>acetylcysteine</i> | T2 | PA-BvD |
| ADCIRCA | T5 | PA; QL (62 EA per 31 days) |
| ADEMPAS | T5 | PA; QL (93 EA per 31 days) |
| ADVAIR DISKUS | T4 | QL (60 EA per 30 days) |
| ADVAIR HFA | T4 | QL (12 GM per 30 days) |
| AIRDUO DIGIHALER | T4 | PA; QL (2 EA per 365 days) |
| AIRDUO RESPICLICK | T4 | QL (1 EA per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation</i> | T3 | QL (17 GM per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020503)</i> | T3 | QL (13.4 GM per 30 days) |
| <i>albuterol sulfate inhalation hfa aerosol inhaler 90 mcg/actuation (nda020983)</i> | T4 | ST; QL (36 GM per 30 days) |
| <i>albuterol sulfate inhalation solution for nebulization 0.63 mg/3 ml, 1.25 mg/3 ml, 2.5 mg/3 ml (0.083 %), 2.5 mg/0.5 ml</i> | T2 | PA-BvD |
| <i>albuterol sulfate oral syrup</i> | T1 | |
| <i>albuterol sulfate oral tablet</i> | T1 | |
| ALVESCO | T4 | QL (12.2 GM per 30 days) |
| ALYQ | T5 | PA; QL (62 EA per 31 days) |
| <i>ambrisentan</i> | T5 | PA; QL (31 EA per 31 days) |
| ANORO ELLIPTA | T3 | QL (60 EA per 30 days) |
| <i>arformoterol</i> | T4 | PA-BvD |
| ARMONAIR DIGIHALER | T4 | PA; QL (2 EA per 365 days) |
| ARNUITY ELLIPTA | T4 | QL (30 EA per 30 days) |
| ASMANEX HFA | T3 | QL (13 GM per 30 days) |
| ASMANEX TWISTHALER INHALATION AEROSOL POWDR BREATH ACTIVATED 110 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (120), 220 MCG/ ACTUATION (30), 220 MCG/ ACTUATION (60) | T3 | QL (1 EA per 30 days) |
| ATROVENT HFA | T3 | QL (25.8 GM per 30 days) |
| AUVI-Q INJECTION AUTO-INJECTOR 0.1 MG/0.1 ML, 0.15 MG/0.15 ML | T4 | ST |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|-----------------------------|
| AUVI-Q INJECTION AUTO-INJECTOR 0.3 MG/0.3 ML | T5 | ST |
| <i>azelastine-fluticasone</i> | T4 | |
| BECONASE AQ | T4 | |
| BERINERT INTRAVENOUS KIT | T5 | PA |
| BEVESPI AEROSPHERE | T4 | QL (10.7 GM per 30 days) |
| <i>bosentan</i> | T5 | PA; QL (62 EA per 31 days) |
| BREO ELLIPTA | T3 | QL (60 EA per 30 days) |
| BREZTRI AEROSPHERE | T3 | QL (10.7 GM per 30 days) |
| BRONCHITOL | T5 | PA; QL (560 EA per 28 days) |
| BROVANA | T4 | PA-BvD |
| <i>budesonide inhalation</i> | T2 | PA-BvD |
| <i>budesonide-formoterol</i> | T4 | QL (10.2 GM per 30 days) |
| <i>carbinoxamine maleate oral liquid</i> | T4 | PA |
| <i>carbinoxamine maleate oral tablet 4 mg</i> | T4 | PA |
| <i>cetirizine oral solution 1 mg/ml</i> | T1 | QL (310 ML per 31 days) |
| CINRYZE | T5 | PA; QL (20 EA per 28 days) |
| CLARINEX ORAL TABLET | T4 | QL (31 EA per 31 days) |
| CLARINEX-D 12 HOUR | T4 | |
| <i>clemastine oral syrup</i> | T2 | |
| <i>clemastine oral tablet 2.68 mg</i> | T2 | |
| COMBIVENT RESPIMAT | T3 | QL (4 GM per 30 days) |
| <i>cromolyn inhalation</i> | T2 | PA-BvD |
| <i>cyproheptadine</i> | T2 | PA |
| DALIRESP ORAL TABLET 250 MCG | T4 | QL (31 EA per 31 days) |
| DALIRESP ORAL TABLET 500 MCG | T3 | QL (31 EA per 31 days) |
| <i>desloratadine</i> | T2 | QL (31 EA per 31 days) |
| DUAKLIR PRESSAIR | T5 | QL (1 EA per 30 days) |
| DULERA | T4 | QL (13 GM per 30 days) |
| DYMISTA | T4 | ST |
| <i>epinephrine injection auto-injector</i> | T3 | |
| EPIPEN 2-PAK | T4 | |
| EPIPEN JR 2-PAK | T4 | |
| ESBRIET ORAL CAPSULE | T5 | PA; QL (279 EA per 31 days) |
| ESBRIET ORAL TABLET 267 MG | T5 | PA; QL (279 EA per 31 days) |
| ESBRIET ORAL TABLET 801 MG | T5 | PA; QL (93 EA per 31 days) |
| FASENRA | T5 | PA; QL (1 ML per 56 days) |
| FASENRA PEN | T5 | PA; QL (1 ML per 56 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| FIRAZYR | T5 | PA; QL (18 ML per 30 days) |
| FLOVENT DISKUS | T3 | QL (60 EA per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 110 MCG/ACTUATION, 220 MCG/ACTUATION | T3 | QL (24 GM per 30 days) |
| FLOVENT HFA INHALATION HFA AEROSOL INHALER 44 MCG/ACTUATION | T3 | QL (12 GM per 30 days) |
| <i>flunisolide</i> | T2 | QL (50 ML per 25 days) |
| <i>fluticasone furoate-vilanterol</i> | T4 | ST; QL (60 EA per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 110 mcg/actuation, 220 mcg/actuation</i> | T4 | ST; QL (24 GM per 30 days) |
| <i>fluticasone propionate inhalation hfa aerosol inhaler 44 mcg/actuation</i> | T4 | ST; QL (12 GM per 30 days) |
| <i>fluticasone propionate nasal</i> | T1 | QL (16 GM per 30 days) |
| <i>fluticasone propion-salmeterol inhalation aerosol powdr breath activated</i> | T3 | QL (1 EA per 30 days) |
| <i>fluticasone propion-salmeterol inhalation blister with device</i> | T3 | QL (60 EA per 30 days) |
| <i>formoterol fumarate</i> | T5 | PA-BvD |
| HAEGARDA | T5 | PA |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> | T2 | PA |
| <i>hydroxyzine hcl oral tablet</i> | T2 | PA |
| <i>hydroxyzine pamoate</i> | T2 | PA |
| <i>icatibant</i> | T5 | PA; QL (18 ML per 30 days) |
| INCRUSE ELLIPTA | T3 | QL (30 EA per 30 days) |
| <i>ipratropium bromide inhalation</i> | T1 | PA-BvD |
| <i>ipratropium-albuterol</i> | T2 | PA-BvD |
| KALYDECO ORAL GRANULES IN PACKET 25 MG | T5 | PA; QL (62 EA per 31 days) |
| KALYDECO ORAL GRANULES IN PACKET 50 MG, 75 MG | T5 | PA; QL (56 EA per 28 days) |
| KALYDECO ORAL TABLET | T5 | PA; QL (62 EA per 31 days) |
| LETAIRIS | T5 | PA; QL (31 EA per 31 days) |
| <i>levalbuterol hcl</i> | T2 | PA-BvD |
| <i>levalbuterol tartrate</i> | T3 | QL (30 GM per 30 days) |
| <i>levocetirizine oral solution</i> | T2 | QL (310 ML per 31 days) |
| <i>levocetirizine oral tablet</i> | T1 | QL (31 EA per 31 days) |
| LONHALA MAGNAIR REFILL | T5 | |
| <i>mometasone nasal</i> | T3 | QL (34 GM per 30 days) |
| <i>montelukast</i> | T2 | QL (31 EA per 31 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| NUCALA SUBCUTANEOUS AUTO-INJECTOR | T5 | PA; QL (3 ML per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN | T5 | PA; QL (3 EA per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | T5 | PA; QL (3 ML per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | T5 | PA; QL (0.4 ML per 28 days) |
| OFEV | T5 | PA; QL (62 EA per 31 days) |
| OMNARIS | T4 | |
| OPSUMIT | T5 | PA; QL (31 EA per 31 days) |
| ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG | T5 | PA; QL (62 EA per 31 days) |
| ORKAMBI ORAL TABLET | T5 | PA; QL (124 EA per 31 days) |
| ORLADEYO | T5 | PA; QL (31 EA per 31 days) |
| PERFOROMIST | T5 | PA-BvD |
| <i>pirfenidone oral tablet 267 mg</i> | T5 | PA; QL (279 EA per 31 days) |
| <i>pirfenidone oral tablet 801 mg</i> | T5 | PA; QL (93 EA per 31 days) |
| PROAIR DIGIHALER | T4 | PA; QL (2 EA per 365 days) |
| PROAIR RESPICLICK | T4 | ST; QL (2 EA per 30 days) |
| <i>promethazine oral</i> | T2 | PA |
| <i>promethazine rectal suppository 12.5 mg, 25 mg</i> | T2 | |
| PROMETHEGAN RECTAL SUPPOSITORY 25 MG, 50 MG | T2 | |
| PULMICORT | T4 | PA-BvD |
| PULMICORT FLEXHALER | T4 | QL (1 EA per 30 days) |
| PULMOZYME | T5 | PA |
| QNASL | T4 | |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 40 MCG/ACTUATION | T3 | QL (10.6 GM per 30 days) |
| QVAR REDIHALER INHALATION HFA AEROSOL BREATH ACTIVATED 80 MCG/ACTUATION | T3 | QL (21.2 GM per 30 days) |
| REVATIO ORAL SUSPENSION FOR RECONSTITUTION | T5 | PA; QL (224 ML per 31 days) |
| REVATIO ORAL TABLET | T5 | PA; QL (93 EA per 31 days) |
| RUCONEST | T5 | PA |
| RYALTRIS | T4 | ST; QL (29 GM per 30 days) |
| RYCLORA | T4 | |
| RYVENT | T4 | PA |
| SAJAZIR | T5 | PA; QL (18 ML per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|------------------------------|
| SEREVENT DISKUS | T3 | QL (60 EA per 30 days) |
| <i>sildenafil (pulm.hypertension) oral suspension for reconstitution</i> | T4 | PA; QL (224 ML per 31 days) |
| <i>sildenafil (pulm.hypertension) oral tablet</i> | T3 | PA; QL (93 EA per 31 days) |
| SINGULAIR | T4 | QL (31 EA per 31 days) |
| SPIRIVA RESPIMAT | T3 | QL (4 GM per 30 days) |
| SPIRIVA WITH HANDIHALER | T3 | QL (30 EA per 30 days) |
| STIOLTO RESPIMAT | T3 | QL (4 GM per 30 days) |
| STRIVERDI RESPIMAT | T4 | QL (4 GM per 30 days) |
| SYMBICORT | T3 | QL (10.2 GM per 30 days) |
| SYMDEKO | T5 | PA; QL (56 EA per 28 days) |
| SYMJEPI | T4 | |
| <i>tadalafil (pulm. hypertension)</i> | T5 | PA; QL (62 EA per 31 days) |
| TAKHZYRO | T5 | PA; QL (4 ML per 28 days) |
| <i>terbutaline oral</i> | T2 | |
| THEO-24 | T4 | |
| <i>theophylline oral solution</i> | T2 | |
| <i>theophylline oral tablet extended release 12 hr 300 mg, 450 mg</i> | T2 | |
| <i>theophylline oral tablet extended release 24 hr</i> | T2 | |
| TRACLEER ORAL TABLET | T5 | PA; QL (62 EA per 31 days) |
| TRACLEER ORAL TABLET FOR SUSPENSION | T5 | PA; QL (124 EA per 31 days) |
| TRELEGY ELLIPTA | T3 | QL (60 EA per 30 days) |
| TRIKAFTA | T5 | PA; QL (84 EA per 28 days) |
| TUDORZA PRESSAIR | T4 | QL (1 EA per 30 days) |
| TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG (112)- 32 MCG (84) | T5 | PA; QL (392 EA per 365 days) |
| TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG | T5 | PA |
| TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16(112)-32(112) -48(28) MCG | T5 | PA; QL (504 EA per 365 days) |
| VENTAVIS | T5 | PA |
| VENTOLIN HFA | T3 | QL (36 GM per 30 days) |
| VISTARIL | T4 | PA |
| WIXELA INHUB | T3 | QL (60 EA per 30 days) |
| XHANCE | T4 | QL (32 ML per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|-----------------------------|
| XOLAIR | T5 | PA |
| XOPENEX | T4 | PA-BvD |
| XOPENEX CONCENTRATE | T4 | PA-BvD |
| XOPENEX HFA | T4 | ST; QL (30 GM per 30 days) |
| YUPELRI | T5 | PA-BvD |
| <i>zafirlukast oral tablet 10 mg</i> | T2 | QL (93 EA per 31 days) |
| <i>zafirlukast oral tablet 20 mg</i> | T2 | QL (62 EA per 31 days) |
| ZETONNA | T4 | |
| <i>zileuton</i> | T5 | PA; QL (124 EA per 31 days) |
| ZYFLO | T4 | PA; QL (124 EA per 31 days) |
| Urologicals | | |
| <i>alfuzosin</i> | T2 | QL (31 EA per 31 days) |
| AVODART | T4 | QL (31 EA per 31 days) |
| <i>bethanechol chloride</i> | T2 | |
| CIALIS ORAL TABLET 2.5 MG | T4 | PA; QL (62 EA per 31 days) |
| CIALIS ORAL TABLET 5 MG | T4 | PA; QL (31 EA per 31 days) |
| CYSTAGON | T3 | |
| <i>darifenacin</i> | T3 | QL (31 EA per 31 days) |
| DETROL | T4 | QL (62 EA per 31 days) |
| DETROL LA | T4 | QL (31 EA per 31 days) |
| DITROPAN XL ORAL TABLET EXTENDED RELEASE 24HR 10 MG | T4 | QL (93 EA per 31 days) |
| DITROPAN XL ORAL TABLET EXTENDED RELEASE 24HR 5 MG | T4 | QL (155 EA per 31 days) |
| <i>dutasteride</i> | T2 | QL (31 EA per 31 days) |
| <i>dutasteride-tamsulosin</i> | T3 | QL (31 EA per 31 days) |
| ELMIRON | T4 | |
| ENTADFI | T4 | PA; QL (31 EA per 31 days) |
| <i>fesoterodine</i> | T3 | QL (31 EA per 31 days) |
| <i>finasteride oral tablet 5 mg</i> | T2 | |
| <i>flavoxate</i> | T2 | |
| FLOMAX | T4 | |
| GELNIQUE TRANSDERMAL GEL IN PACKET | T4 | QL (30 GM per 30 days) |
| GEMTESA | T4 | QL (31 EA per 31 days) |
| JALYN | T4 | QL (31 EA per 31 days) |
| MYRBETRIQ ORAL SUSPENSION,EXTENDED REL RECON | T3 | QL (300 ML per 30 days) |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR | T3 | QL (31 EA per 31 days) |
| <i>oxybutynin chloride oral syrup</i> | T2 | |
| <i>oxybutynin chloride oral tablet</i> | T2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 5 mg</i> | T2 | QL (31 EA per 31 days) |
| <i>oxybutynin chloride oral tablet extended release 24hr 15 mg</i> | T3 | QL (62 EA per 31 days) |
| OXYTROL | T4 | QL (8 EA per 28 days) |
| <i>potassium citrate oral tablet extended release</i> | T2 | |
| PROCYSBI ORAL GRANULES DEL RELEASE IN PACKET | T5 | PA |
| PROSCAR | T4 | |
| RAPAFLO | T4 | |
| <i>silodosin</i> | T4 | |
| <i>solifenacin</i> | T3 | QL (31 EA per 31 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | T4 | PA; QL (62 EA per 31 days) |
| <i>tadalafil oral tablet 5 mg</i> | T4 | PA; QL (31 EA per 31 days) |
| <i>tamsulosin</i> | T1 | |
| <i>tolterodine oral capsule,extended release 24hr</i> | T3 | QL (31 EA per 31 days) |
| <i>tolterodine oral tablet</i> | T3 | QL (62 EA per 31 days) |
| TOVIAZ | T3 | QL (31 EA per 31 days) |
| <i>trospium oral capsule,extended release 24hr</i> | T2 | QL (31 EA per 31 days) |
| <i>trospium oral tablet</i> | T2 | QL (93 EA per 31 days) |
| UROCIT-K 10 | T4 | |
| UROCIT-K 15 | T4 | |
| UROCIT-K 5 | T4 | |
| UROXATRAL | T4 | QL (31 EA per 31 days) |
| VESICARE | T4 | QL (31 EA per 31 days) |
| VESICARE LS | T4 | QL (310 ML per 31 days) |
| Vitamins, Hematinics / Electrolytes | | |
| <i>calcium acetate(phosphat bind)</i> | T2 | |
| CLINIMIX 5%/D15W SULFITE FREE | T4 | PA-BvD |
| CLINIMIX 4.25%/D10W SULF FREE | T4 | PA-BvD |
| CLINIMIX 5%-D20W(SULFITE-FREE) | T4 | PA-BvD |
| CLINIMIX E 4.25%/D10W SUL FREE | T4 | PA-BvD |
| CLINIMIX E 4.25%/D5W SULF FREE | T4 | PA-BvD |
| CLINIMIX E 5%/D15W SULFIT FREE | T4 | PA-BvD |
| CLINIMIX E 5%/D20W SULFIT FREE | T4 | PA-BvD |

| Drug Name | Drug Tier | Requirements/Limits |
|--|------------------|----------------------------|
| CLINISOL SF 15 % | T4 | PA-BvD |
| DOJOLVI | T5 | PA |
| <i>fluoride (sodium) oral tablet</i> | T2 | |
| INTRALIPID INTRAVENOUS EMULSION 20 %, 30 % | T4 | PA-BvD |
| ISOLYTE S PH 7.4 | T3 | PA-BvD |
| ISOLYTE-P IN 5 % DEXTROSE | T3 | PA-BvD |
| KLOR-CON | T3 | |
| KLOR-CON 10 | T3 | |
| KLOR-CON 8 | T3 | |
| KLOR-CON M10 | T1 | |
| KLOR-CON M15 | T1 | |
| KLOR-CON M20 | T1 | |
| K-TAB ORAL TABLET EXTENDED RELEASE 10 MEQ, 20 MEQ | T4 | |
| <i>magnesium sulfate injection</i> | T2 | |
| NUTRILIPID | T4 | PA-BvD |
| PHOSLYRA | T4 | |
| PLASMA-LYTE 148 | T4 | PA-BvD |
| PLASMA-LYTE A | T4 | PA-BvD |
| PLENAMINE | T3 | PA-BvD |
| <i>potassium chlorid-d5-0.45%nacl</i> | T2 | |
| <i>potassium chloride in 0.9%nacl intravenous parenteral solution 20 meq/l, 40 meq/l</i> | T2 | |
| <i>potassium chloride in 5 % dex intravenous parenteral solution 20 meq/l</i> | T2 | |
| <i>potassium chloride in lr-d5 intravenous parenteral solution 20 meq/l</i> | T2 | |
| <i>potassium chloride in water intravenous piggyback 10 meq/100 ml, 20 meq/100 ml, 40 meq/100 ml</i> | T2 | |
| <i>potassium chloride intravenous</i> | T2 | |
| <i>potassium chloride oral capsule, extended release</i> | T1 | |
| <i>potassium chloride oral liquid</i> | T2 | |
| <i>potassium chloride oral tablet extended release</i> | T1 | |
| <i>potassium chloride oral tablet,er particles/crystals</i> | T1 | |
| <i>potassium chloride-0.45 % nacl</i> | T2 | |
| <i>potassium chloride-d5-0.2%nacl intravenous parenteral solution 20 meq/l</i> | T2 | |

| Drug Name | Drug Tier | Requirements/Limits |
|---|------------------|----------------------------|
| <i>potassium chloride-d5-0.9%nacl</i> | T2 | |
| PREMASOL 10 % | T4 | PA-BvD |
| PRENATAL VITAMIN PLUS LOW IRON | T2 | PA |
| PROSOL 20 % | T4 | PA-BvD |
| <i>sodium chloride 0.45 % intravenous parenteral solution</i> | T2 | |
| <i>sodium chloride 3 % hypertonic</i> | T2 | |
| <i>sodium chloride 5 % hypertonic</i> | T2 | |
| TPN ELECTROLYTES | T4 | |
| TRAVASOL 10 % | T3 | PA-BvD |
| TROPHAMINE 10 % | T4 | PA-BvD |

Index of Drugs

| | | | | | |
|--|-------|---|--------|--|-----|
| <i>abacavir</i> | 5 | ADLARITY | 24 | ALTRENO | 64 |
| <i>abacavir-lamivudine</i> | 5 | ADLYXIN | 76 | ALUNBRIG | 17 |
| ABELCET | 5 | ADMELOG SOLOSTAR U-100 INSULIN | 76 | ALVESCO | 106 |
| ABILIFY | 24 | ADMELOG U-100 INSULIN LISPRO | 76 | ALYACEN 1/35 (28) | 96 |
| ABILIFY MAINTENA | 24 | ADVAIR DISKUS | 106 | ALYQ | 106 |
| ABILIFY MYCITE | 24 | ADVAIR HFA | 106 | AMABELZ | 96 |
| <i>abiraterone</i> | 17 | ADZENYS XR-ODT | 24 | <i>amantadine hcl</i> | 5 |
| ABSORICA | 64 | AEMCOLO | 5 | AMARYL | 76 |
| ABSORICA LD | 64 | AFINITOR | 17 | AMBIEN | 25 |
| <i>acamprosate</i> | 73 | AFINITOR DISPERZ | 17 | AMBIEN CR | 25 |
| ACANYA | 64 | AFREZZA | 76 | AMBISOME | 5 |
| <i>acarbose</i> | 76 | AGRYLIN | 73 | <i>ambrisentan</i> | 106 |
| ACCOLATE | 106 | AIMOVIG AUTOINJECTOR | 24, 25 | <i>amcinonide</i> | 64 |
| ACCUPRIL | 53 | AIRDUO DIGIHALER | 106 | AMETHIA | 96 |
| ACCURETIC | 53 | AIRDUO RESPICLICK | 106 | <i>amikacin</i> | 5 |
| ACUTANE | 64 | AJOVY AUTOINJECTOR | 25 | <i>amiloride</i> | 53 |
| <i>acebutolol</i> | 53 | AJOVY SYRINGE | 25 | <i>amiloride-hydrochlorothiazide</i> ... 53 | |
| <i>acetaminophen-caff-dihydrocod</i> | 24 | AKLIEF | 64 | <i>amiodarone</i> | 53 |
| <i>acetaminophen-codeine</i> | 24 | ALA-CORT | 64 | AMITIZA | 84 |
| <i>acetazolamide</i> | 102 | ALA-SCALP | 64 | <i>amitriptyline</i> | 25 |
| <i>acetic acid</i> | 75 | <i>albendazole</i> | 5 | <i>amitriptyline-chlordiazepoxide</i> ... 25 | |
| <i>acetylcysteine</i> | 106 | <i>albuterol sulfate</i> | 106 | <i>amlodipine</i> | 53 |
| ACIPHEX | 84 | <i>alclometasone</i> | 64 | <i>amlodipine-atorvastatin</i> | 53 |
| <i>acitretin</i> | 64 | ALCOHOL PADS | 76 | <i>amlodipine-benazepril</i> | 53 |
| ACTEMRA | 94 | ALDACTAZIDE | 53 | <i>amlodipine-olmesartan</i> | 53 |
| ACTEMRA ACTPEN | 94 | ALDACTONE | 53 | <i>amlodipine-valsartan</i> | 53 |
| ACTHAR | 76 | ALECENSA | 17 | <i>ammonium lactate</i> | 64 |
| ACTHIB (PF) | 89 | <i>alendronate</i> | 94 | AMNESTEEM | 64 |
| ACTICLATE | 5 | <i>alfuzosin</i> | 111 | <i>amoxapine</i> | 25 |
| ACTIMMUNE | 89 | <i>aliskiren</i> | 53 | <i>amoxicil-clarithromy-lansopraz</i> | 84 |
| ACTIQ | 24 | ALKINDI SPRINKLE | 76 | <i>amoxicillin</i> | 5 |
| ACTIVELLA | 96 | <i>allopurinol</i> | 94 | <i>amoxicillin-pot clavulanate</i> | 5 |
| ACTONEL | 94 | ALLZITAL | 25 | <i>amphetamine sulfate</i> | 25 |
| ACTOPLUS MET | 76 | <i>almotriptan malate</i> | 25 | <i>amphotericin b</i> | 5 |
| ACTOS | 76 | ALOCRI | 102 | <i>ampicillin</i> | 5 |
| ACULAR | 102 | <i>alogliptin</i> | 76 | <i>ampicillin sodium</i> | 5 |
| ACULAR LS | 102 | <i>alogliptin-metformin</i> | 76 | <i>ampicillin-sulbactam</i> | 5 |
| ACUVAIL (PF) | 102 | <i>alogliptin-pioglitazone</i> | 76 | AMPYRA | 25 |
| <i>acyclovir</i> | 5, 64 | ALOMIDE | 102 | AMRIX | 25 |
| <i>acyclovir sodium</i> | 5 | <i>alosepron</i> | 84 | AMZEEQ | 64 |
| ACZONE | 64 | ALPHAGAN P | 102 | ANAFRANIL | 25 |
| ADACEL(TDAP | | <i>alprazolam</i> | 25 | <i>anagrelide</i> | 73 |
| ADOLESN/ADULT)(PF) | 89 | ALPRAZOLAM INTENSOL | 25 | <i>anastrozole</i> | 17 |
| <i>adapalene</i> | 64 | ALREX | 102 | ANCOBON | 5 |
| <i>adapalene-benzoyl peroxide</i> | 64 | ALTABAX | 64 | ANDRODERM | 76 |
| ADBRY | 64 | ALTACE | 53 | ANDROGEL | 76 |
| ADCIRCA | 106 | ALTAVERA (28) | 96 | ANGELIQ | 96 |
| ADDERALL | 24 | ALTOPREV | 53 | ANNOVERA | 96 |
| ADDERALL XR | 24 | | | ANORO ELLIPTA | 106 |
| <i>adefovir</i> | 5 | | | ANTARA | 53 |
| ADEMPAS | 106 | | | ANTIVERT | 84 |

| | | | | | |
|-----------------------------------|--------|--------------------------------------|----------|--|---------|
| ANUSOL-HC..... | 84 | <i>atenolol-chlorthalidone</i> | 54 | BARACLUDGE | 6 |
| ANZEMET..... | 84 | ATIVAN | 26 | BASAGLAR KWIKPEN U- | |
| APEXICON E | 64 | <i>atomoxetine</i> | 26 | 100 INSULIN | 77 |
| APIDRA SOLOSTAR U-100 | | <i>atorvastatin</i> | 54 | BAXDELA | 6 |
| INSULIN | 76 | <i>atovaquone</i> | 5 | <i>bcg vaccine, live (pf)</i> | 90 |
| APIDRA U-100 INSULIN | 77 | <i>atovaquone-proguanil</i> | 5 | BECONASE AQ | 107 |
| APLENZIN | 25 | ATRALIN | 64 | BELBUCA | 26 |
| APOKYN | 25 | <i>atropine</i> | 102 | BELSOMRA | 26 |
| <i>apomorphine</i> | 25 | ATROVENT HFA | 106 | <i>benazepril</i> | 54 |
| <i>apraclonidine</i> | 102 | AUBAGIO | 26 | <i>benazepril-hydrochlorothiazide</i> .. | 54 |
| <i>aprepitant</i> | 84 | AUBRA EQ | 96 | BENICAR | 54 |
| APRI | 96 | AURYXIA | 73 | BENICAR HCT | 54 |
| APRISO | 84 | AUSTEDO | 26 | BENLYSTA | 94 |
| APTENSIO XR | 25 | AUVI-Q | 106, 107 | BENZAMYCIN | 65 |
| APTIOM | 25 | AVALIDE | 54 | <i>benznidazole</i> | 6 |
| APTIVUS | 5 | AVAPRO | 54 | <i>benztropine</i> | 26 |
| ARALAST NP | 73 | AVEED | 77 | <i>bepotastine besilate</i> | 102 |
| ARANELLE (28) | 96 | AVIANE | 96 | BEPREVE | 102 |
| ARANESP (IN | | AVITA | 64 | BERINERT | 107 |
| POLYSORBATE) | 90 | AVODART | 111 | BESIVANCE | 102 |
| ARAVA | 94 | AVONEX | 90 | BESREMI | 90 |
| ARAZLO | 64 | AVYCAZ | 5 | <i>betaine</i> | 84 |
| ARCALYST | 90 | AYGESTIN | 96 | <i>betamethasone dipropionate</i> | 65 |
| <i>arformoterol</i> | 106 | AYVAKIT | 17 | <i>betamethasone valerate</i> | 65 |
| ARICEPT | 25 | AZACTAM | 5 | <i>betamethasone, augmented</i> | 65 |
| ARIKAYCE | 5 | AZASAN | 17 | BETAPACE AF | 54 |
| ARIMIDEX | 17 | AZASITE | 102 | BETASERON | 90 |
| <i>aripiprazole</i> | 25, 26 | <i>azathioprine</i> | 17 | <i>betaxolol</i> | 54, 102 |
| ARISTADA | 26 | <i>azelaic acid</i> | 65 | <i>bethanechol chloride</i> | 111 |
| ARISTADA INITIO | 26 | <i>azelastine</i> | 75, 102 | BETHKIS | 6 |
| ARIXTRA | 53, 54 | <i>azelastine-fluticasone</i> | 107 | BETIMOL | 102 |
| <i>armodafinil</i> | 26 | AZELEX | 65 | BETOPTIC S | 102 |
| ARMONAIR DIGIHALER .. | 106 | AZILECT | 26 | BEVESPI AEROSPHERE | 107 |
| ARNUITY ELLIPTA | 106 | <i>azithromycin</i> | 5 | <i>bexarotene</i> | 17 |
| AROMASIN | 17 | AZOPT | 102 | BEXSERO | 90 |
| ARTHROTEC 50 | 26 | AZOR | 54 | BEYAZ | 96 |
| ARTHROTEC 75 | 26 | AZSTARYS | 26 | <i>bicalutamide</i> | 17 |
| ASCOMP WITH CODEINE .. | 26 | <i>aztreonam</i> | 5 | BICILLIN C-R | 6 |
| <i>asenapine maleate</i> | 26 | AZULFIDINE | 84 | BICILLIN L-A | 6 |
| ASHLYNA | 96 | AZULFIDINE EN-TABS | 84 | BIDIL | 54 |
| ASMANEX HFA | 106 | <i>bacitracin</i> | 102 | BIJUVA | 96 |
| ASMANEX TWISTHALER .. | 106 | <i>bacitracin-polymyxin b</i> | 102 | BIKTARVY | 6 |
| <i>aspirin-dipyridamole</i> | 54 | <i>baclofen</i> | 26 | BILTRICIDE | 6 |
| ASPRUZYO SPRINKLE | 54 | BACTRIM | 5 | <i>bimatoprost</i> | 102 |
| ASSURE ID INSULIN | | BACTRIM DS | 6 | BINOSTO | 94 |
| SAFETY | 94 | BAFIERTAM | 26 | <i>bisoprolol fumarate</i> | 54 |
| ASTAGRAF XL | 17 | BALCOLTRA | 96 | <i>bisoprolol-hydrochlorothiazide</i> .. | 54 |
| ATACAND | 54 | <i>balsalazide</i> | 84 | BIVIGAM | 90 |
| ATACAND HCT | 54 | BALVERSA | 17 | BLEPHAMIDE S.O.P. | 102 |
| <i>atazanavir</i> | 5 | BALZIVA (28) | 96 | BLISOVI 24 FE | 96 |
| ATELVIA | 94 | BANZEL | 26 | BLISOVI FE 1.5/30 (28) | 97 |
| <i>atenolol</i> | 54 | BAQSIMI | 77 | BONJESTA | 84 |

| | | | | |
|---|---------|--|--|------------|
| BOOSTRIX TDAP | 90 | CALQUENCE | <i>ceftazidime</i> | 6 |
| <i>bosentan</i> | 107 | (ACALABRUTINIB MAL)..... | <i>ceftriaxone</i> | 6 |
| BOSULIF | 17 | CAMBIA | <i>cefuroxime axetil</i> | 6 |
| BRAFTOVI | 17 | CAMILA | <i>cefuroxime sodium</i> | 6, 7 |
| BREO ELLIPTA | 107 | CAMRESE LO | CELEBREX | 28 |
| BREZTRI AEROSPHERE | 107 | CAMZYOS | <i>celecoxib</i> | 28 |
| BRIELLYN | 97 | CANASA | CELEXA | 28 |
| BRILINTA | 54 | CANCIDAS | CELLCEPT | 17, 18 |
| <i>brimonidine</i> | 102 | <i>candesartan</i> | CELONTIN | 28 |
| <i>brimonidine-timolol</i> | 102 | <i>candesartan-hydrochlorothiazid</i> .. | CENTANY | 65 |
| <i>brinzolamide</i> | 103 | CAPEX | <i>cephalexin</i> | 7 |
| BRIVIACT | 27 | CAPLYTA | CEQUA | 103 |
| <i>bromfenac</i> | 103 | CAPRELSA | CERDELGA | 77 |
| <i>bromocriptine</i> | 27 | <i>captopril</i> | <i>cetirizine</i> | 107 |
| BROMSITE | 103 | CARAC | CETRAXAL | 75 |
| BRONCHITOL | 107 | CARAFATE | <i>cevimeline</i> | 73 |
| BROVANA | 107 | CARBAGLU | CHEMET | 73 |
| BRUKINSA | 17 | <i>carbamazepine</i> | CHENODAL | 84 |
| BRYHALI | 65 | CARBATROL | <i>chlordiazepoxide hcl</i> | 28 |
| <i>budesonide</i> | 84, 107 | <i>carbidopa</i> | <i>chlordiazepoxide-clidinium</i> | 84 |
| <i>budesonide-formoterol</i> | 107 | <i>carbidopa-levodopa</i> | <i>chlorhexidine gluconate</i> | 75 |
| <i>bumetanide</i> | 54 | <i>carbidopa-levodopa-entacapone</i> .. | <i>chloroquine phosphate</i> | 7 |
| BUPAP | 27 | <i>carbinoxamine maleate</i> | <i>chlorpromazine</i> | 28 |
| BUPHENYL | 73 | CARDIZEM | <i>chlorthalidone</i> | 55 |
| <i>buprenorphine</i> | 27 | CARDIZEM CD | <i>chlorzoxazone</i> | 28 |
| <i>buprenorphine hcl</i> | 27 | CARDIZEM LA | CHOLBAM | 84 |
| <i>buprenorphine-naloxone</i> | 27 | CARDURA | <i>cholestyramine (with sugar)</i> | 55 |
| <i>bupropion hcl</i> | 27 | CARDURA XL | CHOLESTYRAMINE | |
| <i>bupropion hcl (smoking deter)</i> | 73 | <i>carglumic acid</i> | LIGHT | 55 |
| <i>bupirone</i> | 27 | <i>carisoprodol</i> | CIALIS | 111 |
| <i>butalbital-acetaminop-caf-cod</i> | 27 | CARNITOR | CIBINQO | 65 |
| <i>butalbital-acetaminophen</i> | 27 | CAROSPIR | <i>ciclopirox</i> | 65 |
| <i>butalbital-acetaminophen-caff</i> | 27 | <i>carteolol</i> | <i>cilostazol</i> | 55 |
| <i>butalbital-aspirin-caffeine</i> | 27 | CARTIA XT | CILOXAN | 103 |
| <i>butorphanol</i> | 27 | <i>carvedilol</i> | CIMDUO | 7 |
| BUTRANS | 27 | <i>carvedilol phosphate</i> | <i>cimetidine</i> | 84 |
| BYDUREON BCISE | 77 | CASODEX | <i>cimetidine hcl</i> | 84 |
| BYETTA | 77 | <i>casprofungin</i> | CIMZIA | 85 |
| BYLVAY | 84 | CATAPRES-TTS-1 | CIMZIA POWDER FOR | |
| BYSTOLIC | 54 | CATAPRES-TTS-2 | RECONST | 85 |
| <i>cabergoline</i> | 77 | CATAPRES-TTS-3 | <i>cinacalcet</i> | 77 |
| CABLIVI | 54 | CAYSTON | CINRYZE | 107 |
| CABOMETYX | 17 | <i>cefaclor</i> | CIPRO | 7 |
| CADUET | 54 | <i>cefadroxil</i> | CIPRO HC | 75 |
| CALAN SR | 54 | <i>cefazolin</i> | CIPRODEX | 75 |
| <i>calcipotriene</i> | 65 | <i>cefdinir</i> | <i>ciprofloxacin hcl</i> | 7, 75, 103 |
| <i>calcipotriene-betamethasone</i> | 65 | <i>cefepime</i> | <i>ciprofloxacin in 5 % dextrose</i> | 7 |
| <i>calcitonin (salmon)</i> | 77 | <i>cefixime</i> | <i>ciprofloxacin-dexamethasone</i> | 75 |
| <i>calcitriol</i> | 65, 77 | <i>cefotetan</i> | <i>ciprofloxacin-fluocinolone</i> | 76 |
| <i>calcium acetate(phosphat bind)</i> .. | 112 | <i>cefoxitin</i> | <i>citalopram</i> | 28 |
| CALQUENCE | 17 | <i>cefpodoxime</i> | CLARAVIS | 65 |
| | | <i>cefprozil</i> | CLARINEX | 107 |

| | | | | | |
|--|-----------|---|--------------|---|---------|
| CLARINEX-D 12 HOUR | 107 | <i>clotrimazole</i> | 7, 66 | CRYSELLE (28) | 97 |
| <i>clarithromycin</i> | 7 | <i>clotrimazole-betamethasone</i> | 66 | CUBICIN RF | 7 |
| <i>clemastine</i> | 107 | <i>clozapine</i> | 28, 29 | CUPRIMINE | 94 |
| CLENPIQ | 85 | CLOZARIL | 29 | CUVPOSA | 85 |
| CLEOCIN | 97 | COARTEM | 7 | <i>cyclobenzaprine</i> | 29 |
| CLEOCIN HCL | 7 | <i>codeine sulfate</i> | 29 | <i>cyclophosphamide</i> | 18 |
| CLEOCIN PEDIATRIC | 7 | <i>codeine-butalbital-asa-caff</i> | 29 | CYCLOSET | 77 |
| CLEOCIN T | 65 | COLAZAL | 85 | <i>cyclosporine</i> | 18, 103 |
| CLIMARA | 97 | <i>colchicine</i> | 94 | <i>cyclosporine modified</i> | 18 |
| CLIMARA PRO | 97 | COLCRYS | 94 | CYMBALTA | 29 |
| CLINDACIN P | 65 | <i>colesevelam</i> | 55 | <i>cyproheptadine</i> | 107 |
| CLINDAGEL | 65 | COLESTID | 55 | CYRED EQ | 97 |
| <i>clindamycin hcl</i> | 7 | <i>colestipol</i> | 55 | CYSTADANE | 85 |
| <i>clindamycin in 5 % dextrose</i> | 7 | <i>colistin (colistimethate na)</i> | 7 | CYSTADROPS | 103 |
| CLINDAMYCIN | | COMBIGAN | 103 | CYSTARAN | 103 |
| PEDIATRIC | 7 | COMBIPATCH | 97 | CYTOMEL | 77 |
| <i>clindamycin phosphate</i> | 7, 65, 97 | COMBIVENT RESPIMAT .. | 107 | CYTOTEC | 85 |
| <i>clindamycin-benzoyl peroxide</i> | 65 | COMBIVIR | 7 | <i>d10 %-0.45 % sodium chloride</i> ...73 | |
| <i>clindamycin-tretinoin</i> | 66 | COMETRIQ | 18 | <i>d2.5 %-0.45 % sodium chloride</i> ..73 | |
| CLINDESSE | 97 | COMPLERA | 7 | <i>d5 % and 0.9 % sodium</i> | |
| CLINIMIX 5%/D15W | | COMPRO | 85 | <i>chloride</i> | 73 |
| SULFITE FREE | 112 | COMTAN | 29 | <i>d5 %-0.45 % sodium chloride</i>73 | |
| CLINIMIX 4.25%/D10W | | CONCERTA | 29 | <i>dabigatran etexilate</i> | 55 |
| SULF FREE | 112 | CONDYLOX | 66 | <i>dalfampridine</i> | 29 |
| CLINIMIX 4.25%/D5W | | CONJUPRI | 55 | DALIRESP | 107 |
| SULFIT FREE | 73 | CONSTULOSE | 85 | DALVANCE | 7 |
| CLINIMIX 5%- | | CONZIP | 29 | <i>danazol</i> | 77 |
| D20W(SULFITE-FREE) | 112 | COPAXONE | 29 | DANTRIUM | 29 |
| CLINIMIX E 2.75%/D5W | | COPIKTRA | 18 | <i>dantrolene</i> | 29 |
| SULF FREE | 73 | CORDRAN | 66 | <i>dapsone</i> | 7, 66 |
| CLINIMIX E 4.25%/D10W | | CORDRAN TAPE LARGE | | DAPTACEL (DTAP | |
| SUL FREE | 112 | ROLL | 66 | PEDIATRIC) (PF) | 90 |
| CLINIMIX E 4.25%/D5W | | COREG | 55 | <i>daptomycin</i> | 7 |
| SULF FREE | 112 | COREG CR | 55 | DARAPRIM | 7 |
| CLINIMIX E 5%/D15W | | CORGARD | 55 | <i>darifenacin</i> | 111 |
| SULFIT FREE | 112 | CORLANOR | 55 | DARTISLA | 85 |
| CLINIMIX E 5%/D20W | | CORTEF | 77 | DAURISMO | 18 |
| SULFIT FREE | 112 | CORTROPHIN GEL | 77 | DAYPRO | 29 |
| CLINISOL SF 15 % | 113 | COSENTYX | 66 | DAYTRANA | 29 |
| <i>clobazam</i> | 28 | COSENTYX (2 SYRINGES) ...66 | | DAYVIGO | 29 |
| <i>clobetasol</i> | 66 | COSENTYX PEN (2 PENS) ...66 | | DDAVP | 77 |
| <i>clobetasol-emollient</i> | 66 | COSOPT | 103 | DEBLITANE | 97 |
| CLOBEX | 66 | COSOPT (PF) | 103 | <i>deferasirox</i> | 73 |
| <i>clocortolone pivalate</i> | 66 | COTELLIC | 18 | <i>deferiprone</i> | 73 |
| CLODAN | 66 | COTEMPLA XR-ODT | 29 | DELESTROGEN | 97 |
| CLODERM | 66 | COZAAR | 55 | DELSTRIGO | 7 |
| <i>clomipramine</i> | 28 | CREON | 85 | DELZICOL | 85 |
| <i>clonazepam</i> | 28 | CRESEMBA | 7 | <i>demeclocycline</i> | 7 |
| <i>clonidine</i> | 55 | CRESTOR | 55 | DEMEROL | 29 |
| <i>clonidine hcl</i> | 28, 55 | CRINONE | 97 | DEMEROL (PF) | 29 |
| <i>clopidogrel</i> | 55 | <i>cromolyn</i> | 85, 103, 107 | DEMSER | 55 |
| <i>clorazepate dipotassium</i> | 28 | CROTAN | 66 | | |

| | | | | | |
|---|-----|---------------------------------------|-------------|--|-----|
| DENAVIR | 66 | <i>diclofenac potassium</i> | 31 | <i>doxercalciferol</i> | 77 |
| DEPAKOTE | 29 | <i>diclofenac sodium</i> | 31, 67, 103 | DOXY-100 | 8 |
| DEPAKOTE ER | 29 | <i>diclofenac-misoprostol</i> | 31 | <i>doxycycline hyclate</i> | 8 |
| DEPAKOTE SPRINKLES | 29 | <i>dicloxacin</i> | 7 | <i>doxycycline monohydrate</i> | 8 |
| DEPEN TITRATABS | 94 | <i>dicyclomine</i> | 85 | <i>doxylamine-pyridoxine (vit b6)</i> ...85 | |
| DEPO-ESTRADIOL | 97 | DIFFERIN | 67 | DRIZALMA SPRINKLE | 31 |
| DEPO-PROVERA | 97 | DIFICID | 7 | <i>dronabinol</i> | 85 |
| DEPO-SUBQ PROVERA 104 | 97 | <i>diflorasone</i> | 67 | <i>drospirenone-e.estradiol-lm.fa</i> ...97 | |
| DEPO-TESTOSTERONE | 77 | DIFLUCAN | 7 | <i>drospirenone-ethinyl estradiol</i> ...97 | |
| DERMA-SMOOTH/FS | | <i>diflunisal</i> | 31 | DROXIA | 18 |
| SCALP OIL | 66 | <i>difluprednate</i> | 103 | <i>droxidopa</i> | 73 |
| DERMOTIC OIL | 76 | DIGITEK | 55, 56 | DUAKLIR PRESSAIR | 107 |
| DESCOVY | 7 | <i>digoxin</i> | 56 | DUAVEE | 97 |
| <i>desipramine</i> | 29 | <i>dihydroergotamine</i> | 31 | DUETACT | 77 |
| <i>desloratadine</i> | 107 | DILANTIN | 31 | DUEXIS | 32 |
| <i>desmopressin</i> | 77 | DILANTIN EXTENDED | 31 | DULERA | 107 |
| <i>desog-e.estradiol/e.estradiol</i>97 | | DILANTIN INFATABS | 31 | <i>duloxetine</i> | 32 |
| <i>desogestrel-ethinyl estradiol</i>97 | | DILANTIN-125 | 31 | DUOBRII | 67 |
| <i>desonide</i> | 66 | DILAUDID | 31 | DUOPA | 32 |
| DESOWEN | 67 | <i>diltiazem hcl</i> | 56 | DUPIXENT PEN | 67 |
| <i>desoximetasone</i> | 67 | DILT-XR | 56 | DUPIXENT SYRINGE | 67 |
| DESOXYN | 29 | <i>dimethyl fumarate</i> | 31 | DUREZOL | 103 |
| DESRX | 67 | DIOVAN | 56 | <i>dutasteride</i> | 111 |
| <i>desvenlafaxine</i> | 29 | DIOVAN HCT | 56 | <i>dutasteride-tamsulosin</i> | 111 |
| <i>desvenlafaxine succinate</i> | 29 | DIPENTUM | 85 | DYANAVEL XR | 32 |
| DETROL | 111 | <i>diphenoxylate-atropine</i> | 85 | DYMISTA | 107 |
| DETROL LA | 111 | DIPROLENE | | DYRENIUM | 56 |
| DEXABLISS | 77 | (AUGMENTED) | 67 | E.E.S. 400 | 8 |
| <i>dexamethasone</i> | 77 | <i>dipyridamole</i> | 56 | E.E.S. GRANULES | 8 |
| <i>dexamethasone sodium</i> | | <i>disopyramide phosphate</i> | 56 | <i>econazole</i> | 67 |
| <i>phosphate</i> | 103 | <i>disulfiram</i> | 73 | EDARBI | 56 |
| DEXEDRINE SPANSULE | 30 | DITROPAN XL | 111 | EDARBYCLOR | 56 |
| DEXILANT | 85 | DIURIL | 56 | EDECIN | 56 |
| <i>dexlansoprazole</i> | 85 | <i>divalproex</i> | 31 | EDLUAR | 32 |
| <i>dexmethylphenidate</i> | 30 | DIVIGEL | 97 | EDURANT | 8 |
| <i>dextroamphetamine sulfate</i> | 30 | <i>dofetilide</i> | 56 | <i>efavirenz</i> | 8 |
| <i>dextroamphetamine-</i> | | DOJOLVI | 113 | <i>efavirenz-emtricitabin-tenofov</i>8 | |
| <i>amphetamine</i> | 30 | DOLISHALE | 97 | <i>efavirenz-lamivu-tenofov disop</i>8 | |
| <i>dextrose 10 % and 0.2 % nacl</i> ...73 | | <i>donepezil</i> | 31 | EFFEXOR XR | 32 |
| <i>dextrose 10 % in water (d10w)</i> ...73 | | DOPTelet (10 TAB PACK) | 56 | EFFIENT | 56 |
| <i>dextrose 5 % in water (d5w)</i>73 | | DOPTelet (15 TAB PACK) | 56 | EFUDEX | 67 |
| <i>dextrose 5%-0.2 % sod chloride</i>73 | | DOPTelet (30 TAB PACK) | 56 | EGRIFTA SV | 90 |
| DHIVY | 30 | DORYX | 8 | ELESTRIN | 97 |
| DIACOMIT | 30 | DORYX MPC | 8 | <i>eletriptan</i> | 32 |
| DIASAT | 30 | <i>dorzolamide</i> | 103 | ELIDEL | 67 |
| DIASAT ACUDIAL | 30 | <i>dorzolamide-timolol</i> | 103 | ELIGARD | 18 |
| <i>diazepam</i> | 30 | <i>dorzolamide-timolol (pf)</i> | 103 | ELIGARD (3 MONTH) | 18 |
| DIAZEPAM INTENSOL | 30 | DOTTI | 97 | ELIGARD (4 MONTH) | 18 |
| <i>diazoxide</i> | 77 | DOVATO | 8 | ELIGARD (6 MONTH) | 18 |
| DIBENZYLINE | 55 | DOVONEX | 67 | ELIQUIS | 56 |
| DICLEGIS | 85 | <i>doxazosin</i> | 56 | ELIQUIS DVT-PE TREAT | |
| <i>diclofenac epolamine</i> | 30 | <i>doxepin</i> | 31, 67 | 30D START | 56 |

| | | | | | |
|--|--------|--|--------|---|--------|
| ELMIRON | 111 | ERAXIS(WATER DILUENT) .. | 9 | EVOXAC | 74 |
| ELURYNG | 97 | <i>ergoloid</i> | 32 | EVRYSDI | 33 |
| ELYXYB | 32 | <i>ergotamine-caffeine</i> | 32 | EXELDERM | 68 |
| EMCYT | 18 | ERIVEDGE | 18 | EXELON PATCH | 33 |
| EMEND | 85 | ERLEADA | 18 | <i>exemestane</i> | 18 |
| EMFLAZA | 77 | <i>erlotinib</i> | 18 | EXFORGE | 57 |
| EMGALITY PEN | 32 | ERRIN | 97 | EXFORGE HCT | 57 |
| EMGALITY SYRINGE | 32 | ERTACZO | 67 | EXJADE | 74 |
| EMOQUETTE | 97 | <i>ertapenem</i> | 9 | EXKIVITY | 18 |
| EMSAM | 32 | ERY PADS | 67 | EXSERVAN | 74 |
| <i>emtricitabine</i> | 8 | ERYGEL | 67 | EXTAVIA | 90 |
| <i>emtricitabine-tenofovir (tdf)</i> | 8 | ERYPED 200 | 9 | EXTINA | 68 |
| EMTRIVA | 8 | ERYPED 400 | 9 | EYSUVIS | 103 |
| EMVERM | 8 | ERY-TAB | 9 | EZALLOR SPRINKLE | 57 |
| <i>enalapril maleate</i> | 56 | ERYTHROCIN | 9 | <i>ezetimibe</i> | 57 |
| <i>enalapril-hydrochlorothiazide</i> | 56 | ERYTHROCIN (AS | | <i>ezetimibe-rosuvastatin</i> | 57 |
| ENBREL | 94 | STEARATE) | 9 | <i>ezetimibe-simvastatin</i> | 57 |
| ENBREL MINI | 94 | <i>erythromycin</i> | 9, 103 | FABIOR | 68 |
| ENBREL SURECLICK | 94 | <i>erythromycin ethylsuccinate</i> | 9 | FALMINA (28) | 98 |
| ENDARI | 74 | <i>erythromycin with ethanol</i> | 67 | <i>famciclovir</i> | 9 |
| ENDOCET | 32 | <i>erythromycin-benzoyl peroxide</i> ...67 | | <i>famotidine</i> | 85 |
| ENGERIX-B (PF) | 90 | ESBRIET | 107 | FANAPT | 33 |
| ENGERIX-B PEDIATRIC | | <i>escitalopram oxalate</i> | 32 | FARESTON | 18 |
| (PF) | 90 | ESGIC | 32 | FARXIGA | 78 |
| <i>enoxaparin</i> | 56, 57 | <i>esomeprazole magnesium</i> | 85 | FASENRA | 107 |
| ENPRESSE | 97 | ESTARYLLA | 97 | FASENRA PEN | 107 |
| ENSKYCE | 97 | <i>estazolam</i> | 33 | <i>febuxostat</i> | 94 |
| ENSPRYNG | 18 | ESTRACE | 97 | <i>felbamate</i> | 33 |
| ENSTILAR | 67 | <i>estradiol</i> | 97, 98 | FELBATOL | 33 |
| <i>entacapone</i> | 32 | <i>estradiol valerate</i> | 98 | FELDENE | 33 |
| ENTADFI | 111 | <i>estradiol-norethindrone acet</i> | 98 | <i>felodipine</i> | 57 |
| <i>entecavir</i> | 8 | ESTRING | 98 | FEMARA | 18 |
| ENTRESTO | 57 | ESTROGEL | 98 | FEMRING | 98 |
| ENULOSE | 85 | <i>eszopiclone</i> | 33 | FEMYNOR | 98 |
| ENVARUS XR | 18 | <i>ethacrynic acid</i> | 57 | <i>fenofibrate</i> | 57 |
| EPCLUSA | 8 | <i>ethambutol</i> | 9 | <i>fenofibrate micronized</i> | 57 |
| EPIDIOLEX | 32 | <i>ethosuximide</i> | 33 | <i>fenofibrate nanocrystallized</i> | 57 |
| EPIDUO | 67 | <i>ethynodiol diac-eth estradiol</i> | 98 | <i>fenofibric acid (choline)</i> | 57 |
| EPIDUO FORTE | 67 | <i>etodolac</i> | 33 | FENOGLIDE | 57 |
| <i>epinastine</i> | 103 | <i>etonogestrel-ethinyl estradiol</i> | 98 | <i>fenoprofen</i> | 33 |
| <i>epinephrine</i> | 107 | <i>etravirine</i> | 9 | <i>fentanyl</i> | 33, 34 |
| EPIPEN 2-PAK | 107 | EUCRISA | 68 | <i>fentanyl citrate</i> | 33 |
| EPIPEN JR 2-PAK | 107 | EUTHYROX | 77 | FENTORA | 34 |
| EPITOL | 32 | EVAMIST | 98 | FERRIPROX | 74 |
| EPIVIR | 9 | EVEKEO | 33 | <i>fesoterodine</i> | 111 |
| EPIVIR HBV | 9 | EVENITY | 94 | FETZIMA | 34 |
| <i>eplerenone</i> | 57 | <i>everolimus (antineoplastic)</i> | 18 | FEXMID | 34 |
| EPOGEN | 90 | <i>everolimus</i> | | FIASP FLEXTOUCH U-100 | |
| EPRONTIA | 32 | <i>(immunosuppressive)</i> | 18 | INSULIN | 78 |
| EPSOLAY | 67 | EVISTA | 94 | FIASP PENFILL U-100 | |
| EPZICOM | 9 | EVOCLIN | 68 | INSULIN | 78 |
| EQUETRO | 32 | EVOTAZ | 9 | FIASP U-100 INSULIN | 78 |

| | | | | | |
|---|---------|---|--------|---|------------|
| FINACEA | 68 | FOCALIN | 35 | GENTAK | 103 |
| <i>finasteride</i> | 111 | FOCALIN XR | 35 | <i>gentamicin</i> | 9, 68, 103 |
| <i> fingolimod</i> | 34 | <i>fondaparinux</i> | 57 | <i>gentamicin in nacl (iso-osm)</i> | 9 |
| FINTEPLA | 34 | FORFIVO XL | 35 | GENVOYA | 10 |
| FINZALA | 98 | <i>formoterol fumarate</i> | 108 | GEODON | 35 |
| FIORICET | 34 | FORTEO | 94 | GILENYA | 35 |
| FIORICET WITH CODEINE | 34 | FORTESTA | 78 | GILOTRIF | 19 |
| FIRAZYR | 108 | FOSAMAX | 94 | GIMOTI | 86 |
| FIRDAPSE | 34 | FOSAMAX PLUS D | 94 | GLASSIA | 74 |
| FIRMAGON KIT W | | <i>fosamprenavir</i> | 9 | <i>glatiramer</i> | 35 |
| DILUENT SYRINGE | 18 | <i>fosfomycin tromethamine</i> | 9 | GLATOPA | 35 |
| FIRVANQ | 9 | <i>fosinopril</i> | 57 | GLEEVEC | 19 |
| FLAC OTIC OIL | 76 | <i>fosinopril-hydrochlorothiazide</i> ... | 57 | <i>glimepiride</i> | 78 |
| FLAGYL | 9 | FOSRENOL | 74 | <i>glipizide</i> | 78 |
| FLAREX | 103 | FOTIVDA | 18 | <i>glipizide-metformin</i> | 78 |
| <i>flavoxate</i> | 111 | FRAGMIN | 57, 58 | GLUCAGEN HYPOKIT | 78 |
| FLEBOGAMMA DIF | 90 | FROVA | 35 | GLUCAGON EMERGENCY | |
| <i>flecainide</i> | 57 | <i>frovatriptan</i> | 35 | KIT (HUMAN) | 78 |
| FLECTOR | 34 | FULPHILA | 90 | GLUCOTROL XL | 78 |
| FLEQSUVY | 34 | <i>furosemide</i> | 58 | GLUMETZA | 78 |
| FLOLIPID | 57 | FUZEON | 9 | <i>glyburide</i> | 78 |
| FLOMAX | 111 | FYAVOLV | 98 | <i>glyburide micronized</i> | 78 |
| FLOVENT DISKUS | 108 | FYCOMPA | 35 | <i>glyburide-metformin</i> | 78 |
| FLOVENT HFA | 108 | <i>gabapentin</i> | 35 | GLYCATE | 86 |
| <i>fluconazole</i> | 9 | GABITRIL | 35 | <i>glycopyrrolate</i> | 86 |
| <i>fluconazole in nacl (iso-osm)</i> | 9 | GALAFOLD | 78 | GLYNASE | 78 |
| <i>flucytosine</i> | 9 | <i>galantamine</i> | 35 | GLYXAMBI | 78 |
| <i>fludrocortisone</i> | 78 | GAMMAGARD LIQUID | 90 | GOCOVRI | 35 |
| <i>flunisolide</i> | 108 | GAMMAGARD S-D (IGA < 1 | | GOLYTELY | 86 |
| <i>fluocinolone</i> | 68 | MCG/ML) | 90 | GRALISE | 35 |
| <i>fluocinolone acetonide oil</i> | 76 | GAMMAKED | 90 | <i>granisetron hcl</i> | 86 |
| <i>fluocinolone and shower cap</i> | 68 | GAMMAPLEX | 90 | GRANIX | 91 |
| <i>fluocinonide</i> | 68 | GAMMAPLEX (WITH | | GRASTEK | 91 |
| FLUOCINONIDE-E | 68 | SORBITOL) | 90 | <i>griseofulvin microsize</i> | 10 |
| <i>fluoride (sodium)</i> | 113 | GAMUNEX-C | 91 | <i>griseofulvin ultramicrosize</i> | 10 |
| <i>fluorometholone</i> | 103 | GARDASIL 9 (PF) | 91 | <i>guanfacine</i> | 35, 58 |
| <i>fluorouracil</i> | 68 | GASTROCROM | 85 | GVOKE | 78 |
| <i>fluoxetine</i> | 34 | <i>gatifloxacin</i> | 103 | GVOKE HYPOPEN 2-PACK | 78 |
| <i>fluoxetine (pmdd)</i> | 34 | GATTEX 30-VIAL | 85 | GVOKE PFS 1-PACK | |
| <i>fluphenazine decanoate</i> | 34 | GAUZE PAD | 94 | SYRINGE | 78 |
| <i>fluphenazine hcl</i> | 34 | GAVILYTE-C | 85 | GYNAZOLE-1 | 98 |
| <i>flurandrenolide</i> | 68 | GAVILYTE-G | 86 | HAEGARDA | 108 |
| <i>flurazepam</i> | 34 | GAVRETO | 18 | HAILEY 24 FE | 98 |
| <i>flurbiprofen</i> | 34 | GELNIQUE | 111 | <i>halcinonide</i> | 68 |
| <i>flurbiprofen sodium</i> | 103 | <i>gemfibrozil</i> | 58 | HALCION | 35 |
| <i>fluticasone furoate-vilanterol</i> ... | 108 | GEMMILY | 98 | HALDOL DECANOATE | 36 |
| <i>fluticasone propionate</i> | 68, 108 | GEMTESA | 111 | <i>halobetasol propionate</i> | 68 |
| <i>fluticasone propion-salmeterol</i> | 108 | GENERESS FE | 98 | HALOG | 68 |
| <i>fluvastatin</i> | 57 | GENERLAC | 86 | <i>haloperidol</i> | 36 |
| <i>fluvoxamine</i> | 35 | GENGRAF | 19 | <i>haloperidol decanoate</i> | 36 |
| FML FORTE | 103 | GENOTROPIN | 91 | <i>haloperidol lactate</i> | 36 |
| FML LIQUIFILM | 103 | GENOTROPIN MINIQUICK | 91 | HARVONI | 10 |

| | | | | | |
|---------------------------------|----|---|------------|---|---------|
| HAVRIX (PF) | 91 | HUMULIN R U-500 (CONC) | | IMVEXXY MAINTENANCE | |
| HELIDAC | 86 | INSULIN | 78 | PACK | 98 |
| HEMADY | 78 | HUMULIN R U-500 (CONC) | | IMVEXXY STARTER PACK | 98 |
| <i>heparin (porcine)</i> | 58 | KWIKPEN | 79 | INBRIJA | 37 |
| HEPSERA | 10 | <i>hydralazine</i> | 58 | INCASSIA | 98 |
| HETLIOZ | 36 | HYDREA | 19 | INCRELEX | 74 |
| HETLIOZ LQ | 36 | <i>hydrochlorothiazide</i> | 58 | INCRUSE ELLIPTA | 108 |
| HIBERIX (PF) | 91 | <i>hydrocodone bitartrate</i> | 36 | <i>indapamide</i> | 58 |
| HIPREX | 10 | <i>hydrocodone-acetaminophen</i> | 36 | INDERAL LA | 58 |
| HORIZANT | 36 | <i>hydrocodone-ibuprofen</i> | 36 | INDOCIN | 37 |
| HUMALOG JUNIOR | | <i>hydrocortisone</i> | 68, 79, 86 | <i>indomethacin</i> | 37 |
| KWIKPEN U-100 | 78 | <i>hydrocortisone butyrate</i> | 68 | INFANRIX (DTAP) (PF) | 91 |
| HUMALOG KWIKPEN | | <i>hydrocortisone valerate</i> | 68 | INGREZZA | 37 |
| INSULIN | 78 | <i>hydrocortisone-acetic acid</i> | 76 | INGREZZA INITIATION | |
| HUMALOG MIX 50-50 | | <i>hydrocortisone-pramoxine</i> | 86 | PACK | 37 |
| INSULN U-100 | 78 | <i>hydromorphone</i> | 36 | INLYTA | 19 |
| HUMALOG MIX 50-50 | | <i>hydromorphone (pf)</i> | 36 | INNOPRAN XL | 58 |
| KWIKPEN | 78 | <i>hydroxychloroquine</i> | 10 | INQOVI | 19 |
| HUMALOG MIX 75-25 | | <i>hydroxyurea</i> | 19 | INREBIC | 19 |
| KWIKPEN | 78 | <i>hydroxyzine hcl</i> | 108 | INSPIRA | 58 |
| HUMALOG MIX 75-25(U- | | <i>hydroxyzine pamoate</i> | 108 | <i>insulin asp prt-insulin aspart</i> | 79 |
| 100)INSULN | 78 | HYFTOR | 69 | <i>insulin aspart u-100</i> | 79 |
| HUMALOG U-100 INSULIN .. | 78 | HYSINGLA ER | 36 | <i>insulin degludec</i> | 79 |
| HUMATIN | 10 | HYZAAR | 58 | <i>insulin glargine</i> | 79 |
| HUMATROPE | 91 | <i>ibandronate</i> | 95 | <i>insulin lispro</i> | 79 |
| HUMIRA | 95 | IBRANCE | 19 | <i>insulin lispro protamin-lispro</i> | 79 |
| HUMIRA PEN | 94 | IBSRELA | 86 | <i>insulin syringe-needle u-100</i> | 94 |
| HUMIRA PEN CROHNS- | | IBU | 36 | INTELENCE | 10 |
| UC-HS START | 94 | <i>ibuprofen</i> | 36 | INTRALIPID | 113 |
| HUMIRA PEN PSOR- | | <i>ibuprofen-famotidine</i> | 36 | INTRAROSA | 98 |
| UVEITS-ADOL HS | 95 | <i>icatibant</i> | 108 | INTRON A | 91 |
| HUMIRA(CF) | 95 | ICLEVIA | 98 | INTROVALE | 98 |
| HUMIRA(CF) PEDI | | ICLUSIG | 19 | INTUNIV ER | 37 |
| CROHNS STARTER | 95 | <i>icosapent ethyl</i> | 58 | INVANZ | 10 |
| HUMIRA(CF) PEN | 95 | IDHIFA | 19 | INVEGA | 37 |
| HUMIRA(CF) PEN | | ILEVRO | 103 | INVEGA HAFYERA | 37 |
| CROHNS-UC-HS | 95 | ILUMYA | 69 | INVEGA SUSTENNA | 37 |
| HUMIRA(CF) PEN | | <i>imatinib</i> | 19 | INVEGA TRINZA | 37, 38 |
| PEDIATRIC UC | 95 | IMBRUVICA | 19 | INVELTYS | 103 |
| HUMIRA(CF) PEN PSOR- | | <i>imipenem-cilastatin</i> | 10 | INVOKAMET | 79 |
| UV-ADOL HS | 95 | <i>imipramine hcl</i> | 36 | INVOKAMET XR | 79 |
| HUMULIN 70/30 U-100 | | <i>imipramine pamoate</i> | 36 | INVOKANA | 79 |
| INSULIN | 78 | <i>imiquimod</i> | 69 | IOPIDINE | 104 |
| HUMULIN 70/30 U-100 | | IMITREX | 36, 37 | IPOL | 91 |
| KWIKPEN | 78 | IMITREX STATDOSE PEN ... | 37 | <i>ipratropium bromide</i> | 76, 108 |
| HUMULIN N NPH INSULIN | | IMITREX STATDOSE | | <i>ipratropium-albuterol</i> | 108 |
| KWIKPEN | 78 | REFILL | 37 | <i>irbesartan</i> | 58 |
| HUMULIN N NPH U-100 | | IMOVAX RABIES | | <i>irbesartan-hydrochlorothiazide</i> .. | 58 |
| INSULIN | 78 | VACCINE (PF) | 91 | IRESSA | 19 |
| HUMULIN R REGULAR U- | | IMPAVIDO | 10 | ISENTRESS | 10 |
| 100 INSULN | 78 | IMPEKLO | 69 | ISENTRESS HD | 10 |
| | | IMURAN | 19 | ISIBLOOM | 98 |

| | | | | | |
|-------------------------------------|--------|---|---------|--|---------|
| ISOLYTE S PH 7.4 | 113 | KENALOG | 69 | LAMICTAL XR STARTER | |
| ISOLYTE-P IN 5 % | | KEPPRA | 38 | (GREEN) | 38 |
| DEXTROSE | 113 | KEPPRA XR | 38 | LAMICTAL XR STARTER | |
| <i>isoniazid</i> | 10 | KERENDIA | 58 | (ORANGE) | 38 |
| ISOPTO CARPINE | 104 | KERYDIN | 69 | <i>lamivudine</i> | 10 |
| ISORDIL | 58 | KESIMPTA PEN | 38 | <i>lamivudine-zidovudine</i> | 10 |
| ISORDIL TITRADOSE | 58 | <i>ketoconazole</i> | 10, 69 | <i>lamotrigine</i> | 38, 39 |
| <i>isosorbide dinitrate</i> | 58 | KETODAN | 69 | LAMPIT | 10 |
| <i>isosorbide mononitrate</i> | 58 | <i>ketoprofen</i> | 38 | LANOXIN | 58, 59 |
| <i>isosorbide-hydralazine</i> | 58 | <i>ketorolac</i> | 38, 104 | <i>lansoprazole</i> | 86 |
| <i>isotretinoin</i> | 69 | KEVEYIS | 38 | <i>lanthanum</i> | 74 |
| <i>isradipine</i> | 58 | KEVZARA | 95 | LANTUS SOLOSTAR U-100 | |
| ISTALOL | 104 | KINERET | 95 | INSULIN | 80 |
| ISTURISA | 79 | KINRIX (PF) | 91 | LANTUS U-100 INSULIN | 80 |
| <i>itraconazole</i> | 10 | KISQALI | 19 | <i>lapatinib</i> | 19 |
| <i>ivermectin</i> | 10, 69 | KISQALI FEMARA CO- | | LARIN 1.5/30 (21) | 99 |
| IXIARO (PF) | 91 | PACK | 19 | LARIN 1/20 (21) | 99 |
| JADENU | 74 | KLARON | 69 | LARIN FE 1.5/30 (28) | 99 |
| JADENU SPRINKLE | 74 | KLISYRI | 19 | LARIN FE 1/20 (28) | 99 |
| JAKAFI | 19 | KLONOPIN | 38 | LASIX | 59 |
| JALYN | 111 | KLOR-CON | 113 | <i>latanoprost</i> | 104 |
| JANTOVEN | 58 | KLOR-CON 10 | 113 | LATUDA | 39 |
| JANUMET | 79 | KLOR-CON 8 | 113 | LAYOLIS FE | 99 |
| JANUMET XR | 79 | KLOR-CON M10 | 113 | <i>ledipasvir-sofosbuvir</i> | 10 |
| JANUVIA | 79 | KLOR-CON M15 | 113 | LEENA 28 | 99 |
| JARDIANCE | 79 | KLOR-CON M20 | 113 | <i>leflunomide</i> | 95 |
| JASMIEL (28) | 98 | KLOXXADO | 38 | <i>lenalidomide</i> | 19 |
| JATENZO | 79 | KOMBIGLYZE XR | 79 | LENVIMA | 19 |
| JAVYGTOR | 79 | KORLYM | 79 | LESCOL XL | 59 |
| JENTADUETO | 79 | KOSELUGO | 19 | LESSINA | 99 |
| JENTADUETO XR | 79 | KRINTAFEL | 10 | LETAIRIS | 108 |
| JINTELI | 98 | KRISTALOSE | 86 | <i>letrozole</i> | 20 |
| JORNAY PM | 38 | K-TAB | 113 | <i>leucovorin calcium</i> | 20 |
| JUBLIA | 69 | KURVELO (28) | 99 | LEUKERAN | 20 |
| JULEBER | 98 | KUVAN | 79 | LEUKINE | 91 |
| JULUCA | 10 | KYNMOBI | 38 | <i>leuprolide</i> | 20 |
| JUNEL 1.5/30 (21) | 98 | <i>l norgest/e.estradiol-e.estrad</i> | 99 | <i>levabuterol hcl</i> | 108 |
| JUNEL 1/20 (21) | 98 | <i>labetalol</i> | 58 | <i>levabuterol tartrate</i> | 108 |
| JUNEL FE 1.5/30 (28) | 98 | <i>lacosamide</i> | 38 | <i>levamlodipine</i> | 59 |
| JUNEL FE 1/20 (28) | 98 | LACRISERT | 104 | LEVEMIR FLEXTOUCH U- | |
| JUNEL FE 24 | 98 | <i>lactulose</i> | 86 | 100 INSULN | 80 |
| JUXTAPID | 58 | LAMICTAL | 38 | LEVEMIR U-100 INSULIN ... | 80 |
| JYNARQUE | 79 | LAMICTAL ODT | 38 | <i>levetiracetam</i> | 39 |
| KAITLIB FE | 98 | LAMICTAL STARTER | | <i>levobunolol</i> | 104 |
| KALETRA | 10 | (BLUE) KIT | 38 | <i>levocarnitine</i> | 74 |
| KALYDECO | 108 | LAMICTAL STARTER | | <i>levocarnitine (with sugar)</i> | 74 |
| KAPVAY | 38 | (GREEN) KIT | 38 | <i>levocetirizine</i> | 108 |
| KARIVA (28) | 98 | LAMICTAL STARTER | | <i>levofloxacin</i> | 10, 104 |
| KATERZIA | 58 | (ORANGE) KIT | 38 | <i>levofloxacin in d5w</i> | 10 |
| KAZANO | 79 | LAMICTAL XR | 38 | LEVONEST (28) | 99 |
| KELNOR 1/35 (28) | 98 | LAMICTAL XR STARTER | | <i>levonorgestrel-ethinyl estrad</i> | 99 |
| KELNOR 1-50 (28) | 98 | (BLUE) | 38 | <i>levonorg-eth estrad triphasic</i> | 99 |

| | | | | | |
|---|-----|---|-----|----------------------------------|-----|
| LEVORA-28 | 99 | LOPROX | 69 | LYVISPAH | 40 |
| <i>levorphanol tartrate</i> | 39 | LOPROX (AS OLAMINE) | 69 | LYZA | 99 |
| LEVO-T | 80 | <i>lorazepam</i> | 39 | MACROBID | 11 |
| <i>levothyroxine</i> | 80 | LORAZEPAM INTENSOL | 39 | MACRODANTIN | 11 |
| LEVOXYL | 80 | LORBRENA | 20 | <i>mafenide acetate</i> | 69 |
| LEXAPRO | 39 | LOREEV XR | 39 | <i>magnesium sulfate</i> | 113 |
| LEXETTE | 69 | LORYNA (28) | 99 | MALARONE | 11 |
| LEXIVA | 11 | LORZONE | 39 | MALARONE PEDIATRIC | 11 |
| LIALDA | 86 | <i>losartan</i> | 59 | <i>malathion</i> | 69 |
| LIBRAX (WITH | | <i>losartan-hydrochlorothiazide</i> | 59 | <i>maraviroc</i> | 11 |
| CLIDINIUM) | 86 | LOSEASONIQUE | 99 | MARINOL | 86 |
| LICART | 39 | LOTEMAX | 104 | MARLISSA (28) | 99 |
| <i>lidocaine</i> | 69 | LOTEMAX SM | 104 | MARPLAN | 40 |
| <i>lidocaine hcl</i> | 69 | LOTENSIN | 59 | MATULANE | 20 |
| LIDOCAINE VISCOUS | 69 | <i>loteprednol etabonate</i> | 104 | MATZIM LA | 59 |
| <i>lidocaine-prilocaine</i> | 69 | LOTREL | 59 | MAVENCLAD (10 TABLET | |
| LIDODERM | 69 | LOTRONEX | 86 | PACK) | 40 |
| <i>linezolid</i> | 11 | <i>lovastatin</i> | 59 | MAVENCLAD (4 TABLET | |
| <i>linezolid in dextrose 5%</i> | 11 | LOVAZA | 59 | PACK) | 40 |
| LINZESS | 86 | LOVENOX | 59 | MAVENCLAD (5 TABLET | |
| <i>lithyronine</i> | 80 | LOW-OGESTREL (28) | 99 | PACK) | 40 |
| LIPITOR | 59 | <i>loxapine succinate</i> | 39 | MAVENCLAD (6 TABLET | |
| LIPOFEN | 59 | <i>lubiprostone</i> | 86 | PACK) | 40 |
| <i>lisinopril</i> | 59 | LUCEMYRA | 39 | MAVENCLAD (7 TABLET | |
| <i>lisinopril-hydrochlorothiazide</i> | 59 | <i>luliconazole</i> | 69 | PACK) | 40 |
| <i>lithium carbonate</i> | 39 | LUMAKRAS | 20 | MAVENCLAD (8 TABLET | |
| LITHOBID | 39 | LUMIGAN | 104 | PACK) | 40 |
| LITHOSTAT | 74 | LUNESTA | 39 | MAVENCLAD (9 TABLET | |
| LIVALO | 59 | LUPKYNIS | 20 | PACK) | 40 |
| LIVMARLI | 86 | LUPRON DEPOT | 20 | MAVYRET | 11 |
| LIVTENCITY | 11 | LUPRON DEPOT (3 | | MAXALT | 40 |
| LO LOESTRIN FE | 99 | MONTH) | 20 | MAXALT-MLT | 40 |
| LOCOID | 69 | LUPRON DEPOT (4 | | MAXIDEX | 104 |
| LOCOID LIPOCREAM | 69 | MONTH) | 20 | MAXITROL | 104 |
| LODINE | 39 | LUPRON DEPOT (6 | | MAXZIDE | 59 |
| LODOSYN | 39 | MONTH) | 20 | MAXZIDE-25MG | 59 |
| LOESTRIN 1.5/30 (21) | 99 | LUTERA (28) | 99 | MAYZENT | 40 |
| LOESTRIN 1/20 (21) | 99 | LUXIQ | 69 | MAYZENT STARTER(FOR | |
| LOESTRIN FE 1.5/30 (28- | | LUZU | 69 | 1MG MAINT) | 40 |
| DAY) | 99 | LYBALVI | 39 | MAYZENT STARTER(FOR | |
| LOESTRIN FE 1/20 (28- | | LYLEQ | 99 | 2MG MAINT) | 40 |
| DAY) | 99 | LYLLANA | 99 | <i>meclizine</i> | 86 |
| LOFENA | 39 | LYNPARZA | 20 | <i>meclofenamate</i> | 40 |
| LOKELMA | 74 | LYRICA | 39 | MEDROL | 80 |
| LOMOTIL | 86 | LYRICA CR | 39 | MEDROL (PAK) | 80 |
| LONHALA MAGNAIR | | LYSODREN | 20 | <i>medroxyprogesterone</i> | 99 |
| REFILL | 108 | LYSTEDA | 99 | <i>mefenamic acid</i> | 40 |
| LONSURF | 20 | LYUMJEV KWIKPEN U-100 | | <i>mefloquine</i> | 11 |
| <i>loperamide</i> | 86 | INSULIN | 80 | <i>megestrol</i> | 20 |
| LOPID | 59 | LYUMJEV KWIKPEN U-200 | | MEKINIST | 20 |
| <i>lopinavir-ritonavir</i> | 11 | INSULIN | 80 | MEKTOVI | 20 |
| LOPRESSOR | 59 | LYUMJEV U-100 INSULIN | 80 | <i>meloxicam</i> | 40 |

| | | | | | |
|--|----------------|---|---------|---|----------|
| <i>meloxicam submicronized</i> | 40 | MICONAZOLE-3 | 99 | <i>mycophenolate sodium</i> | 20 |
| <i>memantine</i> | 40 | MICROGESTIN 1.5/30 (21) | 99 | MYDAYIS | 42 |
| MENACTRA (PF) | 91 | MICROGESTIN 1/20 (21) | 99 | MYFEMBREE | 100 |
| MENEST | 99 | MICROGESTIN 24 FE | 99 | MYFORTIC | 20 |
| MENOSTAR | 99 | MICROGESTIN FE 1.5/30 | | MYORISAN | 70 |
| MENQUADFI (PF) | 91 | (28) | 99 | MYRBETRIQ | 111, 112 |
| MENTAX | 69 | MICROGESTIN FE 1/20 (28) | | MYSOLINE | 42 |
| MENVEO A-C-Y-W-135-DIP | | | 100 | MYTESI | 87 |
| (PF) | 91 | <i>midodrine</i> | 74 | <i>nabumetone</i> | 42 |
| <i>meperidine</i> | 40 | MIGERGOT | 41 | <i>nadolol</i> | 60 |
| <i>meperidine (pf)</i> | 40 | <i>miglitol</i> | 80 | <i>nafacillin</i> | 11 |
| <i>meprobamate</i> | 40 | <i>miglustat</i> | 80 | <i>naftifine</i> | 70 |
| MEPRON | 11 | MIGRANAL | 41 | NAFTIN | 70 |
| <i>mercaptapurine</i> | 20 | MILI | 100 | NALFON | 42 |
| <i>meropenem</i> | 11 | MILLIPRED | 80 | <i>naloxone</i> | 42 |
| MERZEE | 99 | MIMVEY | 100 | <i>naltrexone</i> | 42 |
| <i>mesalamine</i> | 86, 87 | MINASTRIN 24 FE | 100 | NAMENDA | 42 |
| MESNEX | 20 | MINIPRESS | 60 | NAMENDA TITRATION | |
| MESTINON | 40 | MINIVELLE | 100 | PAK | 42 |
| MESTINON TIMESPAN | 40 | <i>minocycline</i> | 11 | NAMENDA XR | 42 |
| <i>metaxalone</i> | 40 | MINOLIRA ER | 11 | NAMZARIC | 42 |
| <i>metformin</i> | 80 | <i>minoxidil</i> | 60 | NAPRELAN CR | 42 |
| <i>methadone</i> | 40, 41 | MIRAPEX ER | 41 | <i>naproxen</i> | 42 |
| <i>methamphetamine</i> | 41 | <i>mirtazapine</i> | 41 | <i>naproxen sodium</i> | 42 |
| <i>methazolamide</i> | 104 | MIRVASO | 70 | <i>naproxen-esomeprazole</i> | 42 |
| <i>methenamine hippurate</i> | 11 | <i>misoprostol</i> | 87 | <i>naratriptan</i> | 42 |
| <i>methimazole</i> | 80 | MITIGARE | 95 | NARCAN | 42 |
| METHITEST | 80 | M-M-R II (PF) | 91 | NARDIL | 43 |
| <i>methocarbamol</i> | 41 | <i>modafinil</i> | 41 | NATACYN | 104 |
| <i>methotrexate sodium</i> | 20 | <i>moexipril</i> | 60 | NATAZIA | 100 |
| <i>methotrexate sodium (pf)</i> | 20 | <i>molindone</i> | 41 | <i>nateglinide</i> | 80 |
| <i>methoxsalen</i> | 69 | <i>mometasone</i> | 70, 108 | NATESTO | 81 |
| <i>methscopolamine</i> | 87 | <i>montelukast</i> | 108 | NATPARA | 81 |
| METHYLIN | 41 | MONUROL | 11 | NATROBA | 70 |
| <i>methylphenidate hcl</i> | 41 | <i>morphine</i> | 41, 42 | NAYZILAM | 43 |
| <i>methylprednisolone</i> | 80 | <i>morphine concentrate</i> | 41 | <i>nebivolol</i> | 60 |
| <i>methyltestosterone</i> | 80 | MOTEGRITY | 87 | NEBUPENT | 12 |
| <i>metoclopramide hcl</i> | 87 | MOUNJARO | 80 | NECON 0.5/35 (28) | 100 |
| <i>metolazone</i> | 59 | MOVANTIK | 87 | <i>nefazodone</i> | 43 |
| <i>metoprolol succinate</i> | 59 | MOVIPREP | 87 | <i>neomycin</i> | 12 |
| <i>metoprolol ta-hydrochlorothiaz</i> .. | 59 | <i>moxifloxacin</i> | 11, 104 | <i>neomycin-bacitracin-poly-hc</i> | 104 |
| <i>metoprolol tartrate</i> | 59 | <i>moxifloxacin-sod.chloride(iso)</i> ... | 11 | <i>neomycin-bacitracin-polymyxin</i> | 104 |
| METROCREAM | 69 | MS CONTIN | 42 | <i>neomycin-polymyxin b-</i> | |
| METROGEL | 69 | MULPLETA | 60 | <i>dexameth</i> | 104 |
| METROLOTION | 69 | MULTAQ | 60 | <i>neomycin-polymyxin-gramicidin</i> | |
| <i>metronidazole</i> | 11, 69, 70, 99 | <i>mupirocin</i> | 70 | | 104 |
| <i>metronidazole in nacl (iso-os)</i> | 11 | <i>mupirocin calcium</i> | 70 | <i>neomycin-polymyxin-hc</i> | 76, 104 |
| <i>metyrosine</i> | 59 | MYALEPT | 80 | NEORAL | 20 |
| <i>mexiletine</i> | 59 | MYAMBUTOL | 11 | NEO-SYNALAR | 70 |
| <i>micafungin</i> | 11 | MYCAPSSA | 20 | NERLYNX | 20 |
| MICARDIS | 59 | MYCOBUTIN | 11 | NESINA | 81 |
| MICARDIS HCT | 59 | <i>mycophenolate mofetil</i> | 20 | NEUAC | 70 |

| | | | | | |
|---|-----|-------------------------------------|--------|---|-------------|
| NEULASTA | 91 | NORPACE CR | 60 | NYVEPRIA | 92 |
| NEUPOGEN | 92 | NORPRAMIN | 43 | OALIVA | 87 |
| NEUPRO | 43 | NORTHERA | 74 | OCELLA | 100 |
| NEURONTIN | 43 | NORTREL 0.5/35 (28) | 100 | OCTAGAM | 92 |
| NEVANAC | 104 | NORTREL 1/35 (21) | 100 | <i>octreotide acetate</i> | 21 |
| <i>nevirapine</i> | 12 | NORTREL 1/35 (28) | 100 | OCUFLOX | 104 |
| NEXAVAR | 20 | NORTREL 7/7/7 (28) | 100 | ODACTRA | 92 |
| NEXIUM | 87 | <i>nortriptyline</i> | 43 | ODEFSEY | 12 |
| NEXIUM PACKET | 87 | NORVASC | 60 | ODOMZO | 21 |
| NEXLETOL | 60 | NORVIR | 12 | OFEV | 109 |
| NEXLIZET | 60 | NOURIANZ | 43 | <i>ofloxacin</i> | 12, 76, 104 |
| NEXTSTELLIS | 100 | NOVOLIN 70/30 U-100 | | <i>olanzapine</i> | 43 |
| <i>niacin</i> | 60 | INSULIN | 81 | <i>olanzapine-fluoxetine</i> | 43 |
| NIACOR | 60 | NOVOLIN 70-30 FLEXPEN | | <i>olmesartan</i> | 60 |
| <i>nicardipine</i> | 60 | U-100 | 81 | <i>olmesartan-amlodipin-hcthiazyd</i> .60 | |
| NICOTROL | 74 | NOVOLIN N FLEXPEN | 81 | <i>olmesartan-hydrochlorothiazide</i> .60 | |
| NICOTROL NS | 74 | NOVOLIN N NPH U-100 | | <i>olopatadine</i> | 76, 104 |
| <i>nifedipine</i> | 60 | INSULIN | 81 | OLUMIANT | 95 |
| NIKKI (28) | 100 | NOVOLIN R FLEXPEN | 81 | OLUX | 70 |
| NILANDRON | 20 | NOVOLIN R REGULAR U- | | OLUX-E | 70 |
| <i>nilutamide</i> | 20 | 100 INSULN | 81 | <i>omega-3 acid ethyl esters</i> | 60 |
| <i>nimodipine</i> | 60 | NOVOLOG FLEXPEN U-100 | | <i>omeprazole</i> | 87 |
| NINLARO | 20 | INSULIN | 81 | <i>omeprazole-sodium bicarbonate</i> .87 | |
| <i>nisoldipine</i> | 60 | NOVOLOG MIX 70-30 U-100 | | OMNARIS | 109 |
| <i>nitazoxanide</i> | 12 | INSULN | 81 | OMNITROPE | 92 |
| <i>nitisinone</i> | 74 | NOVOLOG MIX 70- | | <i>ondansetron</i> | 87 |
| NITRO-BID | 60 | 30FLEXPEN U-100 | 81 | <i>ondansetron hcl</i> | 87 |
| NITRO-DUR | 60 | NOVOLOG PENFILL U-100 | | ONEXTON | 70 |
| <i>nitrofurantoin</i> | 12 | INSULIN | 81 | ONFI | 43 |
| <i>nitrofurantoin macrocrystal</i> | 12 | NOVOLOG U-100 INSULIN | | ONGENTYS | 43 |
| <i>nitrofurantoin monohyd/m-cryst</i> .12 | | ASPART | 81 | ONGLYZA | 81 |
| <i>nitroglycerin</i> | 60 | NOXAFIL | 12 | ONUREG | 21 |
| NITROLINGUAL | 60 | NUBEQA | 21 | ONZETRA XSAIL | 43 |
| NITROSTAT | 60 | NUCALA | 109 | OPSUMIT | 109 |
| NITYR | 74 | NUCYNTA | 43 | OPZELURA | 70 |
| NIVESTYM | 92 | NUCYNTA ER | 43 | ORACEA | 12 |
| <i>nizatidine</i> | 87 | NUEDEXTA | 43 | ORALAIR | 92 |
| NOCDURNA (MEN) | 81 | NUPLAZID | 43 | ORAPRED ODT | 81 |
| NOCDURNA (WOMEN) | 81 | NURTEC ODT | 43 | ORENCIA | 95 |
| NORA-BE | 100 | NUTRILIPID | 113 | ORENCIA CLICKJECT | 95 |
| NORDITROPIN FLEXPRO ... 92 | | NUTROPIN AQ NUSPIN | 92 | ORENITRAM | 60, 61 |
| <i>noreth-ethinyl estradiol-iron</i> 100 | | NUVARING | 100 | ORFADIN | 74 |
| <i>norethindrone (contraceptive)</i> .. 100 | | NUVIGIL | 43 | ORGOVYX | 21 |
| <i>norethindrone acetate</i> | 100 | NUZYRA | 12 | ORIAHNN | 100 |
| <i>norethindrone ac-eth estradiol</i> . 100 | | NYAMYC | 70 | ORLISSA | 81 |
| <i>norethindrone-e.estradiol-iron</i> . 100 | | NYLIA 1/35 (28) | 100 | ORKAMBI | 109 |
| NORGESIC | 43 | NYLIA 7/7/7 (28) | 100 | ORLADEYO | 109 |
| NORGESIC FORTE | 43 | NYMALIZE | 60 | <i>orphenadrine citrate</i> | 43 |
| <i>norgestimate-ethinyl estradiol</i> .. 100 | | NYMYO | 100 | <i>orphenadrine-asa-caffeine</i> | 43 |
| NORITATE | 70 | <i>nystatin</i> | 12, 70 | ORTIKOS | 87 |
| NORLIQVA | 60 | <i>nystatin-triamcinolone</i> | 70 | <i>oseltamivir</i> | 12 |
| NORPACE | 60 | NYSTOP | 70 | OSENI | 81 |

| | | | | | |
|---|--------|---|---------|---|---------|
| OSMOLEX ER | 43 | PEMAZYRE | 21 | PLASMA-LYTE A | 113 |
| OSMOPREP | 87 | <i>pen needle, diabetic</i> | 94 | PLAVIX | 61 |
| OSPHENA | 100 | <i>penicillamine</i> | 95 | PLEGRIDY | 92 |
| OTEZLA | 95 | <i>penicillin g pot in dextrose</i> | 12 | PLENAMINE | 113 |
| OTEZLA STARTER | 95 | <i>penicillin g potassium</i> | 12 | PLENVU | 88 |
| OTOVEL | 76 | <i>penicillin g procaine</i> | 12 | PLIAGLIS | 70 |
| OTREXUP (PF) | 95 | <i>penicillin g sodium</i> | 12 | <i>podofilox</i> | 70 |
| OVIDE | 70 | <i>penicillin v potassium</i> | 12 | <i>polymyxin b sulfate</i> | 13 |
| <i>oxacillin</i> | 12 | PENNSAID | 45 | <i>polymyxin b sulf-trimethoprim</i> .. | 104 |
| <i>oxacillin in dextrose(iso-osm)</i> | 12 | PENTACEL (PF) | 92 | POLYTRIM | 104 |
| <i>oxandrolone</i> | 81 | PENTAM | 12 | POMALYST | 21 |
| <i>oxaprozin</i> | 43 | <i>pentamidine</i> | 12 | PONVORY | 45 |
| <i>oxazepam</i> | 43 | PENTASA | 88 | PONVORY 14-DAY | |
| OXBRYTA | 74 | <i>pentazocine-naloxone</i> | 45 | STARTER PACK | 45 |
| <i>oxcarbazepine</i> | 44 | <i>pentoxifylline</i> | 61 | PORTIA 28 | 100 |
| OXERVATE | 104 | PEPCID | 88 | <i>posaconazole</i> | 13 |
| <i>oxiconazole</i> | 70 | PERCOCET | 45 | <i>potassium chlorid-d5-</i> | |
| OXISTAT | 70 | PERFOROMIST | 109 | <i>0.45%nacl</i> | 113 |
| OXTELLAR XR | 44 | <i>perindopril erbumine</i> | 61 | <i>potassium chloride</i> | 113 |
| <i>oxybutynin chloride</i> | 112 | PERIOGARD | 76 | <i>potassium chloride in 0.9%nacl</i> 113 | |
| <i>oxycodone</i> | 44 | <i>permethrin</i> | 70 | <i>potassium chloride in 5 % dex</i> .. | 113 |
| <i>oxycodone-acetaminophen</i> | 44 | <i>perphenazine</i> | 45 | <i>potassium chloride in lr-d5</i> | 113 |
| OXYCONTIN | 44 | <i>perphenazine-amitriptyline</i> | 45 | <i>potassium chloride in water</i> | 113 |
| <i>oxymorphone</i> | 44 | PERSERIS | 45 | <i>potassium chloride-0.45 % nacl</i> 113 | |
| OXYTROL | 112 | PERTZYE | 88 | <i>potassium chloride-d5-</i> | |
| OZEMPIC | 81 | PEXEVA | 45 | <i>0.2%nacl</i> | 113 |
| PACERONE | 61 | PHEBURANE | 74 | <i>potassium chloride-d5-</i> | |
| <i>paliperidone</i> | 44 | <i>phenelzine</i> | 45 | <i>0.9%nacl</i> | 114 |
| PALYNZIQ | 81 | <i>phenobarbital</i> | 45 | <i>potassium citrate</i> | 112 |
| PAMELOR | 44 | <i>phenoxybenzamine</i> | 61 | PRADAXA | 61 |
| PANCREAZE | 87 | PHENYTEK | 45 | PRALUENT PEN | 61 |
| PANDEL | 70 | <i>phenytoin</i> | 45 | <i>pramipexole</i> | 45 |
| PANRETIN | 70 | <i>phenytoin sodium extended</i> | 45 | <i>prasugrel</i> | 61 |
| <i>pantoprazole</i> | 87, 88 | PHEXXI | 100 | <i>pravastatin</i> | 61 |
| PANZYGA | 92 | PHOSLYRA | 113 | <i>praziquantel</i> | 13 |
| <i>paricalcitol</i> | 81 | PHOSPHOLINE IODIDE | 104 | <i>prazosin</i> | 61 |
| PARLODEL | 44 | PIFELTRO | 12 | PRED FORTE | 104 |
| PARNATE | 44 | <i>pilocarpine hcl</i> | 74, 104 | PRED MILD | 104 |
| <i>paromomycin</i> | 12 | <i>pimecrolimus</i> | 70 | PRED-G S.O.P. | 104 |
| <i>paroxetine hcl</i> | 44 | <i>pimozide</i> | 45 | <i>prednicarbate</i> | 70 |
| <i>paroxetine</i> | | PIMTREA (28) | 100 | <i>prednisolone</i> | 81 |
| <i>mesylate(menop.sym)</i> | 45 | <i>pindolol</i> | 61 | <i>prednisolone acetate</i> | 104 |
| PASER | 12 | <i>pioglitazone</i> | 81 | <i>prednisolone sodium phosphate</i> | |
| PATANASE | 76 | <i>pioglitazone-glimepiride</i> | 81 | | 81, 105 |
| PAXIL | 45 | <i>pioglitazone-metformin</i> | 81 | <i>prednisone</i> | 81, 82 |
| PAXIL CR | 45 | <i>piperacillin-tazobactam</i> | 13 | PREDNISONONE INTENSOL ... | 81 |
| PEDIARIX (PF) | 92 | PIQRAY | 21 | PREFEST | 100 |
| PEDVAX HIB (PF) | 92 | <i>pirfenidone</i> | 109 | <i>pregabalin</i> | 45 |
| <i>peg 3350-electrolytes</i> | 88 | PIRMELLA | 100 | PREHEVBRIO (PF) | 92 |
| <i>peg3350-sod sul-nacl-kcl-asb-c</i> .. | 88 | <i>piroxicam</i> | 45 | PREMARIN | 101 |
| PEGASYS | 92 | PLAQUENIL | 13 | PREMASOL 10 % | 114 |
| <i>peg-electrolyte soln</i> | 88 | PLASMA-LYTE 148 | 113 | PREMPHASE | 101 |

| | | | | | |
|---|-----|--|--------|-----------------------------------|--------|
| PREMPRO | 101 | PROVERA | 101 | RAYOS | 82 |
| PRENATAL VITAMIN PLUS LOW IRON | 114 | PROVIGIL | 45 | RAZADYNE ER | 46 |
| <i>pretomanid</i> | 13 | PROZAC | 45 | REBIF (WITH ALBUMIN) | 93 |
| PREVACID | 88 | PRUDOXIN | 71 | REBIF REBIDOSE | 93 |
| PREVACID SOLUTAB | 88 | PSORCON | 71 | REBIF TITRATION PACK | 93 |
| PREVALITE | 61 | PULMICORT | 109 | RECLIPSEN (28) | 101 |
| PREVYMIS | 13 | PULMICORT FLEXHALER | 109 | RECOMBIVAX HB (PF) | 93 |
| PREZCOBIX | 13 | PULMOZYME | 109 | RECORLEV | 82 |
| PREZISTA | 13 | PURIXAN | 21 | RECTIV | 88 |
| PRIFTIN | 13 | PYLERA | 88 | REDITREX (PF) | 95 |
| PRILOSEC | 88 | <i>pyrazinamide</i> | 13 | REGLAN | 88 |
| <i>primaquine</i> | 13 | <i>pyridostigmine bromide</i> | 45, 46 | REGRANEX | 71 |
| PRIMAXIN IV | 13 | <i>pyrimethamine</i> | 13 | RELAFEN DS | 46 |
| <i>primidone</i> | 45 | PYRUKYND | 74 | RELENZA DISKHALER | 13 |
| PRIORIX (PF) | 92 | QBRELIS | 61 | RELEXXII | 46 |
| PRISTIQ | 45 | QBREXZA | 71 | RELISTOR | 88 |
| PRIVIGEN | 92 | QELBREE | 46 | RELPAK | 46 |
| PROAIR DIGIHALER | 109 | QINLOCK | 21 | RELTONE | 88 |
| PROAIR RESPICLICK | 109 | QNASL | 109 | REMERON | 46 |
| <i>probenecid</i> | 95 | QTERN | 82 | REMERON SOLTAB | 46 |
| <i>probenecid-colchicine</i> | 95 | QUADRACEL (PF) | 93 | RENAGEL | 75 |
| PROCARDIA XL | 61 | QUALAQUIN | 13 | REVELA | 75 |
| PROCENTRA | 45 | QUARTETTE | 101 | <i>repaglinide</i> | 82 |
| <i>prochlorperazine</i> | 88 | QUDEXY XR | 46 | REPATHA PUSHTRONEX | 62 |
| <i>prochlorperazine maleate</i> | 88 | QUESTRAN | 61 | REPATHA SURECLICK | 62 |
| PROCRT | 92 | QUESTRAN LIGHT | 61 | REPATHA SYRINGE | 62 |
| PROCTO-MED HC | 88 | <i>quetiapine</i> | 46 | RESTASIS | 105 |
| PROCTO-PAK | 88 | QUILLICHEW ER | 46 | RESTASIS MULTIDOSE | 105 |
| PROCTOSOL HC | 88 | QUILLIVANT XR | 46 | RESTORIL | 46 |
| PROCTOZONE-HC | 88 | <i>quinapril</i> | 61 | RETACRIT | 93 |
| PROCYSBI | 112 | <i>quinapril-hydrochlorothiazide</i> | 61 | RETEVMO | 21 |
| <i>progesterone micronized</i> | 101 | <i>quinidine gluconate</i> | 62 | RETIN-A | 71 |
| PROGLYCEM | 82 | <i>quinidine sulfate</i> | 62 | RETIN-A MICRO | 71 |
| PROGRAF | 21 | <i>quinine sulfate</i> | 13 | RETIN-A MICRO PUMP | 71 |
| PROLASTIN-C | 74 | QULIPTA | 46 | RETROVIR | 13 |
| PROLATE | 45 | QUVIVIQ | 46 | REVATIO | 109 |
| PROLENSA | 105 | QVAR REDIHALER | 109 | REVCIVI | 75 |
| PROLIA | 95 | RABAVERT (PF) | 93 | REVLIMID | 21 |
| PROMACTA | 61 | <i>rabeprazole</i> | 88 | REXULTI | 46 |
| <i>promethazine</i> | 109 | RADICAVA ORS STARTER KIT SUSP | 46 | REYATAZ | 13 |
| PROMETHEGAN | 109 | <i>raloxifene</i> | 95 | REYVOW | 46 |
| PROMETRIUM | 101 | <i>ramelteon</i> | 46 | REZUROCK | 21 |
| <i>propafenone</i> | 61 | <i>ramipril</i> | 62 | RHOFADE | 71 |
| <i>propranolol</i> | 61 | RANEXA | 62 | RHOPRESSA | 105 |
| <i>propylthiouracil</i> | 82 | <i>ranolazine</i> | 62 | <i>ribavirin</i> | 13 |
| PROQUAD (PF) | 93 | RAPAFLO | 112 | RIDAURA | 95 |
| PROSCAR | 112 | RAPAMUNE | 21 | <i>rifabutin</i> | 13 |
| PROSOL 20 % | 114 | <i>rasagiline</i> | 46 | <i>rifampin</i> | 13 |
| PROTONIX | 88 | RASUVO (PF) | 95 | RILUTEK | 75 |
| PROTOPIC | 70 | RAVICTI | 75 | <i>riluzole</i> | 75 |
| <i>protriptyline</i> | 45 | RAYALDEE | 82 | <i>rimantadine</i> | 13 |
| | | | | RINVOQ | 95, 96 |

| | | | | | |
|------------------------------------|--------|---|--------|--|-----|
| RIOMET | 82 | SCSEMBLIX | 21 | <i>sofosbuvir-velpatasvir</i> | 14 |
| <i>risedronate</i> | 75, 96 | <i>scopolamine base</i> | 89 | <i>solifenacin</i> | 112 |
| RISPERDAL | 47 | SEASONIQUE | 101 | SOLIQUA 100/33 | 82 |
| RISPERDAL CONSTA | 46, 47 | SECUADO | 48 | SOLODYN | 14 |
| <i>risperidone</i> | 47 | SEGLENTIS | 48 | SOLOSEC | 14 |
| RITALIN | 47 | SEGLUROMET | 82 | SOLTAMOX | 22 |
| RITALIN LA | 47 | <i>selegiline hcl</i> | 48 | SOMA | 48 |
| <i>ritonavir</i> | 13 | <i>selenium sulfide</i> | 71 | SOMAVERT | 82 |
| <i>rivastigmine</i> | 47 | SELZENTRY | 13 | SOOLANTRA | 71 |
| <i>rivastigmine tartrate</i> | 47 | SENSIPAR | 82 | <i>sorafenib</i> | 22 |
| RIVELSA | 101 | SEREVENT DISKUS | 110 | SORILUX | 71 |
| <i>rizatriptan</i> | 47 | SEROQUEL | 48 | SORINE | 62 |
| ROBINUL | 88 | SEROQUEL XR | 48 | <i>sotalol</i> | 62 |
| ROBINUL FORTE | 88 | SEROSTIM | 93 | SOTALOL AF | 62 |
| ROCALTROL | 82 | <i>sertraline</i> | 48 | SOTYLIZE | 62 |
| ROCKLATAN | 105 | SETLAKIN | 101 | SOVALDI | 14 |
| <i>ropinirole</i> | 47 | <i>sevelamer carbonate</i> | 75 | <i>spinosad</i> | 71 |
| <i>rosuvastatin</i> | 62 | <i>sevelamer hcl</i> | 75 | SPIRIVA RESPIMAT | 110 |
| ROSZET | 62 | SEYSARA | 14 | SPIRIVA WITH | |
| ROTARIX | 93 | SHAROBEL | 101 | HANDIHALER | 110 |
| ROTATEQ VACCINE | 93 | SHINGRIX (PF) | 93 | <i>spironolactone</i> | 62 |
| ROWASA | 88 | SIGNIFOR | 21 | <i>spironolacton-hydrochlorothiaz.</i> | 62 |
| ROWEEPRA | 47 | SIKLOS | 21 | SPORANOX | 14 |
| ROXICODONE | 47 | <i>sildenafil (pulm.hypertension)</i> .. | 110 | SPRINTEC (28) | 101 |
| ROZEREM | 47 | SILENOR | 48 | SPRITAM | 48 |
| ROZLYTREK | 21 | SILIQ | 71 | SPRIX | 48 |
| RUBRACA | 21 | <i>silodosin</i> | 112 | SPRYCEL | 22 |
| RUCONEST | 109 | SILVADENE | 71 | SPS (WITH SORBITOL) | 75 |
| <i>rufinamide</i> | 47 | <i>silver sulfadiazine</i> | 71 | SRONYX | 101 |
| RUKOBIA | 13 | SIMBRINZA | 105 | SSD | 71 |
| RYALTRIS | 109 | SIMPONI | 96 | STALEVO 100 | 48 |
| RYBELSUS | 82 | <i>simvastatin</i> | 62 | STALEVO 125 | 48 |
| RYCLORA | 109 | SINEMET | 48 | STALEVO 150 | 48 |
| RYDAPT | 21 | SINGULAIR | 110 | STALEVO 200 | 48 |
| RYTARY | 47 | <i>sirolimus</i> | 22 | STALEVO 75 | 48 |
| RYTHMOL SR | 62 | SIRTURO | 14 | STEGLATRO | 82 |
| RYVENT | 109 | SITAVIG | 14 | STEGLUJAN | 82 |
| SABRIL | 47 | SIVEXTRO | 14 | STELARA | 71 |
| SAFYRAL | 101 | SKYRIZI | 71, 89 | STIOLTO RESPIMAT | 110 |
| SAIZEN | 93 | SKYTROFA | 93 | STIVARGA | 22 |
| SAIZEN SAIZENPREP | 93 | SLYND | 101 | STRATTERA | 48 |
| SAJAZIR | 109 | SOANZ | 62 | <i>streptomycin</i> | 14 |
| SALAGEN (PILOCARPINE) .. | 75 | <i>sodium chloride</i> | 75 | STRIBILD | 14 |
| SAMSCA | 82 | <i>sodium chloride 0.45 %</i> | 114 | STRIVERDI RESPIMAT | 110 |
| SANCUSO | 89 | <i>sodium chloride 0.9 %</i> | 75 | STROMEKTOL | 14 |
| SANDIMMUNE | 21 | <i>sodium chloride 3 % hypertonic</i> | | SUBOXONE | 48 |
| SANDOSTATIN | 21 | | 114 | SUCRAID | 89 |
| SANTYL | 71 | <i>sodium chloride 5 % hypertonic</i> | | <i>sucralfate</i> | 89 |
| SAPHRIS | 47 | | 114 | SULAR | 62 |
| <i>sapropterin</i> | 82 | <i>sodium phenylbutyrate</i> | 75 | <i>sulfacetamide sodium</i> | 105 |
| SAVAYSA | 62 | <i>sodium polystyrene sulfonate</i> | 75 | <i>sulfacetamide sodium (acne)</i> | 71 |
| SAVELLA | 96 | <i>sodium,potassium,mag sulfates</i> .. | 89 | <i>sulfacetamide-prednisolone</i> | 105 |

| | | | | | |
|--|--------|--|--------|---|---------|
| <i>sulfadiazine</i> | 14 | TARCEVA | 22 | THIOLA | 75 |
| <i>sulfamethoxazole-trimethoprim</i> .. | 14 | TARGADOX | 14 | THIOLA EC | 75 |
| SULFAMYLON | 71 | TARGRETIN | 22 | <i>thioridazine</i> | 49 |
| <i>sulfasalazine</i> | 89 | TARINA 24 FE | 101 | <i>thiothixene</i> | 49 |
| <i>sulindac</i> | 48 | TARINA FE 1-20 EQ (28) | 101 | THYQUIDITY | 83 |
| <i>sumatriptan</i> | 48 | TARPEYO | 82 | TIADYLT ER | 62 |
| <i>sumatriptan succinate</i> | 48, 49 | TASIGNA | 22 | <i>tiagabine</i> | 49 |
| <i>sumatriptan-naproxen</i> | 49 | TASMAR | 49 | TIAZAC | 62 |
| <i>sunitinib</i> | 22 | <i>tavaborole</i> | 71 | TIBSOVO | 22 |
| SUNOSI | 49 | TAVALISSE | 62 | TICOVAC | 93 |
| SUPRAX | 14 | TAVNEOS | 75 | <i>tigecycline</i> | 14 |
| SUPREP BOWEL PREP KIT .. | 89 | TAYSOFY | 101 | TIGLUTIK | 75 |
| SUSTIVA | 14 | <i>tazarotene</i> | 71, 72 | TIKOSYN | 62 |
| SUTAB | 89 | TAZICEF | 14 | TILIA FE | 101 |
| SUTENT | 22 | TAZORAC | 72 | <i>timolol maleate</i> | 62, 105 |
| SYEDA | 101 | TAZTIA XT | 62 | <i>timolol maleate (pf)</i> | 105 |
| SYMBICORT | 110 | TAZVERIK | 22 | TIMOPTIC OCUDOSE (PF) .. | 105 |
| SYMBYAX | 49 | TDVAX | 93 | TIMOPTIC-XE | 105 |
| SYMDEKO | 110 | TECFIDERA | 49 | <i>tinidazole</i> | 15 |
| SYMFI | 14 | TEFLARO | 14 | <i>tiopronin</i> | 75 |
| SYMFI LO | 14 | TEGRETOL | 49 | TIROSINT | 83 |
| SYMJEPI | 110 | TEGRETOL XR | 49 | TIROSINT-SOL | 83 |
| SYMLINPEN 120 | 82 | TEGSEDI | 49 | TIVICAY | 15 |
| SYMLINPEN 60 | 82 | TEKTRUNA | 62 | TIVICAY PD | 15 |
| SYMPAZAN | 49 | <i>telmisartan</i> | 62 | <i>tizanidine</i> | 49 |
| SYMPROIC | 89 | <i>telmisartan-amlodipine</i> | 62 | TLANDO | 83 |
| SYMTUZA | 14 | <i>telmisartan-hydrochlorothiazid</i> .. | 62 | TOBI | 15 |
| SYNALAR | 71 | <i>temazepam</i> | 49 | TOBI PODHALER | 15 |
| SYNAREL | 82 | TENCON | 49 | TOBRADEX | 105 |
| SYNDROS | 89 | TENIVAC (PF) | 93 | <i>tobramycin</i> | 15, 105 |
| SYNJARDY | 82 | <i>tenofovir disoproxil fumarate</i> | 14 | <i>tobramycin in 0.225 % nacl</i> | 15 |
| SYNJARDY XR | 82 | TENORETIC 100 | 62 | <i>tobramycin sulfate</i> | 15 |
| SYNRIBO | 22 | TENORETIC 50 | 62 | <i>tobramycin-dexamethasone</i> | 105 |
| SYNTHROID | 82 | TENORMIN | 62 | TOBREX | 105 |
| SYPRINE | 75 | TEPMETKO | 22 | <i>tolcapone</i> | 49 |
| TABLOID | 22 | <i>terazosin</i> | 62 | TOLSURA | 15 |
| TABRECTA | 22 | <i>terbinafine hcl</i> | 14 | <i>tolterodine</i> | 112 |
| TACLONEX | 71 | <i>terbutaline</i> | 110 | <i>tolvaptan</i> | 83 |
| <i>tacrolimus</i> | 22, 71 | <i>terconazole</i> | 101 | TOPAMAX | 49 |
| <i>tadalafil</i> | 112 | <i>teriparatide</i> | 96 | TOPICORT | 72 |
| <i>tadalafil (pulm. hypertension)</i> .. | 110 | TESTIM | 83 | <i>topiramate</i> | 49 |
| TAFINLAR | 22 | <i>testosterone</i> | 83 | TOPROL XL | 62 |
| TAGRISO | 22 | <i>testosterone cypionate</i> | 83 | <i>toremifene</i> | 22 |
| TAKHZYRO | 110 | <i>testosterone enanthate</i> | 83 | <i>torse mide</i> | 63 |
| TALICIA | 89 | <i>tetanus, diphtheria tox ped(pf)</i> | 93 | TOSYMRA | 49 |
| TALTZ AUTOINJECTOR | 71 | <i>tetrabenazine</i> | 49 | TOUJEO MAX U-300 | |
| TALTZ SYRINGE | 71 | <i>tetracycline</i> | 14 | SOLOSTAR | 83 |
| TALZENNA | 22 | TEXACORT | 72 | TOUJEO SOLOSTAR U-300 .. | |
| TAMIFLU | 14 | THALITONE | 62 | INSULIN | 83 |
| <i>tamoxifen</i> | 22 | THALOMID | 22 | TOVET EMOLLIENT | 72 |
| <i>tamsulosin</i> | 112 | THEO-24 | 110 | TOVIAZ | 112 |
| TAPERDEX | 82 | <i>theophylline</i> | 110 | TPN ELECTROLYTES | 114 |

| | | | | | |
|--|--------|--------------------------------|--------|---|--------|
| TRACLEER | 110 | <i>trimipramine</i> | 50 | VALCYTE | 15 |
| TRADJENTA | 83 | TRINTELLIX | 50 | <i>valganciclovir</i> | 15 |
| <i>tramadol</i> | 49, 50 | TRI-NYMYO | 101 | VALIUM | 50 |
| <i>tramadol-acetaminophen</i> | 50 | TRI-SPRINTEC (28) | 101 | <i>valproic acid</i> | 50 |
| <i>trandolapril</i> | 63 | TRITOCIN | 72 | <i>valproic acid (as sodium salt)</i> | 50 |
| <i>trandolapril-verapamil</i> | 63 | TRIUMEQ | 15 | <i>valsartan</i> | 63 |
| <i>tranexamic acid</i> | 101 | TRIUMEQ PD | 15 | <i>valsartan-hydrochlorothiazide</i> ... | 63 |
| TRANSDERM-SCOP | 89 | TRIVORA (28) | 101 | VALTOCO | 50 |
| TRANXENE T-TAB | 50 | TRI-VYLIBRA | 101 | VALTRESX | 15 |
| <i>tranylcypramine</i> | 50 | TRI-VYLIBRA LO | 101 | VANCOCIN | 15 |
| TRAVASOL 10 % | 114 | TRIZIVIR | 15 | <i>vancomycin</i> | 15 |
| TRAVATAN Z | 105 | TROKENDI XR | 50 | VANDAZOLE | 101 |
| <i>travoprost</i> | 105 | TROPHAMINE 10 % | 114 | VANOS | 72 |
| <i>trazodone</i> | 50 | <i>tropium</i> | 112 | VAQTA (PF) | 93 |
| TRECTOR | 15 | TRUDHESA | 50 | <i>varenicline</i> | 75 |
| TRELEGY ELLIPTA | 110 | TRULANCE | 89 | VARIVAX (PF) | 93 |
| TRELSTAR | 22 | TRULICITY | 83 | VARUBI | 89 |
| TREMFYA | 72 | TRUMENBA | 93 | VASCEPA | 63 |
| TRESIBA FLEXTOUCH U-100 | 83 | TRUSELTIQ | 22, 23 | VASERETIC | 63 |
| TRESIBA FLEXTOUCH U-200 | 83 | TRUVADA | 15 | VASOTEC | 63 |
| TRESIBA U-100 INSULIN | 83 | TUDORZA PRESSAIR | 110 | VECAMYL | 63 |
| <i>tretinoin</i> | 72 | TUKYSA | 23 | VECTICAL | 72 |
| <i>tretinoin (antineoplastic)</i> | 22 | TURALIO | 23 | VELIVET TRIPHASIC REGIMEN (28) | 101 |
| <i>tretinoin microspheres</i> | 72 | TWINRIX (PF) | 93 | VELPHORO | 75 |
| TREXALL | 22 | TWYNEO | 72 | VELTASSA | 75 |
| TREXIMET | 50 | TYBOST | 15 | VELTIN | 72 |
| TREZIX | 50 | TYDEMY | 101 | VEMLIDY | 15 |
| <i>triamcinolone acetonide</i> | 72, 76 | TYGACIL | 15 | VENCLEXTA | 23 |
| <i>triamterene</i> | 63 | TYKERB | 23 | VENCLEXTA STARTING PACK | 23 |
| <i>triamterene-hydrochlorothiazid</i> .. | 63 | TYMLOS | 96 | <i>venlafaxine</i> | 50 |
| TRIANEX | 72 | TYPHIM VI | 93 | <i>venlafaxine besylate</i> | 50 |
| <i>triazolam</i> | 50 | TYRVAYA | 105 | VENTAVIS | 110 |
| TRIBENZOR | 63 | TYVASO DPI | 110 | VENTOLIN HFA | 110 |
| TRICOR | 63 | UBRELVY | 50 | <i>verapamil</i> | 63 |
| TRIDERM | 72 | UCERIS | 89 | VERDESO | 72 |
| <i>trientine</i> | 75 | UDENYCA | 93 | VEREGEN | 72 |
| TRI-ESTARYLLA | 101 | ULORIC | 96 | VERELAN | 63 |
| <i>trifluoperazine</i> | 50 | ULTRAVATE | 72 | VERELAN PM | 63 |
| <i>trifluridine</i> | 105 | UNASYN | 15 | VERKAZIA | 105 |
| <i>trihexyphenidyl</i> | 50 | UNITHROID | 83 | VERQUVO | 63 |
| TRIJARDY XR | 83 | UPTRAVI | 63 | VERSACLOZ | 50 |
| TRIKAFTA | 110 | UROCIT-K 10 | 112 | VERZENIO | 23 |
| TRI-LEGEST FE | 101 | UROCIT-K 15 | 112 | VESICARE | 112 |
| TRILEPTAL | 50 | UROCIT-K 5 | 112 | VESICARE LS | 112 |
| TRILIPIX | 63 | UROXATRAL | 112 | VESTURA (28) | 102 |
| TRI-LO-ESTARYLLA | 101 | URSO 250 | 89 | VFEND | 15, 16 |
| TRI-LO-SPRINTEC | 101 | URSO FORTE | 89 | VFEND IV | 15 |
| <i>trimethobenzamide</i> | 89 | <i>ursodiol</i> | 89 | VIBERZI | 89 |
| <i>trimethoprim</i> | 15 | VABOMERE | 15 | VIBRAMYCIN | 16 |
| TRI-MILI | 101 | VAGIFEM | 101 | VIBRAMYCIN (CALCIUM) .. | 16 |
| | | <i>valacyclovir</i> | 15 | | |
| | | VALCHLOR | 72 | | |

| | | | | | |
|---------------------------|--------|--------------------------|--------|-----------------------------------|-----|
| VIBRAMYCIN (MONO)..... | 16 | XANAX..... | 51 | ZAVESCA..... | 84 |
| VICTOZA 3-PAK..... | 83 | XANAX XR..... | 51 | ZEBUTAL..... | 52 |
| VIENVA..... | 102 | XARELTO..... | 63, 64 | ZEGALOGUE | |
| <i>vigabatrin</i> | 50 | XARELTO DVT-PE TREAT | | AUTOINJECTOR..... | 84 |
| VIGADRONE..... | 50 | 30D START..... | 63 | ZEGALOGUE SYRINGE..... | 84 |
| VIGAMOX..... | 105 | XATMEP..... | 23 | ZEGERID..... | 89 |
| VIIBRYD..... | 50, 51 | XCOPRI..... | 51 | ZEJULA..... | 24 |
| VIJOICE..... | 23 | XCOPRI MAINTENANCE | | ZELAPAR..... | 52 |
| <i>vilazodone</i> | 51 | PACK..... | 51 | ZELBORAF..... | 24 |
| VIMOVO..... | 51 | XCOPRI TITRATION PACK | 51 | ZEMAIRA..... | 75 |
| VIMPAT..... | 51 | XELJANZ..... | 96 | ZEMBRACE SYMTOUCH..... | 52 |
| VIOKACE..... | 89 | XELJANZ XR..... | 96 | ZEMDRI..... | 16 |
| VIRACEPT..... | 16 | XELPROS..... | 105 | ZEMPLAR..... | 84 |
| VIREAD..... | 16 | XENAZINE..... | 51 | ZENATANE..... | 72 |
| VISTARIL..... | 110 | XENLETA..... | 16 | ZENPEP..... | 89 |
| VITRAKVI..... | 23 | XERESE..... | 72 | ZENZEDI..... | 52 |
| VIVELLE-DOT..... | 102 | XERMELO..... | 23 | ZEPATIER..... | 16 |
| VIVITROL..... | 51 | XGEVA..... | 23 | ZEPOSIA..... | 52 |
| VIVJOA..... | 16 | XHANCE..... | 110 | ZEPOSIA STARTER KIT..... | 52 |
| VIZIMPRO..... | 23 | XIFAXAN..... | 16 | ZEPOSIA STARTER PACK..... | 52 |
| VOGELXO..... | 83 | XIGDUO XR..... | 83, 84 | ZERBAXA..... | 16 |
| VONJO..... | 23 | XIIDRA..... | 105 | ZERVIA TE..... | 105 |
| <i>voriconazole</i> | 16 | XIMINO..... | 16 | ZESTORETIC..... | 64 |
| VOSEVI..... | 16 | XOFLUZA..... | 16 | ZESTRIL..... | 64 |
| VOTRIENT..... | 23 | XOLAIR..... | 111 | ZETIA..... | 64 |
| VOXZOGO..... | 83 | XOLEGEL..... | 72 | ZETONNA..... | 111 |
| VRAYLAR..... | 51 | XOPENEX..... | 111 | ZIAC..... | 64 |
| VTAMA..... | 72 | XOPENEX CONCENTRATE | | ZIAGEN..... | 16 |
| VTOL LQ..... | 51 | | 111 | ZIANA..... | 72 |
| VUITY..... | 105 | XOPENEX HFA..... | 111 | <i>zidovudine</i> | 16 |
| VUMERITY..... | 51 | XOSPATA..... | 23 | ZIEXTENZO..... | 93 |
| VYFEMLA (28)..... | 102 | XPOVIO..... | 23 | <i>zileuton</i> | 111 |
| VYLIBRA..... | 102 | XTAMPZA ER..... | 52 | ZILXI..... | 72 |
| VYNDAMAX..... | 63 | XTANDI..... | 23 | ZIMHI..... | 52 |
| VYNDAQEL..... | 63 | XULANE..... | 102 | ZIOPTAN (PF)..... | 105 |
| VYTORIN 10-10..... | 63 | XULTOPHY 100/3.6..... | 84 | <i>ziprasidone hcl</i> | 52 |
| VYTORIN 10-20..... | 63 | XURIDEN..... | 75 | <i>ziprasidone mesylate</i> | 52 |
| VYTORIN 10-40..... | 63 | XYOSTED..... | 84 | ZIPSOR..... | 52 |
| VYTORIN 10-80..... | 63 | XYREM..... | 52 | ZIRGAN..... | 106 |
| VYVANSE..... | 51 | XYWAV..... | 52 | ZITHROMAX..... | 16 |
| VYZULTA..... | 105 | YASMIN (28)..... | 102 | ZITHROMAX TRI-PAK..... | 16 |
| WAKIX..... | 51 | YAZ (28)..... | 102 | ZITHROMAX Z-PAK..... | 16 |
| <i>warfarin</i> | 63 | YF-VAX (PF)..... | 93 | ZOCOR..... | 64 |
| WELCHOL..... | 63 | YONSA..... | 24 | ZOLINZA..... | 24 |
| WELIREG..... | 23 | YUPELRI..... | 111 | <i>zolmitriptan</i> | 52 |
| WELLBUTRIN SR..... | 51 | YUVAFEM..... | 102 | ZOLOFT..... | 52 |
| WELLBUTRIN XL..... | 51 | ZAFEMY..... | 102 | <i>zolpidem</i> | 52 |
| WINLEVI..... | 72 | <i>zafirlukast</i> | 111 | ZOMACTON..... | 93 |
| WIXELA INHUB..... | 110 | <i>zaleplon</i> | 52 | ZOMIG..... | 52 |
| WYMZYA FE..... | 102 | ZANAFLEX..... | 52 | ZONALON..... | 72 |
| XALATAN..... | 105 | ZARONTIN..... | 52 | ZONEGRAN..... | 53 |
| XALKORI..... | 23 | ZARXIO..... | 93 | <i>zonisamide</i> | 53 |

| | |
|-------------------------------|------------|
| ZONTIVITY | 64 |
| ZORBTIVE | 93 |
| ZORTRESS | 24 |
| ZOSYN IN DEXTROSE | |
| (ISO-OSM) | 16 |
| ZOVIA 1-35 (28) | 102 |
| ZOVIRAX | 16, 72, 73 |
| ZTLIDO | 73 |
| ZUBSOLV | 53 |
| ZYCLARA | 73 |
| ZYDELIG | 24 |
| ZYFLO | 111 |
| ZYKADIA | 24 |
| ZYLET | 106 |
| ZYLOPRIM | 96 |
| ZYMAXID | 106 |
| ZYPITAMAG | 64 |
| ZYPREXA | 53 |
| ZYPREXA RELPREVV | 53 |
| ZYPREXA ZYDIS | 53 |
| ZYTIGA | 24 |
| ZYVOX | 16, 17 |

acitretin

Products Affected

- *acitretin*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

actemra

Products Affected

- **ACTEMRA ACTPEN**
- **ACTEMRA SUBCUTANEOUS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For rheumatoid arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide). For giant cell arteritis, patients must have an adequate trial or intolerance to one systemic corticosteroid (e.g., prednisone). For polyarticular juvenile idiopathic arthritis, patients must have an inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For systemic sclerosis-associated interstitial lung disease (SSc-ILD), patients must have an adequate trial or intolerance to one immunosuppressant (e.g., mycophenolate mofetil, corticosteroids, azathioprine, cyclophosphamide). Documentation of systemic juvenile idiopathic arthritis. |
| Age Restrictions | Deny if less than 18 years of age for systemic sclerosis-associated interstitial lung disease (SSc-ILD), Rheumatoid Arthritis, and Giant Cell Arteritis or less than 2 years of age for Polyarticular Juvenile Idiopathic Arthritis and Systemic Juvenile Idiopathic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

acthar h.p.

Products Affected

- ACTHAR

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Covered for the following indications: 1. Infantile spasms (West syndrome) in children less than 2 years of age. 2. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 3. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 4. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 5. Dermatologic diseases 6. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction 7. Ophthalmic diseases 8. Respiratory diseases 9. Gout and unable to take first-line therapies. 10. Pediatric acquired epileptic aphasia. 11. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). 12. Diagnosis for adrenal insufficiency with trial/failure or contraindication to cosyntropin. For covered indications 2 through 10, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Gout |

actimmune

Products Affected

- ACTIMMUNE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Adbry

Products Affected

- ADBRY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe atopic dermatitis, documentation of all of the following (1-2): 1) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- atopic dermatitis of the face or anogenital involvement -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply - OR- severe atopic dermatitis evidenced by severely damaged skin 2) trial & failure, intolerance, or contraindication to topical tacrolimus or topical pimecrolimus -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For Atopic Dermatitis, patients must have an adequate trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of positive clinical response to therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ADHD Drugs

Products Affected

- *clonidine hcl oral tablet extended release 12 hr* • **KAPVAY**
- *guanfacine oral tablet extended release 24 hr*
- **INTUNIV ER**

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Adlarity

Products Affected

- ADLARITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- one of the following (1 or 2): 1) therapeutic failure or intolerance to donepezil tablets, 2) Unable to take daily oral donepezil due to impaired memory. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

afinitor

Products Affected

- **AFINITOR** *mg, 2.5 mg, 5 mg, 7.5 mg*
- **AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG** • *everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg*
- *everolimus (antineoplastic) oral tablet 10*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy 4) Candidacy for surgical resection |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Afinitor, documentation of failure on generic everolimus tablets is required. For brand Afinitor Disperz, documentation of failure on generic everolimus tablets for suspension is required |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

aimovig

Products Affected

- **AIMOVIG AUTOINJECTOR
SUBCUTANEOUS AUTO-INJECTOR
140 MG/ML, 70 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in average monthly migraine days or number of migraine episodes is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

airduo digihaler

Products Affected

- AIRDUO DIGIHALER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of asthma -AND- Inadequate response to non-digitized LABA/ICS inhaler-AND- Attestation that a digital inhaler is required. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ajovy

Products Affected

- AJOVY AUTOINJECTOR
- AJOVY SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in average monthly migraine days or number of migraine episodes is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

alecensa

Products Affected

- ALECENSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

alkindi

Products Affected

- **ALKINDI SPRINKLE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of adrenocortical insufficiency -AND- Therapeutic failure or intolerance to oral generic hydrocortisone tablets. |
| Age Restrictions | Deny if greater than 17 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ALPHA1-PROTEINASE INHIBITORS

Products Affected

- ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS
- RECON SOLN
- ZEMAIRA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of panacinar emphysema AND documentation of a decline in forced expiratory volume in 1 second (fev1) despite optimal medical therapy (bronchodilators, corticosteroids, oxygen if indicated) AND documentation of phenotype (pi*zz, pi*znull or pi*nullnull) associated with causing serum alpha 1-antitrypsin of less than 80 mg/dl AND documentation of an alpha 1-antitrypsin serum level below the value of 35% of normal (less than 80 mg/dl). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Covered under Part B when furnished incident to a physician service and is not self-administered. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

alunbrig

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLETS,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK) positive |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Amlodipine Liquid

Products Affected

- NORLIQVA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Inability to swallow amlodipine tablets |
| Age Restrictions | Deny if less than 6 years of age for Hypertension |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ampyra

Products Affected

- AMPYRA
- *dalfampridine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | History of seizure disorder, Cr Cl less than 50ml/min |
| Required Medical Information | Documentation of diagnosis -AND- documentation that the patient is ambulatory and has walking impairment as evidenced by one of the following. 1. Functional status score (EDSS score). 2. Timed 25-foot Walk Test (T25W). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For brand Ampyra, documentation of failure on generic dalfampridine. For reauthorization, documentation supporting improvement in walking impairment from baseline is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

anabolic steroids

Products Affected

- **METHITEST**
- *methyltestosterone oral capsule*
- *oxandrolone*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis (methyltestosterone, oxandrolone)-AND- For the diagnosis of osteoporosis (oxandrolone) the trial/failure, intolerance or contraindication to at least 2 federal legend drugs indicated for use in osteoporosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

apokyn

Products Affected

- **APOKYN**
- *apomorphine*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to the following (1. and 2.): 1) a generic pramipexole containing product or a generic ropinirole containing product. 2) generic entacapone, selegiline or rasagiline. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

arikayce

Products Affected

- ARIKAYCE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Mycobacterium avium complex lung disease -AND- attestation of not achieving negative sputum cultures despite at least 6 months with a multidrug background regimen containing a macrolide - AND- Arikayce will be used in conjunction with a background multidrug regimen. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 18 months |
| Other Criteria | For reauthorization, attestation of positive sputum cultures -OR- negative sputum cultures for insufficient period of time (e.g. less than 12 months). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

armonair digihaler

Products Affected

- ARMONAIR DIGIHALER

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of asthma -AND- Inadequate response to non-digitized ICS inhaler-AND- Attestation that a digital inhaler is required. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Aspruzyo Sprinkle

Products Affected

- ASPRUZYO SPRINKLE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic angina -AND- Therapeutic failure, contraindication, or intolerance to one beta-blocker (e.g., propranolol oral solution, metoprolol tartrate, propranolol immediate-release) -AND- Inability to swallow generic ranolazine tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

attr-cm drugs

Products Affected

- VYNDAMAX
- VYNDAQEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) with amyloid deposits on cardiac biopsy or scintigraphy with heart contralateral greater than 1.5 (Grade III) -AND- Cardiac involvement supported by cardiac magnetic resonance, echocardiography or serum cardiac biomarker (e.g. B-type natriuretic peptide, cardiac troponin) - AND- Primary (light chain) amyloidosis has been ruled out by immunohistochemistry, mass spectrometry or scintigraphy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement or delayed disease progression from baseline demonstrated by 6-minute walk test, cardiac function (e.g. LVEF, NYHA class), Kansas City Cardiomyopathy Questionnaire-Overall Summary, number of cardiovascular-related hospitalizations or serum cardiac biomarkers (e.g. B-type natriuretic peptide, cardiac troponin) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

atypical antipsychotics

Products Affected

- ABILIFY MYCITE ORAL TABLET WITH SENSOR AND PATCH 10 MG, 15 MG, 20 MG, 5 MG
- ABILIFY ORAL TABLET
- *aripiprazole*
- REXULTI

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If medication is being used for major depressive disorder, documentation of adjunctive therapy and an adequate trial of 1 alternative antidepressant is required (e.g. SSRI, SNRI, NDRIs, TCA, MAOI). For Rexulti, trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

aubagio

Products Affected

- AUBAGIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of Aubagio and other disease modifying agents such as fingolimod, interferons, Copaxone, Tysabri |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

auryxia

Products Affected

- AURYXIA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | Treatment of iron deficiency anemia |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

austedo

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1-3) 1) Chorea associated with Huntington's disease 2) In patients with comorbid depression, attestation of adequate treatment for depression is required. 3) Attestation that patient is not actively suicidal. -OR- 4) Tardive Dyskinesia |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ayvakit

Products Affected

- AYVAKIT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For unresectable or metastatic Gastrointestinal Stromal Tumor (GIST), PDGFRA exon 18 mutation status. For Advanced Systemic Mastocytosis (AdvSM), platelet count greater than or equal to $50 \times 10^9/L$ AND aggressive systemic mastocytosis, systemic mastocytosis with an associated hematological neoplasm (SM-AHN), or Mast cell leukemia (MCL). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

bafiertam

Products Affected

- **BAFIERTAM**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

balversa

Products Affected

- **BALVERSA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR3 or FGFR2 mutation status as detected by an FDA approved test 2) alternatives tried/failed within labelled time frame |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

banzel

Products Affected

- **BANZEL**
- *rufinamide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Patients with familial short QT syndrome |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- an adequate trial or intolerance of a previous antiepileptic therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

belbuca

Products Affected

- BELBUCA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| | |
|-----------------------|-------------------------------|
| PA Criteria | Criteria Details |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

benlysta

Products Affected

- BENLYSTA SUBCUTANEOUS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of active systemic lupus erythematosus (SLE) -AND- documentation of positive anti-nuclear antibody (ANA) titer (greater than or equal to 1:80) or anti-double-stranded DNA antibody (anti-dsDNA) greater than or equal to 30IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment with use of at least one of the following (alone or in combination): 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -OR- Documentation of active lupus nephritis -AND- documentation of positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- member will continue to receive concomitant standard of care treatment which includes corticosteroids (e.g. prednisone) with at least one of the following: 1.) mycophenolate for induction followed by mycophenolate for maintenance 2.) cyclophosphamide for induction followed by azathioprine for maintenance</p> |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | For reauthorization, attestation of positive clinical response is required. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

benznidazole

Products Affected

- *benznidazole*

| PA Criteria | Criteria Details |
|-------------------------------------|-----------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | Deny if less than 2 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 2 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

berinert

Products Affected

- **BERINERT INTRAVENOUS KIT**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy |
| Required Medical Information | <p>For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p> |
| Age Restrictions | Deny if less than 5 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------------|
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Besremi

Products Affected

- **BESREMI**

| PA Criteria | Criteria Details |
|-------------------------------------|--------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of polycythemia vera |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

bonjesta

Products Affected

- **BONJESTA**
- **DICLEGIS**
- *doxylamine-pyridoxine (vit b6)*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 9 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

bosulif

Products Affected

- **BOSULIF**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND all of the following, if applicable to diagnosis: 1) phase of CML 2) Philadelphia chromosome status 3) alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

braftovi

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Use in wild-type BRAF melanoma or wild-type BRAF CRC |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) alternatives tried/failed 3) concomitant therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

bronchitol

Products Affected

- BRONCHITOL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis -AND- Passed a Bronchitol Tolerance Test -AND- Used in conjunction with standard therapies for the management of cystic fibrosis to improve pulmonary function (e.g. bronchodilators, antibiotics, anti-inflammatory therapy). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of increase in FEV1 |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

brukinsa

Products Affected

- **BRUKINSA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

buphenyl

Products Affected

- **BUPHENYL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment of acute hyperammonemia in urea cycle disorders |
| Required Medical Information | Documentation of chronic management of urea cycle disorders involving deficiencies of carbamylphosphate synthetase, argininosuccinic acid synthetase, or ornithine transcarbamylase. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

butrans

Products Affected

- *buprenorphine*
- **BUTRANS**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of moderate to severe chronic pain -AND- trial and failure of at least two previous federal legend medications for pain, including NSAIDs, tramadol, or opioid analgesics. For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxant (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1)Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2)Patient is not long acting opioid naive. 3)Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4)Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5)Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| | |
|-----------------------|-------------------------------|
| PA Criteria | Criteria Details |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Bylvay

Products Affected

- **BYLVAY ORAL CAPSULE 1,200 MCG, 400 MCG**
- **BYLVAY ORAL PELLETT 200 MCG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following diagnoses (1-2): 1) progressive familial intrahepatic cholestasis confirmed by genetic testing, 2) pruritis - AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cablivi

Products Affected

- **CABLIVI INJECTION KIT**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of acquired thrombocytopenic purpura (aTTP) -AND- Used in conjunction with plasma exchange and immunosuppressive therapy (i.e. systemic corticosteroids or rituximab) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 75 days initial authorization, 28 days reauthorization |
| Other Criteria | For reauthorization, attestation of remaining signs and symptoms of persistent disease (e.g. suppressed ADAMTS 13 activity level remain present) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cabometryx

Products Affected

- **CABOMETRYX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) alternatives tried/failed 2) attestation of first line use 3) concomitant therapy 4) radioactive iodine refractory status |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

calquence

Products Affected

- CALQUENCE
- CALQUENCE (ACALABRUTINIB MAL)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Camzyos

Products Affected

- CAMZYOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy -AND- Left ventricular ejection fraction of greater than or equal to 55% -AND- Valsalva left ventricular outflow tract peak gradient of greater than or equal to 50 mmHg at rest or after provocation -AND- Therapeutic failure or intolerance to one of the following (1 or 2) or contraindication to all: 1) Non-vasodilating beta blocker (e.g. metoprolol) 2) non-dihydropyridine calcium channel blocker (e.g. diltiazem) -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement in pV02 by greater than or equal to 1.5 mL/kg/min plus at least 1 NYHA class reduction or improvement in pV02 by greater than or equal to 3.0 mL/kg/min without NYHA class worsening -AND- Not currently treated with and attestation Camzyos will not be used concomitantly with disopyramide, ranolazine, or combination therapy of beta-blocker and calcium channel blocker |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

caplyta

Products Affected

- CAPLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

caprelsa

Products Affected

- CAPRELSA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

carac

Products Affected

- CARAC

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Trial and failure of 1 generic fluorouracil topical product (with shared indication) is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

carbaglu

Products Affected

- **CARBAGLU**
- *carglumic acid*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use as an adjunct therapy for acute hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency, propionic acidemia (PA), or methylmalonic acidemia (MMA) -OR- maintenance therapy for chronic hyperammonemia due to hepatic enzyme N-acetylglutamate synthase (NAGS) deficiency |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

carbinoxamine

Products Affected

- *carbinoxamine maleate oral liquid*
- *carbinoxamine maleate oral tablet 4 mg*
- **RYVENT**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Failure, contraindication or intolerance to 2 antihistamines indicated for diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

CERDELGA

Products Affected

- CERDELGA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of type 1 Gaucher disease confirmed by the following A. or B. A) With one of the following symptoms (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm ³ . 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B) Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles -AND- Documentation of CYP2D6 metabolizer status (e.g. intermediate metabolizer). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

CF drugs

Products Affected

- **BETHKIS**
 - **PULMOZYME**
 - **TOBI**
 - **TOBI PODHALER INHALATION**
- CAPSULE, W/INHALATION DEVICE**
- *tobramycin in 0.225 % nacl*
 - *tobramycin inhalation*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of cystic fibrosis. For Bethkis: failure on, intolerance to, or contraindication to generic tobramycin inhalation solution |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Inhalation solutions covered under Part B when administered in the home setting using a covered nebulizer (i.e. DME). For reauthorization of tobramycin products, attestation of decrease in sputum density of pseudomonas aeruginosa, increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations. For reauthorization of Pulmozyme, attestation of increase in FEV1 or decrease in number of hospitalizations or pulmonary exacerbations. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

chenodal

Products Affected

- **CHENODAL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of radiolucent gallstones AND an inadequate response or intolerance to ursodiol tablets |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months for initial approval with an additional 12 months upon renewal |
| Other Criteria | Safety of use beyond 24 months is not established. For reauthorization, attestation of partial dissolution of gallstones |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

chloroquine

Products Affected

- *chloroquine phosphate oral tablet 250 mg, 500 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If using for diagnosis of malaria prophylaxis, documentation of duration of travel is required. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Malaria tx and amebiasis: 1 month. Malaria prophylaxis: Travel duration plus 10 wks |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cholbam

Products Affected

- CHOLBAM

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of bile acid synthesis disorders due to single enzyme defects (e.g. AKR1D1, CTX, CYP7A1) -OR- documentation of use as adjunctive therapy for peroxisomal disorders (PDs), including Zellweger spectrum disorders, in patients who exhibit manifestations of liver disease, steatorrhea, or complications from decreased fat soluble vitamin absorption. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cialis

Products Affected

- **CIALIS ORAL TABLET 2.5 MG, 5 MG**
- *tadalafil oral tablet 2.5 mg, 5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of benign prostatic hyperplasia (BPH) and trial/failure of at least two alternative medications in the following classes (alpha-1 adrenergic blockers and/or 5-alpha reductase inhibitors) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Cialis, trial and failure of generic tadalafil is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Cibinqo

Products Affected

- CIBINQO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of all of the following (1-2): 1) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- atopic dermatitis of the face or anogenital involvement -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin, 2) trial & failure, intolerance, or contraindication to topical tacrolimus or topical pimecrolimus -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Atopic Dermatitis, patients must have an adequate trial/failure, intolerance, or contraindication to both preferred products: Dupixent and Rinvoq. For reauthorization, attestation of positive clinical response to therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cimzia

Products Affected

- **CIMZIA**
- **CIMZIA POWDER FOR RECONST**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). For moderate to severe Crohn's disease, inadequate response or intolerance to at least two immunosuppressants (e.g. corticosteroids, azathioprine). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to two nonsteroidal anti-inflammatory drugs (NSAIDs). For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | <p>For Crohn's disease, patients must have an adequate trial or intolerance to both preferred biologic products, Humira and Stelara. For Rheumatoid arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For plaque psoriasis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Skyrizi and Enbrel. For ankylosing spondylitis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For Psoriatic arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Cosentyx, Enbrel, Humira, Xeljanz/Xeljanz XR, Otezla, and Stelara. For initial and induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended initial and induction therapy dosing regimens per indication.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cinryze

Products Affected

- CINRYZE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

Citalopram Capsule

Products Affected

- *citalopram oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder -AND- citalpram 20 mg has been received for greater than or equal to 7 days -AND- Therapeutic failure or intolerance to generic citalopram tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cometriq

Products Affected

- COMETRIQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of progressive, metastatic medullary thyroid cancer |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Copiktra

Products Affected

- **COPIKTRA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

corlanor

Products Affected

- CORLANOR ORAL SOLUTION
- CORLANOR ORAL TABLET 5 MG, 7.5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND all of the following: 1) Normal sinus rhythm. 2) Resting heart rate greater than or equal to 70 beats per minute. 3) Left ventricular ejection fraction less than or equal to 35 percent, when applicable. 4) In adult patients (greater than or equal to 18 years), trial/failure of maximum tolerated dose of one beta-blocker used for treatment of heart failure (e.g., bisoprolol, carvedilol, metoprolol succinate) OR contraindication to beta-blocker use. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For oral solution, attestation of inability to swallow tablets is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Cosentyx

Products Affected

- **COSENTYX (2 SYRINGES)**
- **COSENTYX PEN (2 PENS)**
- **COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. For enthesitis-related arthritis, inadequate response or intolerance to at least 1 non-biologic disease modifying anti-rheumatic drugs (DMARD), or all are contraindicated. |
| Age Restrictions | Deny if less than 6 years of age for moderate to severe plaque psoriasis -OR- less than 2 years of age for psoriatic arthritis -OR- less than 4 years of age for enthesitis-related arthritis -OR- less than 18 years of age for all other indications |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

cotellic

Products Affected

- COTELLIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF V600E or V600K mutation status 2) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

crinone

Products Affected

- CRINONE

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | Use to promote fertility |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Cysteamine Ophthalmic Drops

Products Affected

- CYSTADROPS
- CYSTARAN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystinosis -AND- Attestation of accumulation of corneal cystine crystals |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

daraprim

Products Affected

- **DARAPRIM**
- *pyrimethamine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For primary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 100 cells/mm ³ -AND- Toxoplasma IgG positive -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For secondary prophylaxis of toxoplasmosis gondii infection, CD4 count less than 200 cells/mm ³ . For secondary prophylaxis of cystoisosporiasis with CD4 count less than 200 cells/mm ³ or acute cystoisosporiasis infection: failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. For primary prophylaxis of Pneumocystis jirovecii pneumonia: diagnosis of HIV - AND- CD4 count less than 200 cells/mm ³ -AND- failure, intolerance or contraindication to trimethoprim-sulfamethoxazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Daraprim, trial and failure of generic pyrimethamine is required. |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

Dartisla ODT

Products Affected

- DARTISLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Documentation of adjunctive therapy -AND- Therapeutic failure or intolerance to generic glycopyrrolate 2 mg tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

daurismo

Products Affected

- **DAURISMO ORAL TABLET 100 MG, 25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of newly diagnosed Acute Myeloid Leukemia -AND- Used in combination with cytarabine -AND- At least one comorbidity that preclude use of intensive induction chemotherapy defined as one of the following: 1) Age greater than or equal to 75 2) Severe cardiac or pulmonary comorbidity 3) Reduced renal function 4) Hepatic impairment 5.) Physician attests patient is not a candidate for intensive induction therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

daytrana

Products Affected

- DAYTRANA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | Deny if less than 6 years of age or greater than 17 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

deferasirox

Products Affected

- *deferasirox*
- **EXJADE**
- **JADENU**
- **JADENU SPRINKLE**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For chronic iron overload due to blood transfusions, transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -And- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw). For Chronic Iron Overload in Non-Transfusion-Dependent Thalassemia (NTDT) Syndrome, LIC of at least 5 mg Fe/g dw -AND- serum ferritin greater than 300 mcg/L. |
| Age Restrictions | Deny if less than 2 years of age for chronic iron overload or less than 10 years of age chronic iron overload in NTDT |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Jadenu and brand Exjade, trial and failure of deferasirox (generic Exjade) is required. For reauthorization of chronic iron overload due to blood transfusion, continued requirement for regular blood transfusions -AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw. For reauthorization of chronic iron overload in NTDT syndrome, LIC greater than or equal to 3 mg Fe/g dw. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

diacomit

Products Affected

- **DIACOMIT ORAL CAPSULE 250 MG, 500 MG**
- **DIACOMIT ORAL POWDER IN PACKET 250 MG, 500 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Dravets syndrome - AND- Used in combination with clobazam |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation supporting reduction in seizure frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

dihydroergotamine

Products Affected

- *dihydroergotamine nasal*
- **MIGRANAL**
- **TRUDHESA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute migraine headaches with or without aura -AND- requires non-oral route of administration -AND- therapeutic failure or intolerance to generic sumatriptan nasal spray. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

dojolvi

Products Affected

- DOJOLVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of molecularly confirmed long-chain fatty acid oxidation disorders |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

doptelet

Products Affected

- **DOPTELET (10 TAB PACK)**
- **DOPTELET (15 TAB PACK)**
- **DOPTELET (30 TAB PACK)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -OR- Documentation of chronic immune thrombocytopenia -AND- Trial, intolerance, or inadequate response to corticosteroid therapy, immunoglobulin therapy or splenectomy -AND- One of the following (1 or 2): 1) Platelet count less than or equal to $50 \times 10^9/L$ and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). 2) Platelets count of less than or equal to $30 \times 10^9/L$ |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | For thrombocytopenia with chronic liver disease- 1 mo. For chronic immune thrombocytopenia- 12 mo. |
| Other Criteria | Platelet count is provided for applicable dosing. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

doxepin cream

Products Affected

- *doxepin topical*
- **PRUDOXIN**
- **ZONALON**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- course of therapy will not exceed 8 days -AND- experienced therapeutic failure, intolerance, or contraindication to one of the following (1 or 2): 1) at least 2 generic formulary topical corticosteroids. 2) generic topical tacrolimus or pimecrolimus for topic dermatitis with the facial or anogenital involvement. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

drizalma

Products Affected

- **DRIZALMA SPRINKLE ORAL
CAPSULE, DELAYED REL SPRINKLE
20 MG, 30 MG, 40 MG, 60 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- inability to swallow capsules. For fibromyalgia, members must also have widespread bilateral pain above and below the waist for greater than 3 months duration -AND- At least one (1) fibromyalgia-related symptom (e.g., cognitive impairment, fatigue, sleep disturbance, neurologic symptoms, exercise intolerance). |
| Age Restrictions | Deny if less than 18 years of age in the treatment of fibromyalgia, major depressive disorder, diabetic peripheral neuropathy and chronic musculoskeletal pain -OR- if less than 7 years of age in generalized anxiety disorder |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

duexis

Products Affected

- **DUEXIS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Duexis2

Products Affected

- *ibuprofen-famotidine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen used in combination with famotidine. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than ibuprofen) used in combination with another generic formulary H2-receptor blocker (other than famotidine). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

duobrii

Products Affected

- DUOBRII

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of plaque psoriasis -AND- therapeutic failure or intolerance to generic tazarotene cream -AND- therapeutic failure or intolerance to 1 high-potency topical corticosteroid (e.g. betamethasone dipropionate 0.05%, halobetasol propionate 0.05%) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

dupixent

Products Affected

- **DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML**
- **DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of all of the following (1-3): 1) moderate to severe atopic dermatitis 2) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- atopic dermatitis of the face or anogenital involvement -OR- the member has severe atopic dermatitis evidenced by a large proportion of the member's body surface area is affected making topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin 3) if 2 years or older: trial & failure, intolerance, or contraindication to topical tacrolimus or topical pimecrolimus -OR- the member has severe atopic dermatitis evidenced by a large proportion of the member's body surface area is affected making topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin -OR- Documentation of the following (4-7): 4) moderate-to-severe asthma 5) documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration 6) Blood eosinophils greater than or equal to 150 cells/uL -OR- patient is currently taking daily or alternate-day oral corticosteroids 7) using a medium- or high-dose inhaled corticosteroid and a long acting beta agonist -OR- Documentation of the following (8-9): 8) chronic rhinosinusitis with nasal polyposis (CRSwNP) 9) trial & failure, intolerance or contraindication to intra-nasal corticosteroid and 14 day course of oral corticosteroids -OR- Documentation of the following (10-13): 10) eosinophilic esophagitis 11) weight at least 40 kg 12) esophageal eosinophil count greater than or equal to 15 eos/hpf on esophageal biopsy 13) clinical symptoms of esophageal dysfunction.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------|---|
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of positive clinical response to therapy, for atopic dermatitis -OR- attestation of decreased in rescue medication or oral corticosteroid use, decrease in frequency of severe asthma exacerbation, increase in pulmonary function from baseline (e.g. FEV1) or reduction in reported asthma related symptoms, for asthma -OR- attestation of decrease in nasal polyp score or reduction in nasal congestion/obstruction severity score, for CRSwNP -OR- attestation of histological remission (less than 15 eos/hpf) on esophageal biopsy or reduced severity or frequency of clinical symptoms of esophageal dysfunction, for EoE |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

egfr tyrosine kinase inhibitors

Products Affected

- *erlotinib*
- **EXKIVITY**
- **GILOTRIF**
- **TARCEVA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Gilotrif: tumors with resistant EGFR mutations. Tarceva: use in NSCLC tumors with mutations other than those in FDA-approved indications. Use in combination with platinum based chemotherapy. |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) Epidermal growth factor receptor (EGFR) mutations, including exon 19 deletions or exon 21 (L858R) substitution mutations 2) Alternatives tried/failed 3) Concomitant therapy 4) Line of therapy in which medication will be used |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Tarceva, trial and failure of generic erlotinib is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

egrifta

Products Affected

- EGRIFTA SV

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of HIV and lipodystrophy, member must actively be receiving antiretroviral therapy including protease inhibitors, nucleoside reverse transcriptase inhibitors, or non-nucleoside reverse transcriptase inhibitors |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Elyxyb

Products Affected

- **ELYXYB**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of migraine -AND- Therapeutic failure or intolerance to two generic nonsteroidal anti-inflammatory drugs (NSAIDs). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of reduction in migraine symptoms. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

emflaza

Products Affected

- EMFLAZA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Duchenne muscular dystrophy (DMD) with mutation of dystrophin gene -AND- onset of weakness or history of DMD starting before age 5 -AND- One of the following (1, 2, or 3). 1) Documented trial/failure, intolerance or contraindication to prednisone. 2) Documented trial of prednisone has resulted in intolerable adverse events (e.g. diabetes, hypertension that is difficult to manage, Cushingoid features, truncal obesity, greater than or equal to 10 percent increase in body weight over a 6 month period). 3) Documented severe behavioral adverse event while on prednisone that warrants prednisone dose reduction impacting efficacy for management of DMD (i.e. abnormal behavior, aggression, irritability, disturbance in mood) |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

emgality

Products Affected

- **EMGALITY PEN**
- **EMGALITY SYRINGE
SUBCUTANEOUS SYRINGE 120
MG/ML, 300 MG/3 ML (100 MG/ML X 3)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Episodic Migraine, defined as 4-14 migraine days per month OR Chronic Migraine, defined as 15 or more headaches per month, the following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound or overutilization (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. For episodic cluster headaches, characterized by severe or very severe unilateral orbital, supraorbital, and/or temporal pain lasting 15 to 180 minutes when left untreated -AND- Attack frequency of at least one attack every other day during the cluster period. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For reauthorization, attestation of reduction in average monthly migraine days or number of migraine episodes is required -OR- attestation of reduction in the number of mean weekly cluster headaches from baseline is required. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

enbrel

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION
- ENBREL SUBCUTANEOUS SYRINGE
25 MG/0.5 ML (0.5), 50 MG/ML (1 ML)
- ENBREL SURECLICK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis or less than 2 years of age for Juvenile Idiopathic Arthritis or Less than 4 years of age for Plaque Psoriasis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

endari

Products Affected

- ENDARI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Sickle Cell Disease with 2 or more sickle cell acute complications (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.) -AND-documentation of previous trial of hydroxyurea or plans of continued therapy while taking Endari |
| Age Restrictions | Deny if less than 5 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of stability in sickle cell acute complications or decrease in number of sickle cell acute complications is required (e.g. vaso-occlusive crisis, acute anemia, acute chest syndrome, etc.) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

enspryng

Products Affected

- ENSPRYNG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of neuromyelitis optica spectrum disorder (NMOSD) - AND- Attestation of anti-aquaporin-4 (AQP4) antibody positive -AND- Not used in combination with another monoclonal antibody used for the treatment of NMOSD. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decrease in number of NMOSD relapses. For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Entadfi

Products Affected

- ENTADFI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use for the initial treatment of benign prostatic hyperplasia (BPH) -AND- Trial/failure of finasteride used in combination with tadalafil. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | For reauthorization, attestation that the member is reinitiating treatment for BPH. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

epclusa

Products Affected

- **EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG, 200-50 MG**
- **EPCLUSA ORAL TABLET**
- *sofosbuvir-velpatasvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

epidiolex

Products Affected

- EPIDIOLEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Lennox-Gastaut, Dravet syndromes or Tuberous Sclerosis Complex. For Lennox-Gastaut, trial and failure or intolerance of at least two standard of care treatments (e.g. lamotrigine, clobazam). For Lennox-Gastaut and Dravet syndromes, treatment is in combination with other conventional agents. |
| Age Restrictions | Deny if less than 1 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation supporting reduction in seizure frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Eprontia

Products Affected

- **EPRONTIA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- inability to swallow pills or food. For migraine, therapeutic failure, intolerance, or contraindication to two generic preventive migraine therapies. For partial onset seizures, primary generalized tonic-clonic seizures, or adjunctive treatment of Lennox-Gastaut Syndrome, therapeutic failure, contraindication, or intolerance to two generic anti-epileptic drugs. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

erivedge

Products Affected

- ERIVEDGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced basal cell carcinoma (BCC), which includes metastatic -OR- locally advanced basal cell carcinoma, for whom surgery is inappropriate or in whom recurrence after surgery is documented - AND- is not a candidate for radiation |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

erleada

Products Affected

- ERLEADA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- the member meets one of the following (1 or 2) 1. Documentation of use in combination with a GnRH analog -OR- 2. The member has had a bilateral orchiectomy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

eucrisa

Products Affected

- EUCRISA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1 and 2): 1) mild to moderate atopic dermatitis 2) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement |
| Age Restrictions | Deny if less than 3 months of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | If 2 years of age or older, therapeutic failure of one of the following is required: topical tacrolimus -OR- topical pimecrolimus. Reauthorization or continuation of therapy will be approved when documentation of improvement or response to therapy is provided. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

evekeo

Products Affected

- *amphetamine sulfate*
- **EVEKEO**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Obesity |
| Required Medical Information | Documentation of diagnosis. For narcolepsy the following are required: Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B)Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. |
| Age Restrictions | Deny if less than 6 years of age for narcolepsy or 3 years of age for ADHD |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For narcolepsy, trial and failure, intolerance to 2 of the following generic alternatives is required: immediate release amphetamine/dextroamphetamine, dextroamphetamine, and methylphenidate. For ADHD, trial/failure or intolerance to 2 unique generic stimulants (e.g. methylphenidate) is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

evenity

Products Affected

- **EVENITY SUBCUTANEOUS SYRINGE
210MG/2.34ML (105MG/1.17MLX2)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Postmenopausal woman at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. A cumulative lifetime approval of romosozumab will be limited to a coverage duration of 12 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

evrysdi

Products Affected

- EVRYSDI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of spinal muscular atrophy -AND- Baseline motor function test results (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT) -AND- Not using concomitantly with Spinraza -AND- Molecular genetic testing of 5q SMA showing Homozygous gene deletion, Homozygous conversion mutation or Compound heterozygote |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | For reauthorization, attestation of stable or clinically significant improvement in Spinal Muscular Atrophy associated symptoms (e.g. stabilization or decreased decline in motor function compared to the predicted natural history trajectory of disease) -OR- Stable or improved motor function results compared to baseline (e.g. MFM, CHOP, HINE, RULM, HFMSE, 6MWT). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Exservan

Products Affected

- **EXSERVAN**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of stability or improvement in symptoms of ALS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

fasenra

Products Affected

- FASENRA
- FASENRA PEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of severe asthma -AND- history of at least one asthma exacerbations requiring oral or systemic corticosteroid treatment in the past 12 months -AND- documented pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration despite regular treatment with (a. or b.): a) high dose inhaled corticosteroid and additional asthma controller medication or b.) a medium or high dose inhaled corticosteroid plus a long-acting beta agonist with or without oral corticosteroids and additional asthma controller medication |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Blood eosinophil count (in the absence of other potential causes of eosinophilia, including hypereosinophilic syndromes, neoplastic disease, and known or suspected parasitic infection) greater than or equal to 150 cells/microliter within 6 weeks of initiation of therapy. For induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ferriprox

Products Affected

- *deferiprone*
- **FERRIPROX**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of transfusional iron overload due to thalassemia syndromes, sickle cell disease and other anemias -AND- transfusion history of greater than or equal to 100 mL/kg of packed red blood cells (i.e. at least 20 units of packed red blood cells for a 40 kg person or more in individuals weighing more than 40 kg) -AND- history of serum ferritin consistently greater than 1,000 mcg/L or liver iron concentration (LIC) greater than or equal to 7 iron per gram of liver dry weight (mg Fe/g dw) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Trial and failure of deferasirox (generic Exjade) is required. For reauthorization, continued requirement for regular blood transfusions - AND- serum ferritin level greater than or equal to 500mcg/L or LIC greater than or equal to 3 mg Fe/g dw |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

fetzima

Products Affected

- **FETZIMA ORAL CAPSULE,EXT REL HR 120 MG, 20 MG, 40 MG, 80 MG 24HR DOSE PACK**
- **FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder and trial and failure of two other antidepressants. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

fintepla

Products Affected

- FINTEPLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Dravet syndrome or Lennox-Gastaut syndrome. For Lennox-Gastaut syndrome, therapeutic failure, contraindication, or intolerance to at least 2 standard of care treatments (e.g. lamotrigine, clobazam). |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

firazyr

Products Affected

- **FIRAZYR**
- *icatibant*
- **SAJAZIR**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy |
| Required Medical Information | For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Firazyr, therapeutic failure, intolerance or contraindication to icatibant. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

firdapse

Products Affected

- **FIRDAPSE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

flector

Products Affected

- *diclofenac epolamine*
- **FLECTOR**
- **LICART**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND one of the following (1,2 or 3): 1) trial/failure, intolerance, or contraindication to 2 oral generic NSAIDs one of which must be diclofenac 2) hypersensitivity to oral NSAIDs 3) history or high risk for adverse gastrointestinal effects associated with oral NSAID use. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Fleqsuvy

Products Affected

- FLEQSUVY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

forteo

Products Affected

- **FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML)**
- *teriparatide*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Additional documentation of trial/failure, intolerance or contraindication to preferred parathyroid hormone analog Tymlos is required for applicable indication. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Forteo/teriparatide will be limited to a coverage duration of 24 months in the absence of provider attestation that the member remains at or has returned to having a high risk for fracture |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Fotivda

Products Affected

- FOTIVDA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if applicable to diagnosis, previous therapies tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gabapentin

Products Affected

- *gabapentin oral capsule 100 mg, 300 mg, 400 mg*
- *gabapentin oral solution 250 mg/5 ml*
- *gabapentin oral tablet 600 mg, 800 mg*
- **NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG**
- **NEURONTIN ORAL SOLUTION**
- **NEURONTIN ORAL TABLET 600 MG, 800 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

galafold

Products Affected

- GALAFOLD

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Fabry disease confirmed by biochemical or genetic test -AND- Presence of an amenable GLA variant causing Fabry disease in the clinical context of the patient -AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy - AND- Will not be used concomitantly with enzyme replacement therapy (ERT) e.g. Fabrazyme. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gattex

Products Affected

- **GATTEX 30-VIAL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of short bowel syndrome (SBS) having less than 200 cm of functional small bowel AND if age 18 and older, dependence on parenteral nutrition or intravenous nutritional support for at least 12 months AND requiring parenteral nutrition at least 3 times per week -OR- Documentation of SBS having less than 200 cm of functional small bowel AND age 1 to 17 years of age AND Dependence on parenteral nutrition AND weight of at least 10 kg. |
| Age Restrictions | Deny if less than 1 year of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gavreto

Products Affected

- **GAVRETO**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET mutant or fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate) |
| Age Restrictions | Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gilenya

Products Affected

- *fingolimod*
- **GILENYA ORAL CAPSULE 0.5 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of Gilenya and other disease modifying agents such as interferons, Copaxone, Tysabri |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gimoti

Products Affected

- **GIMOTI**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute or recurrent diabetic gastroparesis -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Therapeutic failure or intolerance to generic metoclopramide tablets or generic metoclopramide solution -AND- If over 65 years of age, member was titrated to a stable dose of metoclopramide tablets or solution at 10mg four times a day before switching to Gimoti therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 weeks |
| Other Criteria | For reauthorization, treatment is for a new episode of diabetic gastroparesis -AND- There has been a 2 week drug holiday without Gimoti since its last administration -AND- Attestation of no signs or symptoms of tardive dyskinesia -AND- Attestation that extended therapy with Gimoti outweighs risk of developing tardive dyskinesia. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gleevec

Products Affected

- **GLEEVEC ORAL TABLET 100 MG, 400 MG**
- *imatinib oral tablet 100 mg, 400 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and all of the following, if applicable to diagnosis 1) Alternatives tried 2) Concomitant therapy 3) mutation status, if applicable to diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Glycate

Products Affected

- **GLYCATE**
- *glycopyrrolate oral tablet 1.5 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of using as an adjunctive treatment for peptic ulcer disease -AND- Therapeutic failure or intolerance to generic glycopyrrolate 1mg tablet |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 Months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy - AND- Additional courses of therapy are required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

gocovri

Products Affected

- **GOCOVRI ORAL
CAPSULE,EXTENDED RELEASE 24HR
137 MG, 68.5 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For dyskinesia associated with Parkinson's disease, documentation of concurrent levodopa-based therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine. For off-episodes of Parkinson's disease, documentation of concurrent carbidopa/levodopa therapy -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine -AND- trial and failure, contraindication, or intolerance to one (1) of the following agents: entacapone, pramipexole, rasagiline, ropinirole, or selegiline. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Gralise

Products Affected

- **GRALISE ORAL TABLET EXTENDED
RELEASE 24 HR 300 MG, 600 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of postherpetic neuralgia (PHN) -AND- Trial and failure or intolerance to generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

grastek

Products Affected

- **GRASTEK**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy |
| Required Medical Information | Documentation of allergic rhinitis and use for Timothy grass pollen or cross reactive grass pollens (Sweet Vernal, Orchard, Perennial Rye, Timothy, Kentucky Blue Grass pollen, Redtop, or meadow fescue) -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent |
| Age Restrictions | Deny if less than 5 years of age or greater than 65 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

growth hormone

Products Affected

- **GENOTROPIN**
- **GENOTROPIN MINIQUICK**
- **HUMATROPE INJECTION CARTRIDGE**
- **NORDITROPIN FLEXPPO**
- **NUTROPIN AQ NUSPIN**
- **OMNITROPE**
- **SAIZEN**
- **SAIZEN SAIZENPREP**
- **SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG**
- **SKYTROFA**
- **ZOMACTON**
- **ZORBTIVE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis, growth chart, bone age, growth velocity, response to stimulation test, when applicable to meet standard diagnostic criteria. Additionally Diagnoses and criteria applicable to Somatropin products (1-3): 1) For growth failure due to chronic kidney disease, glomerular filtration rate is less than 89ml/min per 1.73m*2. 2) For HIV wasting and cachexia, Concurrent use of antiretroviral therapy -AND- weight loss of at least 10 percent from baseline. 3) For short bowel syndrome, receiving optimal management for short bowel syndrome, including specialized nutritional support -AND- less than 200 cm of functional small bowel. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines. Criteria applicable to Somatropin products (1-2): 1) For reauthorization of HIV wasting and cachexia, attestation of increase in weight from start of therapy. 2) For reauthorization of short bowel syndrome, continued dependence on parenteral nutrition/intravenous nutritional support -AND- attestation of increase in weight from baseline or decrease in intravenous parenteral nutrition requirements from baseline. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

haegarda

Products Affected

- HAEGARDA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | <p>For the prophylactic treatment of abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the prophylactic treatment of acute abdominal, facial, or laryngeal attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p> |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

HARVONI

Products Affected

- **HARVONI ORAL PELLETS IN PACKET**
- **HARVONI ORAL TABLET 90-400 MG**
- *ledipasvir-sofosbuvir*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

hemady

Products Affected

- **HEMADY**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of multiple myeloma -AND- used in combination with other anti-myeloma agents -AND- therapeutic failure or intolerance to generic dexamethasone. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

HETLIOZ

Products Affected

- HETLIOZ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of Non-24 Sleep-Wake disorder in patient that is totally blind -AND- evidenced by all the following (1 through 4): 1) history of insomnia, excessive daytime sleepiness, or both alternating with asymptomatic episodes 2) symptoms persistent for at least 3 months 3) daily sleep logs for at least 1 month demonstrating a sleep/wake pattern that delays each day 4) sleep disturbances are not better explained by another current disorder or medication/substance use -OR- Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning) |
| Age Restrictions | Deny if less than 16 years of age for nighttime sleep disturbances in Smith-Magenis Syndrome or deny if less than 18 years of age for Non-24 Hour Sleep-Wake Disorder |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of increased total nighttime sleep or decreased daytime nap duration for Non-24 Sleep-Wake disorder -OR- attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Hetlioz LQ

Products Affected

- HETLIOZ LQ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of Smith-Magenis Syndrome as confirmed by chromosome analysis -AND- patient is experiencing nighttime sleep disturbances (e.g. difficulty falling asleep, shortened sleep cycles, inability to enter REM sleep, or frequent awaking during the night and early in the morning) |
| Age Restrictions | Deny if less than 3 or greater than 15 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy with minimal side effects for Smith-Magenis Syndrome -AND- member is between 3 and 15 years of age |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

high-risk meds

Products Affected

- *amitriptyline*
- *amitriptyline-chlordiazepoxide*
- **AMRIX**
- **ANAFRANIL**
- *benztropine oral*
- *carisoprodol*
- *chlorzoxazone*
- *clomipramine*
- *cyclobenzaprine oral capsule, extended release 24hr*
- *cyclobenzaprine oral tablet 10 mg, 5 mg, 7.5 mg*
- *cyproheptadine*
- *doxepin oral capsule*
- *doxepin oral concentrate*
- *doxepin oral tablet*
- *ergoloid*
- *ergotamine-caffeine*
- **FEXMID**
- *hydroxyzine hcl oral solution 10 mg/5 ml*
- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate*
- *imipramine hcl*
- *imipramine pamoate*
- **LORZONE**
- *metaxalone*
- **NORGESIC**
- **NORGESIC FORTE**
- *orphenadrine citrate oral*
- *orphenadrine-asa-caffeine oral tablet 25-385-30 mg*
- *perphenazine-amitriptyline*
- *promethazine oral*
- **SILENOR**
- **SOMA**
- *trimipramine*
- **VISTARIL**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For all medications subject to this PA group, the following information (1 through 3) is required: 1. Documentation of diagnosis 2. Explanation of risk-benefit profile favoring use of the high-risk medication 3. Attestation of an intent to monitor and address treatment-related adverse events. For target tricyclic antidepressants (TCAs), in addition to criteria 1 through 3 above, trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs for the same indication, if available, is required (e.g. SSRIs and SNRIs). If using a TCA for a medically-accepted indication not shared by the safer alternatives listed, then no trial of alternatives is required. |
| Age Restrictions | Automatic approval if less than 65 years of age |
| Prescriber Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------|-------------------------------------|
| Coverage Duration | 12 months |
| Other Criteria | Pending CMS Review |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

high-risk meds phenobarbital

Products Affected

- *phenobarbital*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Coverage is not provided for use in sedation/insomnia |
| Required Medical Information | For use in seizures the following are required: 1. Explanation of risk-benefit profile favoring use of the high-risk medication 2. Attestation of an intent to monitor and address treatment-related adverse events. 3. For new starts, the trial and failure or documentation of intolerance or contraindication to at least 2 non-high risk alternative drugs used for seizures (e.g. carbamazepine, lamotrigine) is required. |
| Age Restrictions | Automatic approval if less than 65 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Seizure disorders |

homozygous fh

Products Affected

- JUXTAPID ORAL CAPSULE 10 MG, 20 MG, 30 MG, 5 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of homozygous familial hypercholesterolemia (HoFH) supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene -OR- untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents -AND- The member has a current LDL-C greater than 100mg/dL despite use of maximally tolerated statin OR statin intolerance -AND- The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | Patients must have an adequate trial/failure or contraindication to the preferred product Repatha. For reauthorization, documentation showing an LDL-C reduction on Juxtapid therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

horizant

Products Affected

- **HORIZANT ORAL TABLET
EXTENDED RELEASE 300 MG, 600 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of moderate to severe active primary restless leg syndrome -AND- trial and failure of pramipexole or ropinirole -AND- trial and failure of an additional dopaminergic agent, clonidine or pregabalin -OR- Documentation of post herpetic neuralgia and trial and failure of generic gabapentin. When using concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

humira

Products Affected

- HUMIRA PEN
- HUMIRA PEN CROHNS-UC-HS START
- HUMIRA PEN PSOR-UEVITS-ADOL HS
- HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML
- HUMIRA(CF)
- HUMIRA(CF) PEDI CROHNS
- STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML
- HUMIRA(CF) PEN
- HUMIRA(CF) PEN CROHNS-UC-HS
- HUMIRA(CF) PEN PEDIATRIC UC
- HUMIRA(CF) PEN PSOR-UV-ADOL HS

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). For moderate to severe juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. For uveitis, inadequate response or intolerance to 2 immunosuppressants. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, and Ankylosing Spondylitis or less than 12 years of age for Hidradenitis Suppurative or Less than 6 years of age for Crohn's disease or Less than 5 years of age for Ulcerative Colitis or less than 2 years of age for Juvenile Idiopathic Arthritis and Uveitis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | <p>For Crohn's disease in adults (18 years or older), trial of 2 immunosuppressants (e.g. corticosteroids, azathioprine) or monotherapy with infliximab is required. For Crohn's disease in pediatrics, trial of 1 immunosuppressant (e.g. corticosteroids, azathioprine) or monotherapy with infliximab is required. For plaque psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. For rheumatoid arthritis therapy without concomitant methotrexate, doses above plan quantity limit will be approved aligned with recommended weekly dosing regimen. For pediatric ulcerative colitis and hidradenitis suppurativa, doses above plan quantity limit will be approved to align with recommended dosing regimen. Induction therapy or treatment regimens for other indications are aligned with plan quantity limit on Humira starter kit.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Hyftor

Products Affected

- **HYFTOR**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of tuberous sclerosis complex with facial angiofibromas. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy (e.g. decrease in size of facial angiofibromas, decrease in redness of facial angiofibromas) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Ibrance

Products Affected

- **IBRANCE**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer -AND- meets one of the following (1 or 2): 1) documentation of use with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or men -OR- 2) documentation of use with fulvestrant in patients with disease progression following endocrine therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Ibsrela

Products Affected

- **IBSRELA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of irritable bowel syndrome with constipation -AND- failure or intolerance to Linzess -AND- if member is female, failure or intolerance to lubiprostone. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

iclusig

Products Affected

- ICLUSIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment of newly-diagnosed chronic phase CML |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Philadelphia chromosome status 2) T315I status 3) Alternatives tried/failed 4) Candidacy for other tyrosine kinase inhibitor therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

idhifa

Products Affected

- **IDHIFA ORAL TABLET 100 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA approved test |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Products Affected

- **BIVIGAM**
- **FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 %**
- **GAMMAGARD LIQUID**
- **GAMMAGARD S-D (IGA)**
- **GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **GAMMAPLEX**
- **GAMMAPLEX (WITH SORBITOL)**
- **GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %)**
- **OCTAGAM**
- **PANZYGA**
- **PRIVIGEN**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of diagnosis. For select diagnoses the following apply- 1) For Myasthenia Gravis Syndrome, documentation that the patient is refractory to other standard therapies (e.g., cholinesterase inhibitors, corticosteroids, azathioprine) given in therapeutic doses over at least 3 months OR is intolerant of/has a contraindication to those standard therapies. 2) For Multiple Sclerosis, patient is refractory to other standard therapies (e.g., interferons) given in therapeutic doses over at least 3 months OR is intolerant of/has a contraindication to those standard therapies. 3) For Inflammatory Myopathies, the patient is refractory to corticosteroids given in therapeutic doses over at least 4 months OR is intolerant of/has a contraindication to corticosteroids or immunosuppressants. 4) For CLL with Associated Hypogammaglobulinemia, IgG level less than 600mg/dL or evidence of a specific antibody deficiency or recurrent bacterial infections. 5) For Bone Marrow Transplantation, the member is 20 years of age or older and within the first 100 days after transplantation. 6) For Dermatomyositis/Polymyositis, trial and failure, intolerance, or contraindication to standard first line therapy (i.e. corticosteroids or immunosuppressants). 7) For Pediatric HIV, the patient is less than 13 y.o. who have entry CD4 lymphocyte count greater than or equal to 200/mm³ and IgG less than 400mg/dL OR recurrent bacterial infections. 8) For Guillain-Barre syndrome, impaired function by objective assessment and/or objective findings on physical exam at the time of initial therapy and IVIG therapy must be initiated within 2 weeks of symptom onset. 9) For Autoimmune Mucocutaneous Blistering Diseases (e.g. Stevens-Johnson Syndrome), trial and failure, intolerance, or contraindication to conventional therapy (e.g. corticosteroids) or the patient has rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents.</p> |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Covered under Part B when administered in the home to a member with a diagnosis of primary immunodeficiency disease |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Myasthenia Gravis syndrome, Multiple Sclerosis, Inflammatory Myopathies, Polymyositis, Dermatomyositis, Bone Marrow Transplant, Pediatric HIV, Guillain-Barre syndrome, Autoimmune Mucocutaneous Blistering Diseases |

ilumya

Products Affected

- ILUMYA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For psoriasis, patients must have an adequate trial or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

imbruvica

Products Affected

- **IMBRUVICA ORAL CAPSULE 140 MG, 70 MG**
- **IMBRUVICA ORAL SUSPENSION**
- **IMBRUVICA ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) 17p deletion status 2) Alternatives tried/failed 3) concomitant therapy. For suspension, members must also have an inability to swallow oral tablets or oral capsules. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

inbrija

Products Affected

- **INBRIJA INHALATION CAPSULE,
W/INHALATION DEVICE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use for the treatment of intermittent off episodes of Parkinson's disease while on carbidopa/levodopa |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

increlex

Products Affected

- INCRELEX

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of severe primary IGF-1 deficiency and all of the following: 1) Normal or elevated response (greater than 10 ng/ml) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 2) Serum IGF-1 concentration that is less than or equal to three (3) standard deviations below the normal value based on laboratory reference range. 3) Height less than or equal to three (3) standard deviations below normal (at or below the third percentile for gender and age). 4) If female, bone age less than or equal to 14 years. If male, bone age less than or equal to 16. - OR- Documentation of diagnosis of growth hormone deficiency caused by gene deletion and all of the following: 1) Growth velocity at least 2 standard deviations below the age-appropriate mean or height at least 2.25 standard deviations below the age-appropriate mean. 2) Subnormal response (less than 10 ng/mL) to two (2) of the following standard growth hormone stimulation tests: arginine, clonidine, glucagon, insulin, levodopa, propranolol. 3) Development of neutralizing antibodies to growth hormone product(s). 4) If female, bone age of less than or equal to 14 years. If male, bone age less than or equal to 16. |
| Age Restrictions | Deny if greater than 17 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of growth velocity and bone age, as applicable to meet standard continuation of therapy guidelines |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ingrezza

Products Affected

- **INGREZZA INITIATION PACK**
- **INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of tardive dyskinesia |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

inlyta

Products Affected

- INLYTA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Line of therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

inqovi

Products Affected

- INQOVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation chronic myelomonocytic leukemia. Documentation of de novo or secondary myelodysplastic syndrome -AND- One of the following (1 or 2): 1) French American-British MDS subtypes of refractory anemia, refractory anemia with ringed sideroblasts or refractory anemia with excess blasts. 2) International Prognostic Scoring System group of intermediate-1, intermediate-2 or high-risk. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

inrebic

Products Affected

- **INREBIC**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate-2 or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) -AND- If a new start, baseline platelet count of greater than $50 \times 10^9/L$ |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Baseline platelet count to be provided. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

interferon alfa

Products Affected

- **INTRON A INJECTION RECON SOLN
10 MILLION UNIT (1 ML), 50 MILLION
UNIT (1 ML)**
- **PEGASYS**

| PA Criteria | Criteria Details |
|---|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

interleukin-1b blockers

Products Affected

- ARCALYST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), documentation of need for maintenance of remission. For Recurrent Pericarditis (RP), documentation of trial/failure or intolerance to one, or contraindication to all of the following: oral nonsteroidal anti-inflammatory drug (NSAID), systemic corticosteroid, or colchicine. |
| Age Restrictions | Deny if less than 12 years of age for Recurrent Pericarditis and Cryopyrin-Associated Periodic Syndromes |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For DIRA: patient must weigh 10kg or more |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

intrarosa

Products Affected

- INTRAROSA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

IPF AGENTS

Products Affected

- **ESBRIET ORAL CAPSULE**
 - **ESBRIET ORAL TABLET 267 MG, 801 MG**
 - **OFEV**
- *pirfenidone oral tablet 267 mg, 801 mg*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of idiopathic pulmonary fibrosis -AND- baseline forced vital capacity (FVC) of at least 50% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30%. For Ofev only, documentation of systemic sclerosis-associated interstitial lung disease -AND- baseline forced vital capacity (FVC) of at least 40% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- documentation of a high-resolution chest computed tomography (CT) scan demonstrating greater than or equal to 10% pulmonary fibrosis. For Ofev only, documentation of chronic fibrosing interstitial lung disease with progressive phenotype -AND- high resolution chest computing tomography (HRCT) scan demonstrating greater than 10% fibrosing disease -AND- baseline forced vital capacity (FVC) of at least 45% and a percent predicted diffusing capacity of the lungs of carbon monoxide (DLCO) of at least 30% -AND- disease progression in previous 24 months shown by one of the following : 1. Relative decline in FVC greater than or equal to 10% predicted 2. Relative decline in FVC greater than or equal to 5% but less than 10% predicted and either worsening of respiratory symptoms or increased extent of fibrotic changes on HRCT 3. Worsening of respiratory symptoms and increasing extent of fibrotic changes on HRCT |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

iressa

Products Affected

- **IRESSA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Use in tumors with EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations. |
| Required Medical Information | Documentation of diagnosis -AND- the following: 1) EGFR exon 19 deletion mutations or exon 21 (L858R) mutations as detected by an FDA-approved test |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

isturisa

Products Affected

- **ISTURISA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

itraconazole

Products Affected

- *itraconazole*
- **SPORANOX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If using for diagnosis of onychomycosis, confirmation through positive laboratory testing (e.g. KOH preparation, fungal culture, or nail biopsy) is required. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Onychomycosis: 3 months. All other indications: 3 months initial, 12 months reauth |
| Other Criteria | Documentation of trial/failure or intolerance of amphotericin b must be provided for approval in patients with aspergillosis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

jakafi

Products Affected

- **JAKAFI**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis per an accepted risk stratification tool for myelofibrosis (e.g., International Prognostic Scoring System [IPSS]) and if a new start, baseline platelet count of greater than $50 \times 10^9/L$ -OR- documentation of polycythemia vera and inadequate response or intolerance to hydroxyurea -OR- Documentation of steroid refractory acute graft-versus-host disease and prior therapy with at least one systemic corticosteroid -OR- Documentation of chronic graft-versus-host disease with prior failure of at least one systemic therapy. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Baseline platelet count to be provided. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

jynarque

Products Affected

- JYNARQUE ORAL TABLET
- JYNARQUE ORAL TABLETS, SEQUENTIAL

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of rapidly progressing autosomal dominant polycystic kidney disease defined by one of the following: 1.) Historical decline in eGFR greater than or equal to 5mL/min/1.73 m*2 within a 12 month period. 2.) Decline in eGFR of greater than or equal to 2.5mL/min/1.73m*2 over a period of 5 years. 3.) 5% increase in total kidney volume per year by 3 repeat CT or MRI. 4.) Average kidney length greater than 16.5cm. 5.) Family history of end-stage renal disease before age 58. 6.) Mayo imaging classification of 1C, 1D, or 1E. 7.) Kidney bleeds. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, prescriber attestation of slowed decline of kidney function |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kalydeco

Products Affected

- **KALYDECO ORAL GRANULES IN PACKET 25 MG, 50 MG, 75 MG**
- **KALYDECO ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have one mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to ivacaftor based on clinical and or in vitro assay (e.g. G551D, G1244E, G1349D) |
| Age Restrictions | Granules- Deny if less than 4 months or greater than 5 years of age. Tablets- Deny if less than 6 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Kerendia

Products Affected

- **KERENDIA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | eGFR less than or equal to 25 mL/min/1.73 m ² , serum potassium greater than 5.5 mEq/L |
| Required Medical Information | Documentation of type 2 diabetes mellitus with chronic kidney disease - AND- one of the following (1. or 2.): 1) concomitant use of a sodium-glucose Cotransporter-2 (SGLT2) inhibitor. 2) contraindication or intolerance to at least one SGLT2 inhibitor. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation that signs or symptoms of hyperkalemia are not present. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kesimpta

Products Affected

- **KESIMPTA PEN**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

keveyis

Products Affected

- **KEVEYIS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of one of the following: 1. Primary hyperkalemic periodic paralysis 2. Primary hypokalemic periodic paralysis 3. Related variants of primary periodic paralysis |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 2 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation the number of muscle weakness attacks per week has decreased from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kevzara

Products Affected

- **KEVZARA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have an adequate trial or intolerance to two of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kineret

Products Affected

- **KINERET**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For Deficiency of Interleukin-1 Receptor Antagonist (DIRA), therapeutic failure or intolerance to at least one (1) corticosteroid, or all corticosteroids are contraindicated. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kisqali

Products Affected

- **KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 MG, 600 MG/DAY(200 MG X 3)-2.5 MG**
- **KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1), 400 MG/DAY (200 MG X 2), 600 MG/DAY (200 MG X 3)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following. 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

klisyri

Products Affected

- **KLISYRI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of actinic keratosis of the face or scalp -AND- Therapeutic failure or intolerance to 2 of the following 1) generic imiquimod 5% cream 2) fluorouracil 5% topical cream 3) fluorouracil topical solution |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

korlym

Products Affected

- **KORLYM**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hyperglycemia secondary to hypercortisolism in patients with endogenous Cushing's syndrome -AND- Patient is not a candidate for surgery or where surgery has failed -AND- one of the following (1 or 2): 1) Diagnosis of diabetes with trial and failure, intolerance, or contraindication to one previous therapy for Type 2 Diabetes (e.g. metformin, sulfonylureas, insulin) or using in addition to a therapy for Type 2 diabetes. 2) Glucose intolerance |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

koselugo

Products Affected

- **KOSELUGO ORAL CAPSULE 10 MG,
25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- for neurofibromatosis type 1 (NF1), documentation of symptomatic, inoperable plexiform neurofibromas (PN) |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kuvan

Products Affected

- **JAVYGTOR ORAL POWDER IN PACKET 100 MG**
- **KUVAN**
- *sapropterin*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documented diagnosis of PKU -AND- documented baseline Phe level greater than 6 mg/dL -AND- clinical documentation of current weight -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, initial therapy has resulted in decrease in phenylalanine levels from baseline or current phenylalanine levels within the range of 120-360 micromol/L -AND- clinical documentation of current weight is required -AND- sapropterin dihydrochloride dose does not exceed 20 mg/kg/day. For brand Kuvan, a trial and failure of generic sapropterin dihydrochloride is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

kynmobi

Products Affected

- **KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease -AND- for use in acute, intermittent treatment of hypomobility off episodes -AND- experiencing off episodes despite the use of oral carbidopa/levodopa -AND- Therapeutic failure, intolerance, or contraindication to the following (1. and 2.): 1) a generic pramipexole containing product or a generic ropinirole containing product. 2) generic entacapone, selegiline or rasagiline. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lampit

Products Affected

- LAMPIT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Weight of at least 2.5 kg |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 2 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

latuda

Products Affected

- **LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. If medication is being used for bipolar 1 disorder, documentation of trial and failure or intolerance to one other formulary medication indicated in bipolar 1 disorder (e.g. quetiapine) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lenvima

Products Affected

- LENVIMA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1) Radioactive iodine refractory status 2) Microsatellite instability-high status or mismatch repair deficient status 3) Alternatives tried/failed or attestation of first line use 4) Concomitant therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

leukine

Products Affected

- LEUKINE INJECTION RECON SOLN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis: following induction chemotherapy in patients who are 55 years or older with acute myelogenous leukemia (AML) -OR- mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation -OR- acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation -OR- acceleration of myeloid reconstitution following allogeneic BMT -OR- treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic BMT -OR- following acute exposure to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

leukotriene modifiers

Products Affected

- *zileuton*
- **ZYFLO**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of asthma -AND- trial/failure of generic montelukast and generic zafirlukast |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lidoderm

Products Affected

- *lidocaine topical adhesive patch, medicated 5 %*
- **LIDODERM**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of postherpetic neuralgia (PHN) -AND- trial and failure of 1 other agent used to treat PHN (e.g. gabapentin), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation) -OR- documentation of diabetic peripheral neuropathy (DPN) -AND- trial and failure of one other agent used to treat DPN (e.g. duloxetine), inability to swallow oral medication or unable to take an oral medication due to potential adverse events (e.g. sedation) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | diabetic peripheral neuropathy |

Livmarli

Products Affected

- LIVMARLI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following diagnoses (1-2): 1) Alagille syndrome, 2) cholestatic pruritis -AND- Documentation that the member does not have any of the following diagnoses (3-5): 3) decompensated cirrhosis, 4) portal hypertension, 5) history of a hepatic decompensation event. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of improvement in pruritis -AND- attestation that the member has not progressed to any of the following (1-3): 1) portal hypertension, 2) cirrhosis, or 3) experienced a hepatic decompensation event. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Livtencity

Products Affected

- LIVTENCITY

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Diagnosis of CMV prophylaxis. |
| Required Medical Information | Documentation of refractory cytomegalovirus infection or disease as evidenced by antigenemia or polymerase chain reaction (PCR) test -AND- all of the following (1-3): 1) member weighs at least 35 kg, 2) member is a recipient of hematopoietic stem cell transplant -OR- solid organ transplant. 3) member has experienced therapeutic failure to one of the following: ganciclovir, valganciclovir, cidofovir, or foscarnet. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of a previous reduction in CMV DNA level -AND- documentation of one of the following (1-2): 1) new onset symptomatic CMV infection -OR- 2) virologic relapse with treatment-emergent maribavir resistance. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Lokelma

Products Affected

- LOKELMA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 7.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in serum potassium levels following Lokelma administration and continued treatment for hyperkalemia is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Ionsurf

Products Affected

- LONSURF

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic colorectal cancer in patients who have previously been treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and if RAS wild-type, an anti-EGFR therapy -OR- documentation of metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lorbrena

Products Affected

- **LORBRENA ORAL TABLET 100 MG,
25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of ALK-positive metastatic non-small cell lung cancer (NSCLC) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lotronex

Products Affected

- *alosetron oral tablet 0.5 mg, 1 mg*
- **LOTROXEN ORAL TABLET 0.5 MG, 1 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | For irritable bowel syndrome (IBS): Exclude if male gender |
| Required Medical Information | Documentation of chronic severe diarrhea-predominant IBS -AND- trial & failure, intolerance, or contraindication to a generic anti-diarrheal agent (e.g. loperamide) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Initial: 12 weeks. Reauth: 6 months |
| Other Criteria | For reauthorization, attestation that symptoms of IBS continue to persist AND positive clinical response. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Lovaza

Products Affected

- LOVAZA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | For hypertriglyceridemia, triglycerides greater than or equal to 500mg/dL indicating sever hypertriglyceridemia -AND- Therapeutic failure or intolerance to a prescription, generic omega 3 acid ethyl ester capsules |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, reduction in triglyceride levels from baseline for hypertriglyceridemia |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Lumakras

Products Affected

- LUMAKRAS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and all of the following, if applicable to diagnosis 1) KRAS G12C mutation status, as detected by an FDA-approved test 2) Alternatives tried |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lupkynis

Products Affected

- LUPKYNIS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of active lupus nephritis -AND- Concurrent systemic lupus erythematosus documented by positive ANA titer (greater than or equal to 1:80) or anti-dsDNA greater than or equal to 30 IU/mL -AND- Trial, intolerance, or inadequate response to at least 2 of the following standard of care drug classes: 1.) corticosteroids (e.g. prednisone) 2.) antimalarials (e.g. hydroxychloroquine) 3.) immunosuppressants (e.g. azathioprine, mycophenolate mofetil, or methotrexate) -AND- Member will continue to receive concomitant standard of care treatment with corticosteroids (e.g. prednisone) and mycophenolate mofetil. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 24 weeks initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of disease stability or disease improvement |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Lybalvi

Products Affected

- LYBALVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of schizophrenia or bipolar I disorder -AND- One of the following (1 or 2): 1) Therapeutic failure, intolerance or contraindication to generic risperidone and generic quetiapine 2) Currently stable and responding to olanzapine but experiencing weight gain from the medication |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lynparza

Products Affected

- LYNPARZA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) BRCA mutations 2) Genomic instability status 3) Homologous recombinant repair gene mutations 4) HER2 status 5) Alternatives tried/failed 6) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

lyrica

Products Affected

- LYRICA CR
 - LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG
 - LYRICA ORAL SOLUTION
- *pregabalin oral capsule 100 mg, 150 mg, 200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75 mg*
 - *pregabalin oral solution*
 - *pregabalin oral tablet extended release 24 hr*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | For immediate release and controlled release tablets, documentation of DPN and trial/failure or intolerance to duloxetine -OR- PHN and trial/failure or intolerance to gabapentin. For immediate release capsules, documentation of seizures and trial/failure or intolerance to two AEDS - OR- neuropathic pain associated with spinal cord injury -OR- documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine. When using pregabalin products concomitantly with an opiate agonist, attestation of an intent to monitor and address concomitant drug-drug interaction adverse events for opiate potentiators. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Lyvispah

Products Affected

- LYVISPAH

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- the member has an inability to swallow generic baclofen tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mavenclad

Products Affected

- MAVENCLAD (10 TABLET PACK)
- MAVENCLAD (4 TABLET PACK)
- MAVENCLAD (5 TABLET PACK)
- MAVENCLAD (6 TABLET PACK)
- MAVENCLAD (7 TABLET PACK)
- MAVENCLAD (8 TABLET PACK)
- MAVENCLAD (9 TABLET PACK)

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Concomitant use of Mavenclad and other disease modifying agents such as interferons, Copaxone, Tysabri. Treatment duration greater than 24 months. |
| Required Medical Information | Documentation of diagnosis of relapse-remitting multiples sclerosis or active secondary progressive disease -AND- therapeutic failure or intolerance to one other disease modifying therapy (e.g. Avonex, Gilenya, Copaxone) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Coverage beyond 24 months will not be approved. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mavyret

Products Affected

- MAVYRET ORAL PELLETS IN PACKET
- MAVYRET ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mayzent

Products Affected

- MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG
- MAYZENT STARTER(FOR 1MG MAINT)
- MAYZENT STARTER(FOR 2MG MAINT)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of Mayzent and other disease modifying agents such as interferons, Copaxone, Tysabri. |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Testing for CYP2C9 variants has confirmed member does not have CYP2C9*3/*3 genotype |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

megace

Products Affected

- *megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)*
- *megestrol oral tablet*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mekinist

Products Affected

- MEKINIST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mektovi

Products Affected

- MEKTOVI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) BRAF mutation status 2) Concomitant therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

methamphetamine

Products Affected

- **DESOXYN**
- *methamphetamine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Obesity |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For ADHD, trial/failure or intolerance to 2 of the following generic medications: methylphenidate, atomoxetine, or dextroamphetamine/amphetamine is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

motegrity

Products Affected

- **MOTTEGRITY**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic idiopathic constipation -AND- Failure or intolerance to Linzess and Amitiza. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mulpleta

Products Affected

- **MULPLETA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of thrombocytopenia and chronic liver disease - AND- beneficiary is scheduled to undergo a procedure -AND- trial and failure or intolerance to Doptelet |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

myalept

Products Affected

- MYALEPT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of congenital or acquired generalized lipodystrophy - AND- Leptin levels less than 8 ng/mL for males or less than 12 ng/mL for females -AND- the member has a diagnosis of diabetes or fasting insulin levels greater than 30uU/mL or fasting hypertriglyceridemia greater than 200mg/dL -AND- Therapeutic failure to one previous diabetes therapy (e.g. metformin, insulin) or hypertriglyceridemia therapy (e.g. statin, fibrate) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, decrease in HbA1c from baseline, decrease in fasting plasma glucose from baseline or decrease in fasting triglycerides from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

mycapssa

Products Affected

- MYCAPSSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acromegaly -AND- High pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- Previous response to and tolerated treatment with octreotide or lanreotide. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decreased or normalized IGF-1 from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Myfembree

Products Affected

- MYFEMBREE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Diagnosis of severe hepatic impairment or osteoporosis. |
| Required Medical Information | Documentation of Diagnosis. For premenopausal woman with uterine leiomyomas, experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For moderate to severe pain associated with endometriosis in premenopausal woman, if the patient is a female of childbearing age, the patient is not pregnant - AND - Therapeutic failure, contraindication, or intolerance to 2 standard of care treatments (i.e. generic NSAID, combined hormonal contraceptive, progestin, GnRH agonist) -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 18 months reauthorization |
| Other Criteria | For reauthorization of uterine leiomyomas, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. For reauthorization of endometriosis, continued pain associated with endometriosis -AND- attestation of reduction in pain -AND- For women of childbearing age, attestation of not pregnant -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

namenda

Products Affected

- **NAMENDA ORAL TABLET**
- **NAMENDA TITRATION PAK**
- **NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and trial/failure of generic memantine |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

namzarin

Products Affected

- **NAMZARIC**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and trial/failure of generic memantine and generic donepezil |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

natpara

Products Affected

- NATPARA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use as an adjunct to control hypocalcemia in patients with hypoparathyroidism -AND- Serum calcium concentration is greater than 7.5mg/dL -AND- Attestation of sufficient 25-hydroxyvitamin D stores |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, total serum calcium level is greater than 7.5 mg/dL and less than or equal to 10.6 mg/dL |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nayzilam

Products Affected

- NAYZILAM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizure clusters or acute repetitive seizures -AND- Therapeutic failure, contraindication or intolerance to generic diazepam rectal gel delivery system |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nerlynx

Products Affected

- **NERLYNX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following. 1) HER2 mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nexavar

Products Affected

- **NEXAVAR**
- *sorafenib*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For locally recurrent or metastatic, progressive, differentiated thyroid carcinoma, refractory to radioactive iodine treatment |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Nexavar, documentation of trial and failure of generic sorafenib is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nexletol

Products Affected

- NEXLETOL
- NEXLIZET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>1.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite Simon Broome register criteria, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p> <p>2.Hypercholesterolemia ASCVD AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance AND therapeutic failure, intolerance or contraindication to ezetimibe AND must be used with maximally tolerated statin dose or documentation of statin intolerance.</p> |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | For reauthorization, documentation showing an LDL-C reduction from baseline AND attestation of continued use of Nexletol or Nexlizet with a maximally tolerated statin, unless statin intolerant. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statin which resolved upon discontinuation of statin or documentation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ninlaro

Products Affected

- NINLARO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of multiple myeloma -AND- previous treatment with at least 1 prior therapy -AND- used in combination with lenalidomide and dexamethasone |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

NORTHERA

Products Affected

- *droxidopa*
- **NORTHERA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of neurogenic orthostatic hypotension caused by primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, or pure autonomic failure), dopamine beta-hydroxylase deficiency or non-diabetic autonomic neuropathy -AND- documentation of inadequate response, intolerance or contraindication to preferred generic alternative midodrine. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nourianz

Products Affected

- NOURIANZ

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease experiencing off episodes -AND- trial/failure, contraindication or intolerance to two (2) of the following generic products: ropinirole, pramipexole, entacapone, selegiline, or rasagiline -AND- Used as adjunct to levodopa/carbidopa. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nubeqa

Products Affected

- NUBEQA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following if applicable to diagnosis: 1. Concomitant therapy 2. History of a bilateral orchiectomy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nucala

Products Affected

- NUCALA SUBCUTANEOUS AUTO-INJECTOR
- NUCALA SUBCUTANEOUS RECON SOLN
- NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of diagnosis of severe asthma evidenced by pretreatment FEV1 less than 80 percent predicted in adults or FEV1 less than 90 percent predicted in adolescents or FEV1 reversibility of at least 12% after albuterol administration -AND- 1.) A history of 2 or more exacerbations in the previous year or inadequate symptom control with inhaled corticosteroid in combination with 3 months of controller medication (e.g. long-acting beta2-agonist [LABA], leukotriene receptor antagonist [LTRA], theophylline), unless intolerant of or contraindication to all agents -AND- 2 or 3. 2) Greater than or equal to 150 cells/uL screening within 6 weeks of dosing. 3) Greater than or equal to 300 cells/uL within 12 months of screening. -OR- Documentation of eosinophilic granulomatosis with polyangitis (EGPA) in patients who have a history of relapsing or refractory disease and will be receiving concomitant glucocorticoid treatment with or without immunosuppressive therapy -OR- Documentation of hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause for greater than or equal to 6 months -AND- At least 2 HES flares (HES-related worsening of clinical symptoms or blood eosinophil counts requiring an escalation in therapy) within the past 12 months -AND- Stable on HES therapy for at least 4 weeks (chronic or episodic oral corticosteroids, immunosuppressive or cytotoxic therapy) -OR- Documentation of chronic rhinosinusitis with nasal polyps (CRSwNP) and trial/failure, contraindication, or intolerance to an intranasal corticosteroid.</p> |
| Age Restrictions | Deny if less than 6 years old for asthma or less than 12 years old for hypereosiniphilic syndrome |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| | |
|-----------------------|-------------------------------|
| PA Criteria | Criteria Details |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nuedexta

Products Affected

- NUEDEXTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation supporting improvement in symptoms is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nuplazid

Products Affected

- NUPLAZID

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hallucinations and delusions associated with Parkinson's disease psychosis |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

nuvigil

Products Affected

- *armodafinil*
- **NUVIGIL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of shift work sleep disorder (SWSD) as defined by a minimum of 5 night shifts per month and the shift is 6 to 12 hours in duration occurring between 10pm and 8am. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range - OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Nuvigil, documentation of failure on generic modafinil. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ocaliva

Products Affected

- OCALIVA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of primary biliary cholangitis -AND- trial and failure, contraindication, or intolerance to ursodiol monotherapy -AND- will use concomitantly with ursodiol unless contraindicated or intolerant. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

octreotide

Products Affected

- *octreotide acetate injection solution*
- **SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- therapeutic failure or cannot be treated with surgical resection, pituitary irradiation or bromocriptine mesylate at maximally tolerated doses. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

odactra

Products Affected

- ODACTRA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy |
| Required Medical Information | Documentation of allergic rhinitis due to house dust mites -AND- allergic rhinitis with or without conjunctivitis has been confirmed by skin testing for licensed house dust mite allergen extracts or in vitro testing for IgE antibodies to D. pteronyssinus or D. Farina -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent |
| Age Restrictions | Deny if less than 18 years of age or greater than 65 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

odomzo

Products Affected

- ODOMZO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy or for use in patients who are not candidates for surgery or radiation therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

olumiant

Products Affected

- **OLUMIANT ORAL TABLET 1 MG, 2 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Part A covered for Covid-19 in hospitalized patients |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis an inadequate response or intolerance to at least one non-biologic DMARD (e.g., methotrexate, leflunomide). For severe alopecia areata, inadequate response or intolerance to an intralesional corticosteroid or high potency topical corticosteroid, or contraindication to all. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis and Alopecia Areata |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR, with at least 1 being a tumor necrosis factor blocker. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

onfi

Products Affected

- *clobazam oral suspension*
- *clobazam oral tablet*
- **ONFI ORAL SUSPENSION**
- **ONFI ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- adequate trial or intolerance of a previous antiepileptic therapy |
| Age Restrictions | Deny if less than 2 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ongentys

Products Affected

- **ONGENTYS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease experiencing off episodes -AND- Used as adjunct to levodopa/carbidopa -AND- trial/failure, contraindication or intolerance to the following (1. and 2.): 1) entacapone 2) one of the following generic products: rasagiline, pramipexole, ropinirole, selegiline |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

onureg

Products Affected

- ONUREG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acute myeloid leukemia that has achieved first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy -AND- Inability to complete intensive curative therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Opzelura

Products Affected

- OPZELURA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1-4): 1) mild to moderate atopic dermatitis (AD), 2) attestation of up to 20 percent of body surface area (excluding scalp) with AD involvement, 3) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- documentation of facial or anogenital involvement, 4) trial & failure, intolerance, or contraindication to topical generic tacrolimus or topical generic pimecrolimus -OR- Documentation of all of the following (5-7): 5) Nonsegmental vitiligo, 6) body surface area with vitiligo involvement does not exceed 10 percent, 7) trial & failure or intolerance to at least 1 generic, formulary high or ultrahigh potency topical corticosteroid -OR- vitiligo with facial or anogenital involvement |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Initial authorization: 8 weeks for AD, 24 weeks for vitiligo. Reauthorization: 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response to therapy for atopic dermatitis -OR- meaningful repigmentation of affected areas for vitiligo |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

oralair

Products Affected

- **ORALAIR SUBLINGUAL TABLET 300
INDX REACTIVITY**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Asthma (severe, unstable or uncontrolled), concomitant sublingual or subcutaneous immunotherapy, therapy initiation during active allergy season |
| Required Medical Information | Documentation of allergic rhinitis and use for Sweet Vernal, Orchard, Perennial Rye, Timothy or Kentucky Blue Grass pollens -AND- allergic rhinitis with or without conjunctivitis has been confirmed by a pollen specific positive skin test or in vitro testing for pollen-specific IgE antibodies -AND- trial and failure or intolerance to an intranasal steroid and an oral non-sedating antihistamine, intranasal antihistamine or intranasal anticholinergic agent |
| Age Restrictions | Deny if less than 5 years of age or greater than 65 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Member must also be prescribed an epinephrine auto injector. For reauthorization, attestation of improved allergy symptoms is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

orencia

Products Affected

- **ORENCIA CLICKJECT**
- **ORENCIA SUBCUTANEOUS SYRINGE**
125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. methotrexate, leflunomide). For juvenile idiopathic rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. |
| Age Restrictions | Deny if less than 18 years of age for Rheumatoid Arthritis, and Psoriatic Arthritis or less than 2 years of age for Juvenile Idiopathic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For rheumatoid arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Rinvoq and Xeljanz/Xeljanz XR. For psoriatic arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla and Stelara. For juvenile idiopathic arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Xeljanz/Xeljanz solution and Actemra. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

orgovyx

Products Affected

- **ORGOVYX**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced prostate cancer -AND- the member is appropriate to receive androgen deprivation therapy by meeting one of the following (1, 2, or 3) 1. Biochemical (prostate specific antigen) or clinical relapse following local primary intervention 2. Newly diagnosed castration-sensitive metastatic disease 3. Advanced local disease |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy dosing, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimens per indication. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

oriahnn

Products Affected

- **ORIAHNN**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Diagnosis of severe hepatic impairment or osteoporosis. |
| Required Medical Information | Documentation of premenopausal woman with uterine leiomyomas - AND- Experiencing heavy menstrual bleeding -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 18 months reauthorization |
| Other Criteria | For reauthorization, attestation of continued experience of heavy menstrual bleeding -AND- Attestation of decrease in menstrual blood loss -AND- Treatment with a gonadotropin-releasing hormone receptor antagonist in combination with estrogen and progestin does not exceed 24 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Orilissa

Products Affected

- **ORILISSA ORAL TABLET 150 MG, 200 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Diagnosis of severe hepatic impairment or osteoporosis. |
| Required Medical Information | Documentation of female with diagnosis of endometriosis with moderate to severe pain -AND- For women of childbearing age, attestation of not pregnant -AND- Inadequate response, failure or contraindication to 2 standard of care treatments (e.g. NSAIDS, combined hormonal contraceptives, progestin, GnRH agonist, Danazol) -AND- Treatment with Orilissa does not exceed 24 months |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 18 months reauthorization |
| Other Criteria | For reauthorization, Orilissa is continued to be used for pain associated with endometriosis -AND- attestation of reduction in pain -AND- Total cumulative duration of therapy does not exceed 24 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

orkambi

Products Affected

- **ORKAMBI ORAL TABLET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis and homozygous F508del mutation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

orkambi granules

Products Affected

- **ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis and homozygous F508del mutation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

orladeyo

Products Affected

- ORLADEYO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

osmolex

Products Affected

- **OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 322 MG/DAY(129 MG X1-193MG X1)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Parkinson's disease or drug-induced extrapyramidal symptoms -AND- trial and failure, contraindication, or intolerance to immediate-release amantadine |
| Age Restrictions | Deny if less than 18 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

osphena

Products Affected

- OSPHENA

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

OTEZLA

Products Affected

- **OTEZLA**
- **OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate) -OR- inadequate response to phototherapy -OR- contraindication to phototherapy and systemic therapy. For oral ulcers associated with Behcet's Disease, inadequate response or intolerance to topical triamcinolone for acute flare-up of oral ulcers -AND- inadequate response or intolerance to colchicine for prevention of recurrent oral ulcers |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

otrexup

Products Affected

- OTREXUP (PF)

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

oxbryta

Products Affected

- OXBRYTA ORAL TABLET

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea |
| Age Restrictions | Deny if less than 4 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Oxbryta for Suspension

Products Affected

- **OXBRYTA ORAL TABLET FOR SUSPENSION**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of sickle cell disease -AND- Failure, intolerance or contraindication to hydroxyurea -AND- one of the following (1 or 2): 1) is eleven years of age or younger -OR- 2) has an inability to swallow tablets |
| Age Restrictions | Deny if less than 4 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of improvement of sickle cell disease signs, symptoms or complications |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

oxervate

Products Affected

- OXERVATE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment duration greater than 8 weeks per eye |
| Required Medical Information | Documentation of diagnosis -AND- affected eye (e.g. right eye, both eyes). |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 8 weeks |
| Other Criteria | Coverage beyond 8 weeks per eye will not be approved |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

palynziq

Products Affected

- PALYNZIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of phenylketonuria. Member meets the following criteria 1.) Baseline Phe level greater than 600 micrometers/L -AND- 2.) Failure or intolerance to existing management (i.e. Kuvan therapy) -AND- 3.) Has a prescription for epinephrine agent unless contraindicated. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of reduction in baseline pretreatment Phe levels -OR- blood Phe levels are less than or equal to 600 micrometers/L -OR- attestation that additional therapy with Palynziq is needed to allow adequate trial of maximum dose of 60mg per day for 16 weeks or member is not currently on 60mg per day dose. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Panretin

Products Affected

- PANRETIN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous lesions in patients with AIDS-related Kaposi Sarcoma (KS) who are not receiving systemic therapy for KS. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

pemazyre

Products Affected

- PEMAZYRE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) Previous therapies tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Pheburane

Products Affected

- PHEBURANE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- therapeutic failure or intolerance to generic sodium phenylbutyrate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

phenoxybenzamine

Products Affected

- **DIBENZYLINE**
- *phenoxybenzamine*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of excessive sweating and hypertension associated with pheochromocytoma supported by one of the following (1. or 2.): 1. Elevated metanephrines in plasma or urine. 2. Tumor evidence from CT scan or MRI |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Phospholine Iodide

Products Affected

- **PHOSPHOLINE IODIDE**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For diagnosis of elevated intraocular pressure (IOP), the following criteria apply (1 and 2): therapeutic failure or intolerance to generic latanoprost, 2) therapeutic failure, contraindication, or intolerance to one generic ophthalmic alternative that lowers IOP (a. through f.): a) prostaglandin analog, b) ophthalmic beta-blocker, c) alpha-adrenergic agonist, d) carbonic anhydrase inhibitor, e) ophthalmic cholinergic agonist, f) combination products of these classes |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

piqray

Products Affected

- **PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1), 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of HR-positive, HER2-negative advanced or metastatic breast cancer in men and postmenopausal women with disease progression on or after endocrine-based therapy -AND- Used in combination with fulvestrant - AND- PI3K mutation positive as detected by an FDA approved test. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

pomalyst

Products Affected

- POMALYST

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of multiple myeloma, and combination use with dexamethasone, and previous trial of at least 2 therapies including lenalidomide and a proteasome inhibitor, and disease progression on or within 60 days of completion of the last therapy -OR- Documentation of AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV negative |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Ponvory

Products Affected

- **PONVORY**
- **PONVORY 14-DAY STARTER PACK**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

praluent

Products Affected

- PRALUENT PEN

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | 1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool AND LDL-C greater than 100 mg/dL despite use of maximally tolerated statin or statin intolerance. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | <p>Patients must have an adequate trial/failure or contraindication to the preferred product Repatha. Do not used with another PCSK9 inhibitor. For reauthorization, documentation showing an LDL-C reduction on Praluent therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

prenatal vitamins

Products Affected

- **PRENATAL VITAMIN PLUS LOW IRON**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of nutritional supplementation required in a female of child-bearing potential during pre-conception, pregnancy, or lactation |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

prescription drug combo

Products Affected

- acetaminophen-caff-dihydrocod oral capsule
- acetaminophen-codeine oral solution 120-12 mg/5 ml
- acetaminophen-codeine oral tablet
- **ALPRAZOLAM INTENSOL**
- alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg
- alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg
- alprazolam oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg
- **AMBIEN**
- **AMBIEN CR**
- **ASCOMP WITH CODEINE**
- butalbital-acetaminop-caf-cod oral capsule 50-300-40-30 mg, 50-325-40-30 mg
- codeine sulfate
- codeine-butalbital-asa-caff
- **CONZIP**
- **DEMEROL (PF) INJECTION SYRINGE 25 MG/ML**
- **DEMEROL INJECTION SOLUTION 50 MG/ML**
- **DILAUDID ORAL LIQUID**
- **DILAUDID ORAL TABLET**
- **EDLUAR**
- **ENDOCET ORAL TABLET 10-325 MG, 5-325 MG, 7.5-325 MG**
- eszopiclone
- fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5 mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75 mcg/hr, 87.5 mcg/hour
- **FIORICET WITH CODEINE**
- **HALCION ORAL TABLET 0.25 MG**
- hydrocodone bitartrate oral capsule, oral only, er 12hr
- hydrocodone bitartrate oral tablet, oral only, ext. rel. 24 hr
- hydrocodone-acetaminophen oral solution 7.5-325 mg/15 ml
- hydrocodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg
- hydrocodone-ibuprofen
- hydromorphone (pf) injection solution 10 (mg/ml) (5 ml), 10 mg/ml
- hydromorphone oral liquid
- hydromorphone oral tablet
- hydromorphone oral tablet extended release 24 hr 12 mg, 16 mg, 32 mg, 8 mg
- **HYSINGLA ER**
- levorphanol tartrate
- **LUNESTA**
- meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml
- meperidine oral solution
- meperidine oral tablet 50 mg
- methadone oral solution 10 mg/5 ml, 5 mg/5 ml
- methadone oral tablet 10 mg, 5 mg
- morphine concentrate oral solution
- morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg
- morphine oral capsule, extend. release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg
- morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)
- morphine oral tablet
- morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg
- **MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG**
- **NUCYNTA**
- **NUCYNTA ER**
- oxycodone oral capsule
- oxycodone oral concentrate
- oxycodone oral solution
- oxycodone oral tablet 10 mg, 15 mg, 20 mg, 30 mg, 5 mg
- oxycodone oral tablet, oral only, ext. rel. 12 hr 10 mg, 20 mg, 40 mg, 80 mg
- oxycodone-acetaminophen oral solution 5-325 mg/5 ml

- *oxycodone-acetaminophen oral tablet 10-300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg, 5-325 mg, 7.5-300 mg, 7.5-325 mg*
- **OXYCONTIN ORAL TABLET, ORAL ONLY, EXT. REL. 12 HR 10 MG, 15 MG, 20 MG, 30 MG, 40 MG, 60 MG, 80 MG**
- *oxymorphone oral tablet*
- *oxymorphone oral tablet extended release 12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 5 mg, 7.5 mg*
- **PERCOCET**
- **PROLATE ORAL TABLET**
- **ROXICODONE ORAL TABLET 15 MG, 30 MG**
- **SEGLENTIS**
- *tramadol oral capsule, er biphasic 24 hr 17-83*
- *tramadol oral capsule, er biphasic 24 hr 25-75 100 mg, 200 mg*
- *tramadol oral tablet 100 mg, 50 mg*
- *tramadol oral tablet extended release 24 hr*
- *tramadol oral tablet, er multiphasic 24 hr*
- *tramadol-acetaminophen*
- **TREZIX**
- *triazolam*
- **XANAX ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG**
- **XANAX XR ORAL TABLET EXTENDED RELEASE 24 HR 0.5 MG, 1 MG, 2 MG, 3 MG**
- **XTAMPZA ER**
- *zaleplon oral capsule 10 mg, 5 mg*
- *zolpidem*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>For concomitant use of an opiate agonist and substance abuse therapy, documentation that the member has an acute pain condition (e.g. acute traumatic injury) in which treatment with other agents would cause insufficient pain control or if the member requires treatment for pain related to a terminal illness. For concomitant use of an opiate agonist, benzodiazepine, and a centrally acting skeletal muscle relaxant, documentation that the member has tried/failed at least 2 other skeletal muscle relaxants (e.g. methocarbamol, metaxalone), understanding these skeletal muscle relaxants are high-risk medications in geriatric patients AND attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For concomitant use of an opiate agonist and other opiate potentiators (e.g. gabapentinoids, benzodiazepines, sedative-hypnotics) attestation of an intent to monitor and address concomitant drug-drug interaction adverse events. For long acting (e.g. extended release) opioid medications, the following apply (1-5). 1) Pain is severe enough to require daily, around-the-clock, long-term opioid treatment. 2) Patient is not opioid naive. 3) Attestation that non-opiate alternative therapies have been explored (e.g. NSAIDs). 4) Attestation that controlled substance Rx history has been reviewed in the state Prescription Drug Monitoring Program. 5) Attestation of counseling on the potential adverse effects of opioid analgesics, including the risk of misuse, abuse, and addiction.</p> |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Opiate tx for pain+subs. abuse, app. opiate x 1mo. All other combos and dx approve x 12mo. |
| Other Criteria | Opiate agonists will receive automatic approval if no recent claims for a substance abuse therapy (e.g. buprenorphine-naloxone) OR a benzodiazepine (e.g. triazolam, alprazolam) OR a benzodiazepine with a centrally acting skeletal muscle relaxant (e.g., carisoprodol) OR a gabapentinoid OR a sedative-hypnotic. Benzodiazepines (e.g. triazolam, alprazolam) will receive automatic approval if no recent claims for an opiate agonist (e.g. oxycodone, hydrocodone, oxymorphone) or an opiate agonist with a centrally acting skeletal muscle relaxant (e.g. carisoprodol). Sedative-hypnotics (e.g. zolpidem) will receive automatic approval if no recent claims for an opiate agonist. Infusible opiate agonists will be covered under Part B when administered via infusion pump. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

pretomanid

Products Affected

- *pretomanid*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of extensively drug resistant, treatment intolerant or nonresponsive multidrug resistant tuberculosis -AND- Used as part of a combination regimen with bedaquiline and linezolid -AND- Therapeutic failure, contraindication or intolerance to both of the following (1 and 2): 1. A fluoroquinolone antibiotic 2. Isoniazid or Rifampin. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 26 weeks |
| Other Criteria | For reauthorization, additional therapy required due to doses of the regimen being missed for safety reasons |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

proair digihaler

Products Affected

- PROAIR DIGIHALER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of reversible obstructive airway disease (e.g. asthma) or exercise induced bronchospasm -AND- Inadequate response to non-digitized albuterol inhaler -AND- Attestation that a digital inhaler is required. |
| Age Restrictions | Deny if less than 4 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

procysbi

Products Affected

- **PROCYSBI ORAL GRANULES DEL
RELEASE IN PACKET**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- previous trial and failure, intolerance, or contraindication to Cystagon (cysteamine bitartrate immediate-release) |
| Age Restrictions | Deny if less than 1 year of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For granules, attestation of inability to swallow capsules or gastrostomy tube (g-tube) placement is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

prolia

Products Affected

- PROLIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -And- For osteoporosis at high risk for fracture, meeting one of the following (1. thru 4.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 (i.e. osteopenia) -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. 4) Age 40 years or older with T-score between -1.0 and -2.5 -AND- History of glucocorticoid use for at least 3 months at a dose of 5mg per day or more of prednisone (or equivalent). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For osteoporosis and osteopenia, documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Covered under Part B for patients eligible for home health services when provider certifies that patient sustained bone fracture related to post-menopausal osteoporosis and is unable to learn the skills needed to self-administer the drug or is otherwise physically or mentally incapable of administering the drug or family/caregivers are unable or unwilling to administer the drug. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

provigil

Products Affected

- *modafinil*
- **PROVIGIL**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of shift work sleep disorder (SWSD) as defined by a minimum of 5 night shifts per month with at least 3 of those nights occurring consecutively and the shift is 6 to 12 hours in duration occurring between 10pm and 8am. Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B)Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications. Diagnosis of fatigue associated with Multiple Sclerosis (MS)</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, provider attestation of improvement in daytime sleepiness is required. For brand Provigil, documentation of failure on generic modafinil. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Off Label Uses | Fatigue associated with Multiple Sclerosis (MS) |

pulmonary arterial hypertension

Products Affected

- **ADCIRCA**
- **ADEMPAS**
- **ALYQ**
- *ambrisentan*
- *bosentan*
- **LETAIRIS**
- **OPSUMIT**
- **ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG**
- **REVATIO ORAL SUSPENSION FOR RECONSTITUTION**
- **REVATIO ORAL TABLET**
- *sildenafil (pulm.hypertension) oral suspension for reconstitution*
- *sildenafil (pulm.hypertension) oral tablet*
- *tadalafil (pulm. hypertension)*
- **TRACLEER ORAL TABLET**
- **TRACLEER ORAL TABLET FOR SUSPENSION**
- **UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**
- **UPTRAVI ORAL TABLETS,DOSE PACK**
- **VENTAVIS**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of pulmonary arterial hypertension, substantiated by results from right heart catheterization (RHC), defined as a mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, with a pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, and a PVR greater than or equal to 3 Wood units -AND- WHO Group. For bosentan in pediatric individuals, an exception to RHC will be allowed when the risk of RHC outweighs the benefit -AND- prescriber attests alternative studies have been completed (i.e. CT, MRI or specified test ruling out other causes of pulmonary hypertension). For Adempas, additional diagnosis of CTEPH as documented by right heart catheterization and V/Q scan substantiating mPAP greater than 20 mmHg at rest and PWP less than or equal to 15 mmHg and documented presence of occlusive thrombi within the pulmonary arteries will be approved. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | Ventavis covered under Part B when using via nebulizer in the home setting. For brand Adcirca, trial and failure of generic tadalafil or Alyq is required. For brand Letairis, trial and failure of generic ambrisentan is required. For brand Revatio, trial and failure of generic sildenafil is required. For brand Tracleer 62.5mg and 125mg, trial and failure of generic bosentan is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Purified Cortrophin Gel

Products Affected

- CORTROPHIN GEL

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Covered for the following indications: 1. Acute exacerbations of multiple sclerosis (MS) for patients receiving concurrent immunomodulator therapy (e.g., interferon beta, glatiramer acetate, dimethyl fumarate, fingolimod, teriflunomide) 2. Rheumatic disorders for patients receiving maintenance therapy with at least one NSAID, DMARD (e.g. leflunomide) or biologic (e.g. adalimumab) 3. Collagen diseases for members receiving maintenance therapy with at least one antimalarial (e.g. hydroxychloroquine) or immunosuppressant (e.g. azathioprine) 4. Dermatologic diseases, if using for severe psoriasis, then the member is concurrently receiving maintenance therapy with phototherapy, systemic therapy (e.g., methotrexate), or a biologic (e.g. adalimumab). 5. Allergic states (i.e. serum sickness and transfusion reaction due to serum protein reaction), if using for atopic dermatitis, then the member is concurrently receiving maintenance therapy with a topical corticosteroid, topical calcineurin inhibitor, topical PDE-4 inhibitor, or dupilumab. 6. Ophthalmic diseases 7. Respiratory diseases 8. Gout and unable to take first-line therapies. 9. Pediatric acquired epileptic aphasia. 10. Proteinuria in nephrotic syndrome and trial/failure or contraindication to two therapies from any of the following different classes: corticosteroids (e.g., cortisone or dexamethasone), calcineurin inhibitors (e.g., cyclosporine or tacrolimus, per DRUGDEX). For covered indications 1 through 9, limited/unsatisfactory response or intolerance (i.e. severe anaphylaxis) to two corticosteroids (i.e. IV methylprednisolone, IV dexamethasone, or high dose oral steroids) must be documented.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | For reauthorization, the following (1. 2. and 3.) must be met. 1) Prescriber attestation that the member cannot use corticosteroids (e.g. IV methylprednisolone, high dose oral corticosteroids) due to unsatisfactory response, intolerance (e.g. severe anaphylaxis) or experienced a severe adverse event to corticosteroids (e.g. psychosis). 2) If the reauthorization is for the treatment of multiple sclerosis, a rheumatic disorder, dermatologic disease, or nephrotic syndrome, the prescriber attests that H.P. Acthar is being used for a new acute exacerbation and not on a routine basis to prevent an exacerbation as supported by Compendia. 3) If the reauthorization is for treatment of multiple sclerosis, a rheumatic disorder, or collagen disease, the member continues to receive maintenance therapy. |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | Epileptic Aphasia |

Pyrukynd

Products Affected

- **PYRUKYND ORAL TABLET 20 MG, 5 MG, 5 MG (4-WEEK PACK), 50 MG**
- **PYRUKYND ORAL TABLETS,DOSE PACK**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hemolytic anemia with pyruvate kinase deficiency, as supported by one of the following (1-2): 1) mutations in the PKLR gene, 2) reduced activity of the pyruvate kinase enzyme. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 24 weeks initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of increase in hemoglobin level from baseline -OR- decrease in transfusion burden from baseline. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Qelbree

Products Affected

- **QELBREE ORAL
CAPSULE,EXTENDED RELEASE 24HR
100 MG, 150 MG, 200 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of ADHD -AND- trial/failure, intolerance or contraindication to a stimulant and generic atomoxetine |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

qinlock

Products Affected

- QINLOCK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of advanced gastrointestinal stromal tumor -AND- Prior treatment with imatinib and 2 other kinase inhibitors. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

quinine

Products Affected

- **QUALAQUIN**
- *quinine sulfate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Treatment or prevention of leg cramps |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 10 days |
| Other Criteria | Doses for duration greater than 10 days will not be approved |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Qulipta

Products Affected

- QULIPTA

| PA Criteria | Criteria Details |
|------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of Episodic Migraine, defined as 4-14 migraine days per month. The following criteria will apply (1-3). 1) Documentation of average monthly migraine days. 2) Attestation that headaches are not caused by medication rebound (e.g. not taking triptans exceeding more than 18 doses per month) or lifestyle factors (e.g. sleep patterns, caffeine use). 3) Trial and failure or intolerance to one agent from 2 unique prophylactic migraine medication classes: e.g. Anti-epileptic drugs (e.g. topiramate), beta-blockers (e.g. propranolol), calcium-channel blockers (e.g. verapamil), tricyclic antidepressants (e.g. amitriptyline) -OR- contraindication to all prophylactic medication classes. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in migraine frequency |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Radicava

Products Affected

- **RADICAVA ORS STARTER KIT SUSP**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of amyotrophic lateral sclerosis (ALS) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

rasuvo

Products Affected

- **RASUVO (PF)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ravicti

Products Affected

- RAVICTI

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Urea cycle disorders due to N-acetylglutamate synthetase deficiency, Treatment of acute hyperammonemia in urea cycle disorders |
| Required Medical Information | Documentation of chronic management of a urea cycle disorders (UCDs) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Recorlev

Products Affected

- **RECORLEV**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of endogenous Cushing's syndrome AND patient is not a candidate for pituitary surgery or surgery has not been curative |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of mean urine free cortisol (mUFC) less than starting baseline value. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

reditrex

Products Affected

- **REDITREX (PF)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis AND trial/failure, intolerance, or contraindication to oral generic methotrexate tablets |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

regranex

Products Affected

- **REGRANEX**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of lower-extremity diabetic neuropathic ulcer(s) that extends into the subcutaneous tissue or beyond and have an adequate blood supply -AND- being used as an adjunct to standard ulcer care practices (e.g. sharp debridement, non-weight bearing regimen, infection control) -AND- attestation of a wound care plan. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 20 weeks |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

relistor

Products Affected

- **RELISTOR ORAL**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

relistor sc

Products Affected

- **RELISTOR SUBCUTANEOUS SOLUTION**
- **RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of opioid induced constipation (OIC) due to any of the following (1-3): 1) chronic non-cancer pain, 2) advanced illness or active cancer in palliative care or 3) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to 2 of the following (4 to 6): 4) Laxatives 5) lubiprostone 6) Movantik. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

repatha

Products Affected

- **REPATHA PUSHTRONEX**
- **REPATHA SURECLICK**
- **REPATHA SYRINGE**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | <p>1.HoFH supported by genetic confirmation of two mutant alleles at LDLR, APOB, PCSK9, or LDLRAP1 gene OR untreated LDL-C greater than 400mg/dL or TC greater than 500mg/dl with cutaneous or tendon xanthoma before age 10 yrs or HeFH in both parents AND The member has a current LDL-C of greater than 135 mg/dL (if 17 years of age or younger) or greater than 100mg/dL (18 years of age or older) despite use of maximally tolerated statin or statin intolerance AND The member will continue to receive concurrent lipid-lowering therapies for the treatment of HoFH. 2.HeFH supported by presence of causal mutation of FH by genetic testing OR untreated LDL-C greater than or equal to 190 mg/dL or untreated LDL-C greater than or equal to 160 mg/dL before 20 years of age with physical signs of FH (e.g. xanthomas, xanthelasma) OR diagnosis based on WHO criteria/Dutch Lipid Clinical Network criteria with score greater than 8 points, or definite on Simon Broome register, or definite on the Make Early Diagnosis to Prevent Early Deaths tool, AND LDL-C greater than 100 mg/dL if 18 and older or LDL-C greater than 130 if 17 and younger despite use of maximally tolerated statin or statin intolerance. If 17 and younger will continue to receive concurrent lipid-lowering therapies. 3.Hypercholesterolemia ASCVD or Primary Hyperlipidemia AND LDL-C greater than 70 mg/dL despite use of maximally tolerated statin or statin intolerance</p> |
| Age Restrictions | Deny if less than 18 years of age for ASCVD and Primary Hyperlipidemia, or less than 10 years of age for HoFH and HeFH. |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | Do not used with another PCSK9 inhibitor. For reauthorization, documentation showing an LDL-C reduction on Repatha therapy from baseline must be provided. Statin intolerance defined as follows: statin related rhabdomyolysis or skeletal muscle symptoms while receiving at least 2 separate trials of different statins which resolved upon discontinuation of statin or attestation of one of the following during any course of statin therapy: 1. CK increase to 10x upper limit of normal 2. LFTs increase to 3x upper limit of normal 3. Hospitalization due to severe statin-related AEs such as rhabdomyolysis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

retevmo

Products Affected

- **RETEVMO ORAL CAPSULE 40 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis 1) RET fusion status 2) Radioactive iodine-refractory (if radioactive iodine is appropriate) |
| Age Restrictions | Deny if less than 18 years of age for NSCLC or less than 12 years of age for thyroid cancer |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

revlimid

Products Affected

- *lenalidomide*
- **REVLIMID**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Documentation of chronic lymphocytic leukemia outside of a controlled clinical trial |
| Required Medical Information | Diagnosis of multiple myeloma in combination with dexamethasone -OR- diagnosis of multiple myeloma, as maintenance following autologous hematopoietic stem cell transplant (auto-HSCT) -OR- diagnosis of transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities -OR- diagnosis of mantle cell lymphoma (MCL) in which disease has relapsed or progressed after two prior therapies, one of which included bortezomib -OR- diagnosis of follicular lymphoma in combination with a rituximab product -OR- diagnosis of marginal zone lymphoma in combination with a rituximab product after previous treatment. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All Medically-accepted Indications. |
| Off Label Uses | |

Rezurock

Products Affected

- **REZUROCK**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic graft-versus-host disease (cGVHD) -AND- therapeutic failure or intolerance to 2 lines of systemic therapy |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

rinvoq

Products Affected

- **RINVOQ ORAL TABLET EXTENDED
RELEASE 24 HR 15 MG, 30 MG, 45 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of moderate to severe Rheumatoid Arthritis, moderate to severe Refractory Atopic Dermatitis, Ankylosing Spondylitis, Psoriatic Arthritis, or Ulcerative Colitis. For moderate to severe rheumatoid arthritis, an inadequate response or intolerance to at least one non-biologic DMARD (e.g., leflunomide, methotrexate). For moderate to severe refractory atopic dermatitis whose disease is not adequately controlled with other systemic drug products, documentation of all of the following (1-2): 1) trial & failure, intolerance, or contraindication to at least one topical corticosteroid -OR- atopic dermatitis of the face or anogenital involvement -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin, 2) trial & failure, intolerance, or contraindication to topical tacrolimus or topical pimecrolimus -OR- the member has severe atopic dermatitis evidenced by the extent of the member's body surface area affected which makes topical therapy impractical to apply -OR- severe atopic dermatitis evidenced by severely damaged skin. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For diagnoses in which tumor necrosis factor (TNF) blockers are also indicated (e.g., Rheumatoid Arthritis, Psoriatic Arthritis), the member has experienced therapeutic failure or intolerance to at least 1 TNF blocker. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

rozlytrek

Products Affected

- **ROZLYTREK ORAL CAPSULE 100 MG, 200 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For metastatic non-small cell lung cancer, the tumor status is ROS1-positive. For solid tumors with NTRK gene fusion without a known acquired resistance mutation, the tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or the tumors have progressed following treatment. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

rubraca

Products Affected

- RUBRACA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following. 1) BRCA mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ruconest

Products Affected

- RUCONEST

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Member should not be on two acute therapies simultaneously and acute therapy should not be used as prophylactic therapy |
| Required Medical Information | <p>For the treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-4): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. 4) Documentation of member's weight. For the treatment of attacks of hereditary angioedema (HAE) type III with the following (5-9): 5) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 6) Documentation of family history of HAE or FXII mutation 7) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 8) Medications known to cause angioedema have been evaluated and discontinued. 9) Documentation of member's weight.</p> |
| Age Restrictions | Deny if less than 13 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For 18 years of age or older, therapeutic failure, intolerance or contraindication to icatibant. |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

rydapt

Products Affected

- RYDAPT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Use as single agent induction therapy for AML |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) FLT3 mutations 2) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sabril

Products Affected

- **SABRIL**
- *vigabatrin*
- **VIGADRONE**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of refractory complex partial seizures -AND- documentation of adjunctive therapy -AND- an adequate trial or intolerance to at least two alternative treatments (e.g. carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, tiagabine) -OR- documentation of use as monotherapy in treatment of infantile spasms |
| Age Restrictions | Deny if less than 2 years of age in treatment of refractory complex partial seizures -OR- if less than 1 month old and greater than 2 years of age in treatment of infantile spasms |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

samsca

Products Affected

- **SAMSCA**
- *tolvaptan*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic hypervolemic or euvolemic hyponatremia evidenced by (1. or 2.): 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 1 month |
| Other Criteria | Doses must be initiated in the hospital setting to closely monitor serum sodium. Treatment should be limited to 30 days to minimize risk of liver injury. For brand Samsca, a trial and failure of generic tolvaptan is required. For reauthorization, treatment is for a new episode of a clinically significant euvolemic or hypervolemic hyponatremia -AND- on of the following (1. or 2.) 1.) Serum Na less than 125 mEq/L -OR- 2.) Serum NA less than 135mEq/L with symptoms (e.g. nausea, malaise, lethargy, headache, seizures) |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

savella

Products Affected

- SAVELLA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation to support a diagnosis of fibromyalgia and trial/failure or intolerance to duloxetine |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Scemblix

Products Affected

- **SCSEMBLIX ORAL TABLET 20 MG, 40 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) T3151 mutation status 2) Philadelphia chromosome status 3) Alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Sertraline Capsule

Products Affected

- *sertraline oral capsule*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of major depressive disorder or obsessive-compulsive disorder -AND- A sertraline product other than sertraline capsules has been used for initial dosage and titration -AND- Sertraline 100mg or sertraline 125mg has been received for greater than or equal to 7 days - AND- Therapeutic failure or intolerance to generic sertraline immediate release tablets -AND- Therapeutic failure, intolerance or contraindication to at least one other antidepressant (e.g. SNRI, SSRI, TCA, MAOI). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

signifor

Products Affected

- SIGNIFOR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Cushing's disease AND patient is not a candidate for pituitary surgery or surgery has not been curative |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decrease in urinary free cortisol levels from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

siliq

Products Affected

- SILIQ

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 4 months initial authorization, 12 months reauthorization |
| Other Criteria | If on Siliq therapy greater than or equal to 4 months or reauthorization, provider must attestation of improvement in the physician's global assessment score, psoriasis area severity index score, or a decrease in the affected body surface area of psoriatic plaque lesions. For psoriasis, patients must have an adequate trial or intolerance to 2 preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel, and Skyrizi. For psoriasis induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

simponi

Products Affected

- **SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML**
- **SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. Simponi 50mg: For moderate to severe rheumatoid arthritis, inadequate response or intolerance to at least one DMARD (e.g. leflunomide) and Simponi will be used in combination with methotrexate. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). Diagnosis of psoriatic arthritis Simponi 100mg: Diagnosis of moderate to severe ulcerative colitis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For Rheumatoid arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Actemra, Xeljanz/Xeljanz XR and Rinvoq. For psoriatic arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For ankylosing spondylitis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For ulcerative colitis, patients must have an adequate trial or intolerance to the preferred products Humira, Stelara and Xeljanz/Xeljanz XR. For ulcerative colitis indication therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

skyrizi

Products Affected

- SKYRIZI SUBCUTANEOUS PEN INJECTOR
- SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML
- SKYRIZI SUBCUTANEOUS SYRINGE KIT
- SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. For Crohn's disease, attestation of clinical response or remission following IV administration of Skyrizi within 3 months of initiating therapy with Skyrizi SC. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

solaraze

Products Affected

- *diclofenac sodium topical gel 3 %*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial and failure, intolerance, or contraindication to topical fluorouracil |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of 30 day washout period since optimal therapeutic effect may not be evident until 30 days following cessation of therapy AND attestation of previous response to diclofenac sodium 3% topical gel therapy |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

somavert

Products Affected

- SOMAVERT

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For acromegaly, high pretreatment insulin-like growth factor-1 (IGF-1) based on laboratory reference range -AND- inadequate or partial response to surgery or radiotherapy or not a candidate for surgery or radiotherapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization of acromegaly, decreased or normalized IGF-1 from baseline |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sovaldi

Products Affected

- SOVALDI ORAL PELLETS IN PACKET
- SOVALDI ORAL TABLET 400 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir. |
| Age Restrictions | Deny if less than 3 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sprycel

Products Affected

- SPRYCEL

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed 3) Concomitant therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

stelara

Products Affected

- **STELARA SUBCUTANEOUS SOLUTION**
- **STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- documentation of member weight and prescribed dose. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. For Crohn's Disease, inadequate response or intolerance to two immunosuppressants (e.g. corticosteroids, azathioprine) -OR- intolerance to a TNF inhibitor (e.g. Humira) -OR- Contraindication to a TNF inhibitor due to demyelinating disease or heart failure -OR- attestation of clinical response or remission following IV administration of Stelara within 2 months of initiating therapy with Stelara SC. For Ulcerative colitis, attestation of clinical response or remission following IV administration of Stelara within 2 months of initiating therapy with Stelara SC |
| Age Restrictions | Deny if less than 18 years of age for Crohn's Disease and Ulcerative Colitis or less than 6 years of age for Plaque Psoriasis and Psoriatic Arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|---|
| Other Criteria | <p>Must follow recommended dosing guidelines based upon weight.</p> <p>Psoriasis: For patients weighing less than 100 kilograms (220 pounds), 45 mg dosing will be approved. For patients weighing more than 100 kilograms (220 pounds), 90 mg dosing will be approved. Psoriatic Arthritis: 45 mg dosing will be approved. For patients with co-existent moderate to severe plaque psoriasis weighing greater than 100 kilograms (220 pounds), 90 mg dosing will be approved. Induction therapy, doses above plan quantity limit will be approved aligned with recommended induction therapy dosing regimen.</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

stivarga

Products Affected

- **STIVARGA**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic colorectal cancer and trial of a fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy, AND an anti-VEGF therapy AND if RAS wild-type, an anti-EGFR therapy -OR- documentation of locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) after treatment with both imatinib and sunitinib -OR- documentation of hepatocellular cancer AND previous treatment with sorafenib |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sunosi

Products Affected

- **SUNOSI**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. Diagnosis of obstructive sleep apnea/hypopnea syndrome (OSAHS) documented by objective polysomnography as established in accordance with ICSD or DSM V criteria acceptable for all indications |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For narcolepsy and OSAHS, documentation of trial and failure, contraindication or intolerance to modafinil and armodafinil. For reauthorization, provider attestation of improvement in daytime sleepiness is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sutent

Products Affected

- *sunitinib*
- SUTENT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) disease progression on or intolerance to imatinib mesylate 2) high risk of recurrent RCC following nephrectomy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

symdeko

Products Affected

- **SYMDEKO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have either the homozygous F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to tezacaftor/ivacaftor based on clinical and/or in vitro assay (e.g. E56K, R117C, A455E) |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

sympazan

Products Affected

- SYMPAZAN

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizures due to Lennox-Gastaut Syndrome -AND- documentation of adjunctive therapy -AND- adequate trial or intolerance of a previous antiepileptic therapy -AND- unable to tolerate generic clobazam |
| Age Restrictions | Deny if less than 2 years old |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

symproic

Products Affected

- SYMPROIC

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of opioid induced constipation (OIC) due to any of the following (1-2): 1) chronic non-cancer pain, or 2) chronic pain related to prior cancer or its treatments who do not require frequent (e.g., weekly) opioid dosage escalation -AND- documentation of opioid medication use for at least one month -AND- trial and failure, contraindication, or intolerance to at least 2 of the following (3-5): 3) Laxatives, 4) lubiprostone, 5) Movantik |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

syndros

Products Affected

- SYNDROS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of one of the following (1 or 2): 1) anorexia associated with weight loss in patients with AIDS -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules -OR- 2) nausea and vomiting associated with cancer chemotherapy in adults who have trial and failure, contraindication, or intolerance to a conventional antiemetic treatment (e.g., metoclopramide, promethazine, ondansetron, perphenazine, etc.) -and- trial and failure, contraindication, or intolerance to generic dronabinol capsules |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Covered under Part B when the following are met: 1) used for chemotherapy-induced nausea and vomiting. 2) used as full replacement for IV anti-emetic therapy. 3) using within 48 hours of receiving chemotherapy. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tabrecta

Products Affected

- TABRECTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer with MET exon 14 skipping mutation as detected by an FDA approved test. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tagrisso

Products Affected

- TAGRISSO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following. 1) EGFR mutations, if applicable to diagnosis. 2) Alternatives tried/failed. 3) Concomitant therapy, if applicable to diagnosis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

takhzyro

Products Affected

- TAKHZYRO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Member should not be on two prophylactic therapies simultaneously. |
| Required Medical Information | For the prophylactic treatment of attacks of hereditary angioedema (HAE) type I & II with the following (1-3): 1) Low C4 level of less than or equal to 14mg/dL or C4 below lower limit of laboratory reference range and 1 of the following (A or B). A) C1 inhibitor (C1INH) antigen level less than or equal to 19mg/dL or below lower limit of laboratory reference range. B) Normal C1INH antigen level and a low C1INH functional level below laboratory reference range. 2) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 3) Medications known to cause angioedema have been evaluated and discontinued. For the prophylactic treatment of attacks of hereditary angioedema (HAE) type III with the following (4-7): 4) Documentation of clinical laboratory performance C4, C1INH antigen, or C1INH functional level are within normal limits of laboratory reference ranges. 5) Documentation of family history of HAE or FXII mutation 6) Past medical history of at least 1 symptom of moderate or severe angioedema attack (e.g. airway swelling, painful facial distortion) in absence of concomitant hives. 7) Medications known to cause angioedema have been evaluated and discontinued. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

taltz

Products Affected

- TALTZ AUTOINJECTOR
- TALTZ SYRINGE

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. For ankylosing spondylitis, inadequate response or intolerance to one nonsteroidal anti-inflammatory drug (NSAID). For non-radiographic axial spondyloarthritis, inadequate response or intolerance to 2 NSAIDs. |
| Age Restrictions | Deny if less than 18 years of age for Psoriatic Arthritis, Ankylosing Spondylitis and non-radiographic axial spondyloarthritis or less than 6 years of age for Plaque Psoriasis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For psoriatic arthritis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel, Cosentyx, Xeljanz/Xeljanz XR, Otezla, and Stelara. For plaque psoriasis patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Cosentyx, Otezla, Stelara, Enbrel and Skyrizi. For ankylosing spondylitis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Enbrel and Cosentyx. For induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

talzenna

Products Affected

- **TALZENNA ORAL CAPSULE 0.25 MG, 0.5 MG, 0.75 MG, 1 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of deleterious or suspected deleterious gBRCAm, HER2-negative locally advanced or metastatic breast cancer |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

targretin

Products Affected

- *bexarotene oral*
- *bexarotene topical*
- **TARGRETIN ORAL**
- **TARGRETIN TOPICAL**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Targretin gel, documentation of trial and failure of generic bexarotene gel is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Tarpeyo

Products Affected

- TARPEYO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- one (1) of the following (A or B): A) Used in combination with one (1) of the following (1 or 2): 1) angiotensin-converting enzyme inhibitor (ACE-I), or 2) angiotensin II receptor blocker (ARB), -OR- B) Intolerance or contraindication to both of the following (3 and 4): 3) ACE-I, and 4) ARB. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tasigna

Products Affected

- TASIGNA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) Philadelphia Chromosome status (e.g. positive) 2) Alternatives tried/failed |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tavalisse

Products Affected

- TAVALISSE

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For diagnosis of ITP, the following criteria apply (1 and 2): 1) trial, intolerance, or inadequate response to a corticosteroid, immunoglobulin, or splenectomy. 2) One of the following (A or B): A) Platelet count less than or equal to $50 \times 10^9/L$ and has significant mucous member bleeding or at least one risk factor for bleeding (e.g. hypertension, peptic ulcer disease). B) Platelet count of less than or equal to $30 \times 10^9/L$. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Tavneos

Products Affected

- TAVNEOS

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of severe active granulomatosis with polyangiitis or severe active microscopic polyangiitis -AND- Prescriber attests to positive test for anti-PR3 or positive test for anti-MPO -AND- Member will continue to receive concomitant standard of care treatment with systemic glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of therapeutic response defined by disease stability or disease improvement -AND- Member will continue to receive concomitant standard of care treatment with glucocorticoids (e.g. prednisone) and immunosuppressives (e.g. mycophenolate mofetil, azathioprine). |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tazarotene

Products Affected

- **FABIOR**
- *tazarotene topical foam*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tazorac

Products Affected

- *tazarotene topical cream*
- *tazarotene topical gel*
- **TAZORAC TOPICAL CREAM**
- **TAZORAC TOPICAL GEL**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of 1 of the following (A or B). A) Documentation of plaque psoriasis -AND- trial and failure or intolerance to at least one topical corticosteroid (e.g. fluocinonide, mometasone, triamcinolone, betamethasone). B) Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. adapalene, clindamycin, sulfacetamide, erythromycin) one of which must be generic topical tretinoin |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tazverik

Products Affected

- TAZVERIK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of locally advanced or metastatic epithelioid sarcoma - AND- Disease is not eligible for complete resection. Documentation of relapsed or refractory follicular lymphoma -AND-Tumors are EZH2 mutation positive, as detected by FDA approved test, in a member that has received at least 2 prior systemic therapies -OR- Prescriber attests there are no satisfactory alternative treatment options. |
| Age Restrictions | Deny if less than 16 years of age for epithelioid sarcoma or deny if less than 18 years of age for follicular lymphoma |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tecfidera

Products Affected

- dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg, 120 mg (14)- 240 mg (46), 240 mg*
- TECFIDERA ORAL**

**CAPSULE, DELAYED
RELEASE(DR/EC) 120 MG, 120 MG
(14)- 240 MG (46), 240 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | For brand Tecfidera, documentation of failure on generic dimethyl fumarate |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tegsedi

Products Affected

- **TEGSEDI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of polyneuropathy associated with hereditary TTR (hATTR) amyloidosis with mutation in TTR gene confirmed by genetic testing -AND- Neurologic examination shows clinical signs and symptoms of the disease (e.g. peripheral/autonomic neuropathy, motor disability, carpal tunnel, etc.) -AND- Not simultaneously utilizing other gene targeted therapy for polyneuropathy of hATTR |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of positive clinical response |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tepmetko

Products Affected

- **TEPMETKO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer with a MET exon 14 skipping alteration |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

testosterone (androgens)

Products Affected

- **ANDRODERM**
- **ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **AVEED**
- **DEPO-TESTOSTERONE**
- **FORTESTA**
- **JATENZO ORAL CAPSULE 158 MG, 198 MG, 237 MG**
- **NATESTO**
- **TESTIM**
- *testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*
- *testosterone enanthate*
- *testosterone transdermal gel in metered-dose pump*
- *testosterone transdermal gel in packet*
- *testosterone transdermal solution in metered pump w/app*
- **TLANDO**
- **VOGELXO TRANSDERMAL GEL**
- **VOGELXO TRANSDERMAL GEL IN METERED-DOSE PUMP**
- **XYOSTED**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Documentation of primary or secondary hypogonadism in males with testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, radiation or toxic damage -OR- documentation of primary or secondary hypogonadism in males with multiple symptoms of hypogonadism including at least one of the following specific symptoms: height loss due to vertebral fractures, low trauma fractures, low bone density, incomplete or delayed sexual development, breast discomfort, loss of axillar and/or pubic body hair, hot flushes -OR- documentation of HIV infection in men with weight loss -OR- documentation of chronic steroid treatment in men. In all previously noted indications, members must also have documented low total testosterone level below the normal range for the laboratory -OR- a total testosterone level near the lower limit of the normal range with a low free testosterone level which is less than normal based upon the laboratory reference range -OR- the member is not producing any testosterone. Additional approvable indications include female patients with metastatic breast cancer (testosterone enanthate only), primary or secondary hypogonadism in males with testicular failure due to double orchidectomy, and delayed puberty in males (testosterone enanthate only).</p> |
| Age Restrictions | |

| PA Criteria | Criteria Details |
|--------------------------------|--|
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications, Some Medically-accepted Indications. |
| Off Label Uses | HIV Wasting |

thalamid

Products Affected

- **THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Use as monotherapy for ENL treatment in the presence of moderate to severe neuritis |
| Required Medical Information | Documentation of multiple myeloma in combination with dexamethasone -OR- documentation for use in the treatment of cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL) -OR- documentation of therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

thiola

Products Affected

- **THIOLA**
- **THIOLA EC**
- *tiopronin*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following criteria must be met (1-3) 1) member is at least 9 years of age or weighs at least 20kg, 2) Confirmation of cystinuria by at least one 24-hour urine collection with measurement of urinary cysteine levels greater than 400 mg/day, 3) Attestation of failure of urine alkalization with potassium citrate (to achieve pH of 7.0). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of urine cystine concentration less than 250 mg/L-OR- decrease in production of cystine stones is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

thrombopoiesis stimulating agents

Products Affected

- **PROMACTA ORAL POWDER IN PACKET 12.5 MG, 25 MG**
- **PROMACTA ORAL TABLET 12.5 MG, 25 MG, 50 MG, 75 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of chronic immune idiopathic thrombocytopenia purpura and trial and failure of corticosteroid or immunoglobulin therapy or splenectomy -OR- documentation of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy (eltrombopag only)-OR- severe aplastic anemia who have had an insufficient response to immunosuppressive therapy -OR- documentation of first line treatment for severe aplastic anemia and used in combination with at least two immunosuppressive therapies. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Platelet count to be provided |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tibsovo

Products Affected

- TIBSOVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) IDH1 mutation status, 2) alternatives tried/failed, 3) comorbidity that precludes use of intensive induction chemotherapy (i.e. age greater than or equal to 75 years, severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tigan

Products Affected

- *trimethobenzamide oral*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tiglutik

Products Affected

- **TIGLUTIK**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of amyotrophic lateral sclerosis (ALS) -AND- Inability to swallow tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of stability or improvement in symptoms of ALS. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tolsura

Products Affected

- TOLSURA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Unable to tolerate generic itraconazole capsules -AND- Prescriber provides rationale for clinical need of SUBA technology |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation the member is still unable to tolerate generic itraconazole capsules |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

topical lidocaine

Products Affected

- *lidocaine hcl mucous membrane solution 4 % (40 mg/ml)*
- *lidocaine topical ointment*
- *lidocaine-prilocaine topical cream*

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

transmucosal fentanyl citrate

Products Affected

- **ACTIQ BUCCAL LOZENGE ON A HANDLE 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**
- *fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg*
- *fentanyl citrate buccal tablet, effervescent 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg*
- **FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG**

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of therapeutic use and the member is currently receiving and tolerant to long acting opioid therapy |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

trelstar

Products Affected

- **TRELSTAR INTRAMUSCULAR
SUSPENSION FOR RECONSTITUTION**

| PA Criteria | Criteria Details |
|-------------------------------------|-------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tremfya

Products Affected

- TREMFYA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe plaque psoriasis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine) -OR- inadequate response to phototherapy. If not a candidate for phototherapy: treatment with systemic therapy has been ineffective, not tolerated, or is contraindicated. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For psoriasis, patients must have an adequate trial or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Skyrizi. For psoriatic arthritis, patients must have an adequate trial or intolerance to 2 of the preferred products Cosentyx, Humira, Otezla, Stelara, Enbrel and Xeljanz/Xeljanz XR. For psoriasis and psoriatic arthritis induction therapy, doses above plan quantity limit will be approved when aligned with recommended induction therapy dosing regimen. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tretinoin

Products Affected

- *adapalene topical cream*
- *adapalene topical gel 0.3 %*
- *adapalene topical swab*
- **AKLIEF**
- **ALTRENO**
- **ATRALIN**
- **AVITA**
- *clindamycin-tretinoin*
- **DIFFERIN TOPICAL CREAM**
- **DIFFERIN TOPICAL GEL WITH PUMP**
- **DIFFERIN TOPICAL LOTION**
- **RETIN-A**
- **RETIN-A MICRO**
- **RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 %**
- *tretinoin*
- *tretinoin microspheres topical gel*
- **TWYNEO**
- **VELTIN**
- **WINLEVI**
- **ZIANA**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Cosmetic use |
| Required Medical Information | Documentation of acne vulgaris -AND- trial and failure or intolerance of at least two topical acne medications (e.g. clindamycin, sulfacetamide, erythromycin) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

trikafta

Products Affected

- TRIKAFTA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cystic fibrosis (CF) in patients who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator (CFTR gene) that is responsive to elexacaftor/tezacaftor/ivacaftor based on in vitro assay (e.g. E56K, R117C, A455E) |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, documentation supporting improvement or stabilization of FEV1 compared to baseline FEV1 -or- increase in body mass index -or- decreased pulmonary exacerbations -or- improved quality of life as demonstrated by CF Questionnaire is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Truseltiq

Products Affected

- **TRUSELTIQ ORAL CAPSULE 100 MG/DAY (100 MG X 1), 125 MG/DAY(100 MG X1-25MG X1), 50 MG/DAY (25 MG X 2), 75 MG/DAY (25 MG X 3)**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) FGFR2 fusion or other rearrangement as detected by an FDA-approved test 2) Previous therapies tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tukysa

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) Alternatives tried/failed 3) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

turalio

Products Affected

- TURALIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of symptomatic tenosynovial giant cell tumor associated with severe morbidity and functional limitations -AND- patient is not amenable to improvement with surgery or not a candidate for surgery |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tykerb

Products Affected

- *lapatinib*
- **TYKERB**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- All of the following, if applicable to diagnosis: 1) HER2 mutations 2) Alternatives tried/failed 3) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Tykerb, trial and failure of generic lapatinib is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

tymlos

Products Affected

- TYMLOS

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Treatment duration greater than 24 months. |
| Required Medical Information | Documentation of diagnosis -AND- at high risk for fracture, meeting one of the following (1. thru 3.) 1) History of previous hip or vertebral fracture. 2) T-score less than or equal to -2.5. 3) T-score between -1.0 and -2.5 -AND- meets FRAX calculation (A. or B.) A) 10-year risk of major osteoporotic fracture is greater than or equal to 20 percent or B) 10-year risk of hip fracture is greater than or equal to 3 percent. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 24 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one oral bisphosphonate or all are contraindicated. Coverage of human parathyroid hormone related peptide analogs beyond 24 months will not be approved. A cumulative lifetime approval of Tymlos will be limited to a coverage duration of 24 months. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Tyvaso DPI

Products Affected

- **TYVASO DPI INHALATION CARTRIDGE WITH INHALER 16 MCG, 16 MCG (112)- 32 MCG (84), 16(112)-32(112) -48(28) MCG, 32 MCG, 32-48 MCG, 48 MCG, 64 MCG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- results of a right heart catheterization (RHC) meeting all of the following (1., 2., and 3.): 1) mean pulmonary arterial pressure (mPAP) of greater than 20 mmHg at rest, 2) pulmonary capillary wedge pressure (PWP) of less than or equal to 15 mmHg, 3) PVR greater than or equal to 3 Wood units -AND- WHO Group |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

uloric

Products Affected

- *febuxostat*
- ULORIC

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of chronic management of hyperuricemia due to gout -And- trial/failure, intolerance or contraindication to allopurinol. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

VALCHLOR

Products Affected

- VALCHLOR

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of Stage IA or IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy (e.g. topical corticosteroids, topical chemotherapy, local radiation and topical retinoids). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

valtoco

Products Affected

- VALTOCO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of seizure clusters or acute repetitive seizures -AND- Therapeutic failure, contraindication or intolerance to generic diazepam rectal gel delivery system |
| Age Restrictions | Deny if less than 6 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

veltassa

Products Affected

- VELTASSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hyperkalemia as defined by serum potassium level between 5.1 and 6.4 mmol/L on at least two (2) screenings -AND- Modification of medications to reduce serum potassium levels were not successful, when applicable. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 6 months initial authorization, 12 months reauthorization |
| Other Criteria | For reauthorization, attestation of reduction in serum potassium levels following Veltassa administration and continued treatment for hyperkalemia is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Venbysi XR

Products Affected

- *venlafaxine besylate*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- venlafaxine extended-release product at a total daily dose greater than or equal to 75 mg has been received for greater than or equal to 4 days |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

venclexta

Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis and concomitant therapy, if applicable to diagnosis. For newly-diagnosed AML, presence of at least one comorbidity that precludes use of intensive induction chemotherapy (i.e. age greater than or equal to 75 years, severe cardiac or pulmonary comorbidity, reduced renal function, hepatic impairment, or physician attestation) is required. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Verkazia

Products Affected

- VERKAZIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- therapeutic failure or intolerance to two (2) of the following medication classes: 1) generic ophthalmic antihistamines (e.g., olopatadine), 2) generic ophthalmic mast cell stabilizers (e.g., cromolyn sodium), 3) Generic ophthalmic corticosteroids (e.g., dexamethasone, prednisolone, fluorometholone), or all are contraindicated. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

verquvo

Products Affected

- VERQUVO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of heart failure (NYHA Class II to IV) -AND- Left ventricular ejection fraction less than 45% -AND- Hospitalization for heart failure or received outpatient IV diuretics for heart failure -AND- Used in combination with a angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker or Entresto -AND- Used in combination with bisoprolol, carvedilol IR/ER or metoprolol succinate ER. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

verzenio

Products Affected

- VERZENIO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) HR mutation status and HER2 mutation status 2) Alternatives tried/failed 3) Concomitant therapy, if applicable to diagnosis 4) Ki-67 score greater than or equal to 20% per an FDA-approved test, if applicable to diagnosis. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

viberzi

Products Affected

- **VIBERZI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Severe (Child-Pugh C) hepatic impairment |
| Required Medical Information | Documentation of diarrhea predominant, irritable bowel syndrome (IBS-D) -AND- trial/failure or intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

viibryd

Products Affected

- **TRINTELLIX**
 - **VIIBRYD ORAL TABLET**
 - **VIIBRYD ORAL TABLETS,DOSE
PACK 10 MG (7)- 20 MG (23)**
- *vilazodone*

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis major depressive disorder and trial and failure of one other antidepressant |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vioice

Products Affected

- **VIJOICE ORAL TABLET 125 MG, 250 MG/DAY (200 MG X1-50 MG X1), 50 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of severe manifestations of PIK3CA Related Overgrowth Spectrum (PROS) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vimovo

Products Affected

- **VIMOVO**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) Trial/failure of ibuprofen/famotidine. -AND- 2) Trial/failure of naproxen/esomeprazole. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vimovo2

Products Affected

- *naproxen-esomeprazole*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) Trial/failure of naproxen used in combination with omeprazole. -AND- 2) Trial/failure of one additional generic formulary NSAID (other than naproxen) used in combination with another generic formulary PPI (other than omeprazole). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vitrakvi

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation -AND- Tumors are metastatic or surgical resection is likely to result in severe morbidity - AND- There are no satisfactory alternative treatments or tumors have progressed following treatment. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vivjoa

Products Affected

- VIVJOA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of recurrent vulvovaginal candidiasis defined as at least 3 episodes of vulvovaginal candidiasis in less than one year -AND Documentation the member is NOT of reproductive potential defined as postmenopausal or another reason for permanent infertility (e.g., tubal ligation, hysterectomy, salpingo-oophorectomy). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Pending CMS review |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vivlodex

Products Affected

- *meloxicam submicronized*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial and failure or intolerance to generic meloxicam tablets and one additional generic NSAID |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vizimpro

Products Affected

- VIZIMPRO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of metastatic non-small cell lung cancer -AND- one of the following (1 or 2): 1. Epidermal growth factor (EGFR) exon 19 deletions - OR- 2. Epidermal growth factor receptor (EGFR) exon 21 L858R substitution mutations. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vonjo

Products Affected

- VONJO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis of intermediate or high-risk myelofibrosis - AND- attestation of a platelet count of less than $50 \times 10^9/L$. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

voriconazole

Products Affected

- **VFEND IV**
- *voriconazole intravenous*

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- attestation that the beneficiary cannot take oral voriconazole |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 3 months |
| Other Criteria | For reauthorization, attestation of continued indicators of active disease (e.g. histopathology, positive cultures) is required |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vosevi

Products Affected

- VOSEVI

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

votrient

Products Affected

- VOTRIENT

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | Documentation of adipocytic soft tissue sarcoma or gastrointestinal stromal tumor |
| Required Medical Information | Documentation of diagnosis -AND- if applicable to diagnosis, alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Voxzogo

Products Affected

- VOXZOGO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of achondroplasia as evidenced by an FGFR3 gene mutation detected by genetic testing -AND- all of the following (1-2): 1) baseline annualized growth velocity (AGV), 2) attestation that the member's epiphyses have not closed. |
| Age Restrictions | Deny if less than 5 years of age or greater than 17 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of increase in annualized growth velocity (AGV) from baseline and attestation that the member's epiphyses have not closed are required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vraylar

Products Affected

- VRAYLAR ORAL CAPSULE
- VRAYLAR ORAL CAPSULE,DOSE PACK

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- trial, intolerance, or contraindication to one other formulary generic atypical antipsychotic (e.g. quetiapine). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vtama

Products Affected

- VTAMA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of all of the following (1-3). 1) Documentation of plaque psoriasis -AND- 2) trial and failure or intolerance to at least one generic, formulary medium, high, or ultrahigh potency topical corticosteroid (e.g. fluocinonide, triamcinolone, betamethasone) -OR- psoriasis on facial or intertriginous areas -AND- 3) trial and failure, contraindication, or intolerance to one generic, formulary vitamin D analog (e.g., calcipotriene, calcitriol) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Vuity

Products Affected

- VUITY

| PA Criteria | Criteria Details |
|-------------------------------------|------------------------------------|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. |
| Age Restrictions | Deny if less than 18 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

vumerity

Products Affected

- VUMERITY

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use with other disease modifying agents such as interferons, Copaxone, Tysabri, Aubagio, Gilenya |
| Required Medical Information | Documentation of relapsing form of multiple sclerosis (e.g. relapsing-remitting, clinically isolated syndrome, or active secondary progressive disease) -AND- Therapeutic failure or intolerance to generic dimethyl fumarate |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 5 years |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

wakix

Products Affected

- WAKIX

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | <p>Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required.</p> |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | <p>If no diagnosis of cataplexy, trial and failure, intolerance, or contraindication to generic modafinil and a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required -OR- Prescriber attests a significant concern about the potential for illegal drug diversion. For reauthorization, provider attestation of improvement in symptoms of narcolepsy or improvement in symptoms of cataplexy (if applicable).</p> |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Welireg

Products Affected

- **WELIREG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of von Hippel Lindau (VHL) syndrome -AND- one of the following diagnoses not requiring immediate surgery (1, 2, or 3): 1) Renal cell carcinoma. 2) CNS hemangioblastoma. 3) Pancreatic neuroendocrine tumor. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xalkori

Products Affected

- **XALKORI**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) documentation of ALK or ROS1 mutation status |
| Age Restrictions | Deny if less than 18 years of age for NSCLC. Deny if less than 1 year of age or greater than 21 years of age for ALCL. |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Xarelto Suspension

Products Affected

- **XARELTO ORAL SUSPENSION FOR RECONSTITUTION**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Inability to swallow Xarelto (Rivaroxaban) tablets. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, member continues to have an inability to swallow Xarelto (Rivaroxaban) tablets. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xcopri

Products Affected

- **XCOPRI 150MG X1)**
- **XCOPRI MAINTENANCE PACK ORAL • XCOPRI TITRATION PACK
TABLET 250MG/DAY(150 MG X1-
100MG X1), 350 MG/DAY (200 MG X1-**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of partial-onset seizures -AND- Therapeutic failure, intolerance or contraindication to 1 other anti-epileptic drug (e.g. carbamazepine, levetiracetam) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xeljanz

Products Affected

- XELJANZ ORAL TABLET
- XELJANZ XR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For moderate to severe rheumatoid arthritis and an inadequate response or intolerance to methotrexate. Xeljanz immediate release for juvenile idiopathic arthritis, inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) -OR- requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. For ankylosing spondylitis, inadequate response or intolerance to at least one nonsteroidal anti-inflammatory drug (NSAID). |
| Age Restrictions | Deny if less than 18 years of age for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, ankylosing spondylitis, or less than 2 years of age for juvenile idiopathic arthritis |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | The member has experienced inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker. Doses greater than 10 mg per day for Xeljanz and 11 mg per day for Xeljanz XR will not be approved for rheumatoid arthritis and psoriatic arthritis. Doses greater than 20mg per day for Xeljanz and 22 mg per day for Xeljanz XR will not be approved for ulcerative colitis. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xeljanz solution

Products Affected

- XELJANZ ORAL SOLUTION

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of juvenile idiopathic arthritis -AND- Inadequate response or intolerance to at least one DMARD (e.g., methotrexate, leflunomide) or requires initial biologic therapy due to involvement of high-risk joints, high disease activity or at high risk of disabling joint damage. |
| Age Restrictions | Deny if less than 2 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | The member has experienced therapeutic failure or intolerance to at least 1 tumor necrosis factor (TNF) blocker. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xenazine

Products Affected

- *tetrabenazine oral tablet 12.5 mg, 25 mg*
- **XENAZINE ORAL TABLET 12.5 MG, 25 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- if requesting brand Xenazine, trial and failure or intolerance to generic tetrabenazine has been documented - AND- attestation that the beneficiary is not actively suicidal |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | In patients with comorbid depression, attestation of adequate treatment for depression is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xermelo

Products Affected

- XERMELO

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of carcinoid syndrome diarrhea AND used in combination with a somatostatin analog AND trial and failure of somatostatin analog monotherapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xgeva

Products Affected

- XGEVA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis. For hypercalcemia of malignancy, refractory to bisphosphonates. For giant cell tumor of bone, unresectable or surgical resection is likely to result in severe morbidity -AND- one of the following (1. or 2.)- 1.) the member is 18 years old or older -OR- 2.) the member is a skeletally mature adolescent (e.g. has at least one mature long bone) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xifaxan

Products Affected

- XIFAXAN ORAL TABLET 550 MG

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of 1 or 2. 1) Diagnosis of hepatic encephalopathy AND trial/failure, intolerance, or contraindication to lactulose. 2) Diagnosis of Irritable Bowel Syndrome with Diarrhea (IBS-D) AND trial/failure, intolerance to one of the following medications for IBS-D or documentation of contraindication to all: antidiarrheal (e.g., loperamide), antispasmodic (e.g., dicyclomine, hyoscyamine), tricyclic antidepressant (e.g., amitriptyline, nortriptyline). |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Hepatic encephalopathy: 1 year. IBS-D: 14 days. |
| Other Criteria | No more than three courses of rifaximin for the treatment of IBS-D will be approved per lifetime. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xolair

Products Affected

- XOLAIR

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of chronic idiopathic urticaria with trial/failure or intolerance of a second-generation non-sedating H1 antihistamine at the maximum recommended doses (e.g., cetirizine, fexofenadine, loratadine, desloratadine, levocetirizine) -OR- Documentation of moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen -AND- Baseline IgE titre greater than or equal to 30 IU/mL -AND- symptoms that are inadequately controlled despite a 3 month trial of both 1. and 2. 1) medium-dose inhaled corticosteroid or systemic steroid 2) a long-acting beta-agonist or leukotriene antagonist - AND- patient is currently on the optimal dose of a long-acting beta2-agonist, leukotriene modifier, or theophylline -OR- Documentation of add-on maintenance treatment for nasal polyps -AND- trial & failure, intolerance or contraindication to intra-nasal corticosteroids |
| Age Restrictions | Deny if less than 12 years of age in treatment for chronic idiopathic urticaria -OR- deny if less than 6 years of age for severe persistent asthma -OR- deny if less than 18 years of age for nasal polyps |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For reauthorization, attestation of decreased rescue medication or oral corticosteroid use, decrease frequency of exacerbation, increased pulmonary function from baseline or reduction in asthma related symptoms in treatment of asthma -OR- improved symptoms in treatment of CIU -OR- reduction in nasal polyp score or nasal congestion/obstruction severity score in treatment of nasal polyps |
| Indications | All FDA-approved Indications. |

| PA Criteria | Criteria Details |
|-----------------------|-------------------------|
| Off Label Uses | |

xospata

Products Affected

- XOSPATA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- FLT3 mutations, if applicable to diagnosis |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xpovio

Products Affected

- **XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40 MG/WEEK (40 MG X 1), 40MG TWICE WEEK (40 MG X 2), 60 MG/WEEK (60 MG X 1), 60MG TWICE WEEK (120 MG/WEEK), 80 MG/WEEK (40 MG X 2), 80MG TWICE WEEK (160 MG/WEEK)**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of use in combination with dexamethasone for relapse or refractory multiple myeloma with failure, intolerance or contraindication to 5 therapies (e.g. bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab) -OR- Documentation of use in combination with both bortezomib and dexamethasone for relapse or refractory multiple myeloma after receiving 1 prior multiple myeloma therapy -OR- Documentation of relapsing or refractory diffuse large B-cell lymphoma with failure, intolerance or contraindication to at least 2 lines of systemic therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xtandi

Products Affected

- **XTANDI ORAL CAPSULE**
- **XTANDI ORAL TABLET 40 MG, 80 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- one of the following (1. or 2.): 1. Concomitant GnRH analog 2. The member has had a bilateral orchiectomy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xuriden

Products Affected

- XURIDEN

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of hereditary orotic aciduria |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xyrem

Products Affected

- XYREM

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP. If the member has a diagnosis of cataplexy provision of baseline number of cataplexy episodes is required. |
| Age Restrictions | Deny if less than 7 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | If no diagnosis of cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy and cataplexy (if applicable) is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

xywav

Products Affected

- XYWAV

| PA Criteria | Criteria Details |
|------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Diagnosis of narcolepsy -AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) - AND- Documentation of the following (1, 2, or 3): 1) Hypocretin-1 deficiency defined by (A or B), A) Cerebrospinal fluid hypocretin-1 less than 110 pg/mL. B) Cerebrospinal fluid hypocretin-1 less than 1/3 of the normal value based on laboratory reference range -OR- 2) Multiple sleep latency test (MSLT) documenting MSL less than 8 minutes and 2 sleep-onset rapid eye movement periods (SOREMP) -OR- 3) MSLT documenting MSL less than 8 minutes and 1 SOREMP and Polysomnography substantiating 1 SOREMP -AND- Sensitivity to sodium intake due to heart failure, hypertension or impaired renal function. If the member has a diagnosis of cataplexy, provision of baseline number of cataplexy episodes is required. -OR- (II) Diagnosis of idiopathic hypersomnia - AND- Documentation of baseline data of excessive daytime sleepiness (EDS) via the Epworth Sleepiness Scale (ESS) or Maintenance of Wakefulness Test (MWT) -AND- documentation the member does not have cataplexy -AND- documentation of less than 2 SOREMPs -AND- documentation of the following (1, 2, or 3): 1) MSLT documenting MSL less than or equal to 8 minutes -OR- 2) polysomnography demonstrating total sleep time greater than or equal to 660 minutes per 24 hours -OR- 3) wrist actigraphy demonstrating total sleep time greater than or equal to 660 minutes per 24 hours. |
| Age Restrictions | For narcolepsy, deny if less than 7 years of age. For idiopathic hypersomnia, deny if less than 18 years of age. |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |

| PA Criteria | Criteria Details |
|-----------------------|--|
| Other Criteria | If diagnosis of narcolepsy without cataplexy- trial and failure, intolerance, or contraindication to generic modafinil AND a generic CNS stimulant indicated for use in narcolepsy (e.g. methylphenidate, amphetamine salts) is required. For reauthorization, attestation supporting improvement in symptoms of narcolepsy, idiopathic hypersomnia and cataplexy (if applicable) is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

yonsa

Products Affected

- YONSA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- all of the following: 1) Alternatives tried/failed 2) Concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ZAVESCA

Products Affected

- *miglustat*
- ZAVESCA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of mild to moderate type 1 Gaucher disease confirmed by the following (A. or B.) A. (1, 2, 3, 4, or, 5): 1)Hepatomegaly. 2)Splenomegaly. 3)Bone disease (i.e. osteonecrosis, osteopenia, secondary pathologic fractures, bone infarct). 4)Bone marrow complications as defined by anemia with hemoglobin less than or equal to 11.5 g/dL for females or 12.5 g/dL for males or thrombocytopenia with platelet count less than or equal to 120,000/mm ³ -OR- 5)Symptomatic disease (e.g. bone pain, exertional limitation, cachexia). -OR- B. Attestation of deficiency in glucocerebrosidase activity in peripheral leukocytes or genetic testing confirms mutant alleles. |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Documentation of trial/failure or intolerance to at least one enzyme replacement therapy product including Cerezyme, Elelyso, or VPRIV. For brand Zavesca, documentation of failure on generic miglustat. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zejula

Products Affected

- ZEJULA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- Alternatives tried/failed |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zelboraf

Products Affected

- TAFINLAR
- ZELBORAF

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Wild-type BRAF melanoma |
| Required Medical Information | Documentation of diagnosis -AND- both of the following. 1) BRAF mutations, if applicable to diagnosis. 2) Alternatives tried/failed and concomitant therapy, if applicable to diagnosis (e.g. diagnosis of V600K metastatic melanoma and drug regimen of Zelboraf and Cotellic) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zepatier

Products Affected

- ZEPATIER

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Criteria will be applied consistent with current AASLD/IDSA guidance - AND- the member has a contraindication to or is otherwise not a candidate for all regimens recommended by the AASLD/IDSA guidelines containing the following agents: ledipasvir/sofosbuvir, sofosbuvir/velpatasvir, glecaprevir/pibrentasvir. |
| Age Restrictions | Deny if less than 12 years of age |
| Prescriber Restrictions | |
| Coverage Duration | Criteria/duration applied consistent with current AASLD-IDSA guidance |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zeposia

Products Affected

- **ZEPOSIA**
- **ZEPOSIA STARTER KIT**
- **ZEPOSIA STARTER PACK**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | Concomitant use of Zeposia and other disease modifying agents such as interferons, Copaxone, Tysabri. |
| Required Medical Information | Documentation of diagnosis. For moderate to severe active ulcerative colitis, inadequate response or intolerance to one systemic therapy (e.g. methotrexate, cyclosporine). |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | Ulcerative Colitis: 12 months, Multiple Sclerosis: 24 months |
| Other Criteria | For moderate to severe active ulcerative colitis, patients must have an adequate trial or intolerance to 2 of the following preferred products Humira, Xeljanz/Xeljanz XR and Stelara SC. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zolinza

Products Affected

- ZOLINZA

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following 2 systemic therapies. Systemic therapies include bexarotene, interferon alpha, extracorporeal photochemotherapy, PUVA, single agent or combination chemotherapies (e.g. cyclophosphamide, vinblastine, romidepsin) |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ztlido

Products Affected

- ZTLIDO

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of postherpetic neuralgia (PHN) -AND- One of the following (1,2 or 3): 1) trial and failure of 1 other agent used to treat PHN (e.g. gabapentin) 2) Inability to swallow oral medication 3) Unable to take an oral medication due to potential adverse events (e.g. sedation) |
| Age Restrictions | |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | Patients must have an adequate trial/failure or contraindication to Lidoderm or lidocaine patch 5%. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

ZYDELIG

Products Affected

- ZYDELIG

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | First line treatment. Combination use with benadmustine and/or rituximab for the treatment of FL. |
| Required Medical Information | Documentation of diagnosis -AND- all of the following, if applicable to diagnosis: 1) Alternatives tried/failed 2) Concomitant therapy 3) Candidacy for use of rituximab alone |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zykadia

Products Affected

- ZYKADIA

| PA Criteria | Criteria Details |
|-------------------------------------|--|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- ALK mutations, as detected by an FDA approved test. |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

zytiga

Products Affected

- *abiraterone oral tablet 250 mg, 500 mg*
- **ZYTIGA ORAL TABLET 250 MG, 500 MG**

| PA Criteria | Criteria Details |
|-------------------------------------|---|
| Exclusion Criteria | |
| Required Medical Information | Documentation of diagnosis -AND- concomitant therapy |
| Age Restrictions | Deny if less than 18 years of age |
| Prescriber Restrictions | |
| Coverage Duration | 12 months |
| Other Criteria | For brand Zytiga, trial and failure of generic abiraterone is required. |
| Indications | All FDA-approved Indications. |
| Off Label Uses | |

Index of Drugs

| | | | |
|---|-----|--|-----|
| ABILIFY MYCITE ORAL TABLET WITH SENSOR AND PATCH 10 MG, 15 MG, 20 MG, 5 MG | 25 | ALTRENO | 362 |
| ABILIFY ORAL TABLET | 25 | ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG | 16 |
| <i>abiraterone oral tablet 250 mg, 500 mg</i> | 427 | ALUNBRIG ORAL TABLETS,DOSE PACK | 16 |
| <i>acetaminophen-caff-dihydrocod oral capsule</i> | 273 | ALYQ | 282 |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 273 | AMBIEN | 273 |
| <i>acetaminophen-codeine oral tablet</i> | 273 | AMBIEN CR | 273 |
| <i>acitretin</i> | 1 | <i>ambrisentan</i> | 282 |
| ACTEMRA ACTPEN | 2 | <i>amitriptyline</i> | 144 |
| ACTEMRA SUBCUTANEOUS | 2 | <i>amitriptyline-chlordiazepoxide</i> | 144 |
| ACTHAR | 3 | <i>amphetamine sulfate</i> | 110 |
| ACTIMMUNE | 5 | AMPYRA | 18 |
| ACTIQ BUCCAL LOZENGE ON A HANDLE 1,200 MCG, 1,600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG .. | 359 | AMRIX | 144 |
| <i>adapalene topical cream</i> | 362 | ANAFRANIL | 144 |
| <i>adapalene topical gel 0.3 %</i> | 362 | ANDRODERM | 349 |
| <i>adapalene topical swab</i> | 362 | ANDROGEL TRANSDERMAL GEL IN METERED-DOSE PUMP | 349 |
| ADBRY | 6 | APOKYN | 20 |
| ADCIRCA | 282 | <i>apomorphine</i> | 20 |
| ADEMPAS | 282 | ARALAST NP INTRAVENOUS RECON SOLN 1,000 MG | 15 |
| ADLARITY | 8 | ARCALYST | 167 |
| AFINITOR | 9 | ARIKAYCE | 21 |
| AFINITOR DISPERZ ORAL TABLET FOR SUSPENSION 2 MG, 3 MG, 5 MG ...9 | | <i>aripiprazole</i> | 25 |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO-INJECTOR 140 MG/ML, 70 MG/ML | 10 | <i>armodafinil</i> | 236 |
| AIRDUO DIGIHALER | 11 | ARMONAIR DIGIHALER | 22 |
| AJOVY AUTOINJECTOR | 12 | ASCOMP WITH CODEINE | 273 |
| AJOVY SYRINGE | 12 | ASPRUZYO SPRINKLE | 23 |
| AKLIEF | 362 | ATRALIN | 362 |
| ALECENSA | 13 | AUBAGIO | 26 |
| ALKINDI SPRINKLE | 14 | AURYXIA | 27 |
| <i>alose tron oral tablet 0.5 mg, 1 mg</i> | 199 | AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG | 28 |
| ALPRAZOLAM INTENSOL | 273 | AVEED | 349 |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 273 | AVITA | 362 |
| <i>alprazolam oral tablet extended release 24 hr 0.5 mg, 1 mg, 2 mg, 3 mg</i> | 273 | AYVAKIT | 29 |
| <i>alprazolam oral tablet,disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg</i> | 273 | BAFIERTAM | 30 |
| | | BALVERSA | 31 |
| | | BANZEL | 32 |
| | | BELBUCA | 33 |
| | | BENLYSTA SUBCUTANEOUS | 35 |
| | | <i>benznidazole</i> | 37 |
| | | <i>benztropine oral</i> | 144 |
| | | BERINERT INTRAVENOUS KIT | 38 |

| | | | |
|---|-----|---|-----|
| BESREMI | 40 | <i>clobazam oral suspension</i> | 242 |
| BETHKIS | 60 | <i>clobazam oral tablet</i> | 242 |
| <i>bexarotene oral</i> | 338 | <i>clomipramine</i> | 144 |
| <i>bexarotene topical</i> | 338 | <i>clonidine hcl oral tablet extended release</i> | |
| BIVIGAM | 156 | <i>12 hr</i> | 7 |
| BONJESTA | 41 | <i>codeine sulfate</i> | 273 |
| <i>bosentan</i> | 282 | <i>codeine-butalbital-asa-caff</i> | 273 |
| BOSULIF | 42 | COMETRIQ | 71 |
| BRAFTOVI ORAL CAPSULE 75 MG | 43 | CONZIP | 273 |
| BRONCHITOL | 44 | COPIKTRA | 72 |
| BRUKINSA | 45 | CORLANOR ORAL SOLUTION | 73 |
| BUPHENYL | 46 | CORLANOR ORAL TABLET 5 MG, | |
| <i>buprenorphine</i> | 47 | 7.5 MG | 73 |
| <i>butalbital-acetaminop-caf-cod oral capsule</i> | | CORTROPHIN GEL | 284 |
| <i>50-300-40-30 mg, 50-325-40-30 mg</i> | 273 | COSENTYX (2 SYRINGES) | 74 |
| BUTRANS | 47 | COSENTYX PEN (2 PENS) | 74 |
| BYLVAY ORAL CAPSULE 1,200 | | COSENTYX SUBCUTANEOUS | |
| MCG, 400 MCG | 49 | SYRINGE 75 MG/0.5 ML | 74 |
| BYLVAY ORAL PELLET 200 MCG | 49 | COTELLIC | 75 |
| CABLIVI INJECTION KIT | 50 | CRINONE | 76 |
| CABOMETYX | 51 | <i>cyclobenzaprine oral capsule, extended</i> | |
| CALQUENCE | 52 | <i>release 24hr</i> | 144 |
| CALQUENCE (ACALABRUTINIB | | <i>cyclobenzaprine oral tablet 10 mg, 5 mg,</i> | |
| MAL) | 52 | <i>7.5 mg</i> | 144 |
| CAMZYOS | 53 | <i>cyproheptadine</i> | 144 |
| CAPLYTA | 54 | CYSTADROPS | 77 |
| CAPRELSA | 55 | CYSTARAN | 77 |
| CARAC | 56 | <i>dalfampridine</i> | 18 |
| CARBAGLU | 57 | DARAPRIM | 78 |
| <i>carbinoxamine maleate oral liquid</i> | 58 | DARTISLA | 79 |
| <i>carbinoxamine maleate oral tablet 4 mg</i> | 58 | DAURISMO ORAL TABLET 100 MG, | |
| <i>carglumic acid</i> | 57 | 25 MG | 80 |
| <i>carisoprodol</i> | 144 | DAYTRANA | 81 |
| CERDELGA | 59 | <i>deferasirox</i> | 82 |
| CHENODAL | 61 | <i>deferiprone</i> | 115 |
| <i>chloroquine phosphate oral tablet 250 mg,</i> | | DEMEROL (PF) INJECTION | |
| <i>500 mg</i> | 62 | SYRINGE 25 MG/ML | 273 |
| <i>chlorzoxazone</i> | 144 | DEMEROL INJECTION SOLUTION | |
| CHOLBAM | 63 | 50 MG/ML | 273 |
| CIALIS ORAL TABLET 2.5 MG, 5 MG .. | 64 | DEPO-TESTOSTERONE | 349 |
| CIBINQO | 65 | DESOXYN | 213 |
| CIMZIA | 66 | DIACOMIT ORAL CAPSULE 250 MG, | |
| CIMZIA POWDER FOR RECONST | 66 | 500 MG | 83 |
| CINRYZE | 68 | DIACOMIT ORAL POWDER IN | |
| <i>citalopram oral capsule</i> | 70 | PACKET 250 MG, 500 MG | 83 |
| <i>clindamycin-tretinoin</i> | 362 | DIBENZYLINE | 265 |

| | | | |
|--|-----|--|-----|
| DICLEGIS | 41 | ENBREL SUBCUTANEOUS | |
| <i>diclofenac epolamine</i> | 121 | SOLUTION | 100 |
| <i>diclofenac sodium topical gel 3 %</i> | 320 | ENBREL SUBCUTANEOUS SYRINGE | |
| DIFFERIN TOPICAL CREAM | 362 | 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 100 |
| DIFFERIN TOPICAL GEL WITH | | ENBREL SURECLICK | 100 |
| PUMP | 362 | ENDARI | 101 |
| DIFFERIN TOPICAL LOTION | 362 | ENDOCET ORAL TABLET 10-325 | |
| <i>dihydroergotamine nasal</i> | 84 | MG, 5-325 MG, 7.5-325 MG | 273 |
| DILAUDID ORAL LIQUID | 273 | ENSPRYNG | 102 |
| DILAUDID ORAL TABLET | 273 | ENTADFI | 103 |
| <i>dimethyl fumarate oral capsule, delayed</i> | | EPCLUSA ORAL PELLETS IN | |
| <i>release(dr/ec) 120 mg, 120 mg (14)- 240</i> | | PACKET 150-37.5 MG, 200-50 MG | 104 |
| <i>mg (46), 240 mg</i> | 346 | EPCLUSA ORAL TABLET | 104 |
| DOJOLVI | 85 | EPIDIOLEX | 105 |
| DOPTELET (10 TAB PACK) | 86 | EPRONTIA | 106 |
| DOPTELET (15 TAB PACK) | 86 | <i>ergoloid</i> | 144 |
| DOPTELET (30 TAB PACK) | 86 | <i>ergotamine-caffeine</i> | 144 |
| <i>doxepin oral capsule</i> | 144 | ERIVEDGE | 107 |
| <i>doxepin oral concentrate</i> | 144 | ERLEADA | 108 |
| <i>doxepin oral tablet</i> | 144 | <i>erlotinib</i> | 94 |
| <i>doxepin topical</i> | 87 | ESBRIET ORAL CAPSULE | 169 |
| <i>doxylamine-pyridoxine (vit b6)</i> | 41 | ESBRIET ORAL TABLET 267 MG, | |
| DRIZALMA SPRINKLE ORAL | | 801 MG | 169 |
| CAPSULE, DELAYED REL | | <i>eszopiclone</i> | 273 |
| SPRINKLE 20 MG, 30 MG, 40 MG, 60 | | EUCRISA | 109 |
| MG | 88 | EVEKEO | 110 |
| <i>droxidopa</i> | 229 | EVENTY SUBCUTANEOUS | |
| DUEXIS | 89 | SYRINGE 210MG/2.34ML (| |
| DUOBRII | 91 | 105MG/1.17MLX2) | 111 |
| DUPIXENT PEN SUBCUTANEOUS | | <i>everolimus (antineoplastic) oral tablet 10</i> | |
| PEN INJECTOR 200 MG/1.14 ML, 300 | | <i>mg, 2.5 mg, 5 mg, 7.5 mg</i> | 9 |
| MG/2 ML | 92 | <i>everolimus (antineoplastic) oral tablet for</i> | |
| DUPIXENT SYRINGE | | <i>suspension 2 mg, 3 mg, 5 mg</i> | 9 |
| SUBCUTANEOUS SYRINGE 100 | | EVRYSDI | 112 |
| MG/0.67 ML, 200 MG/1.14 ML, 300 | | EXJADE | 82 |
| MG/2 ML | 92 | EXKIVITY | 94 |
| EDLUAR | 273 | EXSERVAN | 113 |
| EGRIFTA SV | 95 | FABIOR | 343 |
| ELYXYB | 96 | FASENRA | 114 |
| EMFLAZA | 97 | FASENRA PEN | 114 |
| EMGALITY PEN | 98 | <i>febuxostat</i> | 370 |
| EMGALITY SYRINGE | | <i>fentanyl citrate buccal lozenge on a handle</i> | |
| SUBCUTANEOUS SYRINGE 120 | | <i>1,200 mcg, 1,600 mcg, 200 mcg, 400 mcg,</i> | |
| MG/ML, 300 MG/3 ML (100 MG/ML X | | <i>600 mcg, 800 mcg</i> | 359 |
| 3) | 98 | | |
| ENBREL MINI | 100 | | |

| | | | |
|---|-----|--|-----|
| <i>fentanyl citrate buccal tablet, effervescent</i> 100 mcg, 200 mcg, 400 mcg, 600 mcg, 800 mcg..... | 359 | GAVRETO | 128 |
| <i>fentanyl transdermal patch 72 hour 100</i> <i>mcg/hr, 12 mcg/hr, 25 mcg/hr, 37.5</i> <i>mcg/hour, 50 mcg/hr, 62.5 mcg/hour, 75</i> <i>mcg/hr, 87.5 mcg/hour</i> | 273 | GENOTROPIN | 136 |
| FENTORA BUCCAL TABLET, EFFERVESCENT 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG | 359 | GENOTROPIN MINIQUICK | 136 |
| FERRIPROX | 115 | GILENYA ORAL CAPSULE 0.5 MG ... | 129 |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK | 116 | GILOTRIF | 94 |
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 116 | GIMOTI | 130 |
| FEXMID | 144 | GLASSIA | 15 |
| <i> fingolimod</i> | 129 | GLEEVEC ORAL TABLET 100 MG, 400 MG | 131 |
| FINTEPLA | 117 | GLYCATE | 132 |
| FIORICET WITH CODEINE | 273 | <i>glycopyrrolate oral tablet 1.5 mg</i> | 132 |
| FIRAZYR | 118 | GOCOVRI ORAL CAPSULE,EXTENDED RELEASE 24HR 137 MG, 68.5 MG | 133 |
| FIRDAPSE | 120 | GRALISE ORAL TABLET EXTENDED RELEASE 24 HR 300 MG, 600 MG | 134 |
| FLEBOGAMMA DIF INTRAVENOUS SOLUTION 10 % | 156 | GRASTEK | 135 |
| FLECTOR | 121 | <i>guanfacine oral tablet extended release 24</i> <i>hr</i> | 7 |
| FLEQSUVY | 122 | HAEGARDA | 138 |
| FORTEO SUBCUTANEOUS PEN INJECTOR 20 MCG/DOSE (600MCG/2.4ML) | 123 | HALCION ORAL TABLET 0.25 MG ... 273 | |
| FORTESTA | 349 | HARVONI ORAL PELLETS IN PACKET | 140 |
| FOTIVDA | 124 | HARVONI ORAL TABLET 90-400 MG | 140 |
| <i>gabapentin oral capsule 100 mg, 300 mg,</i> <i>400 mg</i> | 125 | HEMADY | 141 |
| <i>gabapentin oral solution 250 mg/5 ml</i> | 125 | HETLIOZ | 142 |
| <i>gabapentin oral tablet 600 mg, 800 mg</i> | 125 | HETLIOZ LQ | 143 |
| GALAFOLD | 126 | HORIZANT ORAL TABLET EXTENDED RELEASE 300 MG, 600 MG | 148 |
| GAMMAGARD LIQUID | 156 | HUMATROPE INJECTION CARTRIDGE | 136 |
| GAMMAGARD S-D (IGA < 1 MCG/ML) | 156 | HUMIRA PEN | 149 |
| GAMMAKED INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 156 | HUMIRA PEN CROHNS-UC-HS START | 149 |
| GAMMAPLEX | 156 | HUMIRA PEN PSOR-UVEITS-ADOL HS | 149 |
| GAMMAPLEX (WITH SORBITOL) | 156 | HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 149 |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 156 | HUMIRA(CF) | 149 |
| GATTEX 30-VIAL | 127 | HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 149 |

| | | | |
|---|-----|---|-----|
| HUMIRA(CF) PEN | 149 | INGREZZA ORAL CAPSULE 40 MG, | |
| HUMIRA(CF) PEN CROHNS-UC-HS .. | 149 | 60 MG, 80 MG | 162 |
| HUMIRA(CF) PEN PEDIATRIC UC | 149 | INLYTA | 163 |
| HUMIRA(CF) PEN PSOR-UV-ADOL | | INQOVI | 164 |
| HS | 149 | INREBIC | 165 |
| <i>hydrocodone bitartrate oral capsule, oral</i> | | INTRAROSA | 168 |
| <i>only, er 12hr</i> | 273 | INTRON A INJECTION RECON | |
| <i>hydrocodone bitartrate oral tablet,oral</i> | | SOLN 10 MILLION UNIT (1 ML), 50 | |
| <i>only,ext.rel.24 hr</i> | 273 | MILLION UNIT (1 ML) | 166 |
| <i>hydrocodone-acetaminophen oral solution</i> | | INTUNIV ER | 7 |
| <i>7.5-325 mg/15 ml</i> | 273 | IRESSA | 171 |
| <i>hydrocodone-acetaminophen oral tablet</i> | | ISTURISA | 172 |
| <i>10-300 mg, 10-325 mg, 5-300 mg, 5-325</i> | | <i>itraconazole</i> | 173 |
| <i>mg, 7.5-300 mg, 7.5-325 mg</i> | 273 | JADENU | 82 |
| <i>hydrocodone-ibuprofen</i> | 273 | JADENU SPRINKLE | 82 |
| <i>hydromorphone (pf) injection solution 10</i> | | JAKAFI | 174 |
| <i>(mg/ml) (5 ml), 10 mg/ml</i> | 273 | JATENZO ORAL CAPSULE 158 MG, | |
| <i>hydromorphone oral liquid</i> | 273 | 198 MG, 237 MG | 349 |
| <i>hydromorphone oral tablet</i> | 273 | JAVYGTOR ORAL POWDER IN | |
| <i>hydromorphone oral tablet extended</i> | | PACKET 100 MG | 186 |
| <i>release 24 hr 12 mg, 16 mg, 32 mg, 8 mg</i> ...273 | | JUXTAPID ORAL CAPSULE 10 MG, | |
| <i>hydroxyzine hcl oral solution 10 mg/5 ml</i> .. | 144 | 20 MG, 30 MG, 5 MG | 147 |
| <i>hydroxyzine hcl oral tablet</i> | 144 | JYNARQUE ORAL TABLET | 175 |
| <i>hydroxyzine pamoate</i> | 144 | JYNARQUE ORAL TABLETS, | |
| HYFTOR | 151 | SEQUENTIAL | 175 |
| HYSINGLA ER | 273 | KALYDECO ORAL GRANULES IN | |
| IBRANCE | 152 | PACKET 25 MG, 50 MG, 75 MG | 176 |
| IBSRELA | 153 | KALYDECO ORAL TABLET | 176 |
| <i>ibuprofen-famotidine</i> | 90 | KAPVAY | 7 |
| <i>icatibant</i> | 118 | KERENDIA | 177 |
| ICLUSIG | 154 | KESIMPTA PEN | 178 |
| IDHIFA ORAL TABLET 100 MG, 50 | | KEVEYIS | 179 |
| MG | 155 | KEVZARA | 180 |
| ILUMYA | 158 | KINERET | 181 |
| <i>imatinib oral tablet 100 mg, 400 mg</i> | 131 | KISQALI FEMARA CO-PACK ORAL | |
| IMBRUVICA ORAL CAPSULE 140 | | TABLET 200 MG/DAY(200 MG X 1)- | |
| MG, 70 MG | 159 | 2.5 MG, 400 MG/DAY(200 MG X 2)-2.5 | |
| IMBRUVICA ORAL SUSPENSION | 159 | MG, 600 MG/DAY(200 MG X 3)-2.5 | |
| IMBRUVICA ORAL TABLET | 159 | MG | 182 |
| <i>imipramine hcl</i> | 144 | KISQALI ORAL TABLET 200 | |
| <i>imipramine pamoate</i> | 144 | MG/DAY (200 MG X 1), 400 MG/DAY | |
| INBRIJA INHALATION CAPSULE, | | (200 MG X 2), 600 MG/DAY (200 MG X | |
| W/INHALATION DEVICE | 160 | 3) | 182 |
| INCRELEX | 161 | KLISYRI | 183 |
| INGREZZA INITIATION PACK | 162 | KORLYM | 184 |

| | | | |
|--|-----|--|-----|
| KOSELUGO ORAL CAPSULE 10 MG, 25 MG | 185 | MAVENCLAD (4 TABLET PACK) | 207 |
| KUVAN | 186 | MAVENCLAD (5 TABLET PACK) | 207 |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 187 | MAVENCLAD (6 TABLET PACK) | 207 |
| LAMPIT | 188 | MAVENCLAD (7 TABLET PACK) | 207 |
| <i>lapatinib</i> | 367 | MAVENCLAD (8 TABLET PACK) | 207 |
| LATUDA ORAL TABLET 120 MG, 20 MG, 40 MG, 60 MG, 80 MG | 189 | MAVENCLAD (9 TABLET PACK) | 207 |
| <i>ledipasvir-sofosbuvir</i> | 140 | MAVYRET ORAL PELLETS IN PACKET | 208 |
| <i>lenalidomide</i> | 302 | MAVYRET ORAL TABLET | 208 |
| LENVIMA | 190 | MAYZENT ORAL TABLET 0.25 MG, 1 MG, 2 MG | 209 |
| LETAIRIS | 282 | MAYZENT STARTER(FOR 1MG MAINT) | 209 |
| LEUKINE INJECTION RECON SOLN | 191 | MAYZENT STARTER(FOR 2MG MAINT) | 209 |
| <i>levorphanol tartrate</i> | 273 | <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 210 |
| LICART | 121 | <i>megestrol oral tablet</i> | 210 |
| <i>lidocaine hcl mucous membrane solution 4 % (40 mg/ml)</i> | 358 | MEKINIST | 211 |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> | 193 | MEKTOVI | 212 |
| <i>lidocaine topical ointment</i> | 358 | <i>meloxicam submicronized</i> | 386 |
| <i>lidocaine-prilocaine topical cream</i> | 358 | <i>meperidine (pf) injection solution 100 mg/ml, 25 mg/ml, 50 mg/ml</i> | 273 |
| LIDODERM | 193 | <i>meperidine oral solution</i> | 273 |
| LIVMARLI | 194 | <i>meperidine oral tablet 50 mg</i> | 273 |
| LIVTENCITY | 195 | <i>metaxalone</i> | 144 |
| LOKELMA | 196 | <i>methadone oral solution 10 mg/5 ml, 5 mg/5 ml</i> | 273 |
| LONSURF | 197 | <i>methadone oral tablet 10 mg, 5 mg</i> | 273 |
| LORBRENA ORAL TABLET 100 MG, 25 MG | 198 | <i>methamphetamine</i> | 213 |
| LORZONE | 144 | METHITEST | 19 |
| LOTRONEX ORAL TABLET 0.5 MG, 1 MG | 199 | <i>methyltestosterone oral capsule</i> | 19 |
| LOVAZA | 200 | <i>miglustat</i> | 418 |
| LUMAKRAS | 201 | MIGRANAL | 84 |
| LUNESTA | 273 | <i>modafinil</i> | 280 |
| LUPKYNIS | 202 | <i>morphine concentrate oral solution</i> | 273 |
| LYBALVI | 203 | <i>morphine oral capsule, er multiphase 24 hr 120 mg, 30 mg, 45 mg, 60 mg, 75 mg, 90 mg</i> | 273 |
| LYNPARZA | 204 | <i>morphine oral capsule,extend.release pellets 10 mg, 100 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg</i> | 273 |
| LYRICA CR | 205 | <i>morphine oral solution 10 mg/5 ml, 20 mg/5 ml (4 mg/ml)</i> | 273 |
| LYRICA ORAL CAPSULE 100 MG, 150 MG, 200 MG, 225 MG, 25 MG, 300 MG, 50 MG, 75 MG | 205 | <i>morphine oral tablet</i> | 273 |
| LYRICA ORAL SOLUTION | 205 | | |
| LYVISPAH | 206 | | |
| MAVENCLAD (10 TABLET PACK) | 207 | | |

| | | | |
|---|-----|---|-----|
| <i>morphine oral tablet extended release 100 mg, 15 mg, 200 mg, 30 mg, 60 mg</i> | 273 | NUTROPIN AQ NUSPIN..... | 136 |
| MOTEGRITY..... | 214 | NUVIGIL..... | 236 |
| MS CONTIN ORAL TABLET EXTENDED RELEASE 100 MG, 15 MG, 200 MG, 30 MG, 60 MG | 273 | OCALIVA..... | 237 |
| MULPLETA..... | 215 | OCTAGAM..... | 156 |
| MYALEPT..... | 216 | <i>octreotide acetate injection solution</i> | 238 |
| MYCAPSSA..... | 217 | ODACTRA..... | 239 |
| MYFEMBREE..... | 218 | ODOMZO..... | 240 |
| NAMENDA ORAL TABLET..... | 220 | OFEV..... | 169 |
| NAMENDA TITRATION PAK..... | 220 | OLUMIANT ORAL TABLET 1 MG, 2 MG..... | 241 |
| NAMENDA XR ORAL CAPSULE,SPRINKLE,ER 24HR..... | 220 | OMNITROPE..... | 136 |
| NAMZARIC..... | 221 | ONFI ORAL SUSPENSION..... | 242 |
| <i>naproxen-esomeprazole</i> | 383 | ONFI ORAL TABLET..... | 242 |
| NATESTO..... | 349 | ONGENTYS..... | 243 |
| NATPARA..... | 222 | ONUREG..... | 244 |
| NAYZILAM..... | 223 | OPSUMIT..... | 282 |
| NERLYNX..... | 224 | OPZELURA..... | 245 |
| NEURONTIN ORAL CAPSULE 100 MG, 300 MG, 400 MG..... | 125 | ORALAIR SUBLINGUAL TABLET 300 INDX REACTIVITY..... | 246 |
| NEURONTIN ORAL SOLUTION..... | 125 | ORENCIA CLICKJECT..... | 247 |
| NEURONTIN ORAL TABLET 600 MG, 800 MG..... | 125 | ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML..... | 247 |
| NEXAVAR..... | 225 | ORENITRAM ORAL TABLET EXTENDED RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG, 5 MG..... | 282 |
| NEXLETOL..... | 226 | ORGOVYX..... | 248 |
| NEXLIZET..... | 226 | ORIAHNN..... | 249 |
| NINLARO..... | 228 | ORLISSA ORAL TABLET 150 MG, 200 MG..... | 250 |
| NORDITROPIN FLEXPRO..... | 136 | ORKAMBI ORAL GRANULES IN PACKET 100-125 MG, 150-188 MG..... | 252 |
| NORGESIC..... | 144 | ORKAMBI ORAL TABLET..... | 251 |
| NORGESIC FORTE..... | 144 | ORLADEYO..... | 253 |
| NORLIQVA..... | 17 | <i>orphenadrine citrate oral</i> | 144 |
| NORTHERA..... | 229 | <i>orphenadrine-asa-caffeine oral tablet 25-385-30 mg</i> | 144 |
| NOURIANZ..... | 230 | OSMOLEX ER ORAL TABLET, IR - ER, BIPHASIC 24HR 129 MG, 193 MG, 322 MG/DAY(129 MG X1-193MG X1).. | 254 |
| NUBEQA..... | 231 | OSPHERA..... | 255 |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR..... | 232 | OTEZLA..... | 256 |
| NUCALA SUBCUTANEOUS RECON SOLN..... | 232 | OTEZLA STARTER ORAL TABLETS,DOSE PACK 10 MG (4)-20 MG (4)-30 MG (47)..... | 256 |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML, 40 MG/0.4 ML | 232 | OTREXUP (PF)..... | 257 |
| NUCYNTA..... | 273 | | |
| NUCYNTA ER..... | 273 | | |
| NUDEXTA..... | 234 | | |
| NUPLAZID..... | 235 | | |

| | | | |
|--|-----|---|-----|
| <i>oxandrolone</i> | 19 | <i>pregabalin oral capsule 100 mg, 150 mg,</i> | |
| OXBRYTA ORAL TABLET | 258 | <i>200 mg, 225 mg, 25 mg, 300 mg, 50 mg, 75</i> | |
| OXBRYTA ORAL TABLET FOR | | <i>mg</i> | 205 |
| SUSPENSION | 259 | <i>pregabalin oral solution</i> | 205 |
| OXERVATE | 260 | <i>pregabalin oral tablet extended release 24</i> | |
| <i>oxycodone oral capsule</i> | 273 | <i>hr</i> | 205 |
| <i>oxycodone oral concentrate</i> | 273 | PRENATAL VITAMIN PLUS LOW | |
| <i>oxycodone oral solution</i> | 273 | IRON | 272 |
| <i>oxycodone oral tablet 10 mg, 15 mg, 20</i> | | <i>pretomanid</i> | 276 |
| <i>mg, 30 mg, 5 mg</i> | 273 | PRIVIGEN | 156 |
| <i>oxycodone oral tablet,oral only,ext.rel.12</i> | | PROAIR DIGIHALER | 277 |
| <i>hr 10 mg, 20 mg, 40 mg, 80 mg</i> | 273 | PROCYSBI ORAL GRANULES DEL | |
| <i>oxycodone-acetaminophen oral solution 5-</i> | | RELEASE IN PACKET | 278 |
| <i>325 mg/5 ml</i> | 273 | PROLASTIN-C INTRAVENOUS | |
| <i>oxycodone-acetaminophen oral tablet 10-</i> | | RECON SOLN | 15 |
| <i>300 mg, 10-325 mg, 2.5-325 mg, 5-300 mg,</i> | | PROLATE ORAL TABLET | 273 |
| <i>5-325 mg, 7.5-300 mg, 7.5-325 mg</i> | 273 | PROLIA | 279 |
| OXYCONTIN ORAL TABLET,ORAL | | PROMACTA ORAL POWDER IN | |
| ONLY,EXT.REL.12 HR 10 MG, 15 MG, | | PACKET 12.5 MG, 25 MG | 353 |
| 20 MG, 30 MG, 40 MG, 60 MG, 80 MG | 273 | PROMACTA ORAL TABLET 12.5 | |
| <i>oxymorphone oral tablet</i> | 273 | MG, 25 MG, 50 MG, 75 MG | 353 |
| <i>oxymorphone oral tablet extended release</i> | | <i>promethazine oral</i> | 144 |
| <i>12 hr 10 mg, 15 mg, 20 mg, 30 mg, 40 mg,</i> | | PROVIGIL | 280 |
| <i>5 mg, 7.5 mg</i> | 273 | PRUDOXIN | 87 |
| PALYNZIQ | 261 | PULMOZYME | 60 |
| PANRETIN | 262 | <i>pyrimethamine</i> | 78 |
| PANZYGA | 156 | PYRUKYND ORAL TABLET 20 MG, 5 | |
| PEGASYS | 166 | MG, 5 MG (4-WEEK PACK), 50 MG ... | 286 |
| PEMAZYRE | 263 | PYRUKYND ORAL TABLETS,DOSE | |
| PERCOCET | 273 | PACK | 286 |
| <i>perphenazine-amitriptyline</i> | 144 | QELBREE ORAL | |
| PHEBURANE | 264 | CAPSULE,EXTENDED RELEASE | |
| <i>phenobarbital</i> | 146 | 24HR 100 MG, 150 MG, 200 MG | 287 |
| <i>phenoxybenzamine</i> | 265 | QINLOCK | 288 |
| PHOSPHOLINE IODIDE | 266 | QUALAQUIN | 289 |
| PIQRAY ORAL TABLET 200 | | <i>quinine sulfate</i> | 289 |
| MG/DAY (200 MG X 1), 250 MG/DAY | | QULIPTA | 290 |
| (200 MG X1-50 MG X1), 300 MG/DAY | | RADICAVA ORS STARTER KIT | |
| (150 MG X 2) | 267 | SUSP | 291 |
| <i>pirfenidone oral tablet 267 mg, 801 mg</i> | 169 | RASUVO (PF) | 292 |
| POMALYST | 268 | RAVICTI | 293 |
| PONVORY | 269 | RECORLEV | 294 |
| PONVORY 14-DAY STARTER PACK | 269 | REDITREX (PF) | 295 |
| PRALUENT PEN | 270 | REGRANEX | 296 |
| | | RELISTOR ORAL | 297 |

| | | | |
|---|-----|--|-----|
| RELISTOR SUBCUTANEOUS SOLUTION | 298 | SEROSTIM SUBCUTANEOUS | |
| RELISTOR SUBCUTANEOUS SYRINGE 12 MG/0.6 ML, 8 MG/0.4 ML | 298 | RECON SOLN 4 MG, 5 MG, 6 MG | 136 |
| REPATHA PUSHTRONEX | 299 | <i>sertraline oral capsule</i> | 315 |
| REPATHA SURECLICK | 299 | SIGNIFOR | 316 |
| REPATHA SYRINGE | 299 | <i>sildenafil (pulm.hypertension) oral suspension for reconstitution</i> | 282 |
| RETEVMO ORAL CAPSULE 40 MG, 80 MG | 301 | <i>sildenafil (pulm.hypertension) oral tablet</i> .. | 282 |
| RETIN-A | 362 | SILENOR | 144 |
| RETIN-A MICRO | 362 | SILIQ | 317 |
| RETIN-A MICRO PUMP TOPICAL GEL WITH PUMP 0.06 %, 0.08 % | 362 | SIMPONI SUBCUTANEOUS PEN INJECTOR 100 MG/ML, 50 MG/0.5 ML | 318 |
| REVATIO ORAL SUSPENSION FOR RECONSTITUTION | 282 | SIMPONI SUBCUTANEOUS SYRINGE 100 MG/ML, 50 MG/0.5 ML | 318 |
| REVATIO ORAL TABLET | 282 | SKYRIZI SUBCUTANEOUS PEN INJECTOR | 319 |
| REVLIMID | 302 | SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 319 |
| REXULTI | 25 | SKYRIZI SUBCUTANEOUS SYRINGE KIT | 319 |
| REZUROCK | 303 | SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR | 319 |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 304 | SKYTROFA | 136 |
| ROXICODONE ORAL TABLET 15 MG, 30 MG | 273 | <i>sofosbuvir-velpatasvir</i> | 104 |
| ROZLYTREK ORAL CAPSULE 100 MG, 200 MG | 306 | SOMA | 144 |
| RUBRACA | 307 | SOMAVERT | 321 |
| RUCONEST | 308 | <i>sorafenib</i> | 225 |
| <i>rufinamide</i> | 32 | SOVALDI ORAL PELLETS IN PACKET | 322 |
| RYDAPT | 310 | SOVALDI ORAL TABLET 400 MG | 322 |
| RYVENT | 58 | SPORANOX | 173 |
| SABRIL | 311 | SPRYCEL | 323 |
| SAIZEN | 136 | STELARA SUBCUTANEOUS SOLUTION | 324 |
| SAIZEN SAIZENPREP | 136 | STELARA SUBCUTANEOUS SYRINGE 45 MG/0.5 ML, 90 MG/ML .. | 324 |
| SAJAZIR | 118 | STIVARGA | 326 |
| SAMSCA | 312 | <i>sunitinib</i> | 328 |
| SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 50 MCG/ML, 500 MCG/ML | 238 | SUNOSI | 327 |
| <i>sapropterin</i> | 186 | SUTENT | 328 |
| SAVELLA | 313 | SYMDEKO | 329 |
| SCEMBLIX ORAL TABLET 20 MG, 40 MG | 314 | SYMPAZAN | 330 |
| SEGLENTIS | 273 | SYMPROIC | 331 |
| | | SYNDROS | 332 |
| | | TABRECTA | 333 |
| | | <i>tadalafil (pulm. hypertension)</i> | 282 |

| | | | |
|--|-----|---|-----|
| <i>tadalafil oral tablet 2.5 mg, 5 mg</i> | 64 | TOBI | 60 |
| TAFINLAR | 420 | TOBI PODHALER INHALATION | |
| TAGRISO | 334 | CAPSULE, W/INHALATION DEVICE .. | 60 |
| TAKHZYRO | 335 | <i>tobramycin in 0.225 % nacl</i> | 60 |
| TALTZ AUTOINJECTOR | 336 | <i>tobramycin inhalation</i> | 60 |
| TALTZ SYRINGE | 336 | TOLSURA | 357 |
| TALZENNA ORAL CAPSULE 0.25 | | <i>tolvaptan</i> | 312 |
| MG, 0.5 MG, 0.75 MG, 1 MG | 337 | TRACLEER ORAL TABLET | 282 |
| TARCEVA | 94 | TRACLEER ORAL TABLET FOR | |
| TARGRETIN ORAL | 338 | SUSPENSION | 282 |
| TARGRETIN TOPICAL | 338 | <i>tramadol oral capsule,er biphasic 24 hr 17-</i> | |
| TARPEYO | 339 | <i>83</i> | 273 |
| TASIGNA | 340 | <i>tramadol oral capsule,er biphasic 24 hr 25-</i> | |
| TAVALISSE | 341 | <i>75 100 mg, 200 mg</i> | 273 |
| TAVNEOS | 342 | <i>tramadol oral tablet 100 mg, 50 mg</i> | 273 |
| <i>tazarotene topical cream</i> | 344 | <i>tramadol oral tablet extended release 24 hr</i> | |
| <i>tazarotene topical foam</i> | 343 | | 273 |
| <i>tazarotene topical gel</i> | 344 | <i>tramadol oral tablet, er multiphasic 24 hr..</i> | 273 |
| TAZORAC TOPICAL CREAM | 344 | <i>tramadol-acetaminophen</i> | 273 |
| TAZORAC TOPICAL GEL | 344 | TRELSTAR INTRAMUSCULAR | |
| TAZVERIK | 345 | SUSPENSION FOR | |
| TECFIDERA ORAL | | RECONSTITUTION | 360 |
| CAPSULE,DELAYED | | TREMFYA | 361 |
| RELEASE(DR/EC) 120 MG, 120 MG | | <i>tretinoin</i> | 362 |
| (14)- 240 MG (46), 240 MG | 346 | <i>tretinoin microspheres topical gel</i> | 362 |
| TEGSEDI | 347 | TREZIX | 273 |
| TEPMETKO | 348 | <i>triazolam</i> | 273 |
| <i>teriparatide</i> | 123 | TRIKAFTA | 363 |
| TESTIM | 349 | <i>trimethobenzamide oral</i> | 355 |
| <i>testosterone cypionate intramuscular oil</i> | | <i>trimipramine</i> | 144 |
| <i>100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)</i> ...349 | | TRINTELLIX | 380 |
| <i>testosterone enanthate</i> | 349 | TRUDHESA | 84 |
| <i>testosterone transdermal gel in metered-</i> | | TRUSELTIQ ORAL CAPSULE 100 | |
| <i>dose pump</i> | 349 | MG/DAY (100 MG X 1), 125 | |
| <i>testosterone transdermal gel in packet</i> | 349 | MG/DAY(100 MG X1-25MG X1), 50 | |
| <i>testosterone transdermal solution in</i> | | MG/DAY (25 MG X 2), 75 MG/DAY (25 | |
| <i>metered pump w/app</i> | 349 | MG X 3) | 364 |
| <i>tetrabenazine oral tablet 12.5 mg, 25 mg</i> ...404 | | TUKYSA ORAL TABLET 150 MG, 50 | |
| THALOMID ORAL CAPSULE 100 | | MG | 365 |
| MG, 150 MG, 200 MG, 50 MG | 351 | TURALIO | 366 |
| THIOLA | 352 | TWYNEO | 362 |
| THIOLA EC | 352 | TYKERB | 367 |
| TIBSOVO | 354 | TYMLOS | 368 |
| TIGLUTIK | 356 | | |
| <i>tiopronin</i> | 352 | | |
| TLANDO | 349 | | |

| | |
|---|-----|
| TYVASO DPI INHALATION | |
| CARTRIDGE WITH INHALER 16 | |
| MCG, 16 MCG (112)- 32 MCG (84), | |
| 16(112)-32(112) -48(28) MCG, 32 MCG, | |
| 32-48 MCG, 48 MCG, 64 MCG | 369 |
| ULORIC | 370 |
| UPTRAVI ORAL TABLET 1,000 MCG, | |
| 1,200 MCG, 1,400 MCG, 1,600 MCG, | |
| 200 MCG, 400 MCG, 600 MCG, 800 | |
| MCG | 282 |
| UPTRAVI ORAL TABLETS,DOSE | |
| PACK | 282 |
| VALCHLOR | 371 |
| VALTOCO | 372 |
| VELTASSA | 373 |
| VELTIN | 362 |
| VENCLEXTA | 375 |
| VENCLEXTA STARTING PACK | 375 |
| <i>venlafaxine besylate</i> | 374 |
| VENTAVIS | 282 |
| VERKAZIA | 376 |
| VERQUVO | 377 |
| VERZENIO | 378 |
| VFEND IV | 389 |
| VIBERZI | 379 |
| <i>vigabatrin</i> | 311 |
| VIGADRONE | 311 |
| VIIBRYD ORAL TABLET | 380 |
| VIIBRYD ORAL TABLETS,DOSE | |
| PACK 10 MG (7)- 20 MG (23) | 380 |
| VIJOICE ORAL TABLET 125 MG, 250 | |
| MG/DAY (200 MG X1-50 MG X1), 50 | |
| MG | 381 |
| <i>vilazodone</i> | 380 |
| VIMOVO | 382 |
| VISTARIL | 144 |
| VITRAKVI ORAL CAPSULE 100 MG, | |
| 25 MG | 384 |
| VITRAKVI ORAL SOLUTION | 384 |
| VIVJOA | 385 |
| VIZIMPRO | 387 |
| VOGELXO TRANSDERMAL GEL | 349 |
| VOGELXO TRANSDERMAL GEL IN | |
| METERED-DOSE PUMP | 349 |
| VONJO | 388 |
| <i>voriconazole intravenous</i> | 389 |
| VOSEVI | 390 |
| VOTRIENT | 391 |
| VOXZOGO | 392 |
| VRAYLAR ORAL CAPSULE | 393 |
| VRAYLAR ORAL CAPSULE,DOSE | |
| PACK | 393 |
| VTAMA | 394 |
| VUITY | 395 |
| VUMERITY | 396 |
| VYNDAMAX | 24 |
| VYNDAQEL | 24 |
| WAKIX | 397 |
| WELIREG | 398 |
| WINLEVI | 362 |
| XALKORI | 399 |
| XANAX ORAL TABLET 0.25 MG, 0.5 | |
| MG, 1 MG, 2 MG | 273 |
| XANAX XR ORAL TABLET | |
| EXTENDED RELEASE 24 HR 0.5 MG, | |
| 1 MG, 2 MG, 3 MG | 273 |
| XARELTO ORAL SUSPENSION FOR | |
| RECONSTITUTION | 400 |
| XCOPRI | 401 |
| XCOPRI MAINTENANCE PACK | |
| ORAL TABLET 250MG/DAY(150 MG | |
| X1-100MG X1), 350 MG/DAY (200 MG | |
| X1-150MG X1) | 401 |
| XCOPRI TITRATION PACK | 401 |
| XELJANZ ORAL SOLUTION | 403 |
| XELJANZ ORAL TABLET | 402 |
| XELJANZ XR | 402 |
| XENAZINE ORAL TABLET 12.5 MG, | |
| 25 MG | 404 |
| XERMELO | 405 |
| XGEVA | 406 |
| XIFAXAN ORAL TABLET 550 MG | 407 |
| XOLAIR | 408 |
| XOSPATA | 410 |
| XPROVIO ORAL TABLET 100 | |
| MG/WEEK (50 MG X 2), 40 | |
| MG/WEEK (40 MG X 1), 40MG | |
| TWICE WEEK (40 MG X 2), 60 | |
| MG/WEEK (60 MG X 1), 60MG | |
| TWICE WEEK (120 MG/WEEK), 80 | |
| MG/WEEK (40 MG X 2), 80MG | |
| TWICE WEEK (160 MG/WEEK) | 411 |

| | |
|--|-----|
| XTAMPZA ER | 273 |
| XTANDI ORAL CAPSULE | 412 |
| XTANDI ORAL TABLET 40 MG, 80 | |
| MG | 412 |
| XURIDEN | 413 |
| XYOSTED | 349 |
| XYREM | 414 |
| XYWAV | 415 |
| YONSA | 417 |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 273 |
| ZAVESCA | 418 |
| ZEJULA | 419 |
| ZELBORAF | 420 |
| ZEMAIRA | 15 |
| ZEPATIER | 421 |
| ZEPOSIA | 422 |
| ZEPOSIA STARTER KIT | 422 |
| ZEPOSIA STARTER PACK | 422 |
| ZIANA | 362 |
| <i>zileuton</i> | 192 |
| ZOLINZA | 423 |
| <i>zolpidem</i> | 273 |
| ZOMACTON | 136 |
| ZONALON | 87 |
| ZORBTIVE | 136 |
| ZTLIDO | 424 |
| ZYDELIG | 425 |
| ZYFLO | 192 |
| ZYKADIA | 426 |
| ZYTIGA ORAL TABLET 250 MG, 500 | |
| MG | 427 |

brand adhd

Products Affected

- **ADDERALL 20 MG TABLET**
- **ADDERALL 5 MG TABLET**
- **ADDERALL 7.5 MG TABLET**
- **ADDERALL XR 10 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 15 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 20 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 25 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 30 MG CAPSULE,EXTENDED RELEASE**
- **ADDERALL XR 5 MG CAPSULE,EXTENDED RELEASE**
- **ADZENYS XR-ODT 12.5 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 15.7 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 18.8 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 3.1 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 6.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **ADZENYS XR-ODT 9.4 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **APTENSIO XR 10 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 15 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 20 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 30 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 40 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 50 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **APTENSIO XR 60 MG CAPSULE,EXTENDED RELEASE SPRINKLE**
- **AZSTARYS 26.1 MG-5.2 MG CAPSULE**
- **AZSTARYS 39.2 MG-7.8 MG CAPSULE**
- **AZSTARYS 52.3 MG-10.4 MG CAPSULE**
- **CONCERTA 18 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 27 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 36 MG TABLET,EXTENDED RELEASE**
- **CONCERTA 54 MG TABLET,EXTENDED RELEASE**
- **COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET**
- **DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE**
- **DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE**
- **DYANAVEL XR 10 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 15 MG TABLET, EXTENDED RELEASE**
- **DYANAVEL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION**
- **DYANAVEL XR 20 MG TABLET,**

- **EXTENDED RELEASE**
- **DYANAVEL XR 5 MG TABLET, EXTENDED RELEASE**
- **FOCALIN 10 MG TABLET**
- **FOCALIN 2.5 MG TABLET**
- **FOCALIN 5 MG TABLET**
- **FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 15 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 20 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 25 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 30 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 35 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 40 MG CAPSULE,EXTENDED RELEASE**
- **FOCALIN XR 5 MG CAPSULE,EXTENDED RELEASE**
- **JORNAY PM 100 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 20 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 40 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 60 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **JORNAY PM 80 MG CAPSULE,DELAYED RELEASE,EXTENDED RELEASE SPRINKLE**
- **METHYLIN 10 MG/5 ML ORAL SOLUTION**
- **METHYLIN 5 MG/5 ML ORAL SOLUTION**
- *methylphenidate er 72 mg tablet,extended*

- *release 24 hr*
- **MYDAYIS 12.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 25 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 37.5 MG CAPSULE EXTENDED RELEASE 24 HR**
- **MYDAYIS 50 MG CAPSULE EXTENDED RELEASE 24 HR**
- **QUILLICHEW ER 20 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 30 MG CHEWABLE TABLET, EXTENDED RELEASE**
- **QUILLICHEW ER 40 MG CHEWABLE, EXTENDED RELEASE TABLET**
- **QUILLIVANT XR 5 MG/ML (25 MG/5 ML) ORAL SUSPENSION,EXTEND RELEASE 24HR**
- **RELEXXII 72 MG TABLET,EXTENDED RELEASE**
- **RITALIN 10 MG TABLET**
- **RITALIN 20 MG TABLET**
- **RITALIN 5 MG TABLET**
- **RITALIN LA 10 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 20 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 30 MG CAPSULE,EXTENDED RELEASE**
- **RITALIN LA 40 MG CAPSULE,EXTENDED RELEASE**
- **STRATTERA 10 MG CAPSULE**
- **STRATTERA 100 MG CAPSULE**
- **STRATTERA 18 MG CAPSULE**
- **STRATTERA 25 MG CAPSULE**
- **STRATTERA 40 MG CAPSULE**
- **STRATTERA 60 MG CAPSULE**
- **STRATTERA 80 MG CAPSULE**
- **VYVANSE 10 MG CAPSULE**
- **VYVANSE 10 MG CHEWABLE TABLET**
- **VYVANSE 20 MG CAPSULE**
- **VYVANSE 20 MG CHEWABLE TABLET**
- **VYVANSE 30 MG CAPSULE**
- **VYVANSE 30 MG CHEWABLE TABLET**

- **VYVANSE 40 MG CAPSULE**
- **VYVANSE 40 MG CHEWABLE TABLET**
- **VYVANSE 50 MG CAPSULE**
- **VYVANSE 50 MG CHEWABLE TABLET**
- **VYVANSE 60 MG CAPSULE**
- **VYVANSE 60 MG CHEWABLE TABLET**
- **VYVANSE 70 MG CAPSULE**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of 2 of the following generic ADHD medications (Step 1 drug) when being utilized for the same medically accepted indication: methylphenidate, atomoxetine, dextroamphetamine/amphetamine or dexmethylphenidate in the last 180 days |
|-----------------|---|

brand albuterol

Products Affected

- *albuterol sulfate hfa 90 mcg/actuation aerosol inhaler (nda020983)*
- **PROAIR RESPICLICK 90**

**MCG/ACTUATION BREATH
ACTIVATED**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of albuterol (generic Proair HFA) in the last 90 days |
|-----------------|---|

brand epinephrine

Products Affected

- **AUVI-Q 0.1 MG/0.1 ML INJECTION,AUTO-INJECTOR**
- **AUVI-Q 0.15 MG/0.15 ML AUTO-INJECTOR (FOR 33 LB TO 66 LB PATIENTS)**
- **AUVI-Q 0.3 MG/0.3 ML INJECTION, AUTO-INJECTOR**

Details

| | |
|-----------------|--|
| Criteria | Require a trial of 2 of the following (Step 1 drug): generic epinephrine injection, Epipen or Symjepi in the last 180 days |
|-----------------|--|

brand glaucoma

Products Affected

- **RHOPRESSA 0.02 % EYE DROPS**
- **ROCKLATAN 0.02 %-0.005 % EYE**
- **DROPS**
- **VYZULTA 0.024 % EYE DROPS**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic latanoprost (Step 1 drug) plus one other preferred generic formulary glaucoma drug (Step 1 drug) in the last 180 days |
|-----------------|--|

brand levalbuterol

Products Affected

- **XOPENEX HFA 45 MCG/ACTUATION
AEROSOL INHALER**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of albuterol (generic Proair HFA) and generic levalbuterol in the last 180 days |
|-----------------|---|

Breo Ellipta AG

Products Affected

- *fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder*
- *fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder*

Details

| Criteria | Require a 1 month trial of Breo Ellipta (Step 1 drug) in the last 90 days |
|----------|---|
|----------|---|

celecoxib

Products Affected

- **CELEBREX 100 MG CAPSULE**
 - **CELEBREX 200 MG CAPSULE**
 - **CELEBREX 400 MG CAPSULE**
 - **CELEBREX 50 MG CAPSULE**
- *celecoxib 100 mg capsule*
 - *celecoxib 200 mg capsule*
 - *celecoxib 400 mg capsule*
 - *celecoxib 50 mg capsule*

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of 2 formulary generic NSAIDs (Step 1 drug) in the last 180 days |
|-----------------|--|

Conjupri

Products Affected

- **CONJUPRI 2.5 MG TABLET**
 - **CONJUPRI 5 MG TABLET**
- *levamlodipine 2.5 mg tablet*
 - *levamlodipine 5 mg tablet*

Details

| | |
|-----------------|---|
| Criteria | Require a trial of 2 of the following generic medications (Step 1 drug): amlodipine tablet, felodipine extended-release tablet, or nifedipine 24hr extended-release tablet in the last 180 days |
|-----------------|---|

copaxone

Products Affected

- **COPAXONE 20 MG/ML
SUBCUTANEOUS SYRINGE**
- **COPAXONE 40 MG/ML
SUBCUTANEOUS SYRINGE**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic glatiramer and Glatopa in the last 180 days |
|-----------------|--|

DPP4 Agents

Products Affected

- *alogliptin 12.5 mg tablet*
- *alogliptin 12.5 mg-metformin 1,000 mg tablet*
- *alogliptin 12.5 mg-metformin 500 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 30 mg tablet*
- *alogliptin 12.5 mg-pioglitazone 45 mg tablet*
- *alogliptin 25 mg tablet*
- *alogliptin 25 mg-pioglitazone 15 mg tablet*
- *alogliptin 25 mg-pioglitazone 30 mg tablet*
- *alogliptin 25 mg-pioglitazone 45 mg tablet*
- *alogliptin 6.25 mg tablet*
- **KAZANO 12.5 MG-1,000 MG TABLET**
- **KAZANO 12.5 MG-500 MG TABLET**
- **KOMBIGLYZE XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **KOMBIGLYZE XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **KOMBIGLYZE XR 5 MG-500 MG TABLET,EXTENDED RELEASE**
- **NESINA 12.5 MG TABLET**
- **NESINA 25 MG TABLET**
- **NESINA 6.25 MG TABLET**
- **ONGLYZA 2.5 MG TABLET**
- **ONGLYZA 5 MG TABLET**
- **OSENI 12.5 MG-15 MG TABLET**
- **OSENI 12.5 MG-30 MG TABLET**
- **OSENI 12.5 MG-45 MG TABLET**
- **OSENI 25 MG-15 MG TABLET**
- **OSENI 25 MG-30 MG TABLET**
- **OSENI 25 MG-45 MG TABLET**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of a preferred linagliptan and sitagliptan product in the last 180 days |
|-----------------|---|

DPP4-SGLT2 Combo

Products Affected

- QTERN 10 MG-5 MG TABLET
- QTERN 5 MG-5 MG TABLET
- STEGLUJAN 15 MG-100 MG TABLET
- STEGLUJAN 5 MG-100 MG TABLET

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of Glyxambi and Trijardy the last 180 days |
|-----------------|--|

Dry Eye

Products Affected

- **CEQUA 0.09 % EYE DROPS IN A DROPPERETTE**
- **TYRVAYA 0.03 MG/SPRAY NASAL SPRAY**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of Restasis, cyclosporine eye drop (i.e. generic Restasis) or Xiidra in the last 90 days |
|-----------------|--|

dymista

Products Affected

- **DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY**
- **RYALTRIS 665 MCG-25 MCG/SPRAY NASAL SPRAY**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic azelastine/fluticasone spray in the last 90 days |
|-----------------|---|

Flovent HFA AG

Products Affected

- *fluticasone propionate 110 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 220 mcg/actuation hfa aerosol inhaler*
- *fluticasone propionate 44 mcg/actuation hfa aerosol inhaler*

Details

| Criteria | Require a 1 month trial of Flovent HFA (Step 1 drug) in the last 90 days |
|----------|--|
|----------|--|

Fortamet

Products Affected

- *metformin er 1,000 mg tablet, extended release 24hr*
- *metformin er 500 mg tablet, extended release 24hr*

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days |
|-----------------|--|

GLP1

Products Affected

- **BYDUREON BCISE 2 MG/0.85 ML SUBCUTANEOUS AUTO-INJECTOR**
- **BYETTA 10 MCG/DOSE(250 MCG/ML)2.4 ML SUBCUTANEOUS**
- **PEN INJECTOR**
- **BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of 2 of the following : Mounjaro, Ozempic, Trulicity or Victoza in the last 180 days |
|-----------------|--|

Glumetza

Products Affected

- **GLUMETZA 1,000 MG TABLET,EXTENDED RELEASE**
 - **GLUMETZA 500 MG TABLET,EXTENDED RELEASE**
- *metformin er 1,000 mg 24 hr tablet,extended release*
 - *metformin er 500 mg 24 hr tablet,extended release*

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic metformin IR tablets and generic metformin ER (i.e. generic Glucophage XR) tablets in the last 180 days |
|-----------------|--|

herpetic keratitis

Products Affected

- ZIRGAN 0.15 % EYE GEL

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic trifluridine eye drops (Step 1 drug) in the last 90 days |
|-----------------|---|

Lactulose

Products Affected

- **KRISTALOSE 10 GRAM ORAL PACKET**
 - **KRISTALOSE 20 GRAM ORAL PACKET**
- *lactulose 10 gram oral packet*

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of lactulose solution (Step 1 drug) in the last 90 days |
|-----------------|---|

lupron

Products Affected

- **LUPRON DEPOT 11.25 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 22.5 MG (3 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 3.75 MG INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 30 MG (4 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 45 MG (6 MONTH) INTRAMUSCULAR SYRINGE KIT**
- **LUPRON DEPOT 7.5 MG INTRAMUSCULAR SYRINGE KIT**

Details

| | |
|-----------------|--|
| Criteria | Require a trial of Eligard (Step 1 drug) in the last 180 days when being utilized for the same medically accepted indication |
|-----------------|--|

mupirocin

Products Affected

- **CENTANY 2 % TOPICAL OINTMENT** • *mupirocin calcium 2 % topical cream*

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic mupirocin ointment (Step 1 drug) in the last 90 days |
|-----------------|---|

Riomet

Products Affected

- *metformin 500 mg/5 ml oral solution* **SOLUTION**
- **RIOMET 500 MG/5 ML ORAL**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic metformin IR tablets in the last 90 days -OR- documentation supporting the inability to swallow or difficulty swallowing tablets containing metformin |
|-----------------|---|

Roszet

Products Affected

- *ezetimibe 10 mg-rosuvastatin 10 mg tablet*
 - *ezetimibe 10 mg-rosuvastatin 20 mg tablet*
 - *ezetimibe 10 mg-rosuvastatin 40 mg tablet*
 - *ezetimibe 10 mg-rosuvastatin 5 mg tablet*
- **ROSZET 10 MG-10 MG TABLET**
 - **ROSZET 10 MG-20 MG TABLET**
 - **ROSZET 10 MG-40 MG TABLET**
 - **ROSZET 10 MG-5 MG TABLET**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic rosuvastatin tablets and generic ezetimibe tablets in the last 180 days |
|-----------------|--|

rytary

Products Affected

- **DHIVY 25 MG-100 MG TABLET**
- **RYTARY 23.75 MG-95 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 36.25 MG-145 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 48.75 MG-195 MG CAPSULE,EXTENDED RELEASE**
- **RYTARY 61.25 MG-245 MG CAPSULE,EXTENDED RELEASE**

Details

| | |
|-----------------|---|
| Criteria | Require a trial of generic carbidopa/levodopa product (Step 1 drug) in the last 90 days |
|-----------------|---|

SGLT2 Agents

Products Affected

- **FARXIGA 10 MG TABLET**
- **FARXIGA 5 MG TABLET**
- **SEGLUROMET 2.5 MG-1,000 MG TABLET**
- **SEGLUROMET 2.5 MG-500 MG TABLET**
- **SEGLUROMET 7.5 MG-1,000 MG TABLET**
- **SEGLUROMET 7.5 MG-500 MG TABLET**
- **STEGLATRO 15 MG TABLET**
- **STEGLATRO 5 MG TABLET**
- **XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE**
- **XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE**
- **XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of a preferred canagliflozin product and empagliflozin product in the last 180 days, when being utilized for the same medically accepted indication |
|-----------------|---|

Soanz

Products Affected

- SOAANZ 20 MG TABLET
- SOAANZ 40 MG TABLET
- SOAANZ 60 MG TABLET

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of each generic furosemide tablets and generic torsemide tablets in the last 180 days |
|-----------------|---|

suboxone

Products Affected

- *buprenorphine 2 mg-naloxone 0.5 mg sublingual tablet*
- *buprenorphine 8 mg-naloxone 2 mg sublingual tablet*
- **SUBOXONE 12 MG-3 MG SUBLINGUAL FILM**
- **SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM**
- **SUBOXONE 4 MG-1 MG SUBLINGUAL FILM**
- **SUBOXONE 8 MG-2 MG SUBLINGUAL FILM**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of Zubsolv (Step 1 drug) in the last 90 days |
|-----------------|--|

topical antifungal

Products Affected

- **ERTACZO 2 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL CREAM**
- **EXELDERM 1 % TOPICAL SOLUTION**
- **EXTINA 2 % TOPICAL FOAM**
- **KETODAN 2 % TOPICAL FOAM**
- *naftifine 1 % topical cream*
- *naftifine 2 % topical cream*
- **NAFTIN 1 % TOPICAL GEL**
- **NAFTIN 2 % TOPICAL GEL**
- *oxiconazole 1 % topical cream*
- **OXISTAT 1 % LOTION**
- **OXISTAT 1 % TOPICAL CREAM**
- **XOLEGEL 2 % TOPICAL**

Details

| | |
|-----------------|---|
| Criteria | Require a 1 month trial of generic econazole cream and one of the following: generic ketoconazole cream or ketoconazole shampoo (Step 1 drugs),when being utilized for the same medically accepted indication, in the last 180 days |
|-----------------|---|

Topical Psoriasis

Products Affected

- *calcipotriene 0.005 % topical foam*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical ointment*
- *calcipotriene-betamethasone 0.005 %-0.064 % topical suspension*
- *calcitriol 3 mcg/gram topical ointment*
- **DOVONEX 0.005 % TOPICAL CREAM**
- **ENSTILAR 0.005 %-0.064 % TOPICAL FOAM**
- **SORILUX 0.005 % TOPICAL FOAM**
- **TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT**
- **TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION**
- **VECTICAL 3 MCG/GRAM TOPICAL OINTMENT**

Details

| | |
|-----------------|--|
| Criteria | Require a 1 month trial of generic calcipotriene cream, ointment or solution (Step 1 drug) in the last 90 days |
|-----------------|--|

Index of Drugs

| | |
|--|--|
| ADDERALL 20 MG TABLET1 | <i>alogliptin 25 mg-pioglitazone 30 mg tablet</i> ..12 |
| ADDERALL 5 MG TABLET1 | <i>alogliptin 25 mg-pioglitazone 45 mg tablet</i> ..12 |
| ADDERALL 7.5 MG TABLET1 | <i>alogliptin 6.25 mg tablet</i>12 |
| ADDERALL XR 10 MG | APTENSIO XR 10 MG |
| CAPSULE,EXTENDED RELEASE1 | CAPSULE,EXTENDED RELEASE |
| ADDERALL XR 15 MG | SPRINKLE1 |
| CAPSULE,EXTENDED RELEASE1 | APTENSIO XR 15 MG |
| ADDERALL XR 20 MG | CAPSULE,EXTENDED RELEASE |
| CAPSULE,EXTENDED RELEASE1 | SPRINKLE1 |
| ADDERALL XR 25 MG | APTENSIO XR 20 MG |
| CAPSULE,EXTENDED RELEASE1 | CAPSULE,EXTENDED RELEASE |
| ADDERALL XR 30 MG | SPRINKLE1 |
| CAPSULE,EXTENDED RELEASE1 | APTENSIO XR 30 MG |
| ADDERALL XR 5 MG | CAPSULE,EXTENDED RELEASE |
| CAPSULE,EXTENDED RELEASE1 | SPRINKLE1 |
| ADZENYS XR-ODT 12.5 MG | APTENSIO XR 40 MG |
| EXTENDED RELEASE | CAPSULE,EXTENDED RELEASE |
| DISINTEGRATING TABLET1 | SPRINKLE1 |
| ADZENYS XR-ODT 15.7 MG | APTENSIO XR 50 MG |
| EXTENDED RELEASE | CAPSULE,EXTENDED RELEASE |
| DISINTEGRATING TABLET1 | SPRINKLE1 |
| ADZENYS XR-ODT 18.8 MG | APTENSIO XR 60 MG |
| EXTENDED RELEASE | CAPSULE,EXTENDED RELEASE |
| DISINTEGRATING TABLET1 | SPRINKLE1 |
| ADZENYS XR-ODT 3.1 MG | AUVI-Q 0.1 MG/0.1 ML |
| EXTENDED RELEASE | INJECTION,AUTO-INJECTOR5 |
| DISINTEGRATING TABLET1 | AUVI-Q 0.15 MG/0.15 ML AUTO- |
| ADZENYS XR-ODT 6.3 MG | INJECTOR (FOR 33 LB TO 66 LB |
| EXTENDED RELEASE | PATIENTS)5 |
| DISINTEGRATING TABLET1 | AUVI-Q 0.3 MG/0.3 ML INJECTION, |
| ADZENYS XR-ODT 9.4 MG | AUTO-INJECTOR5 |
| EXTENDED RELEASE | AZSTARYS 26.1 MG-5.2 MG |
| DISINTEGRATING TABLET1 | CAPSULE1 |
| <i>albuterol sulfate hfa 90 mcg/actuation</i> | AZSTARYS 39.2 MG-7.8 MG |
| <i>aerosol inhaler (nda020983)</i>4 | CAPSULE1 |
| <i>alogliptin 12.5 mg tablet</i>12 | AZSTARYS 52.3 MG-10.4 MG |
| <i>alogliptin 12.5 mg-metformin 1,000 mg</i> | CAPSULE1 |
| <i>tablet</i>12 | <i>buprenorphine 2 mg-naloxone 0.5 mg</i> |
| <i>alogliptin 12.5 mg-metformin 500 mg</i> | <i>sublingual tablet</i>29 |
| <i>tablet</i>12 | <i>buprenorphine 8 mg-naloxone 2 mg</i> |
| <i>alogliptin 12.5 mg-pioglitazone 30 mg</i> | <i>sublingual tablet</i>29 |
| <i>tablet</i>12 | BYDUREON BCISE 2 MG/0.85 ML |
| <i>alogliptin 12.5 mg-pioglitazone 45 mg</i> | SUBCUTANEOUS AUTO-INJECTOR ...18 |
| <i>tablet</i>12 | BYETTA 10 MCG/DOSE(250 |
| <i>alogliptin 25 mg tablet</i>12 | MCG/ML)2.4 ML SUBCUTANEOUS |
| <i>alogliptin 25 mg-pioglitazone 15 mg tablet</i> ..12 | PEN INJECTOR18 |

| | | | |
|---|----|---|----|
| BYETTA 5 MCG/DOSE (250 MCG/ML)1.2 ML SUBCUTANEOUS PEN INJECTOR | 18 | DEXEDRINE SPANSULE 15 MG CAPSULE,EXTENDED RELEASE | 1 |
| <i>calcipotriene 0.005 % topical foam</i> | 31 | DHIVY 25 MG-100 MG TABLET | 26 |
| <i>calcipotriene-betamethasone 0.005 %-0.064 % topical ointment</i> | 31 | DOVONEX 0.005 % TOPICAL CREAM | 31 |
| <i>calcipotriene-betamethasone 0.005 %-0.064 % topical suspension</i> | 31 | DYANAVAL XR 10 MG TABLET, EXTENDED RELEASE | 1 |
| <i>calcitriol 3 mcg/gram topical ointment</i> | 31 | DYANAVAL XR 15 MG TABLET, EXTENDED RELEASE | 1 |
| CELEBREX 100 MG CAPSULE | 9 | DYANAVAL XR 2.5 MG/ML ORAL 24 HR EXTENDED RELEASE SUSPENSION | 1 |
| CELEBREX 200 MG CAPSULE | 9 | DYANAVAL XR 20 MG TABLET, EXTENDED RELEASE | 1 |
| CELEBREX 400 MG CAPSULE | 9 | DYANAVAL XR 5 MG TABLET, EXTENDED RELEASE | 1 |
| <i>celecoxib 100 mg capsule</i> | 9 | DYMISTA 137 MCG-50 MCG/SPRAY NASAL SPRAY | 15 |
| <i>celecoxib 200 mg capsule</i> | 9 | ENSTILAR 0.005 %-0.064 % TOPICAL FOAM | 31 |
| <i>celecoxib 400 mg capsule</i> | 9 | ERTACZO 2 % TOPICAL CREAM | 30 |
| <i>celecoxib 50 mg capsule</i> | 9 | EXELDERM 1 % TOPICAL CREAM | 30 |
| CENTANY 2 % TOPICAL OINTMENT | 23 | EXELDERM 1 % TOPICAL SOLUTION | 30 |
| CEQUA 0.09 % EYE DROPS IN A DROPPERETTE | 14 | EXTINA 2 % TOPICAL FOAM | 30 |
| CONCERTA 18 MG TABLET,EXTENDED RELEASE | 1 | <i>ezetimibe 10 mg-rosuvastatin 10 mg tablet</i> .. | 25 |
| CONCERTA 27 MG TABLET,EXTENDED RELEASE | 1 | <i>ezetimibe 10 mg-rosuvastatin 20 mg tablet</i> .. | 25 |
| CONCERTA 36 MG TABLET,EXTENDED RELEASE | 1 | <i>ezetimibe 10 mg-rosuvastatin 40 mg tablet</i> .. | 25 |
| CONCERTA 54 MG TABLET,EXTENDED RELEASE | 1 | <i>ezetimibe 10 mg-rosuvastatin 5 mg tablet</i> | 25 |
| CONJUPRI 2.5 MG TABLET | 10 | FARXIGA 10 MG TABLET | 27 |
| CONJUPRI 5 MG TABLET | 10 | FARXIGA 5 MG TABLET | 27 |
| COPAXONE 20 MG/ML SUBCUTANEOUS SYRINGE | 11 | <i>fluticasone furoate 100 mcg-vilanterol 25 mcg/dose inhalation powder</i> | 8 |
| COPAXONE 40 MG/ML SUBCUTANEOUS SYRINGE | 11 | <i>fluticasone furoate 200 mcg-vilanterol 25 mcg/dose inhalation powder</i> | 8 |
| COTEMPLA XR-ODT 17.3 MG EXTENDED RELEASE DISINTEGRATING TABLET | 1 | <i>fluticasone propionate 110 mcg/actuation hfa aerosol inhaler</i> | 16 |
| COTEMPLA XR-ODT 25.9 MG EXTENDED RELEASE DISINTEGRATING TABLET | 1 | <i>fluticasone propionate 220 mcg/actuation hfa aerosol inhaler</i> | 16 |
| COTEMPLA XR-ODT 8.6 MG EXTENDED RELEASE DISINTEGRATING TABLET | 1 | <i>fluticasone propionate 44 mcg/actuation hfa aerosol inhaler</i> | 16 |
| DEXEDRINE SPANSULE 10 MG CAPSULE,EXTENDED RELEASE | 1 | FOCALIN 10 MG TABLET | 1 |
| | | FOCALIN 2.5 MG TABLET | 1 |
| | | FOCALIN 5 MG TABLET | 1 |
| | | FOCALIN XR 10 MG CAPSULE,EXTENDED RELEASE | 1 |

| | | | |
|--|----|--|----|
| FOCALIN XR 15 MG | | KOMBIGLYZE XR 5 MG-500 MG | |
| CAPSULE,EXTENDED RELEASE | 1 | TABLET,EXTENDED RELEASE | 12 |
| FOCALIN XR 20 MG | | KRISTALOSE 10 GRAM ORAL | |
| CAPSULE,EXTENDED RELEASE | 1 | PACKET | 21 |
| FOCALIN XR 25 MG | | KRISTALOSE 20 GRAM ORAL | |
| CAPSULE,EXTENDED RELEASE | 1 | PACKET | 21 |
| FOCALIN XR 30 MG | | <i>lactulose 10 gram oral packet</i> | 21 |
| CAPSULE,EXTENDED RELEASE | 1 | <i>levamlodipine 2.5 mg tablet</i> | 10 |
| FOCALIN XR 35 MG | | <i>levamlodipine 5 mg tablet</i> | 10 |
| CAPSULE,EXTENDED RELEASE | 1 | LUPRON DEPOT 11.25 MG (3 | |
| FOCALIN XR 40 MG | | MONTH) INTRAMUSCULAR | |
| CAPSULE,EXTENDED RELEASE | 1 | SYRINGE KIT | 22 |
| FOCALIN XR 5 MG | | LUPRON DEPOT 22.5 MG (3 MONTH) | |
| CAPSULE,EXTENDED RELEASE | 1 | INTRAMUSCULAR SYRINGE KIT | 22 |
| GLUMETZA 1,000 MG | | LUPRON DEPOT 3.75 MG | |
| TABLET,EXTENDED RELEASE | 19 | INTRAMUSCULAR SYRINGE KIT | 22 |
| GLUMETZA 500 MG | | LUPRON DEPOT 30 MG (4 MONTH) | |
| TABLET,EXTENDED RELEASE | 19 | INTRAMUSCULAR SYRINGE KIT | 22 |
| JORNAY PM 100 MG | | LUPRON DEPOT 45 MG (6 MONTH) | |
| CAPSULE,DELAYED | | INTRAMUSCULAR SYRINGE KIT | 22 |
| RELEASE,EXTENDED RELEASE | | LUPRON DEPOT 7.5 MG | |
| SPRINKLE | 1 | INTRAMUSCULAR SYRINGE KIT | 22 |
| JORNAY PM 20 MG | | <i>metformin 500 mg/5 ml oral solution</i> | 24 |
| CAPSULE,DELAYED | | <i>metformin er 1,000 mg 24 hr</i> | |
| RELEASE,EXTENDED RELEASE | | <i>tablet,extended release</i> | 19 |
| SPRINKLE | 1 | <i>metformin er 1,000 mg tablet,extended</i> | |
| JORNAY PM 40 MG | | <i>release 24hr</i> | 17 |
| CAPSULE,DELAYED | | <i>metformin er 500 mg 24 hr tablet,extended</i> | |
| RELEASE,EXTENDED RELEASE | | <i>release</i> | 19 |
| SPRINKLE | 1 | <i>metformin er 500 mg tablet,extended</i> | |
| JORNAY PM 60 MG | | <i>release 24hr</i> | 17 |
| CAPSULE,DELAYED | | METHYLIN 10 MG/5 ML ORAL | |
| RELEASE,EXTENDED RELEASE | | SOLUTION | 1 |
| SPRINKLE | 1 | METHYLIN 5 MG/5 ML ORAL | |
| JORNAY PM 80 MG | | SOLUTION | 1 |
| CAPSULE,DELAYED | | <i>methylphenidate er 72 mg tablet,extended</i> | |
| RELEASE,EXTENDED RELEASE | | <i>release 24 hr</i> | 1 |
| SPRINKLE | 1 | <i>mupirocin calcium 2 % topical cream</i> | 23 |
| KAZANO 12.5 MG-1,000 MG TABLET | 12 | MYDAYIS 12.5 MG CAPSULE | |
| KAZANO 12.5 MG-500 MG TABLET | 12 | EXTENDED RELEASE 24 HR | 1 |
| KETODAN 2 % TOPICAL FOAM | 30 | MYDAYIS 25 MG CAPSULE | |
| KOMBIGLYZE XR 2.5 MG-1,000 MG | | EXTENDED RELEASE 24 HR | 1 |
| TABLET,EXTENDED RELEASE | 12 | MYDAYIS 37.5 MG CAPSULE | |
| KOMBIGLYZE XR 5 MG-1,000 MG | | EXTENDED RELEASE 24 HR | 1 |
| TABLET,EXTENDED RELEASE | 12 | MYDAYIS 50 MG CAPSULE | |
| | | EXTENDED RELEASE 24 HR | 1 |

| | | | |
|--|----|---|----|
| <i>naftifine 1 % topical cream</i> | 30 | RITALIN LA 20 MG | |
| <i>naftifine 2 % topical cream</i> | 30 | CAPSULE,EXTENDED RELEASE | 1 |
| NAFTIN 1 % TOPICAL GEL | 30 | RITALIN LA 30 MG | |
| NAFTIN 2 % TOPICAL GEL | 30 | CAPSULE,EXTENDED RELEASE | 1 |
| NESINA 12.5 MG TABLET | 12 | RITALIN LA 40 MG | |
| NESINA 25 MG TABLET | 12 | CAPSULE,EXTENDED RELEASE | 1 |
| NESINA 6.25 MG TABLET | 12 | ROCKLATAN 0.02 %-0.005 % EYE | |
| ONGLYZA 2.5 MG TABLET | 12 | DROPS | 6 |
| ONGLYZA 5 MG TABLET | 12 | ROSZET 10 MG-10 MG TABLET | 25 |
| OSENI 12.5 MG-15 MG TABLET | 12 | ROSZET 10 MG-20 MG TABLET | 25 |
| OSENI 12.5 MG-30 MG TABLET | 12 | ROSZET 10 MG-40 MG TABLET | 25 |
| OSENI 12.5 MG-45 MG TABLET | 12 | ROSZET 10 MG-5 MG TABLET | 25 |
| OSENI 25 MG-15 MG TABLET | 12 | RYALTRIS 665 MCG-25 MCG/SPRAY | |
| OSENI 25 MG-30 MG TABLET | 12 | NASAL SPRAY | 15 |
| OSENI 25 MG-45 MG TABLET | 12 | RYTARY 23.75 MG-95 MG | |
| <i>oxiconazole 1 % topical cream</i> | 30 | CAPSULE,EXTENDED RELEASE | 26 |
| OXISTAT 1 % LOTION | 30 | RYTARY 36.25 MG-145 MG | |
| OXISTAT 1 % TOPICAL CREAM | 30 | CAPSULE,EXTENDED RELEASE | 26 |
| PROAIR RESPICLICK 90 | | RYTARY 48.75 MG-195 MG | |
| MCG/ACTUATION BREATH | | CAPSULE,EXTENDED RELEASE | 26 |
| ACTIVATED | 4 | RYTARY 61.25 MG-245 MG | |
| QTERN 10 MG-5 MG TABLET | 13 | CAPSULE,EXTENDED RELEASE | 26 |
| QTERN 5 MG-5 MG TABLET | 13 | SEGLUROMET 2.5 MG-1,000 MG | |
| QUILLICHEW ER 20 MG | | TABLET | 27 |
| CHEWABLE TABLET, EXTENDED | | SEGLUROMET 2.5 MG-500 MG | |
| RELEASE | 1 | TABLET | 27 |
| QUILLICHEW ER 30 MG | | SEGLUROMET 7.5 MG-1,000 MG | |
| CHEWABLE TABLET, EXTENDED | | TABLET | 27 |
| RELEASE | 1 | SEGLUROMET 7.5 MG-500 MG | |
| QUILLICHEW ER 40 MG | | TABLET | 27 |
| CHEWABLE, EXTENDED RELEASE | | SOAANZ 20 MG TABLET | 28 |
| TABLET | 1 | SOAANZ 40 MG TABLET | 28 |
| QUILLIVANT XR 5 MG/ML (25 MG/5 | | SOAANZ 60 MG TABLET | 28 |
| ML) ORAL SUSPENSION,EXTEND | | SORILUX 0.005 % TOPICAL FOAM ... | 31 |
| RELEASE 24HR | 1 | STEGLATRO 15 MG TABLET | 27 |
| RELEXXII 72 MG | | STEGLATRO 5 MG TABLET | 27 |
| TABLET,EXTENDED RELEASE | 1 | STEGLUJAN 15 MG-100 MG TABLET .. | 13 |
| RHOPRESSA 0.02 % EYE DROPS | 6 | STEGLUJAN 5 MG-100 MG TABLET .. | 13 |
| RIOMET 500 MG/5 ML ORAL | | STRATTERA 10 MG CAPSULE | 1 |
| SOLUTION | 24 | STRATTERA 100 MG CAPSULE | 1 |
| RITALIN 10 MG TABLET | 1 | STRATTERA 18 MG CAPSULE | 1 |
| RITALIN 20 MG TABLET | 1 | STRATTERA 25 MG CAPSULE | 1 |
| RITALIN 5 MG TABLET | 1 | STRATTERA 40 MG CAPSULE | 1 |
| RITALIN LA 10 MG | | STRATTERA 60 MG CAPSULE | 1 |
| CAPSULE,EXTENDED RELEASE | 1 | STRATTERA 80 MG CAPSULE | 1 |

| | | | |
|---|-----------|--|-----------|
| SUBOXONE 12 MG-3 MG SUBLINGUAL FILM..... | 29 | XOLEGEL 2 % TOPICAL..... | 30 |
| SUBOXONE 2 MG-0.5 MG SUBLINGUAL FILM..... | 29 | XOPENEX HFA 45 MCG/ACTUATION AEROSOL INHALER..... | 7 |
| SUBOXONE 4 MG-1 MG SUBLINGUAL FILM..... | 29 | ZIRGAN 0.15 % EYE GEL..... | 20 |
| SUBOXONE 8 MG-2 MG SUBLINGUAL FILM..... | 29 | | |
| TACLONEX 0.005 %-0.064 % TOPICAL OINTMENT..... | 31 | | |
| TACLONEX 0.005 %-0.064 % TOPICAL SUSPENSION..... | 31 | | |
| TYRVAYA 0.03 MG/SPRAY NASAL SPRAY..... | 14 | | |
| VECTICAL 3 MCG/GRAM TOPICAL OINTMENT..... | 31 | | |
| VYVANSE 10 MG CAPSULE..... | 1 | | |
| VYVANSE 10 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 20 MG CAPSULE..... | 1 | | |
| VYVANSE 20 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 30 MG CAPSULE..... | 1 | | |
| VYVANSE 30 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 40 MG CAPSULE..... | 1 | | |
| VYVANSE 40 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 50 MG CAPSULE..... | 1 | | |
| VYVANSE 50 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 60 MG CAPSULE..... | 1 | | |
| VYVANSE 60 MG CHEWABLE TABLET..... | 1 | | |
| VYVANSE 70 MG CAPSULE..... | 1 | | |
| VYZULTA 0.024 % EYE DROPS..... | 6 | | |
| XIGDUO XR 10 MG-1,000 MG TABLET,EXTENDED RELEASE..... | 27 | | |
| XIGDUO XR 10 MG-500 MG TABLET,EXTENDED RELEASE..... | 27 | | |
| XIGDUO XR 2.5 MG-1,000 MG TABLET,EXTENDED RELEASE..... | 27 | | |
| XIGDUO XR 5 MG-1,000 MG TABLET,EXTENDED RELEASE..... | 27 | | |
| XIGDUO XR 5 MG-500 MG TABLET,EXTENDED RELEASE..... | 27 | | |